Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,6121675,Peak mean plasma concentrations,"2. Peak mean plasma concentrations of frusemide were 31.6, 33.6, 43.6 micrograms/ml in the rhesus monkey, cynomolgus monkey and baboon respectively, and concentrations declined with a half-life of about 20 min.","Comparative pharmacokinetics of frusemide in female rhesus monkeys, cynomolgus monkeys and baboons. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121675/),[μg] / [ml],31.6,1498,DB00695,Furosemide
,6121675,Peak mean plasma concentrations,"2. Peak mean plasma concentrations of frusemide were 31.6, 33.6, 43.6 micrograms/ml in the rhesus monkey, cynomolgus monkey and baboon respectively, and concentrations declined with a half-life of about 20 min.","Comparative pharmacokinetics of frusemide in female rhesus monkeys, cynomolgus monkeys and baboons. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121675/),[μg] / [ml],33.6,1499,DB00695,Furosemide
,6121675,Peak mean plasma concentrations,"2. Peak mean plasma concentrations of frusemide were 31.6, 33.6, 43.6 micrograms/ml in the rhesus monkey, cynomolgus monkey and baboon respectively, and concentrations declined with a half-life of about 20 min.","Comparative pharmacokinetics of frusemide in female rhesus monkeys, cynomolgus monkeys and baboons. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121675/),[μg] / [ml],43.6,1500,DB00695,Furosemide
,6121675,half-life,"2. Peak mean plasma concentrations of frusemide were 31.6, 33.6, 43.6 micrograms/ml in the rhesus monkey, cynomolgus monkey and baboon respectively, and concentrations declined with a half-life of about 20 min.","Comparative pharmacokinetics of frusemide in female rhesus monkeys, cynomolgus monkeys and baboons. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6121675/),min,20,1501,DB00695,Furosemide
,6809473,serum clearance of furosemide (Cls),The serum clearance of furosemide (Cls) was between 140 and 201 ml min-1 and on the average the renal clearance was 60% of Cls.,The individual variation in pharmacokinetics and pharmacodynamics of furosemide in young normal male subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6809473/),[ml] / [min],140 and 201,3837,DB00695,Furosemide
,6809473,maximum additional excretion rate of sodium,During the initial 30 min period a maximum additional excretion rate of sodium of 3.3 mmol min-1 was reached at an excretion rate of 0.8 mg furosemide min-1.,The individual variation in pharmacokinetics and pharmacodynamics of furosemide in young normal male subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6809473/),[mM] / [min],3.3,3838,DB00695,Furosemide
,6809473,excretion rate,During the initial 30 min period a maximum additional excretion rate of sodium of 3.3 mmol min-1 was reached at an excretion rate of 0.8 mg furosemide min-1.,The individual variation in pharmacokinetics and pharmacodynamics of furosemide in young normal male subjects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6809473/),mg,0.8,3839,DB00695,Furosemide
,15640375,binding percentage,The binding percentage of furosemide to albumin was approximately 70% in UPA.,"Bucolome, a potent binding inhibitor for furosemide, alters the pharmacokinetics and diuretic effect of furosemide: potential for use of bucolome to restore diuretic response in nephrotic syndrome. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15640375/),%,70,4135,DB00695,Furosemide
,1246013,clearance,"For TEA, clearance (1.5 ml/min-g +/- 0.2 S.E.M.) and extraction (E) (0.83 +/- 0.02) are independent of the degree of azotemia.",Effect of experimental azotemia on renal clearance of furosemide in the dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1246013/),[ml] / [min-g],1.5,4146,DB00695,Furosemide
,1246013,extraction (E),"For TEA, clearance (1.5 ml/min-g +/- 0.2 S.E.M.) and extraction (E) (0.83 +/- 0.02) are independent of the degree of azotemia.",Effect of experimental azotemia on renal clearance of furosemide in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1246013/),,0.83,4147,DB00695,Furosemide
,1246013,Renal plasma flow (RPF),"Renal plasma flow (RPF), calculated as CTEA/ETEA, agreed closely with directly measured RPF (2.0 ml/g-min +/- 0.3).",Effect of experimental azotemia on renal clearance of furosemide in the dog. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1246013/),[ml] / [g-min],2.0,4148,DB00695,Furosemide
,1246013,CF,CF (1.07-0.17 ml/min-g) and EF (0.54-0.06) decreased as a linear function of the increase in uremic serum: (see article).,Effect of experimental azotemia on renal clearance of furosemide in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1246013/),[ml] / [min-g],1.07-0.17,4149,DB00695,Furosemide
,1246013,E,CF (1.07-0.17 ml/min-g) and EF (0.54-0.06) decreased as a linear function of the increase in uremic serum: (see article).,Effect of experimental azotemia on renal clearance of furosemide in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1246013/),,0.54-0.06,4150,DB00695,Furosemide
,7308269,elimination half life (t 1/2 beta),"The mean elimination half life (t 1/2 beta) of Fu averaged 51 +/- 7.7 (+/- SD) min in healthy subjects, 52 +/- 7.7 min in cirrhosis and 200 +/- 57 min in ESRD.",Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7308269/),min,51,4390,DB00695,Furosemide
,7308269,elimination half life (t 1/2 beta),"The mean elimination half life (t 1/2 beta) of Fu averaged 51 +/- 7.7 (+/- SD) min in healthy subjects, 52 +/- 7.7 min in cirrhosis and 200 +/- 57 min in ESRD.",Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7308269/),min,52,4391,DB00695,Furosemide
,7308269,elimination half life (t 1/2 beta),"The mean elimination half life (t 1/2 beta) of Fu averaged 51 +/- 7.7 (+/- SD) min in healthy subjects, 52 +/- 7.7 min in cirrhosis and 200 +/- 57 min in ESRD.",Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7308269/),min,200,4392,DB00695,Furosemide
,7308269,non-renal clearance (Clnr),The non-renal clearance (Clnr) in healthy subjects (56 +/- 28 ml/min) corresponds to the total plasma clearance in functionally anephric patients (54 +/- 18 ml/min).,Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7308269/),[ml] / [min],56,4393,DB00695,Furosemide
,7308269,total plasma clearance,The non-renal clearance (Clnr) in healthy subjects (56 +/- 28 ml/min) corresponds to the total plasma clearance in functionally anephric patients (54 +/- 18 ml/min).,Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7308269/),[ml] / [min],54,4394,DB00695,Furosemide
,30225802,plasma concentrations,"Furosemide plasma concentrations and total body clearance (TBC) were 6.14 mg/l and 22.1 ml/min for the Oliguria group, and 2.63 mg/l and 54.4 ml/min for the Diuresis group, respectively (p < 0.05).",Urine volume as a predicting factor for furosemide clearance during continuous infusion in AKI septic shock patients on hemodiafiltration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30225802/),[mg] / [l],6.14,5052,DB00695,Furosemide
,30225802,plasma concentrations,"Furosemide plasma concentrations and total body clearance (TBC) were 6.14 mg/l and 22.1 ml/min for the Oliguria group, and 2.63 mg/l and 54.4 ml/min for the Diuresis group, respectively (p < 0.05).",Urine volume as a predicting factor for furosemide clearance during continuous infusion in AKI septic shock patients on hemodiafiltration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30225802/),[mg] / [l],2.63,5053,DB00695,Furosemide
,30225802,total body clearance (TBC),"Furosemide plasma concentrations and total body clearance (TBC) were 6.14 mg/l and 22.1 ml/min for the Oliguria group, and 2.63 mg/l and 54.4 ml/min for the Diuresis group, respectively (p < 0.05).",Urine volume as a predicting factor for furosemide clearance during continuous infusion in AKI septic shock patients on hemodiafiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30225802/),[ml] / [min],22.1,5054,DB00695,Furosemide
,30225802,total body clearance (TBC),"Furosemide plasma concentrations and total body clearance (TBC) were 6.14 mg/l and 22.1 ml/min for the Oliguria group, and 2.63 mg/l and 54.4 ml/min for the Diuresis group, respectively (p < 0.05).",Urine volume as a predicting factor for furosemide clearance during continuous infusion in AKI septic shock patients on hemodiafiltration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30225802/),[ml] / [min],54.4,5055,DB00695,Furosemide
,33314204,total clearance,"The mean total clearance and volume of distribution at steady state following IV administration were 0.24 L h-1 kg-1 and 0.17 L/kg, respectively.",Pharmacokinetics and bioavailability of furosemide in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33314204/),[l] / [h·kg],0.24,5081,DB00695,Furosemide
,33314204,volume of distribution at steady state,"The mean total clearance and volume of distribution at steady state following IV administration were 0.24 L h-1 kg-1 and 0.17 L/kg, respectively.",Pharmacokinetics and bioavailability of furosemide in sheep. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33314204/),[l] / [kg],0.17,5082,DB00695,Furosemide
,33314204,peak plasma concentrations,"The mean peak plasma concentrations of IM and SC administration were 10.33 and 3.18 μg/ml at 0.33 and 0.42 hr, respectively.",Pharmacokinetics and bioavailability of furosemide in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33314204/),[μg] / [ml],10.33,5083,DB00695,Furosemide
,33314204,peak plasma concentrations,"The mean peak plasma concentrations of IM and SC administration were 10.33 and 3.18 μg/ml at 0.33 and 0.42 hr, respectively.",Pharmacokinetics and bioavailability of furosemide in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33314204/),[μg] / [ml],3.18,5084,DB00695,Furosemide
,33314204,bioavailability,"The mean bioavailability of IM and SC administration was 97.91% and 37.98%, respectively.",Pharmacokinetics and bioavailability of furosemide in sheep. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33314204/),%,97.91,5085,DB00695,Furosemide
,33314204,bioavailability,"The mean bioavailability of IM and SC administration was 97.91% and 37.98%, respectively.",Pharmacokinetics and bioavailability of furosemide in sheep. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33314204/),%,37.98,5086,DB00695,Furosemide
,23264940,flow rate,"The reconstituted samples were chromatographed on a Zorbax XDB Phenyl column by using a mixture of 0.2% acetic acid buffer, methanol, and acetonitrile (20:16:64, v/v) as the mobile phase at a flow rate of 0.8 mL/min.",Simultaneous Determination of Atorvastatin and Aspirin in Human Plasma by LC-MS/MS: Its Pharmacokinetic Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23264940/),[ml] / [min],0.8,5160,DB00695,Furosemide
,23264940,run time,A run time of 3.0 min for each sample made it possible to analyze more than 300 human plasma samples per day.,Simultaneous Determination of Atorvastatin and Aspirin in Human Plasma by LC-MS/MS: Its Pharmacokinetic Application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23264940/),min,3.0,5161,DB00695,Furosemide
,12457304,serum trough levels,"Beside cyclosporine A at serum trough levels of 240 (195-273) microg/l, five patients additionally received aminoglycosides for at least 2 weeks, and 4 were treated with ganciclovir.","Tolerability, safety and efficacy of conventional amphotericin B administered by 24-hour infusion to lung transplant recipients. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12457304/),[μg] / [l],240,6900,DB00695,Furosemide
,11341359,plasma concentration,"When Eudragit L100-55 was used in an in-situ ileal loop experiment in rats, the pH of the intestinal contents was significantly reduced, from 7.9+/-0.1 to 5.7+/-0.1, and the plasma concentration of furosemide 15 min after administration was about 3 times higher than that in controls, 1.81+/- 0.42microg mL(-1) vs 0.63+/-0.08 microg mL(-1).",Improvement in site-specific intestinal absorption of furosemide by Eudragit L100-55. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11341359/),[μg] / [ml],1.81,7725,DB00695,Furosemide
,11341359,plasma concentration,"When Eudragit L100-55 was used in an in-situ ileal loop experiment in rats, the pH of the intestinal contents was significantly reduced, from 7.9+/-0.1 to 5.7+/-0.1, and the plasma concentration of furosemide 15 min after administration was about 3 times higher than that in controls, 1.81+/- 0.42microg mL(-1) vs 0.63+/-0.08 microg mL(-1).",Improvement in site-specific intestinal absorption of furosemide by Eudragit L100-55. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11341359/),[μg] / [ml],0.63,7726,DB00695,Furosemide
,11341359,AUC,"Furthermore, the AUC of furosemide was significantly increased by a factor of about 1.6 relative to that in controls by the co-administration of Eudragit L100-55, to 21.4+/-4.0 microg h mL(-1) from 13.3+/- 3.9 microg h mL(-1), and the gastrointestinal pH in the midgut and ileum was significantly reduced, with most of the furosemide remaining in these segments at 2 h following the oral administration of furosemide with Eudragit L100-55 to rats.",Improvement in site-specific intestinal absorption of furosemide by Eudragit L100-55. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11341359/),[h·μg] / [ml],21.4,7727,DB00695,Furosemide
,11341359,AUC,"Furthermore, the AUC of furosemide was significantly increased by a factor of about 1.6 relative to that in controls by the co-administration of Eudragit L100-55, to 21.4+/-4.0 microg h mL(-1) from 13.3+/- 3.9 microg h mL(-1), and the gastrointestinal pH in the midgut and ileum was significantly reduced, with most of the furosemide remaining in these segments at 2 h following the oral administration of furosemide with Eudragit L100-55 to rats.",Improvement in site-specific intestinal absorption of furosemide by Eudragit L100-55. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11341359/),[h·μg] / [ml],13.3,7728,DB00695,Furosemide
less,30892891,IC50,"Compounds 10 and 16 were inhibitors for OAT1, and compounds 1-3, 10, and 16 were inhibitors for OAT3 with IC50 values less than 5.0 μM.",Dihydrophenanthrenes from Juncus effusus as Inhibitors of OAT1 and OAT3. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30892891/),μM,5.0,10787,DB00695,Furosemide
,34427339,elimination half-life,"The elimination half-life following IV, IM, and SC administration was 0.71 (0.67-0.76) h, 0.69 (0.61-0.74) h, and 0.70 (0.67-0.79) h, respectively.","Pharmacokinetics of furosemide in goats following intravenous, intramuscular, and subcutaneous administrations. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34427339/),h,0.71,10911,DB00695,Furosemide
,34427339,elimination half-life,"The elimination half-life following IV, IM, and SC administration was 0.71 (0.67-0.76) h, 0.69 (0.61-0.74) h, and 0.70 (0.67-0.79) h, respectively.","Pharmacokinetics of furosemide in goats following intravenous, intramuscular, and subcutaneous administrations. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34427339/),h,0.69,10912,DB00695,Furosemide
,34427339,elimination half-life,"The elimination half-life following IV, IM, and SC administration was 0.71 (0.67-0.76) h, 0.69 (0.61-0.74) h, and 0.70 (0.67-0.79) h, respectively.","Pharmacokinetics of furosemide in goats following intravenous, intramuscular, and subcutaneous administrations. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34427339/),h,0.70,10913,DB00695,Furosemide
,34427339,volume of distribution at steady state,"The volume of distribution at steady state and total clearance for the IV route were 0.17 (0.16-0.19) L/kg and 0.30 (0.27-0.33) L/h/kg, respectively.","Pharmacokinetics of furosemide in goats following intravenous, intramuscular, and subcutaneous administrations. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34427339/),[l] / [kg],0.17,10914,DB00695,Furosemide
,34427339,total clearance,"The volume of distribution at steady state and total clearance for the IV route were 0.17 (0.16-0.19) L/kg and 0.30 (0.27-0.33) L/h/kg, respectively.","Pharmacokinetics of furosemide in goats following intravenous, intramuscular, and subcutaneous administrations. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34427339/),[l] / [h·kg],0.30,10915,DB00695,Furosemide
,34427339,peak plasma concentrations,"The peak plasma concentrations of furosemide following IM and SC administrations were 11.19 (10.33-11.95) and 6.49 (5.92-7.00) μg/ml at 0.23 (0.16-0.25) and 0.39 (0.33-0.42) h, respectively.","Pharmacokinetics of furosemide in goats following intravenous, intramuscular, and subcutaneous administrations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34427339/),[μg] / [ml],11.19,10916,DB00695,Furosemide
,34427339,peak plasma concentrations,"The peak plasma concentrations of furosemide following IM and SC administrations were 11.19 (10.33-11.95) and 6.49 (5.92-7.00) μg/ml at 0.23 (0.16-0.25) and 0.39 (0.33-0.42) h, respectively.","Pharmacokinetics of furosemide in goats following intravenous, intramuscular, and subcutaneous administrations. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34427339/),[μg] / [ml],6.49,10917,DB00695,Furosemide
,34427339,bioavailability,"The bioavailability was 109.84 (104.92-116.99)% and 70.80 (55.77-86.67)% for the IM and SC routes, respectively.","Pharmacokinetics of furosemide in goats following intravenous, intramuscular, and subcutaneous administrations. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34427339/),%,109.84,10918,DB00695,Furosemide
,34427339,bioavailability,"The bioavailability was 109.84 (104.92-116.99)% and 70.80 (55.77-86.67)% for the IM and SC routes, respectively.","Pharmacokinetics of furosemide in goats following intravenous, intramuscular, and subcutaneous administrations. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34427339/),%,70.80,10919,DB00695,Furosemide
,16569489,flow rate,The flow rate was 3.5 ml/min and the effluent was monitored by fluorescence with excitation at 230 nm and emission at 410 nm.,Determination of furosemide in plasma and urine using monolithic silica rod liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16569489/),[ml] / [min],3.5,12425,DB00695,Furosemide
,16569489,retention times,"The retention times for the internal standard (naproxen) and for furosemide were 2.1 and 3.7 min, respectively, and total run time was 8 min.",Determination of furosemide in plasma and urine using monolithic silica rod liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16569489/),min,2.1,12426,DB00695,Furosemide
,16569489,retention times,"The retention times for the internal standard (naproxen) and for furosemide were 2.1 and 3.7 min, respectively, and total run time was 8 min.",Determination of furosemide in plasma and urine using monolithic silica rod liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16569489/),min,3.7,12427,DB00695,Furosemide
,16569489,total run time,"The retention times for the internal standard (naproxen) and for furosemide were 2.1 and 3.7 min, respectively, and total run time was 8 min.",Determination of furosemide in plasma and urine using monolithic silica rod liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16569489/),min,8,12428,DB00695,Furosemide
,3806372,urine outputs,"For example, mean 10-hr urine outputs were 646, 1046, 3156, and 1976 ml and mean 10-hr sodium excretions were 87.0, 142, 383, and 97.2 mmole for treatments I-IV, respectively.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous furosemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806372/),ml,646,13097,DB00695,Furosemide
,3806372,urine outputs,"For example, mean 10-hr urine outputs were 646, 1046, 3156, and 1976 ml and mean 10-hr sodium excretions were 87.0, 142, 383, and 97.2 mmole for treatments I-IV, respectively.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous furosemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806372/),ml,1046,13098,DB00695,Furosemide
,3806372,urine outputs,"For example, mean 10-hr urine outputs were 646, 1046, 3156, and 1976 ml and mean 10-hr sodium excretions were 87.0, 142, 383, and 97.2 mmole for treatments I-IV, respectively.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous furosemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806372/),ml,3156,13099,DB00695,Furosemide
,3806372,urine outputs,"For example, mean 10-hr urine outputs were 646, 1046, 3156, and 1976 ml and mean 10-hr sodium excretions were 87.0, 142, 383, and 97.2 mmole for treatments I-IV, respectively.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous furosemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806372/),ml,1976,13100,DB00695,Furosemide
,3806372,sodium excretions,"For example, mean 10-hr urine outputs were 646, 1046, 3156, and 1976 ml and mean 10-hr sodium excretions were 87.0, 142, 383, and 97.2 mmole for treatments I-IV, respectively.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous furosemide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806372/),mmole,87.0,13101,DB00695,Furosemide
,3806372,sodium excretions,"For example, mean 10-hr urine outputs were 646, 1046, 3156, and 1976 ml and mean 10-hr sodium excretions were 87.0, 142, 383, and 97.2 mmole for treatments I-IV, respectively.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous furosemide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806372/),mmole,142,13102,DB00695,Furosemide
,3806372,sodium excretions,"For example, mean 10-hr urine outputs were 646, 1046, 3156, and 1976 ml and mean 10-hr sodium excretions were 87.0, 142, 383, and 97.2 mmole for treatments I-IV, respectively.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous furosemide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806372/),mmole,383,13103,DB00695,Furosemide
,3806372,sodium excretions,"For example, mean 10-hr urine outputs were 646, 1046, 3156, and 1976 ml and mean 10-hr sodium excretions were 87.0, 142, 383, and 97.2 mmole for treatments I-IV, respectively.",Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous furosemide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3806372/),mmole,97.2,13104,DB00695,Furosemide
,8865375,AeAZ0,"After oral administration of azosemide, the values of AeAZ0 (591 vs 318 micrograms) and CLR (2.22 vs 0.875 mL/min/kg) decreased significantly in the water-deprived rats.",Effect of water deprivation for 48 hours on the pharmacokinetics and pharmacodynamics of azosemide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865375/),μg,591,13975,DB00695,Furosemide
,8865375,AeAZ0,"After oral administration of azosemide, the values of AeAZ0 (591 vs 318 micrograms) and CLR (2.22 vs 0.875 mL/min/kg) decreased significantly in the water-deprived rats.",Effect of water deprivation for 48 hours on the pharmacokinetics and pharmacodynamics of azosemide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865375/),μg,318,13976,DB00695,Furosemide
,8865375,CLR,"After oral administration of azosemide, the values of AeAZ0 (591 vs 318 micrograms) and CLR (2.22 vs 0.875 mL/min/kg) decreased significantly in the water-deprived rats.",Effect of water deprivation for 48 hours on the pharmacokinetics and pharmacodynamics of azosemide in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865375/),[ml] / [kg·min],2.22,13977,DB00695,Furosemide
,8865375,CLR,"After oral administration of azosemide, the values of AeAZ0 (591 vs 318 micrograms) and CLR (2.22 vs 0.875 mL/min/kg) decreased significantly in the water-deprived rats.",Effect of water deprivation for 48 hours on the pharmacokinetics and pharmacodynamics of azosemide in rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865375/),[ml] / [kg·min],0.875,13978,DB00695,Furosemide
,8865375,urine output,The 12-h urine output per g kidney was also reduced significantly in the water-deprived rats after both i.v. (70.3 vs 24.6 mL) and oral (70.7 and 20.7 mL) administration of azosemide.,Effect of water deprivation for 48 hours on the pharmacokinetics and pharmacodynamics of azosemide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865375/),ml,70.3,13979,DB00695,Furosemide
,8865375,urine output,The 12-h urine output per g kidney was also reduced significantly in the water-deprived rats after both i.v. (70.3 vs 24.6 mL) and oral (70.7 and 20.7 mL) administration of azosemide.,Effect of water deprivation for 48 hours on the pharmacokinetics and pharmacodynamics of azosemide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865375/),ml,24.6,13980,DB00695,Furosemide
,8865375,urine output,The 12-h urine output per g kidney was also reduced significantly in the water-deprived rats after both i.v. (70.3 vs 24.6 mL) and oral (70.7 and 20.7 mL) administration of azosemide.,Effect of water deprivation for 48 hours on the pharmacokinetics and pharmacodynamics of azosemide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865375/),ml,70.7,13981,DB00695,Furosemide
,8865375,urine output,The 12-h urine output per g kidney was also reduced significantly in the water-deprived rats after both i.v. (70.3 vs 24.6 mL) and oral (70.7 and 20.7 mL) administration of azosemide.,Effect of water deprivation for 48 hours on the pharmacokinetics and pharmacodynamics of azosemide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865375/),ml,20.7,13982,DB00695,Furosemide
,8865375,urine output,"The 12-h urine output per g kidney of i.v. and oral administration of azosemide in the control rats were similar (70.3 +/- 17.3 vs 70.7 +/- 13.8 mL), although the AeAZ0 after oral administration was significantly smaller than that after i.v. administration (473 +/- 98.5 vs 285 +/- 76.3 micrograms), and similar results were also obtained from the water-deprived rats.",Effect of water deprivation for 48 hours on the pharmacokinetics and pharmacodynamics of azosemide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865375/),ml,70.3,13983,DB00695,Furosemide
,8865375,urine output,"The 12-h urine output per g kidney of i.v. and oral administration of azosemide in the control rats were similar (70.3 +/- 17.3 vs 70.7 +/- 13.8 mL), although the AeAZ0 after oral administration was significantly smaller than that after i.v. administration (473 +/- 98.5 vs 285 +/- 76.3 micrograms), and similar results were also obtained from the water-deprived rats.",Effect of water deprivation for 48 hours on the pharmacokinetics and pharmacodynamics of azosemide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865375/),ml,70.7,13984,DB00695,Furosemide
,8865375,AeAZ0,"The 12-h urine output per g kidney of i.v. and oral administration of azosemide in the control rats were similar (70.3 +/- 17.3 vs 70.7 +/- 13.8 mL), although the AeAZ0 after oral administration was significantly smaller than that after i.v. administration (473 +/- 98.5 vs 285 +/- 76.3 micrograms), and similar results were also obtained from the water-deprived rats.",Effect of water deprivation for 48 hours on the pharmacokinetics and pharmacodynamics of azosemide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865375/),μg,473,13985,DB00695,Furosemide
,8865375,AeAZ0,"The 12-h urine output per g kidney of i.v. and oral administration of azosemide in the control rats were similar (70.3 +/- 17.3 vs 70.7 +/- 13.8 mL), although the AeAZ0 after oral administration was significantly smaller than that after i.v. administration (473 +/- 98.5 vs 285 +/- 76.3 micrograms), and similar results were also obtained from the water-deprived rats.",Effect of water deprivation for 48 hours on the pharmacokinetics and pharmacodynamics of azosemide in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8865375/),μg,285,13986,DB00695,Furosemide
,3941391,mean,"Intestinal perfusion studies were performed in six healthy volunteers during i.v. furosemide administration (mean serum concentration, 3.74 +/- 0.64 microgram/ml).",Clearance of furosemide by the gastrointestinal tract. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3941391/),[μg] / [ml],3.74,17356,DB00695,Furosemide
,3941391,serum concentration,"Intestinal perfusion studies were performed in six healthy volunteers during i.v. furosemide administration (mean serum concentration, 3.74 +/- 0.64 microgram/ml).",Clearance of furosemide by the gastrointestinal tract. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3941391/),[μg] / [ml],3.74,17357,DB00695,Furosemide
,3941391,clearance,Furosemide clearance for the total gastrointestinal tract was 2.1 +/- 0.4 ml/min (mean +/- S.E.M.) compared to a renal clearance of 93.1 +/- 4.6 ml/min.,Clearance of furosemide by the gastrointestinal tract. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3941391/),[ml] / [min],2.1,17358,DB00695,Furosemide
,3941391,renal clearance,Furosemide clearance for the total gastrointestinal tract was 2.1 +/- 0.4 ml/min (mean +/- S.E.M.) compared to a renal clearance of 93.1 +/- 4.6 ml/min.,Clearance of furosemide by the gastrointestinal tract. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3941391/),[ml] / [min],93.1,17359,DB00695,Furosemide
,31365489,half-life,Dehydration and hemorrhage accelerated redistribution but retarded the elimination; the half-life of the infused fluid increased from 36 to 51 min (mean) from 1 L of dehydration and to 95 min from 1 L of hemorrhage.,Kinetics of Ringer's Solution in Extracellular Dehydration and Hemorrhage. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31365489/),min,36 to 51,17861,DB00695,Furosemide
,31365489,half-life,Dehydration and hemorrhage accelerated redistribution but retarded the elimination; the half-life of the infused fluid increased from 36 to 51 min (mean) from 1 L of dehydration and to 95 min from 1 L of hemorrhage.,Kinetics of Ringer's Solution in Extracellular Dehydration and Hemorrhage. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31365489/),min,95,17862,DB00695,Furosemide
,9812177,peak concentrations (Cmax),Mean peak concentrations (Cmax) of 2.86 to 6.50 mg/L were achieved within 1.22 to 2.75 hours of administration.,Clinical pharmacokinetics of nimesulide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),[mg] / [l],2.86 to 6.50,18714,DB00695,Furosemide
,9812177,bioavailability,"When nimesulide was administered in the suppository form, the Cmax was lower and occurred later than after oral administration; the bioavailability of nimesulide via suppository ranged from 54 to 64%, relative to that of orally administered formulations.",Clinical pharmacokinetics of nimesulide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),%,54 to 64,18715,DB00695,Furosemide
,9812177,apparent volume of distribution,Nimesulide is rapidly distributed and has an apparent volume of distribution ranging between 0.18 and 0.39 L/kg.,Clinical pharmacokinetics of nimesulide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),[l] / [kg],0.18 and 0.39,18716,DB00695,Furosemide
,9812177,unbound fraction,It is extensively bound to albumin; the unbound fraction in plasma was 1%.,Clinical pharmacokinetics of nimesulide. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),%,1,18717,DB00695,Furosemide
,9812177,terminal elimination half-life,The estimated mean terminal elimination half-life varied from 1.80 to 4.73 hours.,Clinical pharmacokinetics of nimesulide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),h,1.80 to 4.73,18718,DB00695,Furosemide
,9812177,total plasma clearance,"The total plasma clearance of nimesulide, was 31.02 to 106.16 ml/h/kg, reflecting almost exclusive metabolic clearance.",Clinical pharmacokinetics of nimesulide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),[ml] / [h·kg],31.02 to 106.16,18719,DB00695,Furosemide
,9812177,extraction ratio,"The drug has a low extraction ratio, close to 0.1.",Clinical pharmacokinetics of nimesulide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9812177/),,0.1,18720,DB00695,Furosemide
,9737816,total body clearance,"After i.v. administration, the total body clearance (5.47 versus 7.05 mL min(-1) kg(-1)) was significantly slower in AIDRs and this was due to significantly slower renal clearance (2.35 versus 4.33 mL min(-1) kg(-1)) because the nonrenal clearance was comparable between two groups of rats.",Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737816/),[ml] / [kg·min],5.47,19765,DB00695,Furosemide
,9737816,total body clearance,"After i.v. administration, the total body clearance (5.47 versus 7.05 mL min(-1) kg(-1)) was significantly slower in AIDRs and this was due to significantly slower renal clearance (2.35 versus 4.33 mL min(-1) kg(-1)) because the nonrenal clearance was comparable between two groups of rats.",Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737816/),[ml] / [kg·min],7.05,19766,DB00695,Furosemide
,9737816,renal clearance,"After i.v. administration, the total body clearance (5.47 versus 7.05 mL min(-1) kg(-1)) was significantly slower in AIDRs and this was due to significantly slower renal clearance (2.35 versus 4.33 mL min(-1) kg(-1)) because the nonrenal clearance was comparable between two groups of rats.",Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737816/),[ml] / [kg·min],2.35,19767,DB00695,Furosemide
,9737816,renal clearance,"After i.v. administration, the total body clearance (5.47 versus 7.05 mL min(-1) kg(-1)) was significantly slower in AIDRs and this was due to significantly slower renal clearance (2.35 versus 4.33 mL min(-1) kg(-1)) because the nonrenal clearance was comparable between two groups of rats.",Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737816/),[ml] / [kg·min],4.33,19768,DB00695,Furosemide
,9737816,urinary excretion,The 8 h urinary excretion of furosemide after i.v. administration decreased significantly (2280 versus 3760 microg) in AIDRs due to impaired kidney function; the glomerular filtration rate measured by creatinine clearance was significantly slower (2.86 versus 4.33 mL min(-1) kg(-1)) and both the plasma urea nitrogen (43.5 versus 17.3 mg dL(-1)) and kidney weight (0.953 versus 0.749% of body weight) increased significantly in AIDRs.,Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737816/),μg,2280,19769,DB00695,Furosemide
,9737816,urinary excretion,The 8 h urinary excretion of furosemide after i.v. administration decreased significantly (2280 versus 3760 microg) in AIDRs due to impaired kidney function; the glomerular filtration rate measured by creatinine clearance was significantly slower (2.86 versus 4.33 mL min(-1) kg(-1)) and both the plasma urea nitrogen (43.5 versus 17.3 mg dL(-1)) and kidney weight (0.953 versus 0.749% of body weight) increased significantly in AIDRs.,Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737816/),μg,3760,19770,DB00695,Furosemide
,9737816,urine output,This resulted in a significant decrease in the 8 h urine output per g kidney (17.8 versus 43.6 mL) in AIDRs.,Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737816/),ml,17.8,19771,DB00695,Furosemide
,9737816,urine output,This resulted in a significant decrease in the 8 h urine output per g kidney (17.8 versus 43.6 mL) in AIDRs.,Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737816/),ml,43.6,19772,DB00695,Furosemide
,9737816,area under the plasma concentration-time curve from time 0 to 8 h,"After oral administration, the area under the plasma concentration-time curve from time 0 to 8 h decreased significantly in AIDRs (1200 versus 1910 microg x min mL(-1)) due to considerably decreased absorption of furosemide from gastrointestinal tract of AIDRs.",Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737816/),[min·μg] / [ml],1200,19773,DB00695,Furosemide
,9737816,area under the plasma concentration-time curve from time 0 to 8 h,"After oral administration, the area under the plasma concentration-time curve from time 0 to 8 h decreased significantly in AIDRs (1200 versus 1910 microg x min mL(-1)) due to considerably decreased absorption of furosemide from gastrointestinal tract of AIDRs.",Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737816/),[min·μg] / [ml],1910,19774,DB00695,Furosemide
,9737816,urine output per,"After oral administration, the 8 h urine output per g kidney (18.6 versus 36.4 mL) also decreased significantly in the AIDRs due to significantly decreased 8 h urinary excretion of furosemide (405 versus 2210 microg), however, the 8 h diuretic efficiency increased significantly (127 versus 35.2 mL mg(-1)) in AIDRs.",Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737816/),ml,18.6,19775,DB00695,Furosemide
,9737816,urine output per,"After oral administration, the 8 h urine output per g kidney (18.6 versus 36.4 mL) also decreased significantly in the AIDRs due to significantly decreased 8 h urinary excretion of furosemide (405 versus 2210 microg), however, the 8 h diuretic efficiency increased significantly (127 versus 35.2 mL mg(-1)) in AIDRs.",Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737816/),ml,36.4,19776,DB00695,Furosemide
,9737816,urinary excretion,"After oral administration, the 8 h urine output per g kidney (18.6 versus 36.4 mL) also decreased significantly in the AIDRs due to significantly decreased 8 h urinary excretion of furosemide (405 versus 2210 microg), however, the 8 h diuretic efficiency increased significantly (127 versus 35.2 mL mg(-1)) in AIDRs.",Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737816/),μg,405,19777,DB00695,Furosemide
,9737816,urinary excretion,"After oral administration, the 8 h urine output per g kidney (18.6 versus 36.4 mL) also decreased significantly in the AIDRs due to significantly decreased 8 h urinary excretion of furosemide (405 versus 2210 microg), however, the 8 h diuretic efficiency increased significantly (127 versus 35.2 mL mg(-1)) in AIDRs.",Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737816/),μg,2210,19778,DB00695,Furosemide
,9737816,efficiency,"After oral administration, the 8 h urine output per g kidney (18.6 versus 36.4 mL) also decreased significantly in the AIDRs due to significantly decreased 8 h urinary excretion of furosemide (405 versus 2210 microg), however, the 8 h diuretic efficiency increased significantly (127 versus 35.2 mL mg(-1)) in AIDRs.",Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737816/),[ml] / [mg],127,19779,DB00695,Furosemide
,9737816,efficiency,"After oral administration, the 8 h urine output per g kidney (18.6 versus 36.4 mL) also decreased significantly in the AIDRs due to significantly decreased 8 h urinary excretion of furosemide (405 versus 2210 microg), however, the 8 h diuretic efficiency increased significantly (127 versus 35.2 mL mg(-1)) in AIDRs.",Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737816/),[ml] / [mg],35.2,19780,DB00695,Furosemide
,24938850,clearance (CL),"The average parameter estimates, for a median body weight of 2170 g, were clearance (CL) 0.089 l h(-1) (CV 28%), central volume of distribution (Vc ) 0.908 l (CV 18%), intercompartmental clearance (Q) 0.157 l h(-1) and peripheral volume of distribution (Vp ) 0.560 l.",Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24938850/),[l] / [h],0.089,19891,DB00695,Furosemide
,24938850,central volume of distribution (Vc ),"The average parameter estimates, for a median body weight of 2170 g, were clearance (CL) 0.089 l h(-1) (CV 28%), central volume of distribution (Vc ) 0.908 l (CV 18%), intercompartmental clearance (Q) 0.157 l h(-1) and peripheral volume of distribution (Vp ) 0.560 l.",Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24938850/),l,0.908,19892,DB00695,Furosemide
,24938850,intercompartmental clearance (Q),"The average parameter estimates, for a median body weight of 2170 g, were clearance (CL) 0.089 l h(-1) (CV 28%), central volume of distribution (Vc ) 0.908 l (CV 18%), intercompartmental clearance (Q) 0.157 l h(-1) and peripheral volume of distribution (Vp ) 0.560 l.",Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24938850/),[l] / [h],0.157,19893,DB00695,Furosemide
,24938850,peripheral volume of distribution (Vp ),"The average parameter estimates, for a median body weight of 2170 g, were clearance (CL) 0.089 l h(-1) (CV 28%), central volume of distribution (Vc ) 0.908 l (CV 18%), intercompartmental clearance (Q) 0.157 l h(-1) and peripheral volume of distribution (Vp ) 0.560 l.",Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24938850/),l,0.560,19894,DB00695,Furosemide
,14643505,absolute recovery,The mean absolute recovery for human plasma was 93.5 +/- 4.2% for triflusal and 98.5 +/- 3.1% for HTB.,"Simultaneous determination of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in rat and human plasma by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14643505/),%,93.5,20535,DB00695,Furosemide
,14643505,absolute recovery,The mean absolute recovery for human plasma was 93.5 +/- 4.2% for triflusal and 98.5 +/- 3.1% for HTB.,"Simultaneous determination of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in rat and human plasma by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14643505/),%,98.5,20536,DB00695,Furosemide
,32411731,Tmax,"After rapid absorption (Tmax 0.5-1 h), 61% of the bioavailable torasemide was eliminated unchanged in urine.",Population Pharmacokinetics and Pharmacodynamics Modeling of Torasemide and Furosemide After Oral Repeated Administration in Healthy Dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32411731/),h,0.5-1,20904,DB00695,Furosemide
,32411731,diuresis,The average diuresis increased from baseline (220 ± 53 mL/day for 10 kg dogs) to 730 ±120 mL after the first torasemide administration and up to 1150 ± 252 mL after 10 administrations at the highest dose.,Population Pharmacokinetics and Pharmacodynamics Modeling of Torasemide and Furosemide After Oral Repeated Administration in Healthy Dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32411731/),[ml] / [d],220,20905,DB00695,Furosemide
,32411731,diuresis,The average diuresis increased from baseline (220 ± 53 mL/day for 10 kg dogs) to 730 ±120 mL after the first torasemide administration and up to 1150 ± 252 mL after 10 administrations at the highest dose.,Population Pharmacokinetics and Pharmacodynamics Modeling of Torasemide and Furosemide After Oral Repeated Administration in Healthy Dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32411731/),ml,730,20906,DB00695,Furosemide
,32411731,diuresis,The average diuresis increased from baseline (220 ± 53 mL/day for 10 kg dogs) to 730 ±120 mL after the first torasemide administration and up to 1150 ± 252 mL after 10 administrations at the highest dose.,Population Pharmacokinetics and Pharmacodynamics Modeling of Torasemide and Furosemide After Oral Repeated Administration in Healthy Dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32411731/),ml,1150,20907,DB00695,Furosemide
,32411731,net fluid loss,"For a daily target diuresis of 460 mL/dog/day in severe pulmonary oedema (net fluid loss 240 mL/dog/day), a computed dose of 0.26 mg/kg/day (3.5 mg/kg/day furosemide-equivalent) was selected for clinical studies.",Population Pharmacokinetics and Pharmacodynamics Modeling of Torasemide and Furosemide After Oral Repeated Administration in Healthy Dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32411731/),[ml] / [d·dog],240,20908,DB00695,Furosemide
,8033492,Absolute bioavailability,Absolute bioavailability was essentially 100%.,The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8033492/),%,100,21206,DB00695,Furosemide
,7379446,diuresis at steady state,Continuous intravenous infusion of furosemide (8 mg/hr) to 6 healthy subjects induced an average diuresis at steady state of 667 +/- 144 ml/30 min (+/- SD) with a mean plasma concentration of furosemide of 623 +/- 209 ng/ml.,Renal tubular secretion and effects of furosemide. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7379446/),[ml] / [30·min],667,22404,DB00695,Furosemide
,7379446,plasma concentration,Continuous intravenous infusion of furosemide (8 mg/hr) to 6 healthy subjects induced an average diuresis at steady state of 667 +/- 144 ml/30 min (+/- SD) with a mean plasma concentration of furosemide of 623 +/- 209 ng/ml.,Renal tubular secretion and effects of furosemide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7379446/),[ng] / [ml],623,22405,DB00695,Furosemide
,7379446,urinary output,"The urinary output of Cl- was 50.4 +/- 7.5, of Na+ 47.7 +/- 8.7, and of K+ 5.4 +/- 0.6 mmole/30 min.",Renal tubular secretion and effects of furosemide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7379446/),[mmole] / [30·min],50.4,22406,DB00695,Furosemide
,7379446,urinary output,"The urinary output of Cl- was 50.4 +/- 7.5, of Na+ 47.7 +/- 8.7, and of K+ 5.4 +/- 0.6 mmole/30 min.",Renal tubular secretion and effects of furosemide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7379446/),[mmole] / [30·min],47.7,22407,DB00695,Furosemide
,7379446,urinary output,"The urinary output of Cl- was 50.4 +/- 7.5, of Na+ 47.7 +/- 8.7, and of K+ 5.4 +/- 0.6 mmole/30 min.",Renal tubular secretion and effects of furosemide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7379446/),[mmole] / [30·min],5.4,22408,DB00695,Furosemide
,7379446,Na,"The urinary output of Cl- was 50.4 +/- 7.5, of Na+ 47.7 +/- 8.7, and of K+ 5.4 +/- 0.6 mmole/30 min.",Renal tubular secretion and effects of furosemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7379446/),[mmole] / [30·min],47.7,22409,DB00695,Furosemide
,7379446,Na,"The urinary output of Cl- was 50.4 +/- 7.5, of Na+ 47.7 +/- 8.7, and of K+ 5.4 +/- 0.6 mmole/30 min.",Renal tubular secretion and effects of furosemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7379446/),[mmole] / [30·min],5.4,22410,DB00695,Furosemide
,34038119,human half-life,"However, 2 projected to a short human half-life (∼5 h) that could necessitate more frequent than once a day dosing.","Discovery of MK-8153, a Potent and Selective ROMK Inhibitor and Novel Diuretic/Natriuretic. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34038119/),h,∼5,23104,DB00695,Furosemide
,34038119,human half-life,"This report describes the discovery of a new ROMK inhibitor 22e (MK-8153), with a longer projected human half-life (∼14 h), which should lead to a reduced peak-to-trough ratio, potentially extrapolating to more extended and better tolerated diuretic effects.","Discovery of MK-8153, a Potent and Selective ROMK Inhibitor and Novel Diuretic/Natriuretic. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34038119/),h,∼14,23105,DB00695,Furosemide
,7313302,equilibrium plasma/blood cell concentration ratios,"Furosemide was found to be stable in blood, and the equilibrium plasma/blood cell concentration ratios were about 1.5-2.0 at 0.1-50 micrograms/ml in blood.",Pharmacokinetics of drugs in blood II. Unusual distribution and storage effect of furosemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7313302/),,1.5-2.0,24267,DB00695,Furosemide
,6135581,alpha-,"The alpha-, beta-, and gamma-phase half-lives of 5.6, 22.3, and 158.5 min, respectively, were observed after the 0.5-mg/kg dose.",The pharmacology of furosemide in the horse. V. Pharmacokinetics and blood levels of furosemide after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6135581/),min,5.6,25186,DB00695,Furosemide
,6135581,beta-,"The alpha-, beta-, and gamma-phase half-lives of 5.6, 22.3, and 158.5 min, respectively, were observed after the 0.5-mg/kg dose.",The pharmacology of furosemide in the horse. V. Pharmacokinetics and blood levels of furosemide after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6135581/),min,22.3,25187,DB00695,Furosemide
,6135581,gamma-phase half-lives,"The alpha-, beta-, and gamma-phase half-lives of 5.6, 22.3, and 158.5 min, respectively, were observed after the 0.5-mg/kg dose.",The pharmacology of furosemide in the horse. V. Pharmacokinetics and blood levels of furosemide after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6135581/),min,158.5,25188,DB00695,Furosemide
,6135581,half-lives,"Similarly, the respective half-lives after the 1.0-mg/kg dose were 5.8, 24.1, and 177.2 min.",The pharmacology of furosemide in the horse. V. Pharmacokinetics and blood levels of furosemide after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6135581/),min,5.8,25189,DB00695,Furosemide
,6135581,half-lives,"Similarly, the respective half-lives after the 1.0-mg/kg dose were 5.8, 24.1, and 177.2 min.",The pharmacology of furosemide in the horse. V. Pharmacokinetics and blood levels of furosemide after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6135581/),min,24.1,25190,DB00695,Furosemide
,6135581,half-lives,"Similarly, the respective half-lives after the 1.0-mg/kg dose were 5.8, 24.1, and 177.2 min.",The pharmacology of furosemide in the horse. V. Pharmacokinetics and blood levels of furosemide after intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6135581/),min,177.2,25191,DB00695,Furosemide
,6135581,plasma level,The mean plasma level was 97.9 ng/ml with a range of 41.9 ng/ml to 155.8 ng/ml and a SD of 25.0 ng/ml.,The pharmacology of furosemide in the horse. V. Pharmacokinetics and blood levels of furosemide after intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6135581/),[ng] / [ml],97.9,25192,DB00695,Furosemide
,6135581,plasma level,The mean plasma level was 97.9 ng/ml with a range of 41.9 ng/ml to 155.8 ng/ml and a SD of 25.0 ng/ml.,The pharmacology of furosemide in the horse. V. Pharmacokinetics and blood levels of furosemide after intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6135581/),[ng] / [ml],155.8,25193,DB00695,Furosemide
,6135581,plasma level,The mean plasma level at 4 hr post-dosing was 9.6 ng/ml with a range of 4.0 ng/ml to 19.4 ng/ml and a SD of 3.1 ng/ml.,The pharmacology of furosemide in the horse. V. Pharmacokinetics and blood levels of furosemide after intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6135581/),[ng] / [ml],9.6,25194,DB00695,Furosemide
,6135581,plasma level,The mean plasma level at 4 hr post-dosing was 9.6 ng/ml with a range of 4.0 ng/ml to 19.4 ng/ml and a SD of 3.1 ng/ml.,The pharmacology of furosemide in the horse. V. Pharmacokinetics and blood levels of furosemide after intravenous administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6135581/),[ng] / [ml],19.4,25195,DB00695,Furosemide
,12793843,Area under the concentration-time curve (AUC(tau)),Area under the concentration-time curve (AUC(tau)) over the 12-hour dosage interval was about 30-40% lower than in healthy volunteers (33.90 vs 49.60 mg.,Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),mg,33.90,25881,DB00695,Furosemide
,12793843,Area under the concentration-time curve (AUC(tau)),Area under the concentration-time curve (AUC(tau)) over the 12-hour dosage interval was about 30-40% lower than in healthy volunteers (33.90 vs 49.60 mg.,Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),mg,49.60,25882,DB00695,Furosemide
,12793843,clearance,"The reduced exposure may be due to a greater clearance of levofloxacin (0.204 vs 0.145 L/h/kg [3.40 vs 2.42 mL/min/kg]), leading to a shorter elimination half-life (5.2 vs 7.6 hours).",Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),[l] / [h·kg],0.204,25883,DB00695,Furosemide
,12793843,clearance,"The reduced exposure may be due to a greater clearance of levofloxacin (0.204 vs 0.145 L/h/kg [3.40 vs 2.42 mL/min/kg]), leading to a shorter elimination half-life (5.2 vs 7.6 hours).",Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),[l] / [h·kg],0.145,25884,DB00695,Furosemide
,12793843,clearance,"The reduced exposure may be due to a greater clearance of levofloxacin (0.204 vs 0.145 L/h/kg [3.40 vs 2.42 mL/min/kg]), leading to a shorter elimination half-life (5.2 vs 7.6 hours).",Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),[ml] / [kg·min],3.40,25885,DB00695,Furosemide
,12793843,clearance,"The reduced exposure may be due to a greater clearance of levofloxacin (0.204 vs 0.145 L/h/kg [3.40 vs 2.42 mL/min/kg]), leading to a shorter elimination half-life (5.2 vs 7.6 hours).",Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),[ml] / [kg·min],2.42,25886,DB00695,Furosemide
,12793843,elimination half-life,"The reduced exposure may be due to a greater clearance of levofloxacin (0.204 vs 0.145 L/h/kg [3.40 vs 2.42 mL/min/kg]), leading to a shorter elimination half-life (5.2 vs 7.6 hours).",Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),h,5.2,25887,DB00695,Furosemide
,12793843,elimination half-life,"The reduced exposure may be due to a greater clearance of levofloxacin (0.204 vs 0.145 L/h/kg [3.40 vs 2.42 mL/min/kg]), leading to a shorter elimination half-life (5.2 vs 7.6 hours).",Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),h,7.6,25888,DB00695,Furosemide
,12793843,C(max)/MIC (maximum plasma concentration/minimum inhibitory concentration) ratio,Intravenous levofloxacin 500mg twice daily ensured a median C(max)/MIC (maximum plasma concentration/minimum inhibitory concentration) ratio of 102 and a median 24-hour AUC/MIC ratio of 930 SIT(-1).,Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),,102,25889,DB00695,Furosemide
,12793843,24-hour,Intravenous levofloxacin 500mg twice daily ensured a median C(max)/MIC (maximum plasma concentration/minimum inhibitory concentration) ratio of 102 and a median 24-hour AUC/MIC ratio of 930 SIT(-1).,Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),1/[sit],930,25890,DB00695,Furosemide
,12793843,AUC/MIC ratio,Intravenous levofloxacin 500mg twice daily ensured a median C(max)/MIC (maximum plasma concentration/minimum inhibitory concentration) ratio of 102 and a median 24-hour AUC/MIC ratio of 930 SIT(-1).,Pharmacokinetics and pharmacodynamics of intravenous levofloxacin in patients with early-onset ventilator-associated pneumonia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12793843/),1/[sit],930,25891,DB00695,Furosemide
,436918,t 1/2 a,"The alpha-phase (distribution phase) lasted until 12-16 h after administration and the mean t 1/2 a was 3.6 h (range 2.3-4.7) in patients, and 2.6 h (range 2.3-2.9) in healthy subjects.",Pharmacokinetics of a single oral dose of muzolimine in cardiac failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/436918/),h,3.6,29190,DB00695,Furosemide
,436918,t 1/2 a,"The alpha-phase (distribution phase) lasted until 12-16 h after administration and the mean t 1/2 a was 3.6 h (range 2.3-4.7) in patients, and 2.6 h (range 2.3-2.9) in healthy subjects.",Pharmacokinetics of a single oral dose of muzolimine in cardiac failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/436918/),h,2.6,29191,DB00695,Furosemide
,436918,t 1/2 beta,The mean t 1/2 beta was 13.5 h (range 7.4-22.4) in the patients and 14.0 h (range 12.4-14.6) in healthy subjects.,Pharmacokinetics of a single oral dose of muzolimine in cardiac failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/436918/),h,13.5,29192,DB00695,Furosemide
,436918,t 1/2 beta,The mean t 1/2 beta was 13.5 h (range 7.4-22.4) in the patients and 14.0 h (range 12.4-14.6) in healthy subjects.,Pharmacokinetics of a single oral dose of muzolimine in cardiac failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/436918/),h,14.0,29193,DB00695,Furosemide
,436918,renal clearance,The renal clearance of muzolimine was in the range 2.7-15.3 ml . min-1 in 5 subjects in whom it was investigated.,Pharmacokinetics of a single oral dose of muzolimine in cardiac failure. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/436918/),[ml] / [min],2.7-15.3,29194,DB00695,Furosemide
,2699047,urinary excretion,The urinary excretion of thromboxane B2 was elevated in older subjects (58 +/- 10 vs.,Effects of aging on responses to furosemide. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2699047/),,58,30018,DB00695,Furosemide
,8832915,nonrenal clearance,"The nonrenal clearance of furosemide (2.20 versus 3.53 ml/min/kg) increased significantly, and the 24 h-urinary excretion of furosemide (both the amount and percentages of iv dose) decreased significantly in the YH-439 treated rats when compared with those in the control rats.","Effect of a hepatoprotective agent, YH-439, on the pharmacokinetics of furosemide and azosemide in rats. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8832915/),[ml] / [kg·min],2.20,30378,DB00695,Furosemide
,8832915,nonrenal clearance,"The nonrenal clearance of furosemide (2.20 versus 3.53 ml/min/kg) increased significantly, and the 24 h-urinary excretion of furosemide (both the amount and percentages of iv dose) decreased significantly in the YH-439 treated rats when compared with those in the control rats.","Effect of a hepatoprotective agent, YH-439, on the pharmacokinetics of furosemide and azosemide in rats. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8832915/),[ml] / [kg·min],3.53,30379,DB00695,Furosemide
,23300400,half-life,The patient population had an average half-life of 5.9±1.2 hr and a Vd of 0.4±0.12 L/kg.,An assessment of vancomycin pharmacokinetic variability in pediatric cardiology patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23300400/),h,5.9,31006,DB00695,Furosemide
,23300400,Vd,The patient population had an average half-life of 5.9±1.2 hr and a Vd of 0.4±0.12 L/kg.,An assessment of vancomycin pharmacokinetic variability in pediatric cardiology patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23300400/),[l] / [kg],0.4,31007,DB00695,Furosemide
,21963480,flow rate,"Chromatographic resolution was achieved using a RP-C(18) column (Atlantis, Waters, 150 mm × 4.6 mm, 5 μm) at a flow rate of 1.0 mL min(-1) and an injection volume of 30 μL.",Reversed phase liquid chromatography method with fluorescence detection of gemifloxacin in rat plasma and its application to the pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21963480/),[ml] / [min],1.0,31259,DB00695,Furosemide
,21963480,injection volume,"Chromatographic resolution was achieved using a RP-C(18) column (Atlantis, Waters, 150 mm × 4.6 mm, 5 μm) at a flow rate of 1.0 mL min(-1) and an injection volume of 30 μL.",Reversed phase liquid chromatography method with fluorescence detection of gemifloxacin in rat plasma and its application to the pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21963480/),μl,30,31260,DB00695,Furosemide
,21963480,retention times,"The retention times for GEM and I.S. were approximately 7.5 and 12.6 min, respectively.",Reversed phase liquid chromatography method with fluorescence detection of gemifloxacin in rat plasma and its application to the pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21963480/),min,7.5,31261,DB00695,Furosemide
,21963480,retention times,"The retention times for GEM and I.S. were approximately 7.5 and 12.6 min, respectively.",Reversed phase liquid chromatography method with fluorescence detection of gemifloxacin in rat plasma and its application to the pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21963480/),min,12.6,31262,DB00695,Furosemide
greater,21963480,recovery,The recovery of GEM and I.S. from plasma was greater than 90%.,Reversed phase liquid chromatography method with fluorescence detection of gemifloxacin in rat plasma and its application to the pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21963480/),%,90,31263,DB00695,Furosemide
,6107232,Total plasma clearance,"Total plasma clearance averaged 164 +/- 26 (SD) ml/min, of which 66.2 +/- 6.8% represented renal clearance of unchanged drug.","Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite-specific assay. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6107232/),[ml] / [min],164,32026,DB00695,Furosemide
,6107232,Volume of distribution (steady-state),Volume of distribution (steady-state) was 109 +/- 19 ml/kg.,"Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite-specific assay. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6107232/),[ml] / [kg],109,32027,DB00695,Furosemide
,6107232,absolute bioavailability,"The mean absolute bioavailability of furosemide was 42.8 and 44.0%, as calculated from plasma and urine data, respectively.","Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite-specific assay. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6107232/),%,42.8,32028,DB00695,Furosemide
,6107232,absolute bioavailability,"The mean absolute bioavailability of furosemide was 42.8 and 44.0%, as calculated from plasma and urine data, respectively.","Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite-specific assay. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6107232/),%,44.0,32029,DB00695,Furosemide
,6107232,Protein binding,Protein binding of furosemide in vivo was determined by a spectrofluorimetric HPLC assay and ranged from 98.5 to 99.1%.,"Absorption and disposition of furosemide in healthy volunteers, measured with a metabolite-specific assay. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6107232/),%,98.5 to 99.1,32030,DB00695,Furosemide
,19640235,heart rate,"Two hours after admission, vital signs were blood pressure 259/107 mmHg and heart rate 140 beats/min.",Acute neurotoxicity after yohimbine ingestion by a body builder. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19640235/),[beats] / [min],140,34374,DB00695,Furosemide
,19640235,blood levels,"The yohimbine blood levels at 3, 6, 14, and 22 h after ingestion were 5,240; 2,250; 1,530; and 865 ng/mL, respectively, with a mean half-life of 2 h.",Acute neurotoxicity after yohimbine ingestion by a body builder. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19640235/),,"1,530",34375,DB00695,Furosemide
,19640235,blood levels,"The yohimbine blood levels at 3, 6, 14, and 22 h after ingestion were 5,240; 2,250; 1,530; and 865 ng/mL, respectively, with a mean half-life of 2 h.",Acute neurotoxicity after yohimbine ingestion by a body builder. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19640235/),,865,34376,DB00695,Furosemide
,19640235,half-life,"The yohimbine blood levels at 3, 6, 14, and 22 h after ingestion were 5,240; 2,250; 1,530; and 865 ng/mL, respectively, with a mean half-life of 2 h.",Acute neurotoxicity after yohimbine ingestion by a body builder. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19640235/),h,2,34377,DB00695,Furosemide
,1300128,half-life,"From the urinary excretion data, a slope that indicates a slow elimination was found with a half-life of 12 hours approximately.",Bioavailability study of furosemide prodrugs in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1300128/),h,12,36133,DB00695,Furosemide
,7143205,total body clearance rate,"The pharmacokinetics of intravenous furosemide were studied, determining a total body clearance rate of 117.6 +/- 41.3 ml/min and a harmonic mean half-life of 78 min.",Disposition and absolute bioavailability of furosemide in healthy males. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7143205/),[ml] / [min],117.6,36802,DB00695,Furosemide
,7143205,half-life,"The pharmacokinetics of intravenous furosemide were studied, determining a total body clearance rate of 117.6 +/- 41.3 ml/min and a harmonic mean half-life of 78 min.",Disposition and absolute bioavailability of furosemide in healthy males. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7143205/),min,78,36803,DB00695,Furosemide
,7143205,absolute bioavailability,"The mean absolute bioavailability determined by ratio of areas under the plasma-time curves was 64 and 71% for the solution and tablet, respectively.",Disposition and absolute bioavailability of furosemide in healthy males. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7143205/),%,64,36804,DB00695,Furosemide
,7143205,absolute bioavailability,"The mean absolute bioavailability determined by ratio of areas under the plasma-time curves was 64 and 71% for the solution and tablet, respectively.",Disposition and absolute bioavailability of furosemide in healthy males. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7143205/),%,71,36805,DB00695,Furosemide
,7143205,absolute bioavailability,"The mean absolute bioavailability determined by the ratio of urinary cumulative excretion data was 61 and 66% for the solution and tablet, respectively.",Disposition and absolute bioavailability of furosemide in healthy males. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7143205/),%,61,36806,DB00695,Furosemide
,7143205,absolute bioavailability,"The mean absolute bioavailability determined by the ratio of urinary cumulative excretion data was 61 and 66% for the solution and tablet, respectively.",Disposition and absolute bioavailability of furosemide in healthy males. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7143205/),%,66,36807,DB00695,Furosemide
,1712713,tau,tau averaged 6 hours and was independent of CLcr.,The loop diuretic torasemide in chronic renal failure. Pharmacokinetics and pharmacodynamics. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1712713/),h,6,37324,DB00695,Furosemide
,1712713,half-life (t1/2),"The mean half-life (t1/2) of torasemide was approximately 5 hours and was independent of renal function, since renal clearance accounted for only around 25% of total body clearance.",The loop diuretic torasemide in chronic renal failure. Pharmacokinetics and pharmacodynamics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1712713/),h,5,37325,DB00695,Furosemide
,2352168,recoveries,"The recoveries from plasma were 94.3, 92.9, and 95.6%, and from urine were 77.5, 66.6, and 76.5% for torsemide and metabolites M1 and M5, respectively.",Solid-phase extraction and liquid chromatography of torsemide and metabolites from plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2352168/),%,94.3,41055,DB00695,Furosemide
,2352168,recoveries,"The recoveries from plasma were 94.3, 92.9, and 95.6%, and from urine were 77.5, 66.6, and 76.5% for torsemide and metabolites M1 and M5, respectively.",Solid-phase extraction and liquid chromatography of torsemide and metabolites from plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2352168/),%,92.9,41056,DB00695,Furosemide
,2352168,recoveries,"The recoveries from plasma were 94.3, 92.9, and 95.6%, and from urine were 77.5, 66.6, and 76.5% for torsemide and metabolites M1 and M5, respectively.",Solid-phase extraction and liquid chromatography of torsemide and metabolites from plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2352168/),%,95.6,41057,DB00695,Furosemide
,2352168,recoveries,"The recoveries from plasma were 94.3, 92.9, and 95.6%, and from urine were 77.5, 66.6, and 76.5% for torsemide and metabolites M1 and M5, respectively.",Solid-phase extraction and liquid chromatography of torsemide and metabolites from plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2352168/),%,77.5,41058,DB00695,Furosemide
,2352168,recoveries,"The recoveries from plasma were 94.3, 92.9, and 95.6%, and from urine were 77.5, 66.6, and 76.5% for torsemide and metabolites M1 and M5, respectively.",Solid-phase extraction and liquid chromatography of torsemide and metabolites from plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2352168/),%,66.6,41059,DB00695,Furosemide
,2352168,recoveries,"The recoveries from plasma were 94.3, 92.9, and 95.6%, and from urine were 77.5, 66.6, and 76.5% for torsemide and metabolites M1 and M5, respectively.",Solid-phase extraction and liquid chromatography of torsemide and metabolites from plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2352168/),%,76.5,41060,DB00695,Furosemide
,8368606,t1/2 alpha,"After IV administration, digoxin disposition was described by a 2-compartment model, with a rapid distribution phase (t1/2 alpha = 0.17 hour), followed by a slower elimination phase (beta = 0.096 +/- 0.055 h-1, t1/2 beta = 7.2 hours, where beta is the exponential term from the elimination phase of the concentration vs time curve).",Pharmacokinetics of digoxin administered to horses with congestive heart failure. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368606/),h,0.17,41405,DB00695,Furosemide
,8368606,beta,"After IV administration, digoxin disposition was described by a 2-compartment model, with a rapid distribution phase (t1/2 alpha = 0.17 hour), followed by a slower elimination phase (beta = 0.096 +/- 0.055 h-1, t1/2 beta = 7.2 hours, where beta is the exponential term from the elimination phase of the concentration vs time curve).",Pharmacokinetics of digoxin administered to horses with congestive heart failure. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368606/),1/[h],0.096,41406,DB00695,Furosemide
,8368606,t1/2 beta,"After IV administration, digoxin disposition was described by a 2-compartment model, with a rapid distribution phase (t1/2 alpha = 0.17 hour), followed by a slower elimination phase (beta = 0.096 +/- 0.055 h-1, t1/2 beta = 7.2 hours, where beta is the exponential term from the elimination phase of the concentration vs time curve).",Pharmacokinetics of digoxin administered to horses with congestive heart failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368606/),h,7.2,41407,DB00695,Furosemide
,8368606,Bioavailability,Bioavailability after oral administration was 21.2 +/- 10.8%.,Pharmacokinetics of digoxin administered to horses with congestive heart failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8368606/),%,21.2,41408,DB00695,Furosemide
less,7952799,relative bioavailabilities,The dose-adjusted relative bioavailabilities of the furosemide-charcoal formulations (compared to the reference formulation) remained less than 10%.,Desorption of furosemide from charcoal in vitro and in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7952799/),%,10,41756,DB00695,Furosemide
,12907285,AUC(0- infinity ),The highest AUC(0- infinity ) (3050 micro g l(-1) h) for furosemide (40 mg) was achieved with granules containing 80% MCCh of 150 kDa M(w).,Evaluation of microcrystalline chitosans for gastro-retentive drug delivery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12907285/),[h·μg] / [l],3050,41877,DB00695,Furosemide
,12907285,AUC(0- infinity ),With MCCh of 240 kDa M(w) AUC(0- infinity ) was 1890 micro g l(-1) h.,Evaluation of microcrystalline chitosans for gastro-retentive drug delivery. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12907285/),[h·μg] / [l],1890,41878,DB00695,Furosemide
,29189185,entrapment efficiency,"SLNs of F9 (GMS: Span 60: Pluronic F 68 in 6:2.5:0.2) were optimized for incorporating in to transdermal system (entrapment efficiency 96.5±0.045%, particle size 69.6±1.48nm and in vitro release 94.38±1.02%).",Enhanced Both in vitro and in vivo Kinetics by SLNs Induced Transdermal System of Furosemide: A Novel Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29189185/),%,96.5,42223,DB00695,Furosemide
,29189185,flux,Formulation FS1 (HPMC 4 parts) was optimized for further studies (in vitro release 98.11±1.21% with flux of 58.726±0.023µg/cm2/h) and no significant difference from ex vivo permeation studies was observed.,Enhanced Both in vitro and in vivo Kinetics by SLNs Induced Transdermal System of Furosemide: A Novel Approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29189185/),[μg] / [cm2·h],58.726,42224,DB00695,Furosemide
,16702900,Half-life,"Half-life of lithium in serum was 3.5 +/- 0.8 hours during the first HD, and 29 +/- 14 and 29 +/- 6 hours during therapy with diuretics or supportive treatment, respectively.",Lithium poisoning: pharmacokinetics and clearance during different therapeutic measures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16702900/),h,3.5,42337,DB00695,Furosemide
,16702900,Half-life,"Half-life of lithium in serum was 3.5 +/- 0.8 hours during the first HD, and 29 +/- 14 and 29 +/- 6 hours during therapy with diuretics or supportive treatment, respectively.",Lithium poisoning: pharmacokinetics and clearance during different therapeutic measures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16702900/),h,29,42338,DB00695,Furosemide
,16702900,Half-life,"Half-life of lithium in serum was 3.5 +/- 0.8 hours during the first HD, and 29 +/- 14 and 29 +/- 6 hours during therapy with diuretics or supportive treatment, respectively.",Lithium poisoning: pharmacokinetics and clearance during different therapeutic measures. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16702900/),h,29,42339,DB00695,Furosemide
,16702900,clearance,"Lithium clearance during HD was 160 +/- 15 mL/min, and renal clearance during HD or treatment with diuretics was approximately 20 and 15 +/- 9 mL/min, respectively.",Lithium poisoning: pharmacokinetics and clearance during different therapeutic measures. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16702900/),[ml] / [min],160,42340,DB00695,Furosemide
,16702900,renal clearance,"Lithium clearance during HD was 160 +/- 15 mL/min, and renal clearance during HD or treatment with diuretics was approximately 20 and 15 +/- 9 mL/min, respectively.",Lithium poisoning: pharmacokinetics and clearance during different therapeutic measures. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16702900/),[ml] / [min],20,42341,DB00695,Furosemide
,16702900,renal clearance,"Lithium clearance during HD was 160 +/- 15 mL/min, and renal clearance during HD or treatment with diuretics was approximately 20 and 15 +/- 9 mL/min, respectively.",Lithium poisoning: pharmacokinetics and clearance during different therapeutic measures. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16702900/),[ml] / [min],15,42342,DB00695,Furosemide
,3828484,Vss,"The mean values for Vss were 0.334, 0.478, 0.499, and 0.708 1 kg-1 for 10 s, 30 min, 2 h, and 8 h of infusion, respectively, and the corresponding values for MRT were 17.5, 22.2, 24.8, and 38.1 min.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of furosemide. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828484/),[1] / [kg],0.334,43293,DB00695,Furosemide
,3828484,Vss,"The mean values for Vss were 0.334, 0.478, 0.499, and 0.708 1 kg-1 for 10 s, 30 min, 2 h, and 8 h of infusion, respectively, and the corresponding values for MRT were 17.5, 22.2, 24.8, and 38.1 min.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of furosemide. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828484/),[1] / [kg],0.478,43294,DB00695,Furosemide
,3828484,Vss,"The mean values for Vss were 0.334, 0.478, 0.499, and 0.708 1 kg-1 for 10 s, 30 min, 2 h, and 8 h of infusion, respectively, and the corresponding values for MRT were 17.5, 22.2, 24.8, and 38.1 min.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of furosemide. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828484/),[1] / [kg],0.499,43295,DB00695,Furosemide
,3828484,Vss,"The mean values for Vss were 0.334, 0.478, 0.499, and 0.708 1 kg-1 for 10 s, 30 min, 2 h, and 8 h of infusion, respectively, and the corresponding values for MRT were 17.5, 22.2, 24.8, and 38.1 min.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of furosemide. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828484/),[1] / [kg],0.708,43296,DB00695,Furosemide
,3828484,MRT,"The mean values for Vss were 0.334, 0.478, 0.499, and 0.708 1 kg-1 for 10 s, 30 min, 2 h, and 8 h of infusion, respectively, and the corresponding values for MRT were 17.5, 22.2, 24.8, and 38.1 min.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of furosemide. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828484/),min,17.5,43297,DB00695,Furosemide
,3828484,MRT,"The mean values for Vss were 0.334, 0.478, 0.499, and 0.708 1 kg-1 for 10 s, 30 min, 2 h, and 8 h of infusion, respectively, and the corresponding values for MRT were 17.5, 22.2, 24.8, and 38.1 min.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of furosemide. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828484/),min,22.2,43298,DB00695,Furosemide
,3828484,MRT,"The mean values for Vss were 0.334, 0.478, 0.499, and 0.708 1 kg-1 for 10 s, 30 min, 2 h, and 8 h of infusion, respectively, and the corresponding values for MRT were 17.5, 22.2, 24.8, and 38.1 min.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of furosemide. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828484/),min,24.8,43299,DB00695,Furosemide
,3828484,MRT,"The mean values for Vss were 0.334, 0.478, 0.499, and 0.708 1 kg-1 for 10 s, 30 min, 2 h, and 8 h of infusion, respectively, and the corresponding values for MRT were 17.5, 22.2, 24.8, and 38.1 min.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of furosemide. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828484/),min,38.1,43300,DB00695,Furosemide
,3828484,urine outputs,"The diuretic effects (urine output and urinary excretion of sodium) were generally found to increase with increasing infusion times; the total mean 24 h urine outputs were 1102, 1464, 2190, and 3470 ml for 10 s, 30 min, 2 h, and 8 h of infusion, respectively, and the corresponding values for sodium excretion were 170, 175, 272, and 440 mmol.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of furosemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828484/),ml,1102,43301,DB00695,Furosemide
,3828484,urine outputs,"The diuretic effects (urine output and urinary excretion of sodium) were generally found to increase with increasing infusion times; the total mean 24 h urine outputs were 1102, 1464, 2190, and 3470 ml for 10 s, 30 min, 2 h, and 8 h of infusion, respectively, and the corresponding values for sodium excretion were 170, 175, 272, and 440 mmol.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of furosemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828484/),ml,1464,43302,DB00695,Furosemide
,3828484,urine outputs,"The diuretic effects (urine output and urinary excretion of sodium) were generally found to increase with increasing infusion times; the total mean 24 h urine outputs were 1102, 1464, 2190, and 3470 ml for 10 s, 30 min, 2 h, and 8 h of infusion, respectively, and the corresponding values for sodium excretion were 170, 175, 272, and 440 mmol.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of furosemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828484/),ml,2190,43303,DB00695,Furosemide
,3828484,urine outputs,"The diuretic effects (urine output and urinary excretion of sodium) were generally found to increase with increasing infusion times; the total mean 24 h urine outputs were 1102, 1464, 2190, and 3470 ml for 10 s, 30 min, 2 h, and 8 h of infusion, respectively, and the corresponding values for sodium excretion were 170, 175, 272, and 440 mmol.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of furosemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828484/),ml,3470,43304,DB00695,Furosemide
,3828484,sodium,"The diuretic effects (urine output and urinary excretion of sodium) were generally found to increase with increasing infusion times; the total mean 24 h urine outputs were 1102, 1464, 2190, and 3470 ml for 10 s, 30 min, 2 h, and 8 h of infusion, respectively, and the corresponding values for sodium excretion were 170, 175, 272, and 440 mmol.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of furosemide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828484/),mM,170,43305,DB00695,Furosemide
,3828484,excretion,"The diuretic effects (urine output and urinary excretion of sodium) were generally found to increase with increasing infusion times; the total mean 24 h urine outputs were 1102, 1464, 2190, and 3470 ml for 10 s, 30 min, 2 h, and 8 h of infusion, respectively, and the corresponding values for sodium excretion were 170, 175, 272, and 440 mmol.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of furosemide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828484/),mM,170,43306,DB00695,Furosemide
,3828484,excretion,"The diuretic effects (urine output and urinary excretion of sodium) were generally found to increase with increasing infusion times; the total mean 24 h urine outputs were 1102, 1464, 2190, and 3470 ml for 10 s, 30 min, 2 h, and 8 h of infusion, respectively, and the corresponding values for sodium excretion were 170, 175, 272, and 440 mmol.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of furosemide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828484/),mM,175,43307,DB00695,Furosemide
,3828484,excretion,"The diuretic effects (urine output and urinary excretion of sodium) were generally found to increase with increasing infusion times; the total mean 24 h urine outputs were 1102, 1464, 2190, and 3470 ml for 10 s, 30 min, 2 h, and 8 h of infusion, respectively, and the corresponding values for sodium excretion were 170, 175, 272, and 440 mmol.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of furosemide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828484/),mM,272,43308,DB00695,Furosemide
,3828484,excretion,"The diuretic effects (urine output and urinary excretion of sodium) were generally found to increase with increasing infusion times; the total mean 24 h urine outputs were 1102, 1464, 2190, and 3470 ml for 10 s, 30 min, 2 h, and 8 h of infusion, respectively, and the corresponding values for sodium excretion were 170, 175, 272, and 440 mmol.",Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of furosemide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3828484/),mM,440,43309,DB00695,Furosemide
,109903,half-life,The major disposition phase in dogs has a half-life or approximately 30 minutes and is followed by a slow elimination phase with a half-life of approximately 7 hours.,Plasma and tissue levels of furosemide in dogs and monkeys following single and multiple oral doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/109903/),min,30,44577,DB00695,Furosemide
,109903,half-life,The major disposition phase in dogs has a half-life or approximately 30 minutes and is followed by a slow elimination phase with a half-life of approximately 7 hours.,Plasma and tissue levels of furosemide in dogs and monkeys following single and multiple oral doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/109903/),h,7,44578,DB00695,Furosemide
,109903,half-life,"In the monkey studies, the rapid disposition phase was not observed and the slow disposition phase had a half-life of approximately 11 hours.",Plasma and tissue levels of furosemide in dogs and monkeys following single and multiple oral doses. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/109903/),h,11,44579,DB00695,Furosemide
,3378804,maximum measured levels,The maximum measured levels of boric acid and cinchocaine chloride approximately 6 h after ingestion were 26 micrograms/ml and 71 ng/ml respectively.,Combined boric acid and cinchocaine chloride poisoning in a 12-month-old infant: evaluation of haemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378804/),[μg] / [ml],26,45549,DB00695,Furosemide
,3378804,maximum measured levels,The maximum measured levels of boric acid and cinchocaine chloride approximately 6 h after ingestion were 26 micrograms/ml and 71 ng/ml respectively.,Combined boric acid and cinchocaine chloride poisoning in a 12-month-old infant: evaluation of haemodialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378804/),[ng] / [ml],71,45550,DB00695,Furosemide
,3378804,plasma half-life,The plasma half-life of boric acid was 7.0 h and decreased to 3.6 and 4.4 h during the two haemodialyses.,Combined boric acid and cinchocaine chloride poisoning in a 12-month-old infant: evaluation of haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378804/),h,7.0,45551,DB00695,Furosemide
,3378804,plasma half-life,The plasma half-life of boric acid was 7.0 h and decreased to 3.6 and 4.4 h during the two haemodialyses.,Combined boric acid and cinchocaine chloride poisoning in a 12-month-old infant: evaluation of haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378804/),h,3.6,45552,DB00695,Furosemide
,3378804,plasma half-life,The plasma half-life of boric acid was 7.0 h and decreased to 3.6 and 4.4 h during the two haemodialyses.,Combined boric acid and cinchocaine chloride poisoning in a 12-month-old infant: evaluation of haemodialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378804/),h,4.4,45553,DB00695,Furosemide
,3378804,total body clearance,The total body clearance of boric acid increased correspondingly from 21 ml/min to 41 and 34 ml/min.,Combined boric acid and cinchocaine chloride poisoning in a 12-month-old infant: evaluation of haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378804/),[ml] / [min],21,45554,DB00695,Furosemide
,3378804,total body clearance,The total body clearance of boric acid increased correspondingly from 21 ml/min to 41 and 34 ml/min.,Combined boric acid and cinchocaine chloride poisoning in a 12-month-old infant: evaluation of haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378804/),[ml] / [min],41,45555,DB00695,Furosemide
,3378804,total body clearance,The total body clearance of boric acid increased correspondingly from 21 ml/min to 41 and 34 ml/min.,Combined boric acid and cinchocaine chloride poisoning in a 12-month-old infant: evaluation of haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378804/),[ml] / [min],34,45556,DB00695,Furosemide
,3378804,clearance,The in vitro clearance of boric acid of the dialyser was later determined to be 18 ml/min.,Combined boric acid and cinchocaine chloride poisoning in a 12-month-old infant: evaluation of haemodialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3378804/),[ml] / [min],18,45557,DB00695,Furosemide
,14520682,absorption lag time,"After oral administration to healthy humans in the fasting state, the plasma concentration of azosemide reached its peak at 3-4 h with an absorption lag time of approximately 1 h and a terminal half-life of 2-3 h.",Pharmacokinetics and pharmacodynamics of azosemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520682/),h,1,47148,DB00695,Furosemide
,14520682,terminal half-life,"After oral administration to healthy humans in the fasting state, the plasma concentration of azosemide reached its peak at 3-4 h with an absorption lag time of approximately 1 h and a terminal half-life of 2-3 h.",Pharmacokinetics and pharmacodynamics of azosemide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520682/),h,2-3,47149,DB00695,Furosemide
,14520682,absolute oral bioavailability,The estimated extent of absolute oral bioavailability in humans was approximately 20.4%.,Pharmacokinetics and pharmacodynamics of azosemide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520682/),%,20.4,47150,DB00695,Furosemide
greater,14520682,protein binding,The protein binding to 4% human serum albumin was greater than 95% at azosemide concentrations ranging from 10 to 100 microg/ml using an equilibrium dialysis technique.,Pharmacokinetics and pharmacodynamics of azosemide. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520682/),%,95,47151,DB00695,Furosemide
,14520682,apparent post-pseudodistribution volume of distribution (Vdbeta),"The poor affinity of human tissues to azosemide was supported by the relatively small value of the apparent post-pseudodistribution volume of distribution (Vdbeta), 0.262 l/kg.",Pharmacokinetics and pharmacodynamics of azosemide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520682/),[l] / [kg],0.262,47152,DB00695,Furosemide
,14520682,total body clearance,"In humans, total body clearance, renal clearance and terminal half-life of azosemide were 112 ml/min, 41.6 ml/min and 2.03 h, respectively.",Pharmacokinetics and pharmacodynamics of azosemide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520682/),[ml] / [min],112,47153,DB00695,Furosemide
,14520682,renal clearance,"In humans, total body clearance, renal clearance and terminal half-life of azosemide were 112 ml/min, 41.6 ml/min and 2.03 h, respectively.",Pharmacokinetics and pharmacodynamics of azosemide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520682/),[ml] / [min],41.6,47154,DB00695,Furosemide
,14520682,terminal half-life,"In humans, total body clearance, renal clearance and terminal half-life of azosemide were 112 ml/min, 41.6 ml/min and 2.03 h, respectively.",Pharmacokinetics and pharmacodynamics of azosemide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14520682/),h,2.03,47155,DB00695,Furosemide
,7325754,elimination half-lives,"The elimination half-lives after both oral and i.v. routes were nearly similar, i.e. 1.42 +10.13 and 1.13 +0.06 hours respectively.",Disposition kinetics of furosemide in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7325754/),h,1.42,48057,DB00695,Furosemide
,7325754,elimination half-lives,"The elimination half-lives after both oral and i.v. routes were nearly similar, i.e. 1.42 +10.13 and 1.13 +0.06 hours respectively.",Disposition kinetics of furosemide in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7325754/),h,1.13,48058,DB00695,Furosemide
,7325754,apparent volume of distribution,"The apparent volume of distribution corresponded well to the total body water (about 60%), i.e. 69.64 +5.61 and 52.06+4.82% b.wt. after oral and i.v. routes respectively.",Disposition kinetics of furosemide in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7325754/),%,69.64,48059,DB00695,Furosemide
,7325754,apparent volume of distribution,"The apparent volume of distribution corresponded well to the total body water (about 60%), i.e. 69.64 +5.61 and 52.06+4.82% b.wt. after oral and i.v. routes respectively.",Disposition kinetics of furosemide in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7325754/),%,52.06,48060,DB00695,Furosemide
,7325754,body clearance,"The body clearance of this drug after i.v. and oral administration showed close values, i.e. 5.27 +0.19 and 5.96 +0.14 mg/kg(-1) min(-1) respectively.",Disposition kinetics of furosemide in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7325754/),[mg] / [kg·min],5.27,48061,DB00695,Furosemide
,7325754,body clearance,"The body clearance of this drug after i.v. and oral administration showed close values, i.e. 5.27 +0.19 and 5.96 +0.14 mg/kg(-1) min(-1) respectively.",Disposition kinetics of furosemide in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7325754/),[mg] / [kg·min],5.96,48062,DB00695,Furosemide
,7325754,systemic bioavailablity,"The systemic bioavailablity of furosemide after oral administration amounted to 77.13 +5.24% with a maximum blood conc. (Cmax.) of 22.73 +2.03 microgram/ml, 30 min after administration.",Disposition kinetics of furosemide in dogs. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7325754/),%,77.13,48063,DB00695,Furosemide
,7325754,maximum blood conc. (Cmax.),"The systemic bioavailablity of furosemide after oral administration amounted to 77.13 +5.24% with a maximum blood conc. (Cmax.) of 22.73 +2.03 microgram/ml, 30 min after administration.",Disposition kinetics of furosemide in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7325754/),[μg] / [ml],22.73,48064,DB00695,Furosemide
,26568565,clearance,"The pharmacokinetics of vancomycin was best described by a two-compartment open model; creatinine clearance (CLCR) was related to vancomycin clearance (0.49 ± 0.04 L/h), being diminished by the presence of furosemide (0.34 ± 0.05 L/h).",Pharmacokinetics of vancomycin and dosing recommendations for trauma patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26568565/),[l] / [h],0.49,48750,DB00695,Furosemide
,26568565,V1,"TBW influenced both the central volume of distribution (V1 = 0.74 ± 0.1 L/kg) and peripheral volume of distribution (V2 = 5.9 ± 2 L/kg), but patients with age >65 years showed a larger V1 (1.07 ± 0.1 L/kg).",Pharmacokinetics of vancomycin and dosing recommendations for trauma patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26568565/),[l] / [kg],1.07,48751,DB00695,Furosemide
,26568565,trough concentrations,This final model allowed us to propose a new practical dose guideline to reach higher trough concentrations (15-20 mg/L) and AUC0-24/MIC ratios of more than 400 after 4 days of vancomycin treatment.,Pharmacokinetics of vancomycin and dosing recommendations for trauma patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26568565/),[mg] / [l],15-20,48752,DB00695,Furosemide
more,26568565,AUC0-24/MIC ratios,This final model allowed us to propose a new practical dose guideline to reach higher trough concentrations (15-20 mg/L) and AUC0-24/MIC ratios of more than 400 after 4 days of vancomycin treatment.,Pharmacokinetics of vancomycin and dosing recommendations for trauma patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26568565/),,400,48753,DB00695,Furosemide
,8563699,IC50,"DMP 811 exhibited high binding affinity for the angiotensin II subtype receptor AT1 in rat adrenal tissues with an IC50 of 6 nM, but not for the subtype receptor AT2.",Pharmacology and pharmacokinetics of a novel nonpeptide angiotensin II receptor antagonist--DMP 811. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8563699/),nM,6,57651,DB00695,Furosemide
,8563699,KB,"In the isolated rabbit aorta, DMP 811 inhibited the contractile response to angiotensin II selectively and noncompetitively with a KB value of 0.1 nM.",Pharmacology and pharmacokinetics of a novel nonpeptide angiotensin II receptor antagonist--DMP 811. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8563699/),nM,0.1,57652,DB00695,Furosemide
,8563699,oral bioavailabilities,"DMP 811 has oral bioavailabilities of 7 and 29% in rats and dogs, respectively, after a solution dose and 8 and 13%, respectively, after a suspension or capsule dosing.",Pharmacology and pharmacokinetics of a novel nonpeptide angiotensin II receptor antagonist--DMP 811. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8563699/),%,7,57653,DB00695,Furosemide
,8563699,oral bioavailabilities,"DMP 811 has oral bioavailabilities of 7 and 29% in rats and dogs, respectively, after a solution dose and 8 and 13%, respectively, after a suspension or capsule dosing.",Pharmacology and pharmacokinetics of a novel nonpeptide angiotensin II receptor antagonist--DMP 811. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8563699/),%,29,57654,DB00695,Furosemide
,8563699,oral bioavailabilities,"DMP 811 has oral bioavailabilities of 7 and 29% in rats and dogs, respectively, after a solution dose and 8 and 13%, respectively, after a suspension or capsule dosing.",Pharmacology and pharmacokinetics of a novel nonpeptide angiotensin II receptor antagonist--DMP 811. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8563699/),%,8,57655,DB00695,Furosemide
,8563699,oral bioavailabilities,"DMP 811 has oral bioavailabilities of 7 and 29% in rats and dogs, respectively, after a solution dose and 8 and 13%, respectively, after a suspension or capsule dosing.",Pharmacology and pharmacokinetics of a novel nonpeptide angiotensin II receptor antagonist--DMP 811. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8563699/),%,13,57656,DB00695,Furosemide
,31778632,mass chloride excretion,"Furosemide caused a much greater increase in-urine output and much greater median mass chloride excretion (121.7 mmol [IQR, 81.1-144.6] v 23.3 mmol [IQR, 20.4-57.3]; P < 0.01) than acetazolamide.",A pilot randomised controlled trial evaluating the pharmacodynamic effects of furosemide versus acetazolamide in critically ill patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31778632/),mM,121.7,58352,DB00695,Furosemide
,31778632,mass chloride excretion,"Furosemide caused a much greater increase in-urine output and much greater median mass chloride excretion (121.7 mmol [IQR, 81.1-144.6] v 23.3 mmol [IQR, 20.4-57.3]; P < 0.01) than acetazolamide.",A pilot randomised controlled trial evaluating the pharmacodynamic effects of furosemide versus acetazolamide in critically ill patients. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31778632/),mM,23.3,58353,DB00695,Furosemide
,6861853,elimination half-life,Drug elimination half-life increased from 4.2 h (creatinine clearance 23.0 ml/min) to 22.3 h (creatinine clearance 5.0 ml/min) with decreasing renal function.,Pharmacokinetics and clinical effects of cefuroxime in patients with severe renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861853/),h,4.2,59256,DB00695,Furosemide
,6861853,elimination half-life,Drug elimination half-life increased from 4.2 h (creatinine clearance 23.0 ml/min) to 22.3 h (creatinine clearance 5.0 ml/min) with decreasing renal function.,Pharmacokinetics and clinical effects of cefuroxime in patients with severe renal insufficiency. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861853/),h,22.3,59257,DB00695,Furosemide
,6861853,apparent volume of distribution,"The apparent volume of distribution ranged from 11.6 to 17.9 l, and showed a substantial increase to 29.6 l in the patient with the poorest renal function.",Pharmacokinetics and clinical effects of cefuroxime in patients with severe renal insufficiency. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861853/),l,11.6 to 17.9,59258,DB00695,Furosemide
,6861853,apparent volume of distribution,"The apparent volume of distribution ranged from 11.6 to 17.9 l, and showed a substantial increase to 29.6 l in the patient with the poorest renal function.",Pharmacokinetics and clinical effects of cefuroxime in patients with severe renal insufficiency. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861853/),l,29.6,59259,DB00695,Furosemide
,6861853,extrarenal clearance,A linear correlation was found between the total and renal clearance of cefuroxime and the creatinine clearance; the extrarenal clearance was 8.24 ml/min.,Pharmacokinetics and clinical effects of cefuroxime in patients with severe renal insufficiency. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6861853/),[ml] / [min],8.24,59260,DB00695,Furosemide
,2007318,Total serum clearance,"Total serum clearance (113 +/- 49 ml/min), volume of distribution (11.9 +/- 4.5 L), and elimination half-life (166 +/- 149 minutes) were similar to those reported previously in both healthy control subjects and patients with cirrhosis.",Furosemide absorption in patients with cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2007318/),[ml] / [min],113,59580,DB00695,Furosemide
,2007318,volume of distribution,"Total serum clearance (113 +/- 49 ml/min), volume of distribution (11.9 +/- 4.5 L), and elimination half-life (166 +/- 149 minutes) were similar to those reported previously in both healthy control subjects and patients with cirrhosis.",Furosemide absorption in patients with cirrhosis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2007318/),l,11.9,59581,DB00695,Furosemide
,2007318,elimination half-life,"Total serum clearance (113 +/- 49 ml/min), volume of distribution (11.9 +/- 4.5 L), and elimination half-life (166 +/- 149 minutes) were similar to those reported previously in both healthy control subjects and patients with cirrhosis.",Furosemide absorption in patients with cirrhosis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2007318/),min,166,59582,DB00695,Furosemide
,2007318,Bioavailability,"Bioavailability of 58% +/- 17% (range, 37% to 82%) was comparable to that of previous studies, and there was no difference between patients with mild and those with severe cirrhosis.",Furosemide absorption in patients with cirrhosis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2007318/),%,58,59583,DB00695,Furosemide
,2007318,mean absorption time,"In 9 of 12 patients the mean absorption time was longer than the mean residence time determined after intravenous administration (mean for all patients, 203 +/- 86 versus 134 +/- 101 minutes; p less than 0.05), indicating that furosemide followed a ""flip-flop"" model in these patients.",Furosemide absorption in patients with cirrhosis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2007318/),min,203,59584,DB00695,Furosemide
,2007318,mean absorption time,"In 9 of 12 patients the mean absorption time was longer than the mean residence time determined after intravenous administration (mean for all patients, 203 +/- 86 versus 134 +/- 101 minutes; p less than 0.05), indicating that furosemide followed a ""flip-flop"" model in these patients.",Furosemide absorption in patients with cirrhosis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2007318/),min,134,59585,DB00695,Furosemide
,2007318,mean residence time,"In 9 of 12 patients the mean absorption time was longer than the mean residence time determined after intravenous administration (mean for all patients, 203 +/- 86 versus 134 +/- 101 minutes; p less than 0.05), indicating that furosemide followed a ""flip-flop"" model in these patients.",Furosemide absorption in patients with cirrhosis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2007318/),min,203,59586,DB00695,Furosemide
,2007318,mean residence time,"In 9 of 12 patients the mean absorption time was longer than the mean residence time determined after intravenous administration (mean for all patients, 203 +/- 86 versus 134 +/- 101 minutes; p less than 0.05), indicating that furosemide followed a ""flip-flop"" model in these patients.",Furosemide absorption in patients with cirrhosis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2007318/),min,134,59587,DB00695,Furosemide
exceeding,3351693,Plasma half-life,"Plasma half-life was prolonged in infants less than 31 weeks postconceptional age (gestational + postnatal age), frequently exceeding 24 hours.",Furosemide pharmacokinetics in very low birth weight infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3351693/),h,24,61064,DB00695,Furosemide
exceed,9210443,extraction recoveries,"The extraction recoveries, depending on concentration, exceed 80% for furosemide and 74% for amiloride.",Determination and pharmacokinetics of a furosemide-amiloride drug combination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210443/),%,80,62308,DB00695,Furosemide
,9210443,extraction recoveries,"The extraction recoveries, depending on concentration, exceed 80% for furosemide and 74% for amiloride.",Determination and pharmacokinetics of a furosemide-amiloride drug combination. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210443/),%,74,62309,DB00695,Furosemide
,26026252,glass transition temperature,"The glass solution had a glass transition temperature of 121.3 ± 0.5°C, which was significantly higher than that of the pure drug (101.2°C).",Stabilisation of amorphous furosemide increases the oral drug bioavailability in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26026252/),°c,121.3,62637,DB00695,Furosemide
,26026252,glass transition temperature,"The glass solution had a glass transition temperature of 121.3 ± 0.5°C, which was significantly higher than that of the pure drug (101.2°C).",Stabilisation of amorphous furosemide increases the oral drug bioavailability in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26026252/),°c,101.2,62638,DB00695,Furosemide
,26026252,intrinsic dissolution rate,"The glass solution exhibited fast dissolution in simulated intestinal medium, pH 6.5; the intrinsic dissolution rate was found to be 10.1 ± 0.6 mg/cm(2)/min, which was significantly faster than the pure ASSF.",Stabilisation of amorphous furosemide increases the oral drug bioavailability in rats. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26026252/),[mg] / [cm(2)·min],10.1,62639,DB00695,Furosemide
,26026252,relative oral bioavailability,"The stabilising effect of PVP on ASSF, led to improved relative oral bioavailability in rats of 263%, when compared to the pure ASSF.",Stabilisation of amorphous furosemide increases the oral drug bioavailability in rats. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26026252/),%,263,62640,DB00695,Furosemide
,30062191,bioavailability,Subcutaneous infusion using a biphasic delivery profile resulted in complete bioavailability (99.65%) and equivalent diuresis when compared with intravenous administration.,Subcutaneous Furosemide in Heart Failure: Pharmacokinetic Characteristics of a Newly Buffered Solution. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30062191/),%,99.65,63260,DB00695,Furosemide
,2369756,excretion,"The patients with ascitic cirrhosis (AC) and the control persons were found to have the same plasma furosemide concentrations; however, the AC patients excreted significantly less furosemide into the urine in an 8-hour period than the control persons, which was due especially to lower urine furosemide excretion during the first hour after application in comparison with the control group (75 +/- 6.8 vs. 100.8 +/- 8.8 mumol/h, p less than 0.05).",[Pharmacokinetics and pharmacodynamics of furosemide in liver cirrhosis]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369756/),[μM] / [h],75,63337,DB00695,Furosemide
,2369756,excretion,"The patients with ascitic cirrhosis (AC) and the control persons were found to have the same plasma furosemide concentrations; however, the AC patients excreted significantly less furosemide into the urine in an 8-hour period than the control persons, which was due especially to lower urine furosemide excretion during the first hour after application in comparison with the control group (75 +/- 6.8 vs. 100.8 +/- 8.8 mumol/h, p less than 0.05).",[Pharmacokinetics and pharmacodynamics of furosemide in liver cirrhosis]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369756/),[μM] / [h],100.8,63338,DB00695,Furosemide
,2369756,diuresis,"During the first post-furosemide hour, the AC patients had a significantly lower diuresis (13.3 +/- 2.4 vs. 23.9 +/- 1.1 ml/min, p less than 0.01) as well as natriuresis (1367.4 +/- 771.4 vs. 3242 +/- 137.5 mumol/min, p less than 0.01) than the control group and a significantly lower excretion fraction of sodium than the patients with live cirrhosis without ascites (6.5 +/- 0.8 vs. 10.7 +/- 1.5%, p less than 0.05).",[Pharmacokinetics and pharmacodynamics of furosemide in liver cirrhosis]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369756/),[ml] / [min],13.3,63339,DB00695,Furosemide
,2369756,diuresis,"During the first post-furosemide hour, the AC patients had a significantly lower diuresis (13.3 +/- 2.4 vs. 23.9 +/- 1.1 ml/min, p less than 0.01) as well as natriuresis (1367.4 +/- 771.4 vs. 3242 +/- 137.5 mumol/min, p less than 0.01) than the control group and a significantly lower excretion fraction of sodium than the patients with live cirrhosis without ascites (6.5 +/- 0.8 vs. 10.7 +/- 1.5%, p less than 0.05).",[Pharmacokinetics and pharmacodynamics of furosemide in liver cirrhosis]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369756/),[ml] / [min],23.9,63340,DB00695,Furosemide
,2369756,natriuresis,"During the first post-furosemide hour, the AC patients had a significantly lower diuresis (13.3 +/- 2.4 vs. 23.9 +/- 1.1 ml/min, p less than 0.01) as well as natriuresis (1367.4 +/- 771.4 vs. 3242 +/- 137.5 mumol/min, p less than 0.01) than the control group and a significantly lower excretion fraction of sodium than the patients with live cirrhosis without ascites (6.5 +/- 0.8 vs. 10.7 +/- 1.5%, p less than 0.05).",[Pharmacokinetics and pharmacodynamics of furosemide in liver cirrhosis]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369756/),[μM] / [min],1367.4,63341,DB00695,Furosemide
,2369756,natriuresis,"During the first post-furosemide hour, the AC patients had a significantly lower diuresis (13.3 +/- 2.4 vs. 23.9 +/- 1.1 ml/min, p less than 0.01) as well as natriuresis (1367.4 +/- 771.4 vs. 3242 +/- 137.5 mumol/min, p less than 0.01) than the control group and a significantly lower excretion fraction of sodium than the patients with live cirrhosis without ascites (6.5 +/- 0.8 vs. 10.7 +/- 1.5%, p less than 0.05).",[Pharmacokinetics and pharmacodynamics of furosemide in liver cirrhosis]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369756/),[μM] / [min],3242,63342,DB00695,Furosemide
,2369756,excretion fraction,"During the first post-furosemide hour, the AC patients had a significantly lower diuresis (13.3 +/- 2.4 vs. 23.9 +/- 1.1 ml/min, p less than 0.01) as well as natriuresis (1367.4 +/- 771.4 vs. 3242 +/- 137.5 mumol/min, p less than 0.01) than the control group and a significantly lower excretion fraction of sodium than the patients with live cirrhosis without ascites (6.5 +/- 0.8 vs. 10.7 +/- 1.5%, p less than 0.05).",[Pharmacokinetics and pharmacodynamics of furosemide in liver cirrhosis]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369756/),%,6.5,63343,DB00695,Furosemide
,2369756,excretion fraction,"During the first post-furosemide hour, the AC patients had a significantly lower diuresis (13.3 +/- 2.4 vs. 23.9 +/- 1.1 ml/min, p less than 0.01) as well as natriuresis (1367.4 +/- 771.4 vs. 3242 +/- 137.5 mumol/min, p less than 0.01) than the control group and a significantly lower excretion fraction of sodium than the patients with live cirrhosis without ascites (6.5 +/- 0.8 vs. 10.7 +/- 1.5%, p less than 0.05).",[Pharmacokinetics and pharmacodynamics of furosemide in liver cirrhosis]. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2369756/),%,10.7,63344,DB00695,Furosemide
,8410679,bioavailability,"After oral administration, the extent of bioavailability increased considerably from 27.6% in control rats to 47.0% in PCM rats, probably as a result of decreased gastrointestinal and hepatic first-pass metabolism.",Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8410679/),%,27.6,63702,DB00695,Furosemide
,8410679,bioavailability,"After oral administration, the extent of bioavailability increased considerably from 27.6% in control rats to 47.0% in PCM rats, probably as a result of decreased gastrointestinal and hepatic first-pass metabolism.",Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8410679/),%,47.0,63703,DB00695,Furosemide
,729629,plasma half-life,"The plasma half-life after oral and intravenous administration was 115 +/- 37.1 and 71.8 +/- 26.3 min and plasma clearance was 153 +/- 48 and 152 +/- 23 ml/min, respectively (mean +/- SD).",Pharmacokinetics of furosemide in gestosis of pregnancy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/729629/),min,115,63774,DB00695,Furosemide
,729629,plasma half-life,"The plasma half-life after oral and intravenous administration was 115 +/- 37.1 and 71.8 +/- 26.3 min and plasma clearance was 153 +/- 48 and 152 +/- 23 ml/min, respectively (mean +/- SD).",Pharmacokinetics of furosemide in gestosis of pregnancy. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/729629/),min,71.8,63775,DB00695,Furosemide
,729629,plasma clearance,"The plasma half-life after oral and intravenous administration was 115 +/- 37.1 and 71.8 +/- 26.3 min and plasma clearance was 153 +/- 48 and 152 +/- 23 ml/min, respectively (mean +/- SD).",Pharmacokinetics of furosemide in gestosis of pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/729629/),[ml] / [min],153,63776,DB00695,Furosemide
,729629,plasma clearance,"The plasma half-life after oral and intravenous administration was 115 +/- 37.1 and 71.8 +/- 26.3 min and plasma clearance was 153 +/- 48 and 152 +/- 23 ml/min, respectively (mean +/- SD).",Pharmacokinetics of furosemide in gestosis of pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/729629/),[ml] / [min],152,63777,DB00695,Furosemide
,29403744,flow rate,"The reconstituted samples were chromatographed on a Zorbax SB-C18 column by using a mixture of 5 mM ammonium acetate buffer and acetonitrile (20:80, v/v) as the mobile phase at a flow rate of 0.8 mL/min.",High performance liquid chromatography mass spectrometric method for the simultaneous quantification of pravastatin and aspirin in human plasma: Pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403744/),[ml] / [min],0.8,67953,DB00695,Furosemide
,29403744,run time,A run time of 2.0 min for each sample made it possible to analyze more than 400 human plasma samples per day.,High performance liquid chromatography mass spectrometric method for the simultaneous quantification of pravastatin and aspirin in human plasma: Pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403744/),min,2.0,67954,DB00695,Furosemide
,9884313,unbound fraction,"Compared with control rabbits, in conscious hypoalbuminemic rabbits, furosemide unbound fraction was enhanced from 1.2 +/- 0.1% to 5.5 +/- 0.5% (p <. 001), and its urinary excretion, diuresis, and sodium excretion were reduced by 22% (p <.05).",Role of plasma protein binding on renal metabolism and dynamics of furosemide in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884313/),,1.2,68140,DB00695,Furosemide
,9884313,unbound fraction,"Compared with control rabbits, in conscious hypoalbuminemic rabbits, furosemide unbound fraction was enhanced from 1.2 +/- 0.1% to 5.5 +/- 0.5% (p <. 001), and its urinary excretion, diuresis, and sodium excretion were reduced by 22% (p <.05).",Role of plasma protein binding on renal metabolism and dynamics of furosemide in the rabbit. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9884313/),%,5.,68141,DB00695,Furosemide
,3311532,bioavailability,The bioavailability is about 15% and it has a half-life of 2 to 3 hours.,Clinical pharmacokinetics of some newer diuretics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),%,15,68489,DB00695,Furosemide
,3311532,half-life,The bioavailability is about 15% and it has a half-life of 2 to 3 hours.,Clinical pharmacokinetics of some newer diuretics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),h,2 to 3,68490,DB00695,Furosemide
,3311532,Renal,"Renal and non-renal clearance are 1.32 and 5.4 L/h, respectively.",Clinical pharmacokinetics of some newer diuretics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),[l] / [h],1.32,68491,DB00695,Furosemide
,3311532,non-renal clearance,"Renal and non-renal clearance are 1.32 and 5.4 L/h, respectively.",Clinical pharmacokinetics of some newer diuretics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),[l] / [h],5.4,68492,DB00695,Furosemide
,3311532,plasma half-life,"The plasma half-life of etozolin and ozolinone are 2 and 10 hours, respectively.",Clinical pharmacokinetics of some newer diuretics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),h,2,68493,DB00695,Furosemide
,3311532,plasma half-life,"The plasma half-life of etozolin and ozolinone are 2 and 10 hours, respectively.",Clinical pharmacokinetics of some newer diuretics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),h,10,68494,DB00695,Furosemide
,3311532,plasma half-life,The plasma half-life is approximately 17 hours.,Clinical pharmacokinetics of some newer diuretics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),h,17,68495,DB00695,Furosemide
,3311532,Apparent volume of distribution,Apparent volume of distribution averaged 686 L and renal clearance is 7.2 L/h.,Clinical pharmacokinetics of some newer diuretics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),l,686,68496,DB00695,Furosemide
,3311532,renal clearance,Apparent volume of distribution averaged 686 L and renal clearance is 7.2 L/h.,Clinical pharmacokinetics of some newer diuretics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),[l] / [h],7.2,68497,DB00695,Furosemide
,3311532,Gastrointestinal uptake,Gastrointestinal uptake is at least 80%.,Clinical pharmacokinetics of some newer diuretics. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),%,80,68498,DB00695,Furosemide
,3311532,Protein binding,"Protein binding is about 80%, while terminal plasma half-life is 15 hours and the apparent volume of distribution 25 L.",Clinical pharmacokinetics of some newer diuretics. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),,80,68499,DB00695,Furosemide
,3311532,terminal plasma half-life,"Protein binding is about 80%, while terminal plasma half-life is 15 hours and the apparent volume of distribution 25 L.",Clinical pharmacokinetics of some newer diuretics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),h,15,68500,DB00695,Furosemide
,3311532,apparent volume of distribution,"Protein binding is about 80%, while terminal plasma half-life is 15 hours and the apparent volume of distribution 25 L.",Clinical pharmacokinetics of some newer diuretics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),l,25,68501,DB00695,Furosemide
,3311532,Renal clearance,Renal clearance is 0.3 L/h and non-renal clearance 0.9 L/h.,Clinical pharmacokinetics of some newer diuretics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),[l] / [h],0.3,68502,DB00695,Furosemide
,3311532,non-renal clearance,Renal clearance is 0.3 L/h and non-renal clearance 0.9 L/h.,Clinical pharmacokinetics of some newer diuretics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),[l] / [h],0.9,68503,DB00695,Furosemide
,3311532,protein binding,"The protein binding is about 65%, the apparent volume of distribution is about 1 L/kg and average terminal half-life 10 to 20 hours.",Clinical pharmacokinetics of some newer diuretics. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),%,65,68504,DB00695,Furosemide
,3311532,apparent volume of distribution,"The protein binding is about 65%, the apparent volume of distribution is about 1 L/kg and average terminal half-life 10 to 20 hours.",Clinical pharmacokinetics of some newer diuretics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),[l] / [kg],1,68505,DB00695,Furosemide
,3311532,terminal half-life,"The protein binding is about 65%, the apparent volume of distribution is about 1 L/kg and average terminal half-life 10 to 20 hours.",Clinical pharmacokinetics of some newer diuretics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),h,10 to 20,68506,DB00695,Furosemide
,3311532,non-renal clearance,"Elimination is mainly non-renal, and non-renal clearance ranges between 0.5 and 1.32 L/h.",Clinical pharmacokinetics of some newer diuretics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),[l] / [h],0.5 and 1.32,68507,DB00695,Furosemide
,3311532,Protein binding,Protein binding in healthy subjects is about 95%.,Clinical pharmacokinetics of some newer diuretics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),%,95,68508,DB00695,Furosemide
,3311532,plasma half-life,The plasma half-life of the drug is about 1 hour and apparent volume of distribution averages about 17 L.,Clinical pharmacokinetics of some newer diuretics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),h,1,68509,DB00695,Furosemide
,3311532,apparent volume of distribution,The plasma half-life of the drug is about 1 hour and apparent volume of distribution averages about 17 L.,Clinical pharmacokinetics of some newer diuretics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),l,17,68510,DB00695,Furosemide
,3311532,Renal,"Renal and non-renal clearance are about 6 L/h, although renal clearance is decreased in renal failure: this decrease is correlated with glomerular filtration rate.",Clinical pharmacokinetics of some newer diuretics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),[l] / [h],6,68511,DB00695,Furosemide
,3311532,non-renal clearance,"Renal and non-renal clearance are about 6 L/h, although renal clearance is decreased in renal failure: this decrease is correlated with glomerular filtration rate.",Clinical pharmacokinetics of some newer diuretics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3311532/),[l] / [h],6,68512,DB00695,Furosemide
,10820174,Sodium excretion,Sodium excretion (mean +/- SD) from furosemide alone was 239 +/- 90 versus 240 +/- 115 mEq/8 h with sulfisoxazole.,Urinary protein binding does not affect response to furosemide in patients with nephrotic syndrome. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10820174/),[meq] / [8·h],239,68943,DB00695,Furosemide
,10820174,Sodium excretion,Sodium excretion (mean +/- SD) from furosemide alone was 239 +/- 90 versus 240 +/- 115 mEq/8 h with sulfisoxazole.,Urinary protein binding does not affect response to furosemide in patients with nephrotic syndrome. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10820174/),[meq] / [8·h],240,68944,DB00695,Furosemide
,10820174,overall amount excreted,"Sulfisoxazole had modest effects on serum pharmacokinetics of furosemide but had no effect on either the time course of furosemide urinary excretion or overall amount excreted: 49 +/- 15 mg versus 54 +/- 12 mg for furosemide alone and furosemide plus sulfisoxazole, respectively.",Urinary protein binding does not affect response to furosemide in patients with nephrotic syndrome. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10820174/),mg,54,68945,DB00695,Furosemide
,23009999,plasma concentration,These results were supported by the simulated data where F15 formula showed the highest plasma concentration C-max 1.89mcg/mL after 0.5 hr compared to C-max 1.05mcg/mL after 1hr for the reference.,Impact of chitosan as a disintegrant on the bioavailability of furosemide tablets: in vitro evaluation and in vivo simulation of novel formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23009999/),[mcg] / [ml],1.89,69022,DB00695,Furosemide
,23009999,C-max,These results were supported by the simulated data where F15 formula showed the highest plasma concentration C-max 1.89mcg/mL after 0.5 hr compared to C-max 1.05mcg/mL after 1hr for the reference.,Impact of chitosan as a disintegrant on the bioavailability of furosemide tablets: in vitro evaluation and in vivo simulation of novel formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23009999/),[mcg] / [ml],1.89,69023,DB00695,Furosemide
,23009999,C-max,These results were supported by the simulated data where F15 formula showed the highest plasma concentration C-max 1.89mcg/mL after 0.5 hr compared to C-max 1.05mcg/mL after 1hr for the reference.,Impact of chitosan as a disintegrant on the bioavailability of furosemide tablets: in vitro evaluation and in vivo simulation of novel formulations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23009999/),[mcg] / [ml],1.05,69024,DB00695,Furosemide
,3092347,plasma half-life,The mean plasma half-life of mannitol was 127 min in the absence of uraemia.,Mannitol concentrations in blood plasma in connection with transurethral resection of the prostate using mannitol solution as an irrigating fluid. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3092347/),min,127,70133,DB00695,Furosemide
,3092347,fluid absorption,A fluid absorption of up to 3 litres (mean 1.1 l) was found.,Mannitol concentrations in blood plasma in connection with transurethral resection of the prostate using mannitol solution as an irrigating fluid. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3092347/),l,up,70134,DB00695,Furosemide
,3092347,fluid absorption,A fluid absorption of up to 3 litres (mean 1.1 l) was found.,Mannitol concentrations in blood plasma in connection with transurethral resection of the prostate using mannitol solution as an irrigating fluid. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3092347/),l,3,70135,DB00695,Furosemide
,3092347,fluid absorption,A fluid absorption of up to 3 litres (mean 1.1 l) was found.,Mannitol concentrations in blood plasma in connection with transurethral resection of the prostate using mannitol solution as an irrigating fluid. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3092347/),l,1.1,70136,DB00695,Furosemide
,24151207,CL(R),"A covariate analysis identified creatinine clearance (CL(CR)) as a statistically significant predictor of renal clearance (CL(R)), with a population mean CL(R) of 4.67, 3.11, 1.95 and 1.17 l/h for a subject with normal renal function (CL(CR) = 120 ml/min) or mild (CL(CR) = 80 ml/min), moderate (CL(CR) = 50 ml/min) or severe (CLCR = 30 ml/min) renal impairment.",Population-based meta-analysis of furosemide pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24151207/),[l] / [h],4.67,72756,DB00695,Furosemide
,24151207,CL(R),"A covariate analysis identified creatinine clearance (CL(CR)) as a statistically significant predictor of renal clearance (CL(R)), with a population mean CL(R) of 4.67, 3.11, 1.95 and 1.17 l/h for a subject with normal renal function (CL(CR) = 120 ml/min) or mild (CL(CR) = 80 ml/min), moderate (CL(CR) = 50 ml/min) or severe (CLCR = 30 ml/min) renal impairment.",Population-based meta-analysis of furosemide pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24151207/),[l] / [h],3.11,72757,DB00695,Furosemide
,24151207,CL(R),"A covariate analysis identified creatinine clearance (CL(CR)) as a statistically significant predictor of renal clearance (CL(R)), with a population mean CL(R) of 4.67, 3.11, 1.95 and 1.17 l/h for a subject with normal renal function (CL(CR) = 120 ml/min) or mild (CL(CR) = 80 ml/min), moderate (CL(CR) = 50 ml/min) or severe (CLCR = 30 ml/min) renal impairment.",Population-based meta-analysis of furosemide pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24151207/),[l] / [h],1.95,72758,DB00695,Furosemide
,24151207,CL(R),"A covariate analysis identified creatinine clearance (CL(CR)) as a statistically significant predictor of renal clearance (CL(R)), with a population mean CL(R) of 4.67, 3.11, 1.95 and 1.17 l/h for a subject with normal renal function (CL(CR) = 120 ml/min) or mild (CL(CR) = 80 ml/min), moderate (CL(CR) = 50 ml/min) or severe (CLCR = 30 ml/min) renal impairment.",Population-based meta-analysis of furosemide pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24151207/),[l] / [h],1.17,72759,DB00695,Furosemide
,24151207,Oral bioavailability,Oral bioavailability was 59.1% and non-renal clearance was 2.02 l/h.,Population-based meta-analysis of furosemide pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24151207/),%,59.1,72760,DB00695,Furosemide
,24151207,non-renal clearance,Oral bioavailability was 59.1% and non-renal clearance was 2.02 l/h.,Population-based meta-analysis of furosemide pharmacokinetics. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24151207/),[l] / [h],2.02,72761,DB00695,Furosemide
,17101741,urine volume,"The net increase in urine volume and sodium excretion in the interval of 6 to 12 hours was 4.15 L and 178 mmol/L, respectively, during NXY-059 treatment (P = .93) and 4.34 L and 190 mmol/L, respectively, during placebo treatment (P = .54).",NXY-059 does not significantly interact with furosemide in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17101741/),l,4.15,74769,DB00695,Furosemide
,17101741,urine volume,"The net increase in urine volume and sodium excretion in the interval of 6 to 12 hours was 4.15 L and 178 mmol/L, respectively, during NXY-059 treatment (P = .93) and 4.34 L and 190 mmol/L, respectively, during placebo treatment (P = .54).",NXY-059 does not significantly interact with furosemide in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17101741/),[mM] / [l],178,74770,DB00695,Furosemide
,17101741,urine volume,"The net increase in urine volume and sodium excretion in the interval of 6 to 12 hours was 4.15 L and 178 mmol/L, respectively, during NXY-059 treatment (P = .93) and 4.34 L and 190 mmol/L, respectively, during placebo treatment (P = .54).",NXY-059 does not significantly interact with furosemide in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17101741/),,4,74771,DB00695,Furosemide
,9017769,bioavailability,Mean (+/-SD) bioavailability was 49 +/- 17% (range 12-112%) and coefficients of variation with different products were from 25-43%.,Variable furosemide absorption and poor predictability of response in elderly patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9017769/),%,49,74869,DB00695,Furosemide
,22763905,elimination clearance,Dehydration decreased the elimination clearance of acetated Ringer's solution [median (25th-75th percentile)] from 1.84 (1.23-2.57) to 0.53 (0.41-0.79) mL/kg/min (Wilcoxon matched-pair test P < 0.001) and increased the half-life from 23 (12-37) to 76 (57-101) minutes (P < 0.001).,Detection of dehydration by using volume kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22763905/),[ml] / [kg·min],1.84,74876,DB00695,Furosemide
,22763905,elimination clearance,Dehydration decreased the elimination clearance of acetated Ringer's solution [median (25th-75th percentile)] from 1.84 (1.23-2.57) to 0.53 (0.41-0.79) mL/kg/min (Wilcoxon matched-pair test P < 0.001) and increased the half-life from 23 (12-37) to 76 (57-101) minutes (P < 0.001).,Detection of dehydration by using volume kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22763905/),[ml] / [kg·min],0.53,74877,DB00695,Furosemide
,22763905,half-life,Dehydration decreased the elimination clearance of acetated Ringer's solution [median (25th-75th percentile)] from 1.84 (1.23-2.57) to 0.53 (0.41-0.79) mL/kg/min (Wilcoxon matched-pair test P < 0.001) and increased the half-life from 23 (12-37) to 76 (57-101) minutes (P < 0.001).,Detection of dehydration by using volume kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22763905/),min,23,74878,DB00695,Furosemide
,22763905,half-life,Dehydration decreased the elimination clearance of acetated Ringer's solution [median (25th-75th percentile)] from 1.84 (1.23-2.57) to 0.53 (0.41-0.79) mL/kg/min (Wilcoxon matched-pair test P < 0.001) and increased the half-life from 23 (12-37) to 76 (57-101) minutes (P < 0.001).,Detection of dehydration by using volume kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22763905/),min,76,74879,DB00695,Furosemide
,2348592,urinary excretion rate,Half maximum diuretic response was obtained at 1.5 micrograms/ml of plasma concentration and 100 micrograms/min of urinary excretion rate of furosemide.,The pharmacokinetics and pharmacodynamics of furosemide in anesthetized dogs with normal and experimentally decreased renal function. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2348592/),,1,75402,DB00695,Furosemide
,2348592,urinary excretion rate,Half maximum diuretic response was obtained at 1.5 micrograms/ml of plasma concentration and 100 micrograms/min of urinary excretion rate of furosemide.,The pharmacokinetics and pharmacodynamics of furosemide in anesthetized dogs with normal and experimentally decreased renal function. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2348592/),[μg] / [min],100,75403,DB00695,Furosemide
,6723757,lag-phase,"After a lag-phase of 33.9 +/- 5.4 min the maximum plasma concentration of furosemide was reached after 3.47 +/- 0.66 h, and the elimination half-life was approximately 2 h.",Pharmacokinetic and pharmacodynamic study of the combination of furosemide retard and triamterene. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723757/),min,33.9,76949,DB00695,Furosemide
,6723757,elimination half-life,"After a lag-phase of 33.9 +/- 5.4 min the maximum plasma concentration of furosemide was reached after 3.47 +/- 0.66 h, and the elimination half-life was approximately 2 h.",Pharmacokinetic and pharmacodynamic study of the combination of furosemide retard and triamterene. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723757/),h,2,76950,DB00695,Furosemide
,6723757,lag-phase,"After a lag-phase of 33.0 +/- 17.8 min the maximum plasma concentration of the main metabolite of triamterene, the OH-TA sulphuric acid ester, was reached after 1.7 +/- 0.59 h, and its elimination half-life amounted to 1.25 +/- 0.37 h.",Pharmacokinetic and pharmacodynamic study of the combination of furosemide retard and triamterene. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723757/),min,33.0,76951,DB00695,Furosemide
,6723757,elimination half-life,"After a lag-phase of 33.0 +/- 17.8 min the maximum plasma concentration of the main metabolite of triamterene, the OH-TA sulphuric acid ester, was reached after 1.7 +/- 0.59 h, and its elimination half-life amounted to 1.25 +/- 0.37 h.",Pharmacokinetic and pharmacodynamic study of the combination of furosemide retard and triamterene. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723757/),h,1.25,76952,DB00695,Furosemide
,7781201,bioavailability,[Formula: see text] The present concept is in line with observations indicating that furosemide bioavailability decreases from 60 to 45% in nephrotic syndrome patients whose plasma protein binding is reduced and hepatic clearance increased.,"Saturable first-pass kinetics, plasma protein binding, and the furosemide intricacies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7781201/),%,60,77356,DB00695,Furosemide
,7781201,bioavailability,[Formula: see text] The present concept is in line with observations indicating that furosemide bioavailability decreases from 60 to 45% in nephrotic syndrome patients whose plasma protein binding is reduced and hepatic clearance increased.,"Saturable first-pass kinetics, plasma protein binding, and the furosemide intricacies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7781201/),%,45,77357,DB00695,Furosemide
,3370308,Relative bioavailabilities,"Relative bioavailabilities of Tablet A and B were 89 per cent and 101 per cent, respectively, as determined by AUC, and 79 per cent and 84 per cent, respectively, as determined by urine recovery.",Comparative bioavailability of furosemide from solution and 40 mg tablets with different dissolution characteristics following oral administration in normal men. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370308/),%,89,77663,DB00695,Furosemide
,3370308,Relative bioavailabilities,"Relative bioavailabilities of Tablet A and B were 89 per cent and 101 per cent, respectively, as determined by AUC, and 79 per cent and 84 per cent, respectively, as determined by urine recovery.",Comparative bioavailability of furosemide from solution and 40 mg tablets with different dissolution characteristics following oral administration in normal men. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370308/),%,101,77664,DB00695,Furosemide
,3370308,Relative bioavailabilities,"Relative bioavailabilities of Tablet A and B were 89 per cent and 101 per cent, respectively, as determined by AUC, and 79 per cent and 84 per cent, respectively, as determined by urine recovery.",Comparative bioavailability of furosemide from solution and 40 mg tablets with different dissolution characteristics following oral administration in normal men. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370308/),%,79,77665,DB00695,Furosemide
,3370308,Relative bioavailabilities,"Relative bioavailabilities of Tablet A and B were 89 per cent and 101 per cent, respectively, as determined by AUC, and 79 per cent and 84 per cent, respectively, as determined by urine recovery.",Comparative bioavailability of furosemide from solution and 40 mg tablets with different dissolution characteristics following oral administration in normal men. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370308/),%,84,77666,DB00695,Furosemide
,7654491,"t1/2,z","Probenecid significantly increased the t1/2,z of frusemide from 2.01 +/- 0.68 to 3.40 +/- 1.48 h (P = 0.0015) and significantly decreased oral clearance from 164 +/- 67.0 to 58.3 +/- 28.1 ml min-1 (P = 0.0001).",Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654491/),h,2.01,80763,DB00695,Furosemide
,7654491,"t1/2,z","Probenecid significantly increased the t1/2,z of frusemide from 2.01 +/- 0.68 to 3.40 +/- 1.48 h (P = 0.0015) and significantly decreased oral clearance from 164 +/- 67.0 to 58.3 +/- 28.1 ml min-1 (P = 0.0001).",Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654491/),h,3.40,80764,DB00695,Furosemide
,7654491,oral clearance,"Probenecid significantly increased the t1/2,z of frusemide from 2.01 +/- 0.68 to 3.40 +/- 1.48 h (P = 0.0015) and significantly decreased oral clearance from 164 +/- 67.0 to 58.3 +/- 28.1 ml min-1 (P = 0.0001).",Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654491/),[ml] / [min],164,80765,DB00695,Furosemide
,7654491,oral clearance,"Probenecid significantly increased the t1/2,z of frusemide from 2.01 +/- 0.68 to 3.40 +/- 1.48 h (P = 0.0015) and significantly decreased oral clearance from 164 +/- 67.0 to 58.3 +/- 28.1 ml min-1 (P = 0.0001).",Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654491/),[ml] / [min],58.3,80766,DB00695,Furosemide
,7654491,tmax,"Probenecid significantly increased the tmax of the metabolite frusemide acyl glucuronide from 1.4 to 2.6 h, but had no effect on the tlag, Cmax, t1/2,z and plasma protein binding.",Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654491/),h,1.4,80767,DB00695,Furosemide
,7654491,tmax,"Probenecid significantly increased the tmax of the metabolite frusemide acyl glucuronide from 1.4 to 2.6 h, but had no effect on the tlag, Cmax, t1/2,z and plasma protein binding.",Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654491/),h,2.6,80768,DB00695,Furosemide
,7654491,urinary recoveries,"The urinary recoveries of unchanged frusemide (39.2 +/- 10.2 vs 34.4 +/- 8.6%, P = 0.28) and its acyl glucuronide (12.1 +/- 2.7 vs 11.8 +/- 3.7%, P > 0.8) were not altered by probenecid.",Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654491/),%,39.2,80769,DB00695,Furosemide
,7654491,urinary recoveries,"The urinary recoveries of unchanged frusemide (39.2 +/- 10.2 vs 34.4 +/- 8.6%, P = 0.28) and its acyl glucuronide (12.1 +/- 2.7 vs 11.8 +/- 3.7%, P > 0.8) were not altered by probenecid.",Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654491/),%,34.4,80770,DB00695,Furosemide
,7654491,urinary recoveries,"The urinary recoveries of unchanged frusemide (39.2 +/- 10.2 vs 34.4 +/- 8.6%, P = 0.28) and its acyl glucuronide (12.1 +/- 2.7 vs 11.8 +/- 3.7%, P > 0.8) were not altered by probenecid.",Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654491/),%,12.1,80771,DB00695,Furosemide
,7654491,urinary recoveries,"The urinary recoveries of unchanged frusemide (39.2 +/- 10.2 vs 34.4 +/- 8.6%, P = 0.28) and its acyl glucuronide (12.1 +/- 2.7 vs 11.8 +/- 3.7%, P > 0.8) were not altered by probenecid.",Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654491/),%,11.8,80772,DB00695,Furosemide
,7654491,renal clearance,"However, probenecid decreased the renal clearance of both frusemide (128 +/- 49 vs 44.0 +/- 18.6 ml min-1, P = 0.0002) and the acyl glucuronide (552 +/- 298 vs 158 +/- 94.0 ml min-1, P < 0.0001).",Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654491/),[ml] / [min],128,80773,DB00695,Furosemide
,7654491,renal clearance,"However, probenecid decreased the renal clearance of both frusemide (128 +/- 49 vs 44.0 +/- 18.6 ml min-1, P = 0.0002) and the acyl glucuronide (552 +/- 298 vs 158 +/- 94.0 ml min-1, P < 0.0001).",Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654491/),[ml] / [min],44.0,80774,DB00695,Furosemide
,7654491,renal clearance,"However, probenecid decreased the renal clearance of both frusemide (128 +/- 49 vs 44.0 +/- 18.6 ml min-1, P = 0.0002) and the acyl glucuronide (552 +/- 298 vs 158 +/- 94.0 ml min-1, P < 0.0001).",Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654491/),[ml] / [min],552,80775,DB00695,Furosemide
,7654491,renal clearance,"However, probenecid decreased the renal clearance of both frusemide (128 +/- 49 vs 44.0 +/- 18.6 ml min-1, P = 0.0002) and the acyl glucuronide (552 +/- 298 vs 158 +/- 94.0 ml min-1, P < 0.0001).",Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654491/),[ml] / [min],158,80776,DB00695,Furosemide
,7654491,non-renal clearance,"The non-renal clearance of frusemide (36.7 +/- 21.0 vs 15.2 +/- 13.4 ml min-1, P = 0.0068) was also decreased.",Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654491/),[ml] / [min],36.7,80777,DB00695,Furosemide
,7654491,non-renal clearance,"The non-renal clearance of frusemide (36.7 +/- 21.0 vs 15.2 +/- 13.4 ml min-1, P = 0.0068) was also decreased.",Probenecid inhibits the renal clearance of frusemide and its acyl glucuronide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7654491/),[ml] / [min],15.2,80778,DB00695,Furosemide
,8080005,Prenin,"The creatinine clearance fell (from 90.5 +/- 16.8 to 65.8 +/- 20.9 ml/min; p < 0.05), and Prenin rose (from 16.6 +/- 8.9 to 35.3 +/- 25.3 ng/ml/h; p < 0.02, as did Paldo (from 26.1 +/- 12.3 to 109 +/- 82.6 ng/dl; p < 0.01), indicating extracellular fluid volume contraction; however no significant clinical symptoms of hypovolemia ensued.",Correction of hypokalemia with antialdosterone therapy in Gitelman's syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8080005/),[ng] / [h·ml],16.6,84182,DB00695,Furosemide
,8080005,Prenin,"The creatinine clearance fell (from 90.5 +/- 16.8 to 65.8 +/- 20.9 ml/min; p < 0.05), and Prenin rose (from 16.6 +/- 8.9 to 35.3 +/- 25.3 ng/ml/h; p < 0.02, as did Paldo (from 26.1 +/- 12.3 to 109 +/- 82.6 ng/dl; p < 0.01), indicating extracellular fluid volume contraction; however no significant clinical symptoms of hypovolemia ensued.",Correction of hypokalemia with antialdosterone therapy in Gitelman's syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8080005/),[ng] / [h·ml],35.3,84183,DB00695,Furosemide
,8080005,Paldo,"The creatinine clearance fell (from 90.5 +/- 16.8 to 65.8 +/- 20.9 ml/min; p < 0.05), and Prenin rose (from 16.6 +/- 8.9 to 35.3 +/- 25.3 ng/ml/h; p < 0.02, as did Paldo (from 26.1 +/- 12.3 to 109 +/- 82.6 ng/dl; p < 0.01), indicating extracellular fluid volume contraction; however no significant clinical symptoms of hypovolemia ensued.",Correction of hypokalemia with antialdosterone therapy in Gitelman's syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8080005/),[ng] / [dl],26.1,84184,DB00695,Furosemide
,8080005,Paldo,"The creatinine clearance fell (from 90.5 +/- 16.8 to 65.8 +/- 20.9 ml/min; p < 0.05), and Prenin rose (from 16.6 +/- 8.9 to 35.3 +/- 25.3 ng/ml/h; p < 0.02, as did Paldo (from 26.1 +/- 12.3 to 109 +/- 82.6 ng/dl; p < 0.01), indicating extracellular fluid volume contraction; however no significant clinical symptoms of hypovolemia ensued.",Correction of hypokalemia with antialdosterone therapy in Gitelman's syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8080005/),[ng] / [dl],109,84185,DB00695,Furosemide
,6723758,total body clearance,The i.v. data gave a total body clearance of 162 +/- 10.8 ml/min and a renal clearance of 117 +/- 11.3 ml/min; the volume of distribution at steady state was 8.3 +/- 0.61.,Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723758/),[ml] / [min],162,84226,DB00695,Furosemide
,6723758,renal clearance,The i.v. data gave a total body clearance of 162 +/- 10.8 ml/min and a renal clearance of 117 +/- 11.3 ml/min; the volume of distribution at steady state was 8.3 +/- 0.61.,Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723758/),[ml] / [min],117,84227,DB00695,Furosemide
,6723758,volume of distribution at steady state,The i.v. data gave a total body clearance of 162 +/- 10.8 ml/min and a renal clearance of 117 +/- 11.3 ml/min; the volume of distribution at steady state was 8.3 +/- 0.61.,Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723758/),,8.3,84228,DB00695,Furosemide
,6723758,bio-availability,Oral administration gave a bio-availability of the tablet (fasting) of 51%.,Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723758/),%,51,84229,DB00695,Furosemide
,6723758,mean residence time,"Moment analysis gave a mean residence time after the i.v. dose, MRTi .v., of 51 +/- 1.5 min.",Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6723758/),min,51,84230,DB00695,Furosemide
,27872700,encap,"Acceptable drug loading and encapsulation efficiency of microspheres were obtained to be 70.43 and 85.21 %, respectively.",Pharmacokinetic study of furosemide incorporated PLGA microspheres after oral administration to rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27872700/),%,70.43,88185,DB00695,Furosemide
,27872700,encap,"Acceptable drug loading and encapsulation efficiency of microspheres were obtained to be 70.43 and 85.21 %, respectively.",Pharmacokinetic study of furosemide incorporated PLGA microspheres after oral administration to rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27872700/),%,85.21,88186,DB00695,Furosemide
,27872700,Cmax,"Microspheres provided improved pharmacokinetic parameters (Cmax = 147.94 ng/ml, Tmax = 1.92 hr) in rats as compared with pure drug (Cmax = 75.69 ng/ml, Tmax = 1.5 hr).",Pharmacokinetic study of furosemide incorporated PLGA microspheres after oral administration to rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27872700/),[ng] / [ml],147.94,88187,DB00695,Furosemide
,27872700,Tmax,"Microspheres provided improved pharmacokinetic parameters (Cmax = 147.94 ng/ml, Tmax = 1.92 hr) in rats as compared with pure drug (Cmax = 75.69 ng/ml, Tmax = 1.5 hr).",Pharmacokinetic study of furosemide incorporated PLGA microspheres after oral administration to rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27872700/),h,1.92,88188,DB00695,Furosemide
,27872700,Cmax,"Microspheres provided improved pharmacokinetic parameters (Cmax = 147.94 ng/ml, Tmax = 1.92 hr) in rats as compared with pure drug (Cmax = 75.69 ng/ml, Tmax = 1.5 hr).",Pharmacokinetic study of furosemide incorporated PLGA microspheres after oral administration to rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27872700/),[ng] / [ml],75.69,88189,DB00695,Furosemide
,27872700,Tmax,"Microspheres provided improved pharmacokinetic parameters (Cmax = 147.94 ng/ml, Tmax = 1.92 hr) in rats as compared with pure drug (Cmax = 75.69 ng/ml, Tmax = 1.5 hr).",Pharmacokinetic study of furosemide incorporated PLGA microspheres after oral administration to rat. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27872700/),h,1.5,88190,DB00695,Furosemide
,3032491,Systemic bioavailability,Systemic bioavailability of furosemide appears to be unchanged in the presence of pentopril (0.46 vs. 0.41).,"Inhibition of renal clearance of furosemide by pentopril, an angiotensin-converting enzyme inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3032491/),,0.46,88446,DB00695,Furosemide
,3032491,Systemic bioavailability,Systemic bioavailability of furosemide appears to be unchanged in the presence of pentopril (0.46 vs. 0.41).,"Inhibition of renal clearance of furosemide by pentopril, an angiotensin-converting enzyme inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3032491/),,0.41,88447,DB00695,Furosemide
,3032491,urinary output,"In spite of the decreased CLR and urinary excretion rate of furosemide, the urinary output (1749 vs. 1774 ml/6 hr) and Na+ excretion (757 vs. 816 mEq/6 hr) remained almost unchanged.","Inhibition of renal clearance of furosemide by pentopril, an angiotensin-converting enzyme inhibitor. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3032491/),[ml] / [6·h],1749,88448,DB00695,Furosemide
,3032491,urinary output,"In spite of the decreased CLR and urinary excretion rate of furosemide, the urinary output (1749 vs. 1774 ml/6 hr) and Na+ excretion (757 vs. 816 mEq/6 hr) remained almost unchanged.","Inhibition of renal clearance of furosemide by pentopril, an angiotensin-converting enzyme inhibitor. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3032491/),[ml] / [6·h],1774,88449,DB00695,Furosemide
,3032491,Na+ excretion,"In spite of the decreased CLR and urinary excretion rate of furosemide, the urinary output (1749 vs. 1774 ml/6 hr) and Na+ excretion (757 vs. 816 mEq/6 hr) remained almost unchanged.","Inhibition of renal clearance of furosemide by pentopril, an angiotensin-converting enzyme inhibitor. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3032491/),[meq] / [6·h],757,88450,DB00695,Furosemide
,3032491,Na+ excretion,"In spite of the decreased CLR and urinary excretion rate of furosemide, the urinary output (1749 vs. 1774 ml/6 hr) and Na+ excretion (757 vs. 816 mEq/6 hr) remained almost unchanged.","Inhibition of renal clearance of furosemide by pentopril, an angiotensin-converting enzyme inhibitor. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3032491/),[meq] / [6·h],816,88451,DB00695,Furosemide
,14658727,urine volume,"There was not a statistically significant difference in urine volume over 24 hours between methods; however, urine volume was significantly greater after CRI compared with IA during the first 8 hours ([median 25th percentile, 75th percentile]: 9.6 L [8.9, 14.4] for CRI versus 5.9 L [5.3, 6.0] for IA).",Furosemide continuous rate infusion in the horse: evaluation of enhanced efficacy and reduced side effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14658727/),l,9.6,90550,DB00695,Furosemide
,14658727,urine volume,"There was not a statistically significant difference in urine volume over 24 hours between methods; however, urine volume was significantly greater after CRI compared with IA during the first 8 hours ([median 25th percentile, 75th percentile]: 9.6 L [8.9, 14.4] for CRI versus 5.9 L [5.3, 6.0] for IA).",Furosemide continuous rate infusion in the horse: evaluation of enhanced efficacy and reduced side effects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14658727/),l,5.9,90551,DB00695,Furosemide
,14658727,Cl excretion,"Potassium, Ca, and Cl excretion was greater during CRI than IA (1,133 mmol [1.110, 1,229] versus 764 mmol [709, 904], 102.7 mmol [96.0, 117.2] versus 73.3 mmol [65.0, 73.5], and 1,776 mmol [1,657, 2.378] versus 1,596 mmol [1,457, 1,767], respectively).",Furosemide continuous rate infusion in the horse: evaluation of enhanced efficacy and reduced side effects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14658727/),mM,73.3,90552,DB00695,Furosemide
,14658727,Cl excretion,"Potassium, Ca, and Cl excretion was greater during CRI than IA (1,133 mmol [1.110, 1,229] versus 764 mmol [709, 904], 102.7 mmol [96.0, 117.2] versus 73.3 mmol [65.0, 73.5], and 1,776 mmol [1,657, 2.378] versus 1,596 mmol [1,457, 1,767], respectively).",Furosemide continuous rate infusion in the horse: evaluation of enhanced efficacy and reduced side effects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14658727/),mM,"1,776",90553,DB00695,Furosemide
,14658727,Cl excretion,"Potassium, Ca, and Cl excretion was greater during CRI than IA (1,133 mmol [1.110, 1,229] versus 764 mmol [709, 904], 102.7 mmol [96.0, 117.2] versus 73.3 mmol [65.0, 73.5], and 1,776 mmol [1,657, 2.378] versus 1,596 mmol [1,457, 1,767], respectively).",Furosemide continuous rate infusion in the horse: evaluation of enhanced efficacy and reduced side effects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14658727/),mM,"1,596",90554,DB00695,Furosemide
,14658727,Elimination half-lives,"Elimination half-lives of furosemide were 1.35 and 0.47 hours for CRI and IA, respectively.",Furosemide continuous rate infusion in the horse: evaluation of enhanced efficacy and reduced side effects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14658727/),h,1.35,90555,DB00695,Furosemide
,14658727,Elimination half-lives,"Elimination half-lives of furosemide were 1.35 and 0.47 hours for CRI and IA, respectively.",Furosemide continuous rate infusion in the horse: evaluation of enhanced efficacy and reduced side effects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14658727/),h,0.47,90556,DB00695,Furosemide
,14658727,area under the excretion rate curve,"The area under the excretion rate curve was 1,285.7 and 184.2 mL x mg/mL for CRI and IA, respectively.",Furosemide continuous rate infusion in the horse: evaluation of enhanced efficacy and reduced side effects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14658727/),[mg·ml] / [ml],"1,285.7",90557,DB00695,Furosemide
,14658727,area under the excretion rate curve,"The area under the excretion rate curve was 1,285.7 and 184.2 mL x mg/mL for CRI and IA, respectively.",Furosemide continuous rate infusion in the horse: evaluation of enhanced efficacy and reduced side effects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14658727/),[mg·ml] / [ml],184.2,90558,DB00695,Furosemide
,3240762,elimination half-life time,The 'apparent' elimination half-life time for furosemide is 2.1h and the elimination half-life time for OH-TA-sulphate is 2.0h.,Pharmacodynamics and pharmacokinetics of furosemide-retard and furosemide-retard/triamterene. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3240762/),h,2.0,90729,DB00695,Furosemide
,6626433,serum clearance (CLs),The serum clearance (CLs) was 170 +/- 19 ml min-1 in the young and 129 +/- 11 ml min-1 in the elderly (P less than 0.01) and the average renal clearance (CLr) was 67% of CLs in the young and 58% of CLs in the elderly (NS).,The pharmacokinetics of frusemide are influenced by age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626433/),[ml] / [min],170,92492,DB00695,Furosemide
,6626433,serum clearance (CLs),The serum clearance (CLs) was 170 +/- 19 ml min-1 in the young and 129 +/- 11 ml min-1 in the elderly (P less than 0.01) and the average renal clearance (CLr) was 67% of CLs in the young and 58% of CLs in the elderly (NS).,The pharmacokinetics of frusemide are influenced by age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626433/),[ml] / [min],129,92493,DB00695,Furosemide
,6626433,amount,The average amount of unchanged frusemide in the urine during the first 30 min was 30 +/- 6 mg in the young but only 20 +/- 4 mg in the elderly (P less than 0.01).,The pharmacokinetics of frusemide are influenced by age. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626433/),mg,30,92494,DB00695,Furosemide
,6626433,amount,The average amount of unchanged frusemide in the urine during the first 30 min was 30 +/- 6 mg in the young but only 20 +/- 4 mg in the elderly (P less than 0.01).,The pharmacokinetics of frusemide are influenced by age. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626433/),mg,20,92495,DB00695,Furosemide
,6626433,Vd ss,The Vd ss did not differ between the two age groups (0.130 1 kg-1) but the elimination half-life was 70 +/- 20 min in the young and 102 +/- 33 min in the elderly (P less than 0.05).,The pharmacokinetics of frusemide are influenced by age. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626433/),[1] / [kg],0.130,92496,DB00695,Furosemide
,6626433,elimination half-life,The Vd ss did not differ between the two age groups (0.130 1 kg-1) but the elimination half-life was 70 +/- 20 min in the young and 102 +/- 33 min in the elderly (P less than 0.05).,The pharmacokinetics of frusemide are influenced by age. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626433/),min,70,92497,DB00695,Furosemide
,6626433,elimination half-life,The Vd ss did not differ between the two age groups (0.130 1 kg-1) but the elimination half-life was 70 +/- 20 min in the young and 102 +/- 33 min in the elderly (P less than 0.05).,The pharmacokinetics of frusemide are influenced by age. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6626433/),min,102,92498,DB00695,Furosemide
,3102501,T1/2 beta,"T1/2 beta varied from 23 to 78 min, VD from 11 to 48 l/m2, Cl tot from 12 to 42 l/h per m2, and AUC from 138 to 1221 micrograms/h per l, confirming previously reported data.",Relationship between clinical parameters and pharmacokinetics of mitomycin C. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3102501/),min,23 to 78,92987,DB00695,Furosemide
,3102501,VD,"T1/2 beta varied from 23 to 78 min, VD from 11 to 48 l/m2, Cl tot from 12 to 42 l/h per m2, and AUC from 138 to 1221 micrograms/h per l, confirming previously reported data.",Relationship between clinical parameters and pharmacokinetics of mitomycin C. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3102501/),[l] / [m2],11 to 48,92988,DB00695,Furosemide
,3102501,Cl tot,"T1/2 beta varied from 23 to 78 min, VD from 11 to 48 l/m2, Cl tot from 12 to 42 l/h per m2, and AUC from 138 to 1221 micrograms/h per l, confirming previously reported data.",Relationship between clinical parameters and pharmacokinetics of mitomycin C. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3102501/),[l] / [h·m2],12 to 42,92989,DB00695,Furosemide
,3102501,AUC,"T1/2 beta varied from 23 to 78 min, VD from 11 to 48 l/m2, Cl tot from 12 to 42 l/h per m2, and AUC from 138 to 1221 micrograms/h per l, confirming previously reported data.",Relationship between clinical parameters and pharmacokinetics of mitomycin C. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3102501/),[μg] / [h·l],138 to 1221,92990,DB00695,Furosemide
,1783363,rate of absorption (tmax,The rate of absorption (tmax = 3 h) and the bioavailability of the two diuretics were not significantly modified by their combination.,Combination of long-acting furosemide and instant-acting amiloride: pharmacokinetics and pharmacodynamics in human subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783363/),h,3,95158,DB00695,Furosemide
,1783363,plasma half-life,"Furosemide plasma half-life was 2.77 +/- 1.04 h after the combination treatment and 2.76 +/- 0.98 h alone, amiloride plasma half-life was respectively 15.7 +/- 4.6 h and 14.6 +/- 3.7 h.",Combination of long-acting furosemide and instant-acting amiloride: pharmacokinetics and pharmacodynamics in human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783363/),h,2.77,95159,DB00695,Furosemide
,1783363,plasma half-life,"Furosemide plasma half-life was 2.77 +/- 1.04 h after the combination treatment and 2.76 +/- 0.98 h alone, amiloride plasma half-life was respectively 15.7 +/- 4.6 h and 14.6 +/- 3.7 h.",Combination of long-acting furosemide and instant-acting amiloride: pharmacokinetics and pharmacodynamics in human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783363/),h,2.76,95160,DB00695,Furosemide
,1783363,plasma half-life,"Furosemide plasma half-life was 2.77 +/- 1.04 h after the combination treatment and 2.76 +/- 0.98 h alone, amiloride plasma half-life was respectively 15.7 +/- 4.6 h and 14.6 +/- 3.7 h.",Combination of long-acting furosemide and instant-acting amiloride: pharmacokinetics and pharmacodynamics in human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783363/),h,15.7,95161,DB00695,Furosemide
,1783363,plasma half-life,"Furosemide plasma half-life was 2.77 +/- 1.04 h after the combination treatment and 2.76 +/- 0.98 h alone, amiloride plasma half-life was respectively 15.7 +/- 4.6 h and 14.6 +/- 3.7 h.",Combination of long-acting furosemide and instant-acting amiloride: pharmacokinetics and pharmacodynamics in human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1783363/),h,14.6,95162,DB00695,Furosemide
,6889429,Bioavailability,Bioavailability of the preparations with modified release properties--an enteric-coated tablet and a sustained release preparation in the form of a capsule containing diffusion pellets--was calculated to 80% of that of the rapid releasing tablet used as a standard.,The pharmaceutical and biological availability of commercial preparations of furosemide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6889429/),%,80,95445,DB00695,Furosemide
,2495004,IC50,"Its IC50 values for renin activity in human, squirrel monkey, marmoset, dog, hog, rabbit and rat plasma were 3.3, 6.6, 2.4, 42, 110, 86 and 3500 nM, respectively, and 26 microM for cathepsin D.","A novel nonpeptidic, orally active renin inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495004/),nM,3.3,96711,DB00695,Furosemide
,2495004,IC50,"Its IC50 values for renin activity in human, squirrel monkey, marmoset, dog, hog, rabbit and rat plasma were 3.3, 6.6, 2.4, 42, 110, 86 and 3500 nM, respectively, and 26 microM for cathepsin D.","A novel nonpeptidic, orally active renin inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495004/),nM,6.6,96712,DB00695,Furosemide
,2495004,IC50,"Its IC50 values for renin activity in human, squirrel monkey, marmoset, dog, hog, rabbit and rat plasma were 3.3, 6.6, 2.4, 42, 110, 86 and 3500 nM, respectively, and 26 microM for cathepsin D.","A novel nonpeptidic, orally active renin inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495004/),nM,2.4,96713,DB00695,Furosemide
,2495004,IC50,"Its IC50 values for renin activity in human, squirrel monkey, marmoset, dog, hog, rabbit and rat plasma were 3.3, 6.6, 2.4, 42, 110, 86 and 3500 nM, respectively, and 26 microM for cathepsin D.","A novel nonpeptidic, orally active renin inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495004/),nM,42,96714,DB00695,Furosemide
,2495004,IC50,"Its IC50 values for renin activity in human, squirrel monkey, marmoset, dog, hog, rabbit and rat plasma were 3.3, 6.6, 2.4, 42, 110, 86 and 3500 nM, respectively, and 26 microM for cathepsin D.","A novel nonpeptidic, orally active renin inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495004/),nM,110,96715,DB00695,Furosemide
,2495004,IC50,"Its IC50 values for renin activity in human, squirrel monkey, marmoset, dog, hog, rabbit and rat plasma were 3.3, 6.6, 2.4, 42, 110, 86 and 3500 nM, respectively, and 26 microM for cathepsin D.","A novel nonpeptidic, orally active renin inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495004/),nM,86,96716,DB00695,Furosemide
,2495004,IC50,"Its IC50 values for renin activity in human, squirrel monkey, marmoset, dog, hog, rabbit and rat plasma were 3.3, 6.6, 2.4, 42, 110, 86 and 3500 nM, respectively, and 26 microM for cathepsin D.","A novel nonpeptidic, orally active renin inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495004/),nM,3500,96717,DB00695,Furosemide
,2495004,IC50,"Its IC50 values for renin activity in human, squirrel monkey, marmoset, dog, hog, rabbit and rat plasma were 3.3, 6.6, 2.4, 42, 110, 86 and 3500 nM, respectively, and 26 microM for cathepsin D.","A novel nonpeptidic, orally active renin inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495004/),μM,26,96718,DB00695,Furosemide
,2495004,oral bioavailability,Pepsin and angiotensin converting enzyme were hardly inhibited at 10(-4) M. BW-175 showed an oral bioavailability of 2.8% at 10 mg/kg and 9.7% at 30 mg/kg in rats.,"A novel nonpeptidic, orally active renin inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495004/),%,2.8,96719,DB00695,Furosemide
,2495004,oral bioavailability,Pepsin and angiotensin converting enzyme were hardly inhibited at 10(-4) M. BW-175 showed an oral bioavailability of 2.8% at 10 mg/kg and 9.7% at 30 mg/kg in rats.,"A novel nonpeptidic, orally active renin inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2495004/),%,9.7,96720,DB00695,Furosemide
,4091871,terminal elimination half-life,RPH 2823 has a terminal elimination half-life of 3 h.,Pharmacodynamics and pharmacokinetics of the basic triamterene analogue dimethylaminohydroxypropoxytriamterene. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4091871/),h,3,97383,DB00695,Furosemide
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,0.58,98193,DB00695,Furosemide
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,2.1,98194,DB00695,Furosemide
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,1.4,98195,DB00695,Furosemide
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,1.1,98196,DB00695,Furosemide
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,4.4,98197,DB00695,Furosemide
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,0.5,98198,DB00695,Furosemide
,23222033,time to maximum plasma concentration (tmax),"Compared with controls, the RYGB group had significantly lower time to maximum plasma concentration (tmax) for caffeine (0.58 ± 0.5 vs 2.1 ± 2.2 hours, P < 0.0001), tolbutamide (1.4 ± 1.8 vs 2.1 ± 2.2 hours, P = 0.0001), omeprazole (1.1 ± 1.1 vs 4.4 ± 1.3 hours, P < 0.0001), and oral midazolam (0.5 ± 0.2 vs 0.7 ± 0.4 hours, P < 0.01).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,0.7,98199,DB00695,Furosemide
,23222033,tmax,"Compared with controls, the RYGB group had brisk natriuresis, with significantly lower tmax for urine sodium (1.3 ± 0.5 vs 3.1 ± 2.3 hours, P < 0.02) and correspondingly lower tmax for furosemide (1.8 ± 0.3 vs 4.2 ± 1.2 hours, P = 0.006).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,1.3,98200,DB00695,Furosemide
,23222033,tmax,"Compared with controls, the RYGB group had brisk natriuresis, with significantly lower tmax for urine sodium (1.3 ± 0.5 vs 3.1 ± 2.3 hours, P < 0.02) and correspondingly lower tmax for furosemide (1.8 ± 0.3 vs 4.2 ± 1.2 hours, P = 0.006).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,3.1,98201,DB00695,Furosemide
,23222033,tmax,"Compared with controls, the RYGB group had brisk natriuresis, with significantly lower tmax for urine sodium (1.3 ± 0.5 vs 3.1 ± 2.3 hours, P < 0.02) and correspondingly lower tmax for furosemide (1.8 ± 0.3 vs 4.2 ± 1.2 hours, P = 0.006).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,1.8,98202,DB00695,Furosemide
,23222033,tmax,"Compared with controls, the RYGB group had brisk natriuresis, with significantly lower tmax for urine sodium (1.3 ± 0.5 vs 3.1 ± 2.3 hours, P < 0.02) and correspondingly lower tmax for furosemide (1.8 ± 0.3 vs 4.2 ± 1.2 hours, P = 0.006).",Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23222033/),h,4.2,98203,DB00695,Furosemide
,7781259,time to reach maximum concentration [tmax],"Torsemide (time to reach maximum concentration [tmax], 1.1 +/- 0.9 hour) was more rapidly absorbed than furosemide (tmax, 2.4 +/- 2.5 hours), the absorption of which was delayed compared with that in healthy volunteers.","Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7781259/),h,1.1,100350,DB00695,Furosemide
,7781259,tmax,"Torsemide (time to reach maximum concentration [tmax], 1.1 +/- 0.9 hour) was more rapidly absorbed than furosemide (tmax, 2.4 +/- 2.5 hours), the absorption of which was delayed compared with that in healthy volunteers.","Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7781259/),h,2.4,100351,DB00695,Furosemide
,6678312,bioavailability,"Potential causes for reported incomplete (usually 40-60%) and often highly variable (e.g., 11-79%) bioavailability of furosemide in humans were investigated.",Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6678312/),,40,101222,DB00695,Furosemide
,6678312,bioavailability,"Potential causes for reported incomplete (usually 40-60%) and often highly variable (e.g., 11-79%) bioavailability of furosemide in humans were investigated.",Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6678312/),,11-79,101223,DB00695,Furosemide
less,6678312,hepatic first-pass elimination (HFPE),The drug was found to be fairly stable in gastric fluids and its hepatic first-pass elimination (HFPE) was estimated to be much less than 6% based on published i.v. data.,Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6678312/),%,6,101224,DB00695,Furosemide
,6678312,oral bioavailability,"Based on plasma data, oral bioavailability in four rats was only 30%, and the HFPE much less than 10%.",Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6678312/),%,30,101225,DB00695,Furosemide
less,6678312,oral bioavailability,"Based on plasma data, oral bioavailability in four rats was only 30%, and the HFPE much less than 10%.",Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6678312/),%,10,101226,DB00695,Furosemide
,9629992,elimination half-life,"The elimination half-life was significantly higher (p < 0.05) in Middle Eastern subjects (2.9+/-0.7 h) than in Asian subjects (2.2+/-0.6 h), while the maximal plasma concentration (Cmax) in Asian subjects (1,087+/-262 ng/ml) was significantly higher (p < 0.05) compared with Middle Eastern Arabs (776+/-163 ng/ml).",Comparative pharmacokinetics and pharmacodynamics of furosemide in Middle Eastern and in Asian subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9629992/),h,2.9,103322,DB00695,Furosemide
,9629992,elimination half-life,"The elimination half-life was significantly higher (p < 0.05) in Middle Eastern subjects (2.9+/-0.7 h) than in Asian subjects (2.2+/-0.6 h), while the maximal plasma concentration (Cmax) in Asian subjects (1,087+/-262 ng/ml) was significantly higher (p < 0.05) compared with Middle Eastern Arabs (776+/-163 ng/ml).",Comparative pharmacokinetics and pharmacodynamics of furosemide in Middle Eastern and in Asian subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9629992/),h,2.2,103323,DB00695,Furosemide
,9629992,maximal plasma concentration (Cmax),"The elimination half-life was significantly higher (p < 0.05) in Middle Eastern subjects (2.9+/-0.7 h) than in Asian subjects (2.2+/-0.6 h), while the maximal plasma concentration (Cmax) in Asian subjects (1,087+/-262 ng/ml) was significantly higher (p < 0.05) compared with Middle Eastern Arabs (776+/-163 ng/ml).",Comparative pharmacokinetics and pharmacodynamics of furosemide in Middle Eastern and in Asian subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9629992/),[ng] / [ml],"1,087",103324,DB00695,Furosemide
,9629992,maximal plasma concentration (Cmax),"The elimination half-life was significantly higher (p < 0.05) in Middle Eastern subjects (2.9+/-0.7 h) than in Asian subjects (2.2+/-0.6 h), while the maximal plasma concentration (Cmax) in Asian subjects (1,087+/-262 ng/ml) was significantly higher (p < 0.05) compared with Middle Eastern Arabs (776+/-163 ng/ml).",Comparative pharmacokinetics and pharmacodynamics of furosemide in Middle Eastern and in Asian subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9629992/),[ng] / [ml],776,103325,DB00695,Furosemide
,9629992,mean residence time (MRT),The mean residence time (MRT) and the operative apparent volume of distribution (Vd/F) were significantly greater in Middle Eastern Arabs (4.5+/-0.9 h and 54.1+/-14.91) than in Asian subjects (3.6+/-0.8 h and 38.6+/-16.51).,Comparative pharmacokinetics and pharmacodynamics of furosemide in Middle Eastern and in Asian subjects. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9629992/),h,4.5,103326,DB00695,Furosemide
,9629992,mean residence time (MRT),The mean residence time (MRT) and the operative apparent volume of distribution (Vd/F) were significantly greater in Middle Eastern Arabs (4.5+/-0.9 h and 54.1+/-14.91) than in Asian subjects (3.6+/-0.8 h and 38.6+/-16.51).,Comparative pharmacokinetics and pharmacodynamics of furosemide in Middle Eastern and in Asian subjects. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9629992/),h,3.6,103327,DB00695,Furosemide
,9629992,operative apparent volume of distribution (Vd/F),The mean residence time (MRT) and the operative apparent volume of distribution (Vd/F) were significantly greater in Middle Eastern Arabs (4.5+/-0.9 h and 54.1+/-14.91) than in Asian subjects (3.6+/-0.8 h and 38.6+/-16.51).,Comparative pharmacokinetics and pharmacodynamics of furosemide in Middle Eastern and in Asian subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9629992/),,54.1,103328,DB00695,Furosemide
,9629992,operative apparent volume of distribution (Vd/F),The mean residence time (MRT) and the operative apparent volume of distribution (Vd/F) were significantly greater in Middle Eastern Arabs (4.5+/-0.9 h and 54.1+/-14.91) than in Asian subjects (3.6+/-0.8 h and 38.6+/-16.51).,Comparative pharmacokinetics and pharmacodynamics of furosemide in Middle Eastern and in Asian subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9629992/),,38.6,103329,DB00695,Furosemide
,9629992,cumulative urinary excretion,The mean cumulative urinary excretion of furosemide in 8 h was 5.6 mg (range 1.6-15.2 mg) for Arabs and 6.1 mg (range 2.1-15.9 mg) for Asians.,Comparative pharmacokinetics and pharmacodynamics of furosemide in Middle Eastern and in Asian subjects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9629992/),mg,5.6,103330,DB00695,Furosemide
,9629992,cumulative urinary excretion,The mean cumulative urinary excretion of furosemide in 8 h was 5.6 mg (range 1.6-15.2 mg) for Arabs and 6.1 mg (range 2.1-15.9 mg) for Asians.,Comparative pharmacokinetics and pharmacodynamics of furosemide in Middle Eastern and in Asian subjects. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9629992/),mg,6.1,103331,DB00695,Furosemide
,9627074,QT intervals,"Although the potency of QND for QT prolongation was not affected by hypokalaemia, the QT intervals before drug administration were significantly prolonged in hypokalaemic rats (65.90 +/- 1.40 vs 56.60 +/- 0.748 msec, mean +/- SEM, p < 0.0001).",Effects of hypokalaemia on arrhythmogenic risk of quinidine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9627074/),ms,65.90,104276,DB00695,Furosemide
,9627074,QT intervals,"Although the potency of QND for QT prolongation was not affected by hypokalaemia, the QT intervals before drug administration were significantly prolonged in hypokalaemic rats (65.90 +/- 1.40 vs 56.60 +/- 0.748 msec, mean +/- SEM, p < 0.0001).",Effects of hypokalaemia on arrhythmogenic risk of quinidine in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9627074/),ms,56.60,104277,DB00695,Furosemide
,1941559,nonrenal clearance,The nonrenal clearance (4.58 versus 6.18 mL/min/kg) increased significantly in PB-treated rats.,Effects of phenobarbital and 3-methylcholanthrene pretreatment on the pharmacokinetics and pharmacodynamics of furosemide in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941559/),[ml] / [kg·min],4.58,104862,DB00695,Furosemide
,1941559,nonrenal clearance,The nonrenal clearance (4.58 versus 6.18 mL/min/kg) increased significantly in PB-treated rats.,Effects of phenobarbital and 3-methylcholanthrene pretreatment on the pharmacokinetics and pharmacodynamics of furosemide in rats. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941559/),[ml] / [kg·min],6.18,104863,DB00695,Furosemide
,1941559,urinary excretion,"The 8-h urine output per 100 g of body weight increased significantly in PB-treated rats; however, the 8-h urinary excretion of furosemide per 100 g of body weight (797 versus 635 micrograms) decreased significantly in PB-treated rats.",Effects of phenobarbital and 3-methylcholanthrene pretreatment on the pharmacokinetics and pharmacodynamics of furosemide in rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941559/),μg,797,104864,DB00695,Furosemide
,1941559,urinary excretion,"The 8-h urine output per 100 g of body weight increased significantly in PB-treated rats; however, the 8-h urinary excretion of furosemide per 100 g of body weight (797 versus 635 micrograms) decreased significantly in PB-treated rats.",Effects of phenobarbital and 3-methylcholanthrene pretreatment on the pharmacokinetics and pharmacodynamics of furosemide in rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1941559/),μg,635,104865,DB00695,Furosemide
,639832,serum clearance,"The average serum clearance was 66 ml/min in the patients and 219 ml/min in the normal subjects, and the corresponding weight corrected clearances were 1.33 ml/min . kg and 2.96 ml/min .",Pharmacokinetics of furosemide in anephric patients and in normal subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/639832/),[ml] / [min],66,105949,DB00695,Furosemide
,639832,serum clearance,"The average serum clearance was 66 ml/min in the patients and 219 ml/min in the normal subjects, and the corresponding weight corrected clearances were 1.33 ml/min . kg and 2.96 ml/min .",Pharmacokinetics of furosemide in anephric patients and in normal subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/639832/),[ml] / [min],219,105950,DB00695,Furosemide
,639832,weight corrected clearances,"The average serum clearance was 66 ml/min in the patients and 219 ml/min in the normal subjects, and the corresponding weight corrected clearances were 1.33 ml/min . kg and 2.96 ml/min .",Pharmacokinetics of furosemide in anephric patients and in normal subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/639832/),[ml] / [kg·min],1.33,105951,DB00695,Furosemide
,639832,weight corrected clearances,"The average serum clearance was 66 ml/min in the patients and 219 ml/min in the normal subjects, and the corresponding weight corrected clearances were 1.33 ml/min . kg and 2.96 ml/min .",Pharmacokinetics of furosemide in anephric patients and in normal subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/639832/),[ml] / [min],2.96,105952,DB00695,Furosemide
,690779,apparent volume of distribution,The mean (+/- SE) apparent volume of distribution was 829.2 +/- 118.9 ml/kg; t1/2 was 7.7 +/- 1.0 hour; elimination rate constant was 0.102 +/- 0.013/hour and plasma clearance was 81.61 +/- 14.98 ml/kg/hour.,Pharmacokinetic disposition and protein binding of furosemide in newborn infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/690779/),[ml] / [kg],829.2,106590,DB00695,Furosemide
,690779,t1/2,The mean (+/- SE) apparent volume of distribution was 829.2 +/- 118.9 ml/kg; t1/2 was 7.7 +/- 1.0 hour; elimination rate constant was 0.102 +/- 0.013/hour and plasma clearance was 81.61 +/- 14.98 ml/kg/hour.,Pharmacokinetic disposition and protein binding of furosemide in newborn infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/690779/),h,7.7,106591,DB00695,Furosemide
,690779,elimination rate constant,The mean (+/- SE) apparent volume of distribution was 829.2 +/- 118.9 ml/kg; t1/2 was 7.7 +/- 1.0 hour; elimination rate constant was 0.102 +/- 0.013/hour and plasma clearance was 81.61 +/- 14.98 ml/kg/hour.,Pharmacokinetic disposition and protein binding of furosemide in newborn infants. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/690779/),1/[h],0.102,106592,DB00695,Furosemide
,690779,plasma clearance,The mean (+/- SE) apparent volume of distribution was 829.2 +/- 118.9 ml/kg; t1/2 was 7.7 +/- 1.0 hour; elimination rate constant was 0.102 +/- 0.013/hour and plasma clearance was 81.61 +/- 14.98 ml/kg/hour.,Pharmacokinetic disposition and protein binding of furosemide in newborn infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/690779/),[ml] / [h·kg],81.61,106593,DB00695,Furosemide
,9172005,time to peak concentrations,"The test preparation (A) was found to achieve a considerably higher concentration (17.2 +/- 9.304 mg/l) than the reference preparation (11.1 +/- 6.484 mg/l); the time to peak concentrations was statistically significantly shorter for the test preparation (1.033 +/- 0.743 h) than for the reference preparation (1.656 +/- 0.586), and the areas under the concentration curves were statistically significantly greater for the examined preparation (65.9 mg.h/l) than for the reference preparation (46.845 mg.h/l).",Determination of bioequivalence of two furosemide preparations; the effect of high doses of furosemide on some pharmacokinetic parameters. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9172005/),h,1.033,108617,DB00695,Furosemide
,9172005,time to peak concentrations,"The test preparation (A) was found to achieve a considerably higher concentration (17.2 +/- 9.304 mg/l) than the reference preparation (11.1 +/- 6.484 mg/l); the time to peak concentrations was statistically significantly shorter for the test preparation (1.033 +/- 0.743 h) than for the reference preparation (1.656 +/- 0.586), and the areas under the concentration curves were statistically significantly greater for the examined preparation (65.9 mg.h/l) than for the reference preparation (46.845 mg.h/l).",Determination of bioequivalence of two furosemide preparations; the effect of high doses of furosemide on some pharmacokinetic parameters. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9172005/),,1.656,108618,DB00695,Furosemide
,9172005,areas under the concentration curves,"The test preparation (A) was found to achieve a considerably higher concentration (17.2 +/- 9.304 mg/l) than the reference preparation (11.1 +/- 6.484 mg/l); the time to peak concentrations was statistically significantly shorter for the test preparation (1.033 +/- 0.743 h) than for the reference preparation (1.656 +/- 0.586), and the areas under the concentration curves were statistically significantly greater for the examined preparation (65.9 mg.h/l) than for the reference preparation (46.845 mg.h/l).",Determination of bioequivalence of two furosemide preparations; the effect of high doses of furosemide on some pharmacokinetic parameters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9172005/),[h·mg] / [l],65.9,108619,DB00695,Furosemide
,9172005,areas under the concentration curves,"The test preparation (A) was found to achieve a considerably higher concentration (17.2 +/- 9.304 mg/l) than the reference preparation (11.1 +/- 6.484 mg/l); the time to peak concentrations was statistically significantly shorter for the test preparation (1.033 +/- 0.743 h) than for the reference preparation (1.656 +/- 0.586), and the areas under the concentration curves were statistically significantly greater for the examined preparation (65.9 mg.h/l) than for the reference preparation (46.845 mg.h/l).",Determination of bioequivalence of two furosemide preparations; the effect of high doses of furosemide on some pharmacokinetic parameters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9172005/),[h·mg] / [l],46.845,108620,DB00695,Furosemide
,9172005,relative bioavailability,"The relative bioavailability of the test preparation was 129%, i.e. it was not bioequivalent with the reference preparation.",Determination of bioequivalence of two furosemide preparations; the effect of high doses of furosemide on some pharmacokinetic parameters. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9172005/),%,129,108621,DB00695,Furosemide
,22674769,flow rate,"Chromatographic separation was achieved on a Zorbax XDB-Phenyl (4.6 × 75 mm, 3.5 µm) column using an isocratic mobile phase (5 mm ammonium acetate:methanol, 20:80, v/v) at a flow rate of 0.8 mL/min with a total run time of 2.2 min.",Simultaneous determination of carisoprodol and aspirin in human plasma using liquid chromatography-tandem mass spectrometry in polarity switch mode: application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22674769/),[ml] / [min],0.8,110441,DB00695,Furosemide
,22674769,total run time,"Chromatographic separation was achieved on a Zorbax XDB-Phenyl (4.6 × 75 mm, 3.5 µm) column using an isocratic mobile phase (5 mm ammonium acetate:methanol, 20:80, v/v) at a flow rate of 0.8 mL/min with a total run time of 2.2 min.",Simultaneous determination of carisoprodol and aspirin in human plasma using liquid chromatography-tandem mass spectrometry in polarity switch mode: application to a human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22674769/),min,2.2,110442,DB00695,Furosemide
,6519165,Absolute bioavailability,Absolute bioavailability was 56% for Lasix and 55% for Furix (AUC).,Implications of intraindividual variability in bioavailability studies of furosemide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519165/),%,56,111161,DB00695,Furosemide
,6519165,Absolute bioavailability,Absolute bioavailability was 56% for Lasix and 55% for Furix (AUC).,Implications of intraindividual variability in bioavailability studies of furosemide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519165/),%,55,111162,DB00695,Furosemide
,6519165,Rate of absorption,"Rate of absorption, quantified as MAT, was 128 min for Lasix and 98 min for Furix (16 observations).",Implications of intraindividual variability in bioavailability studies of furosemide. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519165/),min,128,111163,DB00695,Furosemide
,6519165,Rate of absorption,"Rate of absorption, quantified as MAT, was 128 min for Lasix and 98 min for Furix (16 observations).",Implications of intraindividual variability in bioavailability studies of furosemide. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519165/),min,98,111164,DB00695,Furosemide
,6519165,MAT,"Rate of absorption, quantified as MAT, was 128 min for Lasix and 98 min for Furix (16 observations).",Implications of intraindividual variability in bioavailability studies of furosemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519165/),min,128,111165,DB00695,Furosemide
,6519165,MAT,"Rate of absorption, quantified as MAT, was 128 min for Lasix and 98 min for Furix (16 observations).",Implications of intraindividual variability in bioavailability studies of furosemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519165/),min,98,111166,DB00695,Furosemide
,6519165,mean residence time,"Since MAT was significantly longer (p less than 0.001) than the mean residence time after the i.v. dose (57 min), absorption was evidently the rate-limiting step in the overall kinetics of oral furosemide.",Implications of intraindividual variability in bioavailability studies of furosemide. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6519165/),min,57,111167,DB00695,Furosemide
,6148869,plasma elimination half-life,In nine patients the plasma elimination half-life of unchanged nadolol averaged 26 hours following a single 40 mg oral dose during the interdialytic period.,Nadolol in hypertensive patients maintained on long-term hemodialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6148869/),h,26,111216,DB00695,Furosemide
,9046346,IC50,"Compound 14n (3-tert-butyl-1-propyl-5-[[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-y l] methyl]-1H-pyrazole-4-carboxylic acid, UR-7280) shows high potency both in vitro (IC50 = 3 nM) and in vivo (iv, 61.2 +/- 10% decrease in blood pressure at 0.3 mg/kg; po, 30 mmHg fall in blood pressure at 0.3 mg/kg), in comparison to losartan (IC50 = 59 nM; iv, 62.5 +/- 8.9% decrease in blood pressure at 1 mg/kg; po, 13 mmHg fall in blood pressure at 3 mg/kg).",Synthesis and structure-activity relationship of a new series of potent AT1 selective angiotensin II receptor antagonists: 5-(biphenyl-4-ylmethyl)pyrazoles. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9046346/),nM,3,114810,DB00695,Furosemide
,9046346,IC50,"Compound 14n (3-tert-butyl-1-propyl-5-[[2'-(1H-tetrazol-5-yl)-1,1'-biphenyl-4-y l] methyl]-1H-pyrazole-4-carboxylic acid, UR-7280) shows high potency both in vitro (IC50 = 3 nM) and in vivo (iv, 61.2 +/- 10% decrease in blood pressure at 0.3 mg/kg; po, 30 mmHg fall in blood pressure at 0.3 mg/kg), in comparison to losartan (IC50 = 59 nM; iv, 62.5 +/- 8.9% decrease in blood pressure at 1 mg/kg; po, 13 mmHg fall in blood pressure at 3 mg/kg).",Synthesis and structure-activity relationship of a new series of potent AT1 selective angiotensin II receptor antagonists: 5-(biphenyl-4-ylmethyl)pyrazoles. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9046346/),nM,59,114811,DB00695,Furosemide
,11204745,flow rate,"Both compounds were extracted from human plasma with ethyl acetate at pH 1 and were chromatographed using Shim-Pack GLC-CN column and a mobile phase consisting of acetonitrile and 20 mM ammonium acetate buffer solution pH 7, 4:1 (v/v) at a flow rate 1 ml min(-1).",High-performance liquid chromatography-mass spectrometric analysis of furosemide in plasma and its use in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204745/),[ml] / [min],1,115645,DB00695,Furosemide
,11204745,Detection limit,Detection limit for furosemide in plasma was 10 ng ml(-1).,High-performance liquid chromatography-mass spectrometric analysis of furosemide in plasma and its use in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204745/),[ng] / [ml],10,115646,DB00695,Furosemide
,11204745,extraction recovery percentages,The extraction recovery percentages of furosemide and IS from plasma were in the range 89.3-97.1%.,High-performance liquid chromatography-mass spectrometric analysis of furosemide in plasma and its use in pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204745/),%,89.3-97.1,115647,DB00695,Furosemide
,2095345,F,A slight reduction in the area under the concentration-time curve (AUC) of plasma furosemide was found for the fixed combination (AUC480) F2.58 micrograms.h.ml-1; F + T 2.46 micrograms.h.ml-1; FT 1.97 micrograms.h.ml-1.,Comparison of the diuretic effect and absorption of a single dose of furosemide and free and the fixed combinations of furosemide and triamterene in healthy male adults. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095345/),[h·μg] / [ml],2.58,117150,DB00695,Furosemide
,2095345,F + T,A slight reduction in the area under the concentration-time curve (AUC) of plasma furosemide was found for the fixed combination (AUC480) F2.58 micrograms.h.ml-1; F + T 2.46 micrograms.h.ml-1; FT 1.97 micrograms.h.ml-1.,Comparison of the diuretic effect and absorption of a single dose of furosemide and free and the fixed combinations of furosemide and triamterene in healthy male adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095345/),[h·μg] / [ml],2.46,117151,DB00695,Furosemide
,2095345,FT,A slight reduction in the area under the concentration-time curve (AUC) of plasma furosemide was found for the fixed combination (AUC480) F2.58 micrograms.h.ml-1; F + T 2.46 micrograms.h.ml-1; FT 1.97 micrograms.h.ml-1.,Comparison of the diuretic effect and absorption of a single dose of furosemide and free and the fixed combinations of furosemide and triamterene in healthy male adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095345/),[h·μg] / [ml],1.97,117152,DB00695,Furosemide
,2095345,AUC480,There was a significant reduction in the AUC480 of plasma triamterene (F + T 204.9 micrograms.h.l-1; FT 130.2 micrograms.h.l-1).,Comparison of the diuretic effect and absorption of a single dose of furosemide and free and the fixed combinations of furosemide and triamterene in healthy male adults. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095345/),[h·μg] / [l],204.9,117153,DB00695,Furosemide
,2095345,AUC480,There was a significant reduction in the AUC480 of plasma triamterene (F + T 204.9 micrograms.h.l-1; FT 130.2 micrograms.h.l-1).,Comparison of the diuretic effect and absorption of a single dose of furosemide and free and the fixed combinations of furosemide and triamterene in healthy male adults. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095345/),[h·μg] / [l],130.2,117154,DB00695,Furosemide
,2095345,F + T,There was a significant reduction in the AUC480 of plasma triamterene (F + T 204.9 micrograms.h.l-1; FT 130.2 micrograms.h.l-1).,Comparison of the diuretic effect and absorption of a single dose of furosemide and free and the fixed combinations of furosemide and triamterene in healthy male adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095345/),[h·μg] / [l],204.9,117155,DB00695,Furosemide
,2095345,FT,There was a significant reduction in the AUC480 of plasma triamterene (F + T 204.9 micrograms.h.l-1; FT 130.2 micrograms.h.l-1).,Comparison of the diuretic effect and absorption of a single dose of furosemide and free and the fixed combinations of furosemide and triamterene in healthy male adults. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095345/),[h·μg] / [l],130.2,117156,DB00695,Furosemide
,2095345,excretion,Sodium excretion after F + T and FT was more pronounced than after F (F + T 302 mmol; FT 311 mmol; F259 mmol).,Comparison of the diuretic effect and absorption of a single dose of furosemide and free and the fixed combinations of furosemide and triamterene in healthy male adults. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095345/),mM,302,117157,DB00695,Furosemide
,2095345,excretion,Sodium excretion after F + T and FT was more pronounced than after F (F + T 302 mmol; FT 311 mmol; F259 mmol).,Comparison of the diuretic effect and absorption of a single dose of furosemide and free and the fixed combinations of furosemide and triamterene in healthy male adults. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2095345/),mM,311,117158,DB00695,Furosemide
,6872415,bioavailability,"Consequently, bumetanide has an estimated bioavailability of 80% (approximately 40% for furosemide).",Bumetanide and furosemide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6872415/),%,80,118669,DB00695,Furosemide
,6872415,bioavailability,"Consequently, bumetanide has an estimated bioavailability of 80% (approximately 40% for furosemide).",Bumetanide and furosemide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6872415/),%,40,118670,DB00695,Furosemide
,6872415,dose inducing half-maximal response,"The relationship between the logarithm of the urinary bumetanide excretion rate and the logarithm of the sodium excretion rate was described by a sigmoid-shaped dose-response curve, with a dose inducing half-maximal response of 1 +/- 0.04 micrograms/min; it was 69.8 micrograms/min for furosemide.",Bumetanide and furosemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6872415/),[μg] / [min],1,118671,DB00695,Furosemide
,6872415,dose inducing half-maximal response,"The relationship between the logarithm of the urinary bumetanide excretion rate and the logarithm of the sodium excretion rate was described by a sigmoid-shaped dose-response curve, with a dose inducing half-maximal response of 1 +/- 0.04 micrograms/min; it was 69.8 micrograms/min for furosemide.",Bumetanide and furosemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6872415/),[μg] / [min],69.8,118672,DB00695,Furosemide
,1712269,terminal half-life,"In clinical pharmacology studies, cilazapril, after its bioactivation to cilazaprilat, was characterised as a potent, reversible angiotensin converting enzyme (ACE) inhibitor with a terminal half-life of 30 to 50 hours, which is consistent with saturable binding to ACE.",Clinical pharmacology of cilazapril. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1712269/),h,30 to 50,120675,DB00695,Furosemide
less,3948304,elimination half-life (t1/2,The elimination half-life (t1/2 less than 80 min) allows autologous bone marrow transplantation 24 h after the drug administration.,Pharmacokinetics of high-dose melphalan in children and adults. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3948304/),min,80,121683,DB00695,Furosemide
,10454086,ratio of sodium:chloride excretion,"Administration of frusemide without phenylbutazone led to diuresis, natriuresis, kaliuresis and chloruresis, and altered the ratio of sodium:chloride excretion from 0.4 to 1.0 in the first hour of diuresis.",Attenuation by phenylbutazone of the renal effects and excretion of frusemide in horses. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454086/),,0.4,127126,DB00695,Furosemide
,10454086,ratio of sodium:chloride excretion,"Administration of frusemide without phenylbutazone led to diuresis, natriuresis, kaliuresis and chloruresis, and altered the ratio of sodium:chloride excretion from 0.4 to 1.0 in the first hour of diuresis.",Attenuation by phenylbutazone of the renal effects and excretion of frusemide in horses. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10454086/),,1.0,127127,DB00695,Furosemide
,1660546,urinary,"The urinary amount of furosemide in the Li-treated rats was significantly lower than that in the control animals [Li group (n = 12): 514 +/- 75 (mean +/- S.E.) vs. control group (n = 12): 916 +/- 85 micrograms/kg/6 hr, P less than 0.01].",Influence of chronic lithium treatment on urinary amount of furosemide in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1660546/),[μg] / [6·h·kg],51,127528,DB00695,Furosemide
,1660546,urinary,"The urinary amount of furosemide in the Li-treated rats was significantly lower than that in the control animals [Li group (n = 12): 514 +/- 75 (mean +/- S.E.) vs. control group (n = 12): 916 +/- 85 micrograms/kg/6 hr, P less than 0.01].",Influence of chronic lithium treatment on urinary amount of furosemide in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1660546/),[μg] / [6·h·kg],91,127529,DB00695,Furosemide
,637676,F clearance,In normal children the mean F clearance is 296.,[Pharmacokinetic study of intravenous furosemide in nephrotic syndrome in children]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/637676/),,296,130675,DB00695,Furosemide
,31375096,systemic clearance,There were no significant differences in systemic clearance based on the geometric mean (95% confidence interval) (409 (347-482) mL/h/kg) for 4 h and 320 (177-580) mL/h/kg) for 24 h) between horses that were exercised 4- and 24-h post-furosemide administration.,Pharmacokinetics of furosemide in thoroughbred horses subjected to supramaximal treadmill exercise with and without controlled access to water. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31375096/),[ml] / [h·kg],409,131327,DB00695,Furosemide
,31375096,systemic clearance,There were no significant differences in systemic clearance based on the geometric mean (95% confidence interval) (409 (347-482) mL/h/kg) for 4 h and 320 (177-580) mL/h/kg) for 24 h) between horses that were exercised 4- and 24-h post-furosemide administration.,Pharmacokinetics of furosemide in thoroughbred horses subjected to supramaximal treadmill exercise with and without controlled access to water. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31375096/),[ml] / [h·kg],320,131328,DB00695,Furosemide
,6828331,Bioavailability,Bioavailability of F in the nephrotic children averaged 58.8% indicating that the gastrointestinal absorption of the drug was unaffected by the disease and by the age of the patients.,Pharmacokinetics of furosemide urinary elimination by nephrotic children. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6828331/),%,58.8,131388,DB00695,Furosemide
,6828331,elimination half-life of F,"The elimination half-life of F, calculated from the drug urinary excretion data in the NS patients was 2.06 +/- 0.96 h (mean +/- SD), whereas in the control children, it was 2.14 +/- 0.69 h.",Pharmacokinetics of furosemide urinary elimination by nephrotic children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6828331/),h,2.06,131389,DB00695,Furosemide
,6828331,elimination half-life of F,"The elimination half-life of F, calculated from the drug urinary excretion data in the NS patients was 2.06 +/- 0.96 h (mean +/- SD), whereas in the control children, it was 2.14 +/- 0.69 h.",Pharmacokinetics of furosemide urinary elimination by nephrotic children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6828331/),h,2.14,131390,DB00695,Furosemide
,3557737,half-life,Average values of the half-life (205 +/- 28 min) and renal clearance (0.8 +/- 0.09 ml/min/kg) were similar to those reported by previous investigators.,Steady state absorption kinetics and pharmacodynamics of furosemide in congestive heart failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3557737/),min,205,133469,DB00695,Furosemide
,3557737,renal clearance,Average values of the half-life (205 +/- 28 min) and renal clearance (0.8 +/- 0.09 ml/min/kg) were similar to those reported by previous investigators.,Steady state absorption kinetics and pharmacodynamics of furosemide in congestive heart failure. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3557737/),[ml] / [kg·min],0.8,133470,DB00695,Furosemide
,1233253,gastrointestinal uptake,The average gastrointestinal uptake estimated by comparison of the urinary recovery of label and the areas under the plasma curves after the two routes of administration was 65%.,On the fate of furosemide in man. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233253/),%,65,133643,DB00695,Furosemide
,1233253,half life of radio,The half life of radioactivity in the plasma after oral 35S-furosemide was 90 +/- 17 min (estimated on the slope between 2 and 6 h); the corresponding figure after 35S-furosemide i.v. was 47-53 min (slope 0.5-4 h).,On the fate of furosemide in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233253/),min,90,133644,DB00695,Furosemide
,1233253,half life of radio,The half life of radioactivity in the plasma after oral 35S-furosemide was 90 +/- 17 min (estimated on the slope between 2 and 6 h); the corresponding figure after 35S-furosemide i.v. was 47-53 min (slope 0.5-4 h).,On the fate of furosemide in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233253/),min,47-53,133645,DB00695,Furosemide
,1233253,total urinary recovery of label,"The total urinary recovery of label (5-7 d) after oral and intravenous administration was 55.1 +/- 3.2 (mean +/- SD) and 82-84%, respectively.",On the fate of furosemide in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233253/),%,5,133646,DB00695,Furosemide
,1233253,total urinary recovery of label,"The total urinary recovery of label (5-7 d) after oral and intravenous administration was 55.1 +/- 3.2 (mean +/- SD) and 82-84%, respectively.",On the fate of furosemide in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233253/),%,55.1,133647,DB00695,Furosemide
,1233253,total urinary recovery of label,"The total urinary recovery of label (5-7 d) after oral and intravenous administration was 55.1 +/- 3.2 (mean +/- SD) and 82-84%, respectively.",On the fate of furosemide in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233253/),%,82-84,133648,DB00695,Furosemide
,598405,half-life of,The half-life of the fall in concentration of muzolimine in plasma was 3.7 up to 10 h after its administration.,Comparison of the pharmacodynamic effects of furosemide and BAY g 2821 and correlation of the pharmacodynamics and pharmacokinetics of BAY g 2821 (muzolimine). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/598405/),,3.7,133772,DB00695,Furosemide
,3694431,t1/2 alpha,"On the basis of the results, it was demonstrated that disposition of furosemide in man can be described by a two-compartment open model with the following average parameters: t1/2 alpha = 0.237 +/- 0.069 h, t1/2 beta = 1.29 +/- 0.20 h and Vss = 8.46 +/- 2.171.",A study on furosemide disposition in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694431/),h,0.237,134379,DB00695,Furosemide
,3694431,t1/2 beta,"On the basis of the results, it was demonstrated that disposition of furosemide in man can be described by a two-compartment open model with the following average parameters: t1/2 alpha = 0.237 +/- 0.069 h, t1/2 beta = 1.29 +/- 0.20 h and Vss = 8.46 +/- 2.171.",A study on furosemide disposition in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694431/),h,1.29,134380,DB00695,Furosemide
,3694431,Vss,"On the basis of the results, it was demonstrated that disposition of furosemide in man can be described by a two-compartment open model with the following average parameters: t1/2 alpha = 0.237 +/- 0.069 h, t1/2 beta = 1.29 +/- 0.20 h and Vss = 8.46 +/- 2.171.",A study on furosemide disposition in man. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694431/),,8.46,134381,DB00695,Furosemide
,3694431,first-order absorption rate constant ka,"After oral administration of furosemide solution, the drug was rapidly absorbed from the gastrointestinal tract with a first-order absorption rate constant ka of 2.33 +/- 0.93 h-1 but there was a lag time of about 6.45 min for drug resolution and entering the absorption site.",A study on furosemide disposition in man. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694431/),1/[h],2.33,134382,DB00695,Furosemide
,3694431,lag time,"After oral administration of furosemide solution, the drug was rapidly absorbed from the gastrointestinal tract with a first-order absorption rate constant ka of 2.33 +/- 0.93 h-1 but there was a lag time of about 6.45 min for drug resolution and entering the absorption site.",A study on furosemide disposition in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694431/),min,6.45,134383,DB00695,Furosemide
,3694431,oral relative bioavailability,"The oral relative bioavailability was estimated as 83 +/- 14%, which was higher than reported values.",A study on furosemide disposition in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694431/),%,83,134384,DB00695,Furosemide
,3694431,systemic clearance (CLs),"The systemic clearance (CLs) and renal clearance (CLr), following bolus intravenous dosing were 7.60 +/- 2.29 and 6.44 +/- 1.81 l/h, respectively.",A study on furosemide disposition in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694431/),[l] / [h],7.60,134385,DB00695,Furosemide
,3694431,renal clearance (CLr),"The systemic clearance (CLs) and renal clearance (CLr), following bolus intravenous dosing were 7.60 +/- 2.29 and 6.44 +/- 1.81 l/h, respectively.",A study on furosemide disposition in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694431/),[l] / [h],6.44,134386,DB00695,Furosemide
,3694431,nonrenal clearance ratio (CRnr),"The oral route did not influence CLs and CLr on the whole, but the nonrenal clearance ratio (CRnr) after oral dosing (15.7 +/- 4.8%) was significantly higher than that after intravenous administration (11.2 +/- 4.0%), which can be explained by a first-pass effect of the liver-portal system.",A study on furosemide disposition in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694431/),%,15.7,134387,DB00695,Furosemide
,3694431,nonrenal clearance ratio (CRnr),"The oral route did not influence CLs and CLr on the whole, but the nonrenal clearance ratio (CRnr) after oral dosing (15.7 +/- 4.8%) was significantly higher than that after intravenous administration (11.2 +/- 4.0%), which can be explained by a first-pass effect of the liver-portal system.",A study on furosemide disposition in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3694431/),%,11.2,134388,DB00695,Furosemide
,3370058,plasma elimination half-life,In accordance with the pharmacodynamic characteristics plasma elimination half-life of torasemide was about 1.5 h in the rat and bioavailability was nearly complete.,Chemistry and pharmacological properties of the pyridine-3-sulfonylurea derivative torasemide. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370058/),h,1.5,135635,DB00695,Furosemide
,28685495,relative bioavailability,"The relative bioavailability of rosuvastatin was essentially unchanged when administered with metformin in T1 and T2, but in T3 it increased to 152% for AUC0-tz (90% CI 135-171%) and 154% for C max (90% CI 132-180%).",Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28685495/),%,152,136188,DB00695,Furosemide
,28685495,relative bioavailability,"The relative bioavailability of rosuvastatin was essentially unchanged when administered with metformin in T1 and T2, but in T3 it increased to 152% for AUC0-tz (90% CI 135-171%) and 154% for C max (90% CI 132-180%).",Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28685495/),%,154,136189,DB00695,Furosemide
,2844083,oral bioavailability,"The angiotensin-converting enzyme inhibitor, lisinopril, has an oral bioavailability of 25 percent +/- 4 percent, which is unaffected by food.",Pharmacokinetics of lisinopril. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2844083/),%,25,139309,DB00695,Furosemide
,2844083,accumulation half-life,The accumulation half-life averages 12.6 hours despite a terminal serum half-life of approximately 40 hours.,Pharmacokinetics of lisinopril. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2844083/),h,12.6,139310,DB00695,Furosemide
,2844083,terminal serum half-life,The accumulation half-life averages 12.6 hours despite a terminal serum half-life of approximately 40 hours.,Pharmacokinetics of lisinopril. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2844083/),h,40,139311,DB00695,Furosemide
,7086702,T 1/2,We observed a T 1/2 of 55 min and protein binding of 65% as determined in vitro by equilibrium dialysis.,"Vancomycin in rabbits: pharmacokinetics, extravascular diffusion, renal excretion and interactions with furosemide. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7086702/),min,55,139679,DB00695,Furosemide
,7086702,fractional excretion,Vancomycin appeared to be secreted by renal tubules (fractional excretion: 177 +/- 44%).,"Vancomycin in rabbits: pharmacokinetics, extravascular diffusion, renal excretion and interactions with furosemide. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7086702/),%,177,139680,DB00695,Furosemide
,7151641,elimination half-life of F,The elimination half-life of F calculated from the drug cumulative urinary excretion data was 0.598 +/- 0.24 h.,Urinary elimination kinetics and diuretic effect of intravenous furosemide in nephrotic children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7151641/),h,0.598,140721,DB00695,Furosemide
,43224,Recovery,Recovery of furosemide and its metabolites from urine in 24 hr varied between 30 and 98% of the administered dose.,Biotransformation of furosemide in patients with acute pulmonary edema. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/43224/),%,30 and 98,140813,DB00695,Furosemide
,30339054,elimination half-life,"After IV administration the elimination half-life was (mean and coefficient of variation) 2.25 h (72%), systemic clearance was 149 ml/kg/h (27.4%) and volume of distribution was 227 ml/kg (22%).","Pharmacokinetics of furosemide after intravenous, oral and transdermal administration to cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30339054/),h,2.25,141244,DB00695,Furosemide
,30339054,systemic clearance,"After IV administration the elimination half-life was (mean and coefficient of variation) 2.25 h (72%), systemic clearance was 149 ml/kg/h (27.4%) and volume of distribution was 227 ml/kg (22%).","Pharmacokinetics of furosemide after intravenous, oral and transdermal administration to cats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30339054/),[ml] / [h·kg],149,141245,DB00695,Furosemide
,30339054,volume of distribution,"After IV administration the elimination half-life was (mean and coefficient of variation) 2.25 h (72%), systemic clearance was 149 ml/kg/h (27.4%) and volume of distribution was 227 ml/kg (22%).","Pharmacokinetics of furosemide after intravenous, oral and transdermal administration to cats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30339054/),[ml] / [kg],227,141246,DB00695,Furosemide
,30339054,terminal half-life,"After oral administration the terminal half-life was 1.2 h (18.7%), peak concentration was 3.4 μg/ml (51.7%) and bioavailability was 48.4%.","Pharmacokinetics of furosemide after intravenous, oral and transdermal administration to cats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30339054/),h,1.2,141247,DB00695,Furosemide
,30339054,peak concentration,"After oral administration the terminal half-life was 1.2 h (18.7%), peak concentration was 3.4 μg/ml (51.7%) and bioavailability was 48.4%.","Pharmacokinetics of furosemide after intravenous, oral and transdermal administration to cats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30339054/),[μg] / [ml],3.4,141248,DB00695,Furosemide
,30339054,bioavailability,"After oral administration the terminal half-life was 1.2 h (18.7%), peak concentration was 3.4 μg/ml (51.7%) and bioavailability was 48.4%.","Pharmacokinetics of furosemide after intravenous, oral and transdermal administration to cats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30339054/),%,48.4,141249,DB00695,Furosemide
,30339054,oral dose absorbed,"The oral dose absorbed was approximately 50%, but the absorption from transdermal administration was negligible.","Pharmacokinetics of furosemide after intravenous, oral and transdermal administration to cats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30339054/),%,50,141250,DB00695,Furosemide
<,12520254,troughs,"Population pharmacokinetics were evaluated at 1, 2, and 4 weeks' postnatal age; zidovudine doses were adjusted to maintain troughs <3 microM.",Pharmacokinetics and tolerance of zidovudine in preterm infants. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12520254/),μM,3,142484,DB00695,Furosemide
,3304768,half-life,"Dexamethasone is rapidly eliminated, the short half-life (about 3 hours) indicating that dosage intervals should be kept small.",Clinical pharmacokinetic considerations in the treatment of increased intracranial pressure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3304768/),h,3,143709,DB00695,Furosemide
,3304768,elimination half-life,"Following single doses, pentobarbitone has a relatively long elimination half-life (about 22 hours).",Clinical pharmacokinetic considerations in the treatment of increased intracranial pressure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3304768/),h,22,143710,DB00695,Furosemide
,8061834,F,"The limit of quantitation of F in plasma is 0.007 microgram/ml, Fgluc 0.010 microgram/ml.",Determination of furosemide with its acyl glucuronide in human plasma and urine by means of direct gradient high-performance liquid chromatographic analysis with fluorescence detection. Preliminary pharmacokinetics and effect of probenecid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061834/),[μg] / [ml],0.007,144155,DB00695,Furosemide
,8061834,Fgluc,"The limit of quantitation of F in plasma is 0.007 microgram/ml, Fgluc 0.010 microgram/ml.",Determination of furosemide with its acyl glucuronide in human plasma and urine by means of direct gradient high-performance liquid chromatographic analysis with fluorescence detection. Preliminary pharmacokinetics and effect of probenecid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061834/),[μg] / [ml],0.010,144156,DB00695,Furosemide
,8061834,F,"The limits of quantitation in urine are respectively: F 0.10 microgram/ml, Fgluc 0.15 microgram/ml.",Determination of furosemide with its acyl glucuronide in human plasma and urine by means of direct gradient high-performance liquid chromatographic analysis with fluorescence detection. Preliminary pharmacokinetics and effect of probenecid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061834/),[μg] / [ml],0.10,144157,DB00695,Furosemide
,8061834,Fgluc,"The limits of quantitation in urine are respectively: F 0.10 microgram/ml, Fgluc 0.15 microgram/ml.",Determination of furosemide with its acyl glucuronide in human plasma and urine by means of direct gradient high-performance liquid chromatographic analysis with fluorescence detection. Preliminary pharmacokinetics and effect of probenecid. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8061834/),[μg] / [ml],0.15,144158,DB00695,Furosemide
,7452492,plasma clearance,Indomethacin significantly decreased plasma clearance of furosemide from 1.84 +/- 0.36 to 1.10 +/- 0.08 ml/kg/min (P < 0.2) and renal clearance of furosemide from 1.05 +/- 0.23 to 0.60 +/- 0.06 ml/kg/min (P < 0.05).,Pharmacokinetic-dynamic analysis of the indomethacin-furosemide interaction in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7452492/),[ml] / [kg·min],1.84,145403,DB00695,Furosemide
,7452492,plasma clearance,Indomethacin significantly decreased plasma clearance of furosemide from 1.84 +/- 0.36 to 1.10 +/- 0.08 ml/kg/min (P < 0.2) and renal clearance of furosemide from 1.05 +/- 0.23 to 0.60 +/- 0.06 ml/kg/min (P < 0.05).,Pharmacokinetic-dynamic analysis of the indomethacin-furosemide interaction in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7452492/),[ml] / [kg·min],1.10,145404,DB00695,Furosemide
,7452492,renal clearance,Indomethacin significantly decreased plasma clearance of furosemide from 1.84 +/- 0.36 to 1.10 +/- 0.08 ml/kg/min (P < 0.2) and renal clearance of furosemide from 1.05 +/- 0.23 to 0.60 +/- 0.06 ml/kg/min (P < 0.05).,Pharmacokinetic-dynamic analysis of the indomethacin-furosemide interaction in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7452492/),[ml] / [kg·min],1.05,145405,DB00695,Furosemide
,7452492,renal clearance,Indomethacin significantly decreased plasma clearance of furosemide from 1.84 +/- 0.36 to 1.10 +/- 0.08 ml/kg/min (P < 0.2) and renal clearance of furosemide from 1.05 +/- 0.23 to 0.60 +/- 0.06 ml/kg/min (P < 0.05).,Pharmacokinetic-dynamic analysis of the indomethacin-furosemide interaction in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7452492/),[ml] / [kg·min],0.60,145406,DB00695,Furosemide
,7452492,nonrenal clearance,"The nonrenal clearance of furosemide decreased, but not significantly, from 0.80 +/- 0.17 to 0.50 +/- 0.10 ml/kg/min.",Pharmacokinetic-dynamic analysis of the indomethacin-furosemide interaction in man. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7452492/),[ml] / [kg·min],0.80,145407,DB00695,Furosemide
,7452492,nonrenal clearance,"The nonrenal clearance of furosemide decreased, but not significantly, from 0.80 +/- 0.17 to 0.50 +/- 0.10 ml/kg/min.",Pharmacokinetic-dynamic analysis of the indomethacin-furosemide interaction in man. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7452492/),[ml] / [kg·min],0.50,145408,DB00695,Furosemide
,9674715,maximum plasma concentration,"Following diuresis, maximum plasma concentration increased from 11.0+/-5.0 microg/mL to 13.9+/-6.8 with torsemide (P <0.05) and from 3.1< or =1.5 to 3.9+/-1.9 with furosemide (P=0.16).",The effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and torsemide in patients with heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9674715/),[μg] / [ml],11.0,146140,DB00695,Furosemide
,9674715,maximum plasma concentration,"Following diuresis, maximum plasma concentration increased from 11.0+/-5.0 microg/mL to 13.9+/-6.8 with torsemide (P <0.05) and from 3.1< or =1.5 to 3.9+/-1.9 with furosemide (P=0.16).",The effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and torsemide in patients with heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9674715/),[μg] / [ml],13.9,146141,DB00695,Furosemide
,9674715,maximum plasma concentration,"Following diuresis, maximum plasma concentration increased from 11.0+/-5.0 microg/mL to 13.9+/-6.8 with torsemide (P <0.05) and from 3.1< or =1.5 to 3.9+/-1.9 with furosemide (P=0.16).",The effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and torsemide in patients with heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9674715/),<,3.1,146142,DB00695,Furosemide
,9674715,maximum plasma concentration,"Following diuresis, maximum plasma concentration increased from 11.0+/-5.0 microg/mL to 13.9+/-6.8 with torsemide (P <0.05) and from 3.1< or =1.5 to 3.9+/-1.9 with furosemide (P=0.16).",The effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and torsemide in patients with heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9674715/),[μg] / [ml],3.9,146143,DB00695,Furosemide
,9674715,time to maximum concentration,The time to maximum concentration decreased from 1.40+/-.82 h to 0.81+/-0.36 with torsemide (P <0.01).,The effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and torsemide in patients with heart failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9674715/),h,1.40,146144,DB00695,Furosemide
,9674715,time to maximum concentration,The time to maximum concentration decreased from 1.40+/-.82 h to 0.81+/-0.36 with torsemide (P <0.01).,The effects of diuresis on the pharmacokinetics of the loop diuretics furosemide and torsemide in patients with heart failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9674715/),,0.81,146145,DB00695,Furosemide
,9731952,plasma clearance (CLp),Median plasma clearance (CLp) of furosemide in anaesthetized horses with BUL was 1.4 mL/min/kg.,The pharmacokinetics of furosemide in anaesthetized horses after bilateral ureteral ligation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9731952/),[ml] / [kg·min],1.4,146342,DB00695,Furosemide
,9731952,Apparent steady state volume of distribution (Vd(ss)),Apparent steady state volume of distribution (Vd(ss)) ranged from 169 to 880 mL/kg and the elimination half life (t1/2) ranged from 83 min to 209 h.,The pharmacokinetics of furosemide in anaesthetized horses after bilateral ureteral ligation. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9731952/),[ml] / [kg],169 to 880,146343,DB00695,Furosemide
,9731952,elimination half life (t1/2),Apparent steady state volume of distribution (Vd(ss)) ranged from 169 to 880 mL/kg and the elimination half life (t1/2) ranged from 83 min to 209 h.,The pharmacokinetics of furosemide in anaesthetized horses after bilateral ureteral ligation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9731952/),min,83,146344,DB00695,Furosemide
,9731952,elimination half life (t1/2),Apparent steady state volume of distribution (Vd(ss)) ranged from 169 to 880 mL/kg and the elimination half life (t1/2) ranged from 83 min to 209 h.,The pharmacokinetics of furosemide in anaesthetized horses after bilateral ureteral ligation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9731952/),h,209,146345,DB00695,Furosemide
,8641327,tmax,"In the patients, absorption was also variable and was markedly delayed (tmax 128 vs 90 min) but more complete (bioavailability 70.1 vs 53.6%).",Furosemide disposition in patients on CAPD. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8641327/),min,128,146508,DB00695,Furosemide
,8641327,tmax,"In the patients, absorption was also variable and was markedly delayed (tmax 128 vs 90 min) but more complete (bioavailability 70.1 vs 53.6%).",Furosemide disposition in patients on CAPD. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8641327/),min,90,146509,DB00695,Furosemide
,8641327,bioavailability,"In the patients, absorption was also variable and was markedly delayed (tmax 128 vs 90 min) but more complete (bioavailability 70.1 vs 53.6%).",Furosemide disposition in patients on CAPD. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8641327/),%,70.1,146510,DB00695,Furosemide
,8641327,bioavailability,"In the patients, absorption was also variable and was markedly delayed (tmax 128 vs 90 min) but more complete (bioavailability 70.1 vs 53.6%).",Furosemide disposition in patients on CAPD. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8641327/),%,53.6,146511,DB00695,Furosemide
,8641327,elimination half-life,The mean elimination half-life was significantly longer in the patients following both the oral (228 vs 65.1 min) and intravenous dose (195 vs 60.3 min).,Furosemide disposition in patients on CAPD. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8641327/),min,228,146512,DB00695,Furosemide
,8641327,elimination half-life,The mean elimination half-life was significantly longer in the patients following both the oral (228 vs 65.1 min) and intravenous dose (195 vs 60.3 min).,Furosemide disposition in patients on CAPD. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8641327/),min,65.1,146513,DB00695,Furosemide
,8641327,elimination half-life,The mean elimination half-life was significantly longer in the patients following both the oral (228 vs 65.1 min) and intravenous dose (195 vs 60.3 min).,Furosemide disposition in patients on CAPD. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8641327/),min,195,146514,DB00695,Furosemide
,8641327,elimination half-life,The mean elimination half-life was significantly longer in the patients following both the oral (228 vs 65.1 min) and intravenous dose (195 vs 60.3 min).,Furosemide disposition in patients on CAPD. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8641327/),min,60.3,146515,DB00695,Furosemide
,8641327,total body clearance,The total body clearance of furosemide in the volunteers was 138 ml x min(-1) and this was much lower in the CAPD patients (61.9 ml x min(-1)) in whom the renal clearance was negligible.,Furosemide disposition in patients on CAPD. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8641327/),[ml] / [min],138,146516,DB00695,Furosemide
,8641327,total body clearance,The total body clearance of furosemide in the volunteers was 138 ml x min(-1) and this was much lower in the CAPD patients (61.9 ml x min(-1)) in whom the renal clearance was negligible.,Furosemide disposition in patients on CAPD. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8641327/),[ml] / [min],61.9,146517,DB00695,Furosemide
≈,33704925,absolute bioavailability,"Mathematical modeling determined that equivalent exposures in plasma with the approved dose of the IV edaravone formulation, as reported previously, could be achieved when the oral edaravone formulation was administered at a dose of ≈100 mg, with an absolute bioavailability of ≈60%.","Evaluation of Pharmacokinetics, Safety, and Drug-Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33704925/),%,60,147401,DB00695,Furosemide
,26691,sensitivity,"The sensitivity is 0.1 and 0.25 microgram per ml plasma and urine, respectively.",A simplified assay of furosemide in plasma and urine by high-pressure liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26691/),[μg] / [ml],0.1,148187,DB00695,Furosemide
,26691,sensitivity,"The sensitivity is 0.1 and 0.25 microgram per ml plasma and urine, respectively.",A simplified assay of furosemide in plasma and urine by high-pressure liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26691/),[μg] / [ml],0.25,148188,DB00695,Furosemide
,7880980,urinary excretion,"After i.v. administration, the 8 h urinary excretion of furosemide/g kidney (397 versus 572 micrograms) was significantly lower and the non-renal clearance (5.78 versus 3.94 ml min-1 kg-1) was significantly faster in SHRs of 16 weeks of age than in age-matched control Wistar rats.",Pharmacokinetics and pharmacodynamics of furosemide after intravenous and oral administration to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7880980/),μg,397,150079,DB00695,Furosemide
,7880980,urinary excretion,"After i.v. administration, the 8 h urinary excretion of furosemide/g kidney (397 versus 572 micrograms) was significantly lower and the non-renal clearance (5.78 versus 3.94 ml min-1 kg-1) was significantly faster in SHRs of 16 weeks of age than in age-matched control Wistar rats.",Pharmacokinetics and pharmacodynamics of furosemide after intravenous and oral administration to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7880980/),μg,572,150080,DB00695,Furosemide
,7880980,non-renal clearance,"After i.v. administration, the 8 h urinary excretion of furosemide/g kidney (397 versus 572 micrograms) was significantly lower and the non-renal clearance (5.78 versus 3.94 ml min-1 kg-1) was significantly faster in SHRs of 16 weeks of age than in age-matched control Wistar rats.",Pharmacokinetics and pharmacodynamics of furosemide after intravenous and oral administration to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7880980/),[ml] / [kg·min],5.78,150081,DB00695,Furosemide
,7880980,non-renal clearance,"After i.v. administration, the 8 h urinary excretion of furosemide/g kidney (397 versus 572 micrograms) was significantly lower and the non-renal clearance (5.78 versus 3.94 ml min-1 kg-1) was significantly faster in SHRs of 16 weeks of age than in age-matched control Wistar rats.",Pharmacokinetics and pharmacodynamics of furosemide after intravenous and oral administration to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7880980/),[ml] / [kg·min],3.94,150082,DB00695,Furosemide
,7880980,urine output,"After i.v. administration of furosemide, the 8 h urine output (9.93 versus 16.5 ml) and 8 h urinary excretion of sodium (1.21 versus 2.05 mmol) and chloride (1.37 versus 2.17 mmol) per gram of kidney in SHRs of 16 weeks of age were lower than those in age-matched Wistar rats, this could be due to the significantly smaller amount of furosemide excreted in 8 h urine per gram of kidney.",Pharmacokinetics and pharmacodynamics of furosemide after intravenous and oral administration to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7880980/),ml,9.93,150083,DB00695,Furosemide
,7880980,urine output,"After i.v. administration of furosemide, the 8 h urine output (9.93 versus 16.5 ml) and 8 h urinary excretion of sodium (1.21 versus 2.05 mmol) and chloride (1.37 versus 2.17 mmol) per gram of kidney in SHRs of 16 weeks of age were lower than those in age-matched Wistar rats, this could be due to the significantly smaller amount of furosemide excreted in 8 h urine per gram of kidney.",Pharmacokinetics and pharmacodynamics of furosemide after intravenous and oral administration to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7880980/),ml,16.5,150084,DB00695,Furosemide
,7880980,urinary excretion,"After i.v. administration of furosemide, the 8 h urine output (9.93 versus 16.5 ml) and 8 h urinary excretion of sodium (1.21 versus 2.05 mmol) and chloride (1.37 versus 2.17 mmol) per gram of kidney in SHRs of 16 weeks of age were lower than those in age-matched Wistar rats, this could be due to the significantly smaller amount of furosemide excreted in 8 h urine per gram of kidney.",Pharmacokinetics and pharmacodynamics of furosemide after intravenous and oral administration to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7880980/),mM,1.21,150085,DB00695,Furosemide
,7880980,urinary excretion,"After i.v. administration of furosemide, the 8 h urine output (9.93 versus 16.5 ml) and 8 h urinary excretion of sodium (1.21 versus 2.05 mmol) and chloride (1.37 versus 2.17 mmol) per gram of kidney in SHRs of 16 weeks of age were lower than those in age-matched Wistar rats, this could be due to the significantly smaller amount of furosemide excreted in 8 h urine per gram of kidney.",Pharmacokinetics and pharmacodynamics of furosemide after intravenous and oral administration to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7880980/),mM,2.05,150086,DB00695,Furosemide
,7880980,urinary excretion,"After i.v. administration of furosemide, the 8 h urine output (9.93 versus 16.5 ml) and 8 h urinary excretion of sodium (1.21 versus 2.05 mmol) and chloride (1.37 versus 2.17 mmol) per gram of kidney in SHRs of 16 weeks of age were lower than those in age-matched Wistar rats, this could be due to the significantly smaller amount of furosemide excreted in 8 h urine per gram of kidney.",Pharmacokinetics and pharmacodynamics of furosemide after intravenous and oral administration to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7880980/),mM,1.37,150087,DB00695,Furosemide
,7880980,urinary excretion,"After i.v. administration of furosemide, the 8 h urine output (9.93 versus 16.5 ml) and 8 h urinary excretion of sodium (1.21 versus 2.05 mmol) and chloride (1.37 versus 2.17 mmol) per gram of kidney in SHRs of 16 weeks of age were lower than those in age-matched Wistar rats, this could be due to the significantly smaller amount of furosemide excreted in 8 h urine per gram of kidney.",Pharmacokinetics and pharmacodynamics of furosemide after intravenous and oral administration to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7880980/),mM,2.17,150088,DB00695,Furosemide
,25305049,peak plasma tolvaptan concentration,"The peak plasma tolvaptan concentration and area under the plasma concentration-time curve were 379.41 ± 149.69 ng/mL and 4,657.38 ± 2,741.79 ng·h/mL, respectively, in HF patients with advanced kidney dysfunction.",Efficacy of tolvaptan added to furosemide in heart failure patients with advanced kidney dysfunction: a pharmacokinetic and pharmacodynamic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25305049/),[ng] / [ml],379.41,150399,DB00695,Furosemide
,25305049,area under the plasma concentration-time curve,"The peak plasma tolvaptan concentration and area under the plasma concentration-time curve were 379.41 ± 149.69 ng/mL and 4,657.38 ± 2,741.79 ng·h/mL, respectively, in HF patients with advanced kidney dysfunction.",Efficacy of tolvaptan added to furosemide in heart failure patients with advanced kidney dysfunction: a pharmacokinetic and pharmacodynamic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25305049/),[h·ng] / [ml],"4,657.38",150400,DB00695,Furosemide
,4005391,time to Cpmax,"Mean time to Cpmax was 50 minutes, with no differences observed among doses.",Pharmacokinetics of furosemide after three different single oral doses. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4005391/),min,50,151160,DB00695,Furosemide
,7758252,time to achieve maximal systemic concentrations (tmax,"The pharmacokinetics of dipyrone are characterised by rapid hydrolysis to the active moiety 4-methyl-amino-antipyrine (MAA), which has 85% bioavailability after oral administration in tablet form, and takes a short time to achieve maximal systemic concentrations (tmax of 1.2 to 2.0 hours).",Clinical pharmacokinetics of dipyrone and its metabolites. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758252/),h,1.2 to 2.0,151448,DB00695,Furosemide
,7758252,Absolute bioavailability,"Absolute bioavailability after intramuscular and rectal administration is 87 and 54%, respectively.",Clinical pharmacokinetics of dipyrone and its metabolites. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758252/),%,87,151449,DB00695,Furosemide
,7758252,Absolute bioavailability,"Absolute bioavailability after intramuscular and rectal administration is 87 and 54%, respectively.",Clinical pharmacokinetics of dipyrone and its metabolites. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758252/),%,54,151450,DB00695,Furosemide
,7758252,elimination half-life (t1/2),"MAA is further metabolised with a mean elimination half-life (t1/2) of 2.6 to 3.5 hours to 4-formyl-amino-antipyrine (FAA), which is an end-metabolite, and to 4-amino-antipyrine (AA), which is then acetylated to 4-acetyl-amino-antipyrine (AAA) by the polymorphic N-acetyl-transferase (t1/2 of AA is 3.8 hours in rapid acetylators and 5.5 hours in slow acetylators).",Clinical pharmacokinetics of dipyrone and its metabolites. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758252/),h,2.6 to 3.5,151451,DB00695,Furosemide
,7758252,t1/2,"MAA is further metabolised with a mean elimination half-life (t1/2) of 2.6 to 3.5 hours to 4-formyl-amino-antipyrine (FAA), which is an end-metabolite, and to 4-amino-antipyrine (AA), which is then acetylated to 4-acetyl-amino-antipyrine (AAA) by the polymorphic N-acetyl-transferase (t1/2 of AA is 3.8 hours in rapid acetylators and 5.5 hours in slow acetylators).",Clinical pharmacokinetics of dipyrone and its metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758252/),h,3.8,151452,DB00695,Furosemide
,7758252,t1/2,"MAA is further metabolised with a mean elimination half-life (t1/2) of 2.6 to 3.5 hours to 4-formyl-amino-antipyrine (FAA), which is an end-metabolite, and to 4-amino-antipyrine (AA), which is then acetylated to 4-acetyl-amino-antipyrine (AAA) by the polymorphic N-acetyl-transferase (t1/2 of AA is 3.8 hours in rapid acetylators and 5.5 hours in slow acetylators).",Clinical pharmacokinetics of dipyrone and its metabolites. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758252/),h,5.5,151453,DB00695,Furosemide
less,7758252,Protein binding,Protein binding of the 4 main metabolites is less than 60%.,Clinical pharmacokinetics of dipyrone and its metabolites. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758252/),%,60,151454,DB00695,Furosemide
,7758252,volume of distribution,The volume of distribution of MAA is about 1.15 L/kg of lean body mass.,Clinical pharmacokinetics of dipyrone and its metabolites. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7758252/),[l] / [kg],1.15,151455,DB00695,Furosemide
,7592177,terminal elimination constant,The following mean pharmacokinetic parameters were found for the patient group: terminal elimination constant 0.0101/h (normal 0.0214/h); mean residence time 134 h (normal 46.7h); area under the curve 200 h.mg/L(normal 69.4 h.mg/L); plasma clearance 0.96 L/h.kg(normal 2.16 L/h.kg).,Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7592177/),1/[h],0.0101,152104,DB00695,Furosemide
,7592177,mean residence time,The following mean pharmacokinetic parameters were found for the patient group: terminal elimination constant 0.0101/h (normal 0.0214/h); mean residence time 134 h (normal 46.7h); area under the curve 200 h.mg/L(normal 69.4 h.mg/L); plasma clearance 0.96 L/h.kg(normal 2.16 L/h.kg).,Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7592177/),h,134,152105,DB00695,Furosemide
,7592177,area under the curve,The following mean pharmacokinetic parameters were found for the patient group: terminal elimination constant 0.0101/h (normal 0.0214/h); mean residence time 134 h (normal 46.7h); area under the curve 200 h.mg/L(normal 69.4 h.mg/L); plasma clearance 0.96 L/h.kg(normal 2.16 L/h.kg).,Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7592177/),[h·mg] / [l],200,152106,DB00695,Furosemide
,7592177,plasma clearance,The following mean pharmacokinetic parameters were found for the patient group: terminal elimination constant 0.0101/h (normal 0.0214/h); mean residence time 134 h (normal 46.7h); area under the curve 200 h.mg/L(normal 69.4 h.mg/L); plasma clearance 0.96 L/h.kg(normal 2.16 L/h.kg).,Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7592177/),[l] / [h·kg],0.96,152107,DB00695,Furosemide
,25345937,V,"The mobile phase of the pre- treatment column was water-methanol (95:5, V/V) with a volume percentage of formic acid of 0.1%.",[Detection of plasma and urine furosemide based on online enrichment and restricted- access media coupled with high-performance liquid chromatography]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25345937/),,95,152456,DB00695,Furosemide
,25345937,V/V,"The mobile phase of the analytical column was methanol-water (65:35, V/V) for plasma and methanol-water (55:45, V/V) for urine samples, all containing a volume percentage of formic acid of 0.1% with a flow rate of 1 ml/min.",[Detection of plasma and urine furosemide based on online enrichment and restricted- access media coupled with high-performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25345937/),,65,152457,DB00695,Furosemide
,25345937,V/V,"The mobile phase of the analytical column was methanol-water (65:35, V/V) for plasma and methanol-water (55:45, V/V) for urine samples, all containing a volume percentage of formic acid of 0.1% with a flow rate of 1 ml/min.",[Detection of plasma and urine furosemide based on online enrichment and restricted- access media coupled with high-performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25345937/),,55,152458,DB00695,Furosemide
,25345937,V/V,"The mobile phase of the analytical column was methanol-water (65:35, V/V) for plasma and methanol-water (55:45, V/V) for urine samples, all containing a volume percentage of formic acid of 0.1% with a flow rate of 1 ml/min.",[Detection of plasma and urine furosemide based on online enrichment and restricted- access media coupled with high-performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25345937/),,45,152459,DB00695,Furosemide
,25345937,flow rate,"The mobile phase of the analytical column was methanol-water (65:35, V/V) for plasma and methanol-water (55:45, V/V) for urine samples, all containing a volume percentage of formic acid of 0.1% with a flow rate of 1 ml/min.",[Detection of plasma and urine furosemide based on online enrichment and restricted- access media coupled with high-performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25345937/),[ml] / [min],1,152460,DB00695,Furosemide
,25345937,recoveries,The average recoveries of furosemide at 3 spiked levels ranged from 101.82% to 113.36% for plasma and from 98.75% to 112.27% for urine samples.,[Detection of plasma and urine furosemide based on online enrichment and restricted- access media coupled with high-performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25345937/),%,101.82,152461,DB00695,Furosemide
,25345937,recoveries,The average recoveries of furosemide at 3 spiked levels ranged from 101.82% to 113.36% for plasma and from 98.75% to 112.27% for urine samples.,[Detection of plasma and urine furosemide based on online enrichment and restricted- access media coupled with high-performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25345937/),%,113.36,152462,DB00695,Furosemide
,25345937,recoveries,The average recoveries of furosemide at 3 spiked levels ranged from 101.82% to 113.36% for plasma and from 98.75% to 112.27% for urine samples.,[Detection of plasma and urine furosemide based on online enrichment and restricted- access media coupled with high-performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25345937/),%,98.75,152463,DB00695,Furosemide
,25345937,recoveries,The average recoveries of furosemide at 3 spiked levels ranged from 101.82% to 113.36% for plasma and from 98.75% to 112.27% for urine samples.,[Detection of plasma and urine furosemide based on online enrichment and restricted- access media coupled with high-performance liquid chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25345937/),%,112.27,152464,DB00695,Furosemide
,25345937,AUC(0→24),The pharmacokinetic parameters AUC(0→24) was 6.265 g/(ml·h) with a t(1/2) of 2.447 h and a C(Max) of 1.414 g/ml.,[Detection of plasma and urine furosemide based on online enrichment and restricted- access media coupled with high-performance liquid chromatography]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25345937/),[g] / [h·ml],6.265,152465,DB00695,Furosemide
,25345937,t(1/2),The pharmacokinetic parameters AUC(0→24) was 6.265 g/(ml·h) with a t(1/2) of 2.447 h and a C(Max) of 1.414 g/ml.,[Detection of plasma and urine furosemide based on online enrichment and restricted- access media coupled with high-performance liquid chromatography]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25345937/),h,2.447,152466,DB00695,Furosemide
,25345937,C(Max),The pharmacokinetic parameters AUC(0→24) was 6.265 g/(ml·h) with a t(1/2) of 2.447 h and a C(Max) of 1.414 g/ml.,[Detection of plasma and urine furosemide based on online enrichment and restricted- access media coupled with high-performance liquid chromatography]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25345937/),[g] / [ml],1.414,152467,DB00695,Furosemide
,25345937,cumulative excretory rate,The mean cumulative excretory rate of furosemide in the urine of rats over 24 h was 32.50%-39.08%.,[Detection of plasma and urine furosemide based on online enrichment and restricted- access media coupled with high-performance liquid chromatography]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25345937/),%,32.50,152468,DB00695,Furosemide
,25345937,cumulative excretory rate,The mean cumulative excretory rate of furosemide in the urine of rats over 24 h was 32.50%-39.08%.,[Detection of plasma and urine furosemide based on online enrichment and restricted- access media coupled with high-performance liquid chromatography]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25345937/),%,39.08,152469,DB00695,Furosemide
,4025553,Fractional excretion (FE),Fractional excretion (FE) of A1 was 39.4 +/- 4.2% in these hydropenic experiments (FENa = 0.3 +/- 0.1%).,Renal handling of aluminum in the rat: clearance and micropuncture studies. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025553/),%,39.4,156489,DB00695,Furosemide
,4025553,FENa,Fractional excretion (FE) of A1 was 39.4 +/- 4.2% in these hydropenic experiments (FENa = 0.3 +/- 0.1%).,Renal handling of aluminum in the rat: clearance and micropuncture studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025553/),%,0.3,156490,DB00695,Furosemide
,4025553,FENa,"The natriuresis produced by volume expansion (FENa = 1.0, 3.0, 8.4, and 7.9%) and furosemide (FENa = 4.2, 6.0, 6.6, and 6.7%) were comparable.",Renal handling of aluminum in the rat: clearance and micropuncture studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025553/),%,1.0,156491,DB00695,Furosemide
,4025553,FENa,"The natriuresis produced by volume expansion (FENa = 1.0, 3.0, 8.4, and 7.9%) and furosemide (FENa = 4.2, 6.0, 6.6, and 6.7%) were comparable.",Renal handling of aluminum in the rat: clearance and micropuncture studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025553/),%,3.0,156492,DB00695,Furosemide
,4025553,FENa,"The natriuresis produced by volume expansion (FENa = 1.0, 3.0, 8.4, and 7.9%) and furosemide (FENa = 4.2, 6.0, 6.6, and 6.7%) were comparable.",Renal handling of aluminum in the rat: clearance and micropuncture studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025553/),%,8.4,156493,DB00695,Furosemide
,4025553,FENa,"The natriuresis produced by volume expansion (FENa = 1.0, 3.0, 8.4, and 7.9%) and furosemide (FENa = 4.2, 6.0, 6.6, and 6.7%) were comparable.",Renal handling of aluminum in the rat: clearance and micropuncture studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025553/),%,7.9,156494,DB00695,Furosemide
,4025553,FENa,"The natriuresis produced by volume expansion (FENa = 1.0, 3.0, 8.4, and 7.9%) and furosemide (FENa = 4.2, 6.0, 6.6, and 6.7%) were comparable.",Renal handling of aluminum in the rat: clearance and micropuncture studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025553/),%,4.2,156495,DB00695,Furosemide
,4025553,FENa,"The natriuresis produced by volume expansion (FENa = 1.0, 3.0, 8.4, and 7.9%) and furosemide (FENa = 4.2, 6.0, 6.6, and 6.7%) were comparable.",Renal handling of aluminum in the rat: clearance and micropuncture studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025553/),%,6.0,156496,DB00695,Furosemide
,4025553,FENa,"The natriuresis produced by volume expansion (FENa = 1.0, 3.0, 8.4, and 7.9%) and furosemide (FENa = 4.2, 6.0, 6.6, and 6.7%) were comparable.",Renal handling of aluminum in the rat: clearance and micropuncture studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025553/),%,6.6,156497,DB00695,Furosemide
,4025553,FENa,"The natriuresis produced by volume expansion (FENa = 1.0, 3.0, 8.4, and 7.9%) and furosemide (FENa = 4.2, 6.0, 6.6, and 6.7%) were comparable.",Renal handling of aluminum in the rat: clearance and micropuncture studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4025553/),%,6.7,156498,DB00695,Furosemide
,7768248,O-E,In the short study the median O-E was 10.6 mmol.mg-1 (range 1.9-22.0) and delta-E 6.2 mmol.mg-1 (range 1.3-11.2).,Sensitivity of residual nephrons to high dose furosemide described by diuretic efficiency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768248/),[mM] / [mg],10.6,160523,DB00695,Furosemide
,7768248,delta-E,In the short study the median O-E was 10.6 mmol.mg-1 (range 1.9-22.0) and delta-E 6.2 mmol.mg-1 (range 1.3-11.2).,Sensitivity of residual nephrons to high dose furosemide described by diuretic efficiency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768248/),[mM] / [mg],6.2,160524,DB00695,Furosemide
,7768248,fractional excretion,The fractional excretion of sodium FENa was significantly increased from 9.6% (range 4.1-22.9) to 27% (range 14.6-56.2) during F treatment.,Sensitivity of residual nephrons to high dose furosemide described by diuretic efficiency. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768248/),%,9.6,160525,DB00695,Furosemide
,7768248,fractional excretion,The fractional excretion of sodium FENa was significantly increased from 9.6% (range 4.1-22.9) to 27% (range 14.6-56.2) during F treatment.,Sensitivity of residual nephrons to high dose furosemide described by diuretic efficiency. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768248/),%,27,160526,DB00695,Furosemide
,7768248,O-E,In the long-term study median O-E was 6.4 mmol.,Sensitivity of residual nephrons to high dose furosemide described by diuretic efficiency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768248/),mM,6.4,160527,DB00695,Furosemide
,7768248,F excretion,min-1 x 1.73 m-2 and median F excretion from 11.8 to 7.5 mg per day.,Sensitivity of residual nephrons to high dose furosemide described by diuretic efficiency. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7768248/),[mg] / [d],11.8 to 7.5,160528,DB00695,Furosemide
,833762,Metabolic clearance,Metabolic clearance was found to decrease from 1.74+/-0.11 ml/min in animals which received furosemide alone to 1.06+/-0.10 ml/min in animals which received both furosemide and probenecid.,Metabolic clearance of furosemide in the rat. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/833762/),[ml] / [min],1.74,161846,DB00695,Furosemide
,833762,Metabolic clearance,Metabolic clearance was found to decrease from 1.74+/-0.11 ml/min in animals which received furosemide alone to 1.06+/-0.10 ml/min in animals which received both furosemide and probenecid.,Metabolic clearance of furosemide in the rat. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/833762/),[ml] / [min],1.06,161847,DB00695,Furosemide
,2257863,AUC,"Probenecid 500 mg q.i.d. for 7 days significantly accelerated the overall elimination of phenprocoumon, as indicated by a decrease in AUC from 295 to 157 micrograms.",The effects of frusemide and probenecid on the pharmacokinetics of phenprocoumon. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2257863/),μg,295,163054,DB00695,Furosemide
,2257863,AUC,"Probenecid 500 mg q.i.d. for 7 days significantly accelerated the overall elimination of phenprocoumon, as indicated by a decrease in AUC from 295 to 157 micrograms.",The effects of frusemide and probenecid on the pharmacokinetics of phenprocoumon. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2257863/),μg,157,163055,DB00695,Furosemide
,8971430,peak plasma concentration,3. Breakfast significantly reduced the peak plasma concentration of frusemide from 2.35 +/- 0.49 to 0.51 +/- 0.19 mg l-1 (95% confidence intervals (95% CI) = 1.39 to 2.28 mg l-1) and delayed the time to peak concentration from 0.69 +/- 0.21 to 1.91 +/- 0.93 h (95% CI = 0.41 to 2.03 h).,Effect of food on the absorption of frusemide and bumetanide in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971430/),[mg] / [l],2.35,163693,DB00695,Furosemide
,8971430,peak plasma concentration,3. Breakfast significantly reduced the peak plasma concentration of frusemide from 2.35 +/- 0.49 to 0.51 +/- 0.19 mg l-1 (95% confidence intervals (95% CI) = 1.39 to 2.28 mg l-1) and delayed the time to peak concentration from 0.69 +/- 0.21 to 1.91 +/- 0.93 h (95% CI = 0.41 to 2.03 h).,Effect of food on the absorption of frusemide and bumetanide in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971430/),[mg] / [l],0.51,163694,DB00695,Furosemide
,8971430,time to peak concentration,3. Breakfast significantly reduced the peak plasma concentration of frusemide from 2.35 +/- 0.49 to 0.51 +/- 0.19 mg l-1 (95% confidence intervals (95% CI) = 1.39 to 2.28 mg l-1) and delayed the time to peak concentration from 0.69 +/- 0.21 to 1.91 +/- 0.93 h (95% CI = 0.41 to 2.03 h).,Effect of food on the absorption of frusemide and bumetanide in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971430/),h,0.69,163695,DB00695,Furosemide
,8971430,time to peak concentration,3. Breakfast significantly reduced the peak plasma concentration of frusemide from 2.35 +/- 0.49 to 0.51 +/- 0.19 mg l-1 (95% confidence intervals (95% CI) = 1.39 to 2.28 mg l-1) and delayed the time to peak concentration from 0.69 +/- 0.21 to 1.91 +/- 0.93 h (95% CI = 0.41 to 2.03 h).,Effect of food on the absorption of frusemide and bumetanide in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971430/),h,1.91,163696,DB00695,Furosemide
,8971430,oral bioavailability,The oral bioavailability of frusemide was significantly reduced by approximately 30% (75.6 +/- 10.6 to 43.2 +/- 16.8%; 95% CI = 13.5 to 51.4%).,Effect of food on the absorption of frusemide and bumetanide in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971430/),%,75.6,163697,DB00695,Furosemide
,8971430,oral bioavailability,The oral bioavailability of frusemide was significantly reduced by approximately 30% (75.6 +/- 10.6 to 43.2 +/- 16.8%; 95% CI = 13.5 to 51.4%).,Effect of food on the absorption of frusemide and bumetanide in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971430/),%,43.2,163698,DB00695,Furosemide
,8971430,peak concentration,"4. With bumetanide, the meal also significantly reduced the peak concentration from 0.097 +/- 0.015 to 0.036 +/- 0.012 mg l-1 (95% CI = 0.048 to 0.073 mg l-1) and delayed the time to peak from 0.53 +/- 0.08 to 1.36 +/- 0.72 h (95% CI = 0.23 to 1.44 h).",Effect of food on the absorption of frusemide and bumetanide in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971430/),[mg] / [l],0.097,163699,DB00695,Furosemide
,8971430,peak concentration,"4. With bumetanide, the meal also significantly reduced the peak concentration from 0.097 +/- 0.015 to 0.036 +/- 0.012 mg l-1 (95% CI = 0.048 to 0.073 mg l-1) and delayed the time to peak from 0.53 +/- 0.08 to 1.36 +/- 0.72 h (95% CI = 0.23 to 1.44 h).",Effect of food on the absorption of frusemide and bumetanide in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971430/),[mg] / [l],0.036,163700,DB00695,Furosemide
,8971430,time to peak,"4. With bumetanide, the meal also significantly reduced the peak concentration from 0.097 +/- 0.015 to 0.036 +/- 0.012 mg l-1 (95% CI = 0.048 to 0.073 mg l-1) and delayed the time to peak from 0.53 +/- 0.08 to 1.36 +/- 0.72 h (95% CI = 0.23 to 1.44 h).",Effect of food on the absorption of frusemide and bumetanide in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971430/),h,0.53,163701,DB00695,Furosemide
,8971430,time to peak,"4. With bumetanide, the meal also significantly reduced the peak concentration from 0.097 +/- 0.015 to 0.036 +/- 0.012 mg l-1 (95% CI = 0.048 to 0.073 mg l-1) and delayed the time to peak from 0.53 +/- 0.08 to 1.36 +/- 0.72 h (95% CI = 0.23 to 1.44 h).",Effect of food on the absorption of frusemide and bumetanide in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8971430/),h,1.36,163702,DB00695,Furosemide
,33848384,CL,The estimated mean CL was 16.5 mL/kg/h.,Furosemide clearance in very preterm neonates early in life: a pilot study using scavenged samples. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33848384/),[ml] / [h·kg],16.5,164212,DB00695,Furosemide
,33848384,distribution volume (Vd),"The mean distribution volume (Vd) and elimination half-life (t1/2) was 0.37 L/kg and 15.3 h, respectively.",Furosemide clearance in very preterm neonates early in life: a pilot study using scavenged samples. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33848384/),[l] / [kg],0.37,164213,DB00695,Furosemide
,33848384,elimination half-life (t1/2),"The mean distribution volume (Vd) and elimination half-life (t1/2) was 0.37 L/kg and 15.3 h, respectively.",Furosemide clearance in very preterm neonates early in life: a pilot study using scavenged samples. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33848384/),h,15.3,164214,DB00695,Furosemide
,2394955,elimination half-life,The elimination half-life of furosemide was 1.27 hours.,Bioavailability and pharmacokinetics of furosemide marketed in Thailand. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394955/),h,1.27,164337,DB00695,Furosemide
,2394955,peak plasma levels,The mean individual peak plasma levels ranged from 0.61-1.12 micrograms/ml and the time required to reach the peak ranged from 1.63-2.00 hours.,Bioavailability and pharmacokinetics of furosemide marketed in Thailand. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394955/),[μg] / [ml],0.61-1.12,164338,DB00695,Furosemide
,2394955,time required to reach the peak,The mean individual peak plasma levels ranged from 0.61-1.12 micrograms/ml and the time required to reach the peak ranged from 1.63-2.00 hours.,Bioavailability and pharmacokinetics of furosemide marketed in Thailand. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394955/),h,1.63-2.00,164339,DB00695,Furosemide
,2394955,relative bioavailability,"The relative bioavailability of furosemide with respect to brand A were 70.29, 113.41, and 94.93 per cent for brand B, C and D, respectively.",Bioavailability and pharmacokinetics of furosemide marketed in Thailand. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394955/),%,70.29,164340,DB00695,Furosemide
,2394955,relative bioavailability,"The relative bioavailability of furosemide with respect to brand A were 70.29, 113.41, and 94.93 per cent for brand B, C and D, respectively.",Bioavailability and pharmacokinetics of furosemide marketed in Thailand. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394955/),%,113.41,164341,DB00695,Furosemide
,2394955,relative bioavailability,"The relative bioavailability of furosemide with respect to brand A were 70.29, 113.41, and 94.93 per cent for brand B, C and D, respectively.",Bioavailability and pharmacokinetics of furosemide marketed in Thailand. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2394955/),%,94.93,164342,DB00695,Furosemide
,8785407,total clearance,"In the control group, the total clearance of furosemide was 18.65 +/- 1.01 mL/ min per kg; urinary and metabolic clearances of furosemide were 7.95 +/- 0.65 and 10.70 +/- 1.11 mL/min per kg, respectively.",Role of the kidneys in the metabolism of furosemide: its inhibition by probenecid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785407/),[ml] / [kg·min],18.65,170562,DB00695,Furosemide
,8785407,urinary,"In the control group, the total clearance of furosemide was 18.65 +/- 1.01 mL/ min per kg; urinary and metabolic clearances of furosemide were 7.95 +/- 0.65 and 10.70 +/- 1.11 mL/min per kg, respectively.",Role of the kidneys in the metabolism of furosemide: its inhibition by probenecid. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785407/),[ml] / [kg·min],7.95,170563,DB00695,Furosemide
,8785407,metabolic clearances,"In the control group, the total clearance of furosemide was 18.65 +/- 1.01 mL/ min per kg; urinary and metabolic clearances of furosemide were 7.95 +/- 0.65 and 10.70 +/- 1.11 mL/min per kg, respectively.",Role of the kidneys in the metabolism of furosemide: its inhibition by probenecid. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785407/),[ml] / [kg·min],7.95,170564,DB00695,Furosemide
,8785407,metabolic clearances,"In the control group, the total clearance of furosemide was 18.65 +/- 1.01 mL/ min per kg; urinary and metabolic clearances of furosemide were 7.95 +/- 0.65 and 10.70 +/- 1.11 mL/min per kg, respectively.",Role of the kidneys in the metabolism of furosemide: its inhibition by probenecid. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785407/),[ml] / [kg·min],10.70,170565,DB00695,Furosemide
,8785407,total clearance,"In anephric rabbits, total clearance was reduced by 85% to 2.69 +/- 0.26 mL/min per kg (P < 0.001), secondary to the abolition of furosemide renal excretion and to the reduction in metabolic clearance from 10.70 +/- 1.11 to 2.69 +/- 0.26 mL/min per kg (P < 0.001).",Role of the kidneys in the metabolism of furosemide: its inhibition by probenecid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785407/),[ml] / [kg·min],2.69,170566,DB00695,Furosemide
,8785407,metabolic clearance,"In anephric rabbits, total clearance was reduced by 85% to 2.69 +/- 0.26 mL/min per kg (P < 0.001), secondary to the abolition of furosemide renal excretion and to the reduction in metabolic clearance from 10.70 +/- 1.11 to 2.69 +/- 0.26 mL/min per kg (P < 0.001).",Role of the kidneys in the metabolism of furosemide: its inhibition by probenecid. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785407/),[ml] / [kg·min],10.70,170567,DB00695,Furosemide
,8785407,metabolic clearance,"In anephric rabbits, total clearance was reduced by 85% to 2.69 +/- 0.26 mL/min per kg (P < 0.001), secondary to the abolition of furosemide renal excretion and to the reduction in metabolic clearance from 10.70 +/- 1.11 to 2.69 +/- 0.26 mL/min per kg (P < 0.001).",Role of the kidneys in the metabolism of furosemide: its inhibition by probenecid. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785407/),[ml] / [kg·min],2.69,170568,DB00695,Furosemide
,8785407,total clearance,"The pretreatment with probenecid reduced the total clearance of furosemide by 80%, to 3.62 +/- 0.24 mL/min per kg (P < 0.001), because of a reduction of 90 and 75% in urinary and metabolic clearances, respectively.",Role of the kidneys in the metabolism of furosemide: its inhibition by probenecid. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785407/),[ml] / [kg·min],3.62,170569,DB00695,Furosemide
,8708993,half-lives,"Two half-lives could be distinguished in the plasma elimination of both frusemide and its conjugate, with values of 1.25 +/- 0.75 and 30.4 +/- 11.5 h for frusemide and 1.31 +/- 0.60 and 33.2 +/- 28.0 h for the conjugate.",Frusemide and its acyl glucuronide show a short and long phase in elimination kinetics and pharmacodynamic effect in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8708993/),h,1.25,171004,DB00695,Furosemide
,8708993,half-lives,"Two half-lives could be distinguished in the plasma elimination of both frusemide and its conjugate, with values of 1.25 +/- 0.75 and 30.4 +/- 11.5 h for frusemide and 1.31 +/- 0.60 and 33.2 +/- 28.0 h for the conjugate.",Frusemide and its acyl glucuronide show a short and long phase in elimination kinetics and pharmacodynamic effect in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8708993/),h,30.4,171005,DB00695,Furosemide
,8708993,half-lives,"Two half-lives could be distinguished in the plasma elimination of both frusemide and its conjugate, with values of 1.25 +/- 0.75 and 30.4 +/- 11.5 h for frusemide and 1.31 +/- 0.60 and 33.2 +/- 28.0 h for the conjugate.",Frusemide and its acyl glucuronide show a short and long phase in elimination kinetics and pharmacodynamic effect in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8708993/),h,1.31,171006,DB00695,Furosemide
,8708993,half-lives,"Two half-lives could be distinguished in the plasma elimination of both frusemide and its conjugate, with values of 1.25 +/- 0.75 and 30.4 +/- 11.5 h for frusemide and 1.31 +/- 0.60 and 33.2 +/- 28.0 h for the conjugate.",Frusemide and its acyl glucuronide show a short and long phase in elimination kinetics and pharmacodynamic effect in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8708993/),h,33.2,171007,DB00695,Furosemide
,8708993,excretion,"In the same two periods the excretion of the glucuronide was 13.4 +/- 4.7 and 1.9 +/- 1.1%, respectively.",Frusemide and its acyl glucuronide show a short and long phase in elimination kinetics and pharmacodynamic effect in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8708993/),%,13.4,171008,DB00695,Furosemide
,8708993,excretion,"In the same two periods the excretion of the glucuronide was 13.4 +/- 4.7 and 1.9 +/- 1.1%, respectively.",Frusemide and its acyl glucuronide show a short and long phase in elimination kinetics and pharmacodynamic effect in man. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8708993/),%,1.9,171009,DB00695,Furosemide
,8708993,renal clearance,"The mean renal clearance of frusemide was 90.2 +/- 16.9 mL min-1 during the first period and 91.5 +/- 29.3 mL min-1 in the remaining period, during which the stimulation of urine production was absent.",Frusemide and its acyl glucuronide show a short and long phase in elimination kinetics and pharmacodynamic effect in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8708993/),[ml] / [min],90.2,171010,DB00695,Furosemide
,8708993,renal clearance,"The mean renal clearance of frusemide was 90.2 +/- 16.9 mL min-1 during the first period and 91.5 +/- 29.3 mL min-1 in the remaining period, during which the stimulation of urine production was absent.",Frusemide and its acyl glucuronide show a short and long phase in elimination kinetics and pharmacodynamic effect in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8708993/),[ml] / [min],91.5,171011,DB00695,Furosemide
,8708993,renal clearance,"The renal clearance of the acyl glucuronide was 702 +/- 221 mL min-1 in the first period, but only 109 +/- 51.0 mL min-1 in the second period.",Frusemide and its acyl glucuronide show a short and long phase in elimination kinetics and pharmacodynamic effect in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8708993/),[ml] / [min],702,171012,DB00695,Furosemide
,8708993,renal clearance,"The renal clearance of the acyl glucuronide was 702 +/- 221 mL min-1 in the first period, but only 109 +/- 51.0 mL min-1 in the second period.",Frusemide and its acyl glucuronide show a short and long phase in elimination kinetics and pharmacodynamic effect in man. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8708993/),[ml] / [min],109,171013,DB00695,Furosemide
,8708993,urine production,The stimulated urine production in the first 6 h after administration amounted to 2260 +/- 755 mL (measured urine production minus baseline value of 1 mL min-1 (360 mL).,Frusemide and its acyl glucuronide show a short and long phase in elimination kinetics and pharmacodynamic effect in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8708993/),ml,2260,171014,DB00695,Furosemide
,8708993,urine production,The stimulated urine production in the first 6 h after administration amounted to 2260 +/- 755 mL (measured urine production minus baseline value of 1 mL min-1 (360 mL).,Frusemide and its acyl glucuronide show a short and long phase in elimination kinetics and pharmacodynamic effect in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8708993/),[ml] / [min],1,171015,DB00695,Furosemide
,8708993,production,This reduced production (0.82 mL min-1) is equivalent to an 18% reduction in the average urine flow rate of 1 mL min-1.,Frusemide and its acyl glucuronide show a short and long phase in elimination kinetics and pharmacodynamic effect in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8708993/),[ml] / [min],0.82,171016,DB00695,Furosemide
,8708993,urine flow rate,This reduced production (0.82 mL min-1) is equivalent to an 18% reduction in the average urine flow rate of 1 mL min-1.,Frusemide and its acyl glucuronide show a short and long phase in elimination kinetics and pharmacodynamic effect in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8708993/),[ml] / [min],1,171017,DB00695,Furosemide
,2532460,terminal half-life,"In clinical pharmacology studies cilazapril, after its bioactivation to cilazaprilat, was characterized as a potent, reversible angiotensin-converting enzyme (ACE) inhibitor with a terminal half-life of 30 to 50 hours consistent with saturable binding to ACE.",Clinical pharmacology of cilazapril. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2532460/),h,30 to 50,171142,DB00695,Furosemide
,7190082,peak plasma platinum concentration,"There was no difference in peak plasma platinum concentration (3.91 micrograms/ml +/- 1.41 micrograms/ml), terminal plasma half-life (116--288 hours), peak concentration of unbound platinum (0.7 micrograms/ml), or 24-hour urinary platinum excretion (6.7--17.2% of administered dose) between the objective responder and the nonresponders.","High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7190082/),[μg] / [ml],3.91,171286,DB00695,Furosemide
,7190082,terminal plasma half-life,"There was no difference in peak plasma platinum concentration (3.91 micrograms/ml +/- 1.41 micrograms/ml), terminal plasma half-life (116--288 hours), peak concentration of unbound platinum (0.7 micrograms/ml), or 24-hour urinary platinum excretion (6.7--17.2% of administered dose) between the objective responder and the nonresponders.","High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7190082/),h,116,171287,DB00695,Furosemide
,7190082,peak concentration of unbound platinum,"There was no difference in peak plasma platinum concentration (3.91 micrograms/ml +/- 1.41 micrograms/ml), terminal plasma half-life (116--288 hours), peak concentration of unbound platinum (0.7 micrograms/ml), or 24-hour urinary platinum excretion (6.7--17.2% of administered dose) between the objective responder and the nonresponders.","High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7190082/),[μg] / [ml],0.7,171288,DB00695,Furosemide
,10702552,D(a),"D(a) values were similar to D(M) in 10 patients (D(a) approximately D(M) group) (20.52 +/- 8.40 mg/kg/day versus 18.81 +/- 7.24 mg/kg; P = 0.15), whereas much higher dosages were required in the other eight patients (D(a) >>",High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702552/),[mg] / [d·kg],20.52,172327,DB00695,Furosemide
,10702552,D(a),"D(a) values were similar to D(M) in 10 patients (D(a) approximately D(M) group) (20.52 +/- 8.40 mg/kg/day versus 18.81 +/- 7.24 mg/kg; P = 0.15), whereas much higher dosages were required in the other eight patients (D(a) >>",High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702552/),[mg] / [kg],18.81,172328,DB00695,Furosemide
,10702552,steady-state trough concentration (C(min ss)),D(M) group) (26.78 +/- 3.01 mg/kg/day versus 18.95 +/- 3.41 mg/kg/day; P < 0.0001) despite no major difference in attained vancomycin steady-state trough concentration (C(min ss)) (9.22 +/- 1. 33 mg/L versus 8.99 +/- 1.26 mg/L; = 0.75) or estimated creatinine clearance (1.23 +/- 0.49 mL/min/kg versus 1.21 +/- 0.24 mL/min/kg; P = 0.95) being found between the two groups.,High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702552/),[mg] / [l],9.22,172329,DB00695,Furosemide
,10702552,steady-state trough concentration (C(min ss)),D(M) group) (26.78 +/- 3.01 mg/kg/day versus 18.95 +/- 3.41 mg/kg/day; P < 0.0001) despite no major difference in attained vancomycin steady-state trough concentration (C(min ss)) (9.22 +/- 1. 33 mg/L versus 8.99 +/- 1.26 mg/L; = 0.75) or estimated creatinine clearance (1.23 +/- 0.49 mL/min/kg versus 1.21 +/- 0.24 mL/min/kg; P = 0.95) being found between the two groups.,High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702552/),[mg] / [l],8.99,172330,DB00695,Furosemide
,10702552,C(min ss),"D(M) patients the withdrawal of cotreatment with haemodynamically active drugs was followed by a sudden substantial increase in the vancomycin C(min ss) (13.30 +/- 1. 13 mg/L versus 8.79 +/- 0.87 mg/L; P < 0.01), despite no major change in bodyweight or estimated creatinine clearance being observed.",High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702552/),[mg] / [l],13.30,172331,DB00695,Furosemide
,10702552,C(min ss),"D(M) patients the withdrawal of cotreatment with haemodynamically active drugs was followed by a sudden substantial increase in the vancomycin C(min ss) (13.30 +/- 1. 13 mg/L versus 8.79 +/- 0.87 mg/L; P < 0.01), despite no major change in bodyweight or estimated creatinine clearance being observed.",High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10702552/),[mg] / [l],8.79,172332,DB00695,Furosemide
,7249487,peak plasma concentrations,"In general, peak plasma concentrations of 2 to 3 microgram/ml are achieved with 1 to 2 hours, but concomitant ingestion of food reduces and delays the peak concentrations without reducing the amount absorbed.",Clinical Pharmacokinetics of indomethacin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7249487/),[μg] / [ml],2 to 3,172594,DB00695,Furosemide
,7249487,biological half-life,The drug has a biological half-life of about 5 to 10 hours and a plasma clearance of 1 to 2.5ml/kg/min.,Clinical Pharmacokinetics of indomethacin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7249487/),h,5 to 10,172595,DB00695,Furosemide
,7249487,plasma clearance,The drug has a biological half-life of about 5 to 10 hours and a plasma clearance of 1 to 2.5ml/kg/min.,Clinical Pharmacokinetics of indomethacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7249487/),[ml] / [kg·min],1 to 2.5,172596,DB00695,Furosemide
,26809959,peak MTX/PDX concentration,"After PDX administration, his 1-hour peak MTX/PDX concentration increased to 0.58 μmol/L.",Pralatrexate Monitoring Using a Commercially Available Methotrexate Assay to Avoid Potential Drug Interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26809959/),[μM] / [l],0.58,175241,DB00695,Furosemide
,1432568,half-life,"The half-life of boric acid in serum was 13.46 h, whereas it was shortened to 3.76 h during hemodialysis.",Clinical management of boric acid ingestion: pharmacokinetic assessment of efficacy of hemodialysis for treatment of acute boric acid poisoning. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1432568/),h,13.46,176368,DB00695,Furosemide
,1432568,half-life,"The half-life of boric acid in serum was 13.46 h, whereas it was shortened to 3.76 h during hemodialysis.",Clinical management of boric acid ingestion: pharmacokinetic assessment of efficacy of hemodialysis for treatment of acute boric acid poisoning. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1432568/),h,3.76,176369,DB00695,Furosemide
,1432568,total body clearance,"The total body clearance was 0.99 l/h, while it increased to 3.53 l/h by hemodialysis.",Clinical management of boric acid ingestion: pharmacokinetic assessment of efficacy of hemodialysis for treatment of acute boric acid poisoning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1432568/),[l] / [h],0.99,176370,DB00695,Furosemide
,1432568,total body clearance,"The total body clearance was 0.99 l/h, while it increased to 3.53 l/h by hemodialysis.",Clinical management of boric acid ingestion: pharmacokinetic assessment of efficacy of hemodialysis for treatment of acute boric acid poisoning. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1432568/),[l] / [h],3.53,176371,DB00695,Furosemide
,1432568,additional removal,The additional removal of boric acid by hemodialysis was estimated to be about 5 g.,Clinical management of boric acid ingestion: pharmacokinetic assessment of efficacy of hemodialysis for treatment of acute boric acid poisoning. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1432568/),g,5,176372,DB00695,Furosemide
,3708119,peak concentration,"There were no statistically significant differences among the seven products for the mean peak concentration (1.01-1.29 micrograms/ml), mean time of peak (1.2-2.1 h) or mean area under the plasma concentration-time curves, which differed by less than 14 per cent.",Bioavailability of seven furosemide tablets in man. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3708119/),[μg] / [ml],1.01-1.29,176708,DB00695,Furosemide
,3708119,time of peak,"There were no statistically significant differences among the seven products for the mean peak concentration (1.01-1.29 micrograms/ml), mean time of peak (1.2-2.1 h) or mean area under the plasma concentration-time curves, which differed by less than 14 per cent.",Bioavailability of seven furosemide tablets in man. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3708119/),h,1.2-2.1,176709,DB00695,Furosemide
,11511790,area under the concentration-time curve (AUC,"No significant differences in the pharmacokinetic parameters between the two treatments were observed: area under the concentration-time curve (AUC: 12.7+/-2.2 vs 15.1+/-4.4 g/ml hr), total plasma clearance (253+/-41 vs 256+/-54 ml/min), volume of distribution (341+/-34 vs 494+/-153 ml/kg), elimination half life (4.0+/-1.1 vs 4.6+/-0.8 hr), and urine furosemide excretion of the administered amount (16.5+/-7.3 vs 7.5+/-1.6%).",Does albumin preinfusion potentiate diuretic action of furosemide in patients with nephrotic syndrome? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11511790/),[g] / [h·ml],12.7,177090,DB00695,Furosemide
,11511790,area under the concentration-time curve (AUC,"No significant differences in the pharmacokinetic parameters between the two treatments were observed: area under the concentration-time curve (AUC: 12.7+/-2.2 vs 15.1+/-4.4 g/ml hr), total plasma clearance (253+/-41 vs 256+/-54 ml/min), volume of distribution (341+/-34 vs 494+/-153 ml/kg), elimination half life (4.0+/-1.1 vs 4.6+/-0.8 hr), and urine furosemide excretion of the administered amount (16.5+/-7.3 vs 7.5+/-1.6%).",Does albumin preinfusion potentiate diuretic action of furosemide in patients with nephrotic syndrome? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11511790/),[g] / [h·ml],15.1,177091,DB00695,Furosemide
,11511790,total plasma clearance,"No significant differences in the pharmacokinetic parameters between the two treatments were observed: area under the concentration-time curve (AUC: 12.7+/-2.2 vs 15.1+/-4.4 g/ml hr), total plasma clearance (253+/-41 vs 256+/-54 ml/min), volume of distribution (341+/-34 vs 494+/-153 ml/kg), elimination half life (4.0+/-1.1 vs 4.6+/-0.8 hr), and urine furosemide excretion of the administered amount (16.5+/-7.3 vs 7.5+/-1.6%).",Does albumin preinfusion potentiate diuretic action of furosemide in patients with nephrotic syndrome? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11511790/),[ml] / [min],253,177092,DB00695,Furosemide
,11511790,total plasma clearance,"No significant differences in the pharmacokinetic parameters between the two treatments were observed: area under the concentration-time curve (AUC: 12.7+/-2.2 vs 15.1+/-4.4 g/ml hr), total plasma clearance (253+/-41 vs 256+/-54 ml/min), volume of distribution (341+/-34 vs 494+/-153 ml/kg), elimination half life (4.0+/-1.1 vs 4.6+/-0.8 hr), and urine furosemide excretion of the administered amount (16.5+/-7.3 vs 7.5+/-1.6%).",Does albumin preinfusion potentiate diuretic action of furosemide in patients with nephrotic syndrome? ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11511790/),[ml] / [min],256,177093,DB00695,Furosemide
,11511790,volume of distribution,"No significant differences in the pharmacokinetic parameters between the two treatments were observed: area under the concentration-time curve (AUC: 12.7+/-2.2 vs 15.1+/-4.4 g/ml hr), total plasma clearance (253+/-41 vs 256+/-54 ml/min), volume of distribution (341+/-34 vs 494+/-153 ml/kg), elimination half life (4.0+/-1.1 vs 4.6+/-0.8 hr), and urine furosemide excretion of the administered amount (16.5+/-7.3 vs 7.5+/-1.6%).",Does albumin preinfusion potentiate diuretic action of furosemide in patients with nephrotic syndrome? ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11511790/),[ml] / [kg],341,177094,DB00695,Furosemide
,11511790,volume of distribution,"No significant differences in the pharmacokinetic parameters between the two treatments were observed: area under the concentration-time curve (AUC: 12.7+/-2.2 vs 15.1+/-4.4 g/ml hr), total plasma clearance (253+/-41 vs 256+/-54 ml/min), volume of distribution (341+/-34 vs 494+/-153 ml/kg), elimination half life (4.0+/-1.1 vs 4.6+/-0.8 hr), and urine furosemide excretion of the administered amount (16.5+/-7.3 vs 7.5+/-1.6%).",Does albumin preinfusion potentiate diuretic action of furosemide in patients with nephrotic syndrome? ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11511790/),[ml] / [kg],494,177095,DB00695,Furosemide
,11511790,elimination half life,"No significant differences in the pharmacokinetic parameters between the two treatments were observed: area under the concentration-time curve (AUC: 12.7+/-2.2 vs 15.1+/-4.4 g/ml hr), total plasma clearance (253+/-41 vs 256+/-54 ml/min), volume of distribution (341+/-34 vs 494+/-153 ml/kg), elimination half life (4.0+/-1.1 vs 4.6+/-0.8 hr), and urine furosemide excretion of the administered amount (16.5+/-7.3 vs 7.5+/-1.6%).",Does albumin preinfusion potentiate diuretic action of furosemide in patients with nephrotic syndrome? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11511790/),h,4.0,177096,DB00695,Furosemide
,11511790,elimination half life,"No significant differences in the pharmacokinetic parameters between the two treatments were observed: area under the concentration-time curve (AUC: 12.7+/-2.2 vs 15.1+/-4.4 g/ml hr), total plasma clearance (253+/-41 vs 256+/-54 ml/min), volume of distribution (341+/-34 vs 494+/-153 ml/kg), elimination half life (4.0+/-1.1 vs 4.6+/-0.8 hr), and urine furosemide excretion of the administered amount (16.5+/-7.3 vs 7.5+/-1.6%).",Does albumin preinfusion potentiate diuretic action of furosemide in patients with nephrotic syndrome? ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11511790/),h,4.6,177097,DB00695,Furosemide
,11511790,excretion,"No significant differences in the pharmacokinetic parameters between the two treatments were observed: area under the concentration-time curve (AUC: 12.7+/-2.2 vs 15.1+/-4.4 g/ml hr), total plasma clearance (253+/-41 vs 256+/-54 ml/min), volume of distribution (341+/-34 vs 494+/-153 ml/kg), elimination half life (4.0+/-1.1 vs 4.6+/-0.8 hr), and urine furosemide excretion of the administered amount (16.5+/-7.3 vs 7.5+/-1.6%).",Does albumin preinfusion potentiate diuretic action of furosemide in patients with nephrotic syndrome? ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11511790/),%,16.5,177098,DB00695,Furosemide
,11511790,excretion,"No significant differences in the pharmacokinetic parameters between the two treatments were observed: area under the concentration-time curve (AUC: 12.7+/-2.2 vs 15.1+/-4.4 g/ml hr), total plasma clearance (253+/-41 vs 256+/-54 ml/min), volume of distribution (341+/-34 vs 494+/-153 ml/kg), elimination half life (4.0+/-1.1 vs 4.6+/-0.8 hr), and urine furosemide excretion of the administered amount (16.5+/-7.3 vs 7.5+/-1.6%).",Does albumin preinfusion potentiate diuretic action of furosemide in patients with nephrotic syndrome? ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11511790/),%,7.5,177099,DB00695,Furosemide
,16948809,tmax,RWJ-351647 had a tmax of 1 to 1.1 h and mean half-life of 10.4-17.4 h.,"Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16948809/),h,1 to 1.1,178046,DB00695,Furosemide
,16948809,half-life,RWJ-351647 had a tmax of 1 to 1.1 h and mean half-life of 10.4-17.4 h.,"Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16948809/),h,10.4-17.4,178047,DB00695,Furosemide
,1820878,relative bioavailability,The relative bioavailability of preparation A was about 67% in study 1 compared to study 2.,Multiple peaks and low bioavailability of furosemide correlate with the volume of fluid ingested. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820878/),%,67,178816,DB00695,Furosemide
,1820878,relative bioavailability,Preparation B showed a relative bioavailability of 59% in study 1 compared to study 2.,Multiple peaks and low bioavailability of furosemide correlate with the volume of fluid ingested. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1820878/),%,59,178817,DB00695,Furosemide
,7159689,terminal half-life,The terminal half-life of furosemide was found to change from 29 min for the 10 mg kg-1 dose to 49 min for the 40 mg kg-1 dose.,Dose-dependent pharmacokinetics of furosemide in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7159689/),min,29,179446,DB00695,Furosemide
,7159689,terminal half-life,The terminal half-life of furosemide was found to change from 29 min for the 10 mg kg-1 dose to 49 min for the 40 mg kg-1 dose.,Dose-dependent pharmacokinetics of furosemide in the rat. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7159689/),min,49,179447,DB00695,Furosemide
,3053209,extrarenal clearance,The extrarenal clearance increased from 3.9 to 14.0 ml.min-1 with decreasing renal function.,The pharmacokinetics of ceftazidime in patients with impaired renal function and concurrent frusemide therapy. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3053209/),[ml] / [min],3.9,182458,DB00695,Furosemide
,3053209,extrarenal clearance,The extrarenal clearance increased from 3.9 to 14.0 ml.min-1 with decreasing renal function.,The pharmacokinetics of ceftazidime in patients with impaired renal function and concurrent frusemide therapy. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3053209/),[ml] / [min],14.0,182459,DB00695,Furosemide
,9474471,bioavailablity,"It is well absorbed and yields a bioavailablity of about 80% in healthy individuals, even higher in patients with oedema.",Clinical pharmacokinetics and pharmacodynamics of torasemide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9474471/),%,80,183581,DB00695,Furosemide
,9474471,volume of distribution,The volume of distribution of torasemide was determined as 0.2 L/kg as compared with 0.11 to 0.18 L/kg for furosemide.,Clinical pharmacokinetics and pharmacodynamics of torasemide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9474471/),[l] / [kg],0.2,183582,DB00695,Furosemide
,9474471,volume of distribution,The volume of distribution of torasemide was determined as 0.2 L/kg as compared with 0.11 to 0.18 L/kg for furosemide.,Clinical pharmacokinetics and pharmacodynamics of torasemide. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9474471/),[l] / [kg],0.11 to 0.18,183583,DB00695,Furosemide
,9474471,maximum natriuretic effect,The maximum natriuretic effect of all loop diuretics amounts to about 3 mmol Na+/min.,Clinical pharmacokinetics and pharmacodynamics of torasemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9474471/),[mM·na+] / [min],3,183584,DB00695,Furosemide
,33435470,Km,"Rosmarinic acid showed organic anion transporter (OAT)1-mediated active transport with a Km of 26.5 μM and a Vmax of 69.0 pmol/min in HEK293 cells overexpressing OAT1, and the plasma concentrations of rosmarinic acid were increased by the co-injection of probenecid because of decreased renal excretion due to OAT1 inhibition.",Involvement of Organic Anion Transporters in the Pharmacokinetics and Drug Interaction of Rosmarinic Acid. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33435470/),μM,26.5,186352,DB00695,Furosemide
,33435470,Vmax,"Rosmarinic acid showed organic anion transporter (OAT)1-mediated active transport with a Km of 26.5 μM and a Vmax of 69.0 pmol/min in HEK293 cells overexpressing OAT1, and the plasma concentrations of rosmarinic acid were increased by the co-injection of probenecid because of decreased renal excretion due to OAT1 inhibition.",Involvement of Organic Anion Transporters in the Pharmacokinetics and Drug Interaction of Rosmarinic Acid. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33435470/),[pM] / [min],69.0,186353,DB00695,Furosemide
,33435470,IC50,"Rosmarinic acid inhibited the transport activities of OAT1, OAT3, organic anion transporting polypeptide (OATP)1B1, and OATP1B3 with IC50 values of 60.6 μM, 1.52 μM, 74.8 μM, and 91.3 μM, respectively, and the inhibitory effect of rosmarinic acid on OAT3 transport activity caused an in vivo pharmacokinetic interaction with furosemide by inhibiting its renal excretion and by increasing its plasma concentration.",Involvement of Organic Anion Transporters in the Pharmacokinetics and Drug Interaction of Rosmarinic Acid. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33435470/),μM,60.6,186354,DB00695,Furosemide
,33435470,IC50,"Rosmarinic acid inhibited the transport activities of OAT1, OAT3, organic anion transporting polypeptide (OATP)1B1, and OATP1B3 with IC50 values of 60.6 μM, 1.52 μM, 74.8 μM, and 91.3 μM, respectively, and the inhibitory effect of rosmarinic acid on OAT3 transport activity caused an in vivo pharmacokinetic interaction with furosemide by inhibiting its renal excretion and by increasing its plasma concentration.",Involvement of Organic Anion Transporters in the Pharmacokinetics and Drug Interaction of Rosmarinic Acid. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33435470/),μM,1.52,186355,DB00695,Furosemide
,33435470,IC50,"Rosmarinic acid inhibited the transport activities of OAT1, OAT3, organic anion transporting polypeptide (OATP)1B1, and OATP1B3 with IC50 values of 60.6 μM, 1.52 μM, 74.8 μM, and 91.3 μM, respectively, and the inhibitory effect of rosmarinic acid on OAT3 transport activity caused an in vivo pharmacokinetic interaction with furosemide by inhibiting its renal excretion and by increasing its plasma concentration.",Involvement of Organic Anion Transporters in the Pharmacokinetics and Drug Interaction of Rosmarinic Acid. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33435470/),μM,74.8,186356,DB00695,Furosemide
,33435470,IC50,"Rosmarinic acid inhibited the transport activities of OAT1, OAT3, organic anion transporting polypeptide (OATP)1B1, and OATP1B3 with IC50 values of 60.6 μM, 1.52 μM, 74.8 μM, and 91.3 μM, respectively, and the inhibitory effect of rosmarinic acid on OAT3 transport activity caused an in vivo pharmacokinetic interaction with furosemide by inhibiting its renal excretion and by increasing its plasma concentration.",Involvement of Organic Anion Transporters in the Pharmacokinetics and Drug Interaction of Rosmarinic Acid. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33435470/),μM,91.3,186357,DB00695,Furosemide
,523503,oral availability,"The extent of oral availability, determined by the ratio of areas under the oral to intravenous plasma concentration-time curve, averaged 61%, but varied widely from patient to patient, from 34 to 80%.",Pharmacokinetics of furosemide in patients with congestive heart failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/523503/),%,61,186812,DB00695,Furosemide
,523503,oral availability,"The extent of oral availability, determined by the ratio of areas under the oral to intravenous plasma concentration-time curve, averaged 61%, but varied widely from patient to patient, from 34 to 80%.",Pharmacokinetics of furosemide in patients with congestive heart failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/523503/),%,34,186813,DB00695,Furosemide
,523503,lag time before appearance,"Absorption of the drug was often delayed, with a lag time before appearance in the plasma averaging 28 +/- (SD) 15 min.",Pharmacokinetics of furosemide in patients with congestive heart failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/523503/),min,28,186814,DB00695,Furosemide
,523503,volume of distribution,"The volume of distribution of furosemide (averaging 114 ml/kg) was not diminished in the presence of congestive failure; likewise, drug clearance and elimination half-lives are similar to values reported in normal subjects.",Pharmacokinetics of furosemide in patients with congestive heart failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/523503/),[ml] / [kg],114,186815,DB00695,Furosemide
,3608350,total clearance,"Although total clearance was the same with all doses (about 0.45 ml/min/kg), renal clearance and the fraction of unchanged drug appearing in the urine decreased with higher doses raising the question of saturable renal secretion.","Clinical pharmacology of torasemide, a new loop diuretic. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3608350/),[ml] / [kg·min],0.45,188327,DB00695,Furosemide
,27033999,relative bioavailability,A relative bioavailability of 220% for the ASSF in microcontainers compared to ASSF in capsules is found.,Polymeric microcontainers improve oral bioavailability of furosemide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27033999/),%,220,189595,DB00695,Furosemide
,7291727,maximum A/V ratios,"The maximum A/V ratios shortly after a rapid intravenous bolus dose were 277-, 15-, 34-, 33-, 5.4- and 3240-fold, respectively, for the above six drugs.",Arterial-venous plasma concentration differences of six drugs in the dog and rabbit after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7291727/),,27,190508,DB00695,Furosemide
,7291727,maximum A/V ratios,"The maximum A/V ratios shortly after a rapid intravenous bolus dose were 277-, 15-, 34-, 33-, 5.4- and 3240-fold, respectively, for the above six drugs.",Arterial-venous plasma concentration differences of six drugs in the dog and rabbit after intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7291727/),,15,190509,DB00695,Furosemide
,6148397,bioavailability,There is a linear relationship between the percentage dissolution in 30 min and the bioavailability relative to an oral solution of frusemide over the bioavailability range 76-97%.,An in-vivo-in-vitro correlation for the bioavailability of frusemide tablets. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6148397/),%,76-97,194627,DB00695,Furosemide
,3790195,peak excretion time,"Excepting a shift in the peak excretion time to 4-5 h, no meaningful pharmacokinetic differences were found when Apetinil-Depot, a retard formulation, was administered.",The influence of diuretics on the excretion and metabolism of doping agents. Etilamfetamine. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3790195/),h,4-5,195425,DB00695,Furosemide
,9646006,plasma half-life,"Unlike other oxicams, lornoxicam has a relatively short plasma half-life (3 to 5 hours).",Clinical pharmacokinetics of lornoxicam. A short half-life oxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646006/),h,3 to 5,196622,DB00695,Furosemide
,9646006,half-life,Glucoroconjugated metabolites are excreted in urine and faeces with a half-life of about 11 hours.,Clinical pharmacokinetics of lornoxicam. A short half-life oxicam. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646006/),h,11,196623,DB00695,Furosemide
,3084762,renal clearance,"The kinetics of furosemide were not affected by any of the experimental conditions except HCHO, in which the renal clearance of furosemide was reduced from 7.5 +/- 1.4 ml/min/kg (controls) to 2.7 +/- 0.7 ml/min/kg (P less than .05).",Furosemide pharmacodynamics: effect of respiratory and acid-base disturbances. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3084762/),[ml] / [kg·min],7.5,198418,DB00695,Furosemide
,3084762,renal clearance,"The kinetics of furosemide were not affected by any of the experimental conditions except HCHO, in which the renal clearance of furosemide was reduced from 7.5 +/- 1.4 ml/min/kg (controls) to 2.7 +/- 0.7 ml/min/kg (P less than .05).",Furosemide pharmacodynamics: effect of respiratory and acid-base disturbances. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3084762/),[ml] / [kg·min],2.7,198419,DB00695,Furosemide
,17875188,peak excretion rate,Sodium excretion was higher after sublingual compared with oral administration (peak excretion rate 1.8 vs.,Sublingual administration of furosemide: new application of an old drug. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17875188/),,1.8,198676,DB00695,Furosemide
,1510797,urinary recovery,The percentages of mean urinary recovery of Furosemide for the prodrug and for the standard solution of the drug were 20.84 and 14.36 respectively.,"Development of absorption furosemide prodrugs: synthesis, in vitro and in vivo evaluation. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1510797/),,20.84,198821,DB00695,Furosemide
,1510797,urinary recovery,The percentages of mean urinary recovery of Furosemide for the prodrug and for the standard solution of the drug were 20.84 and 14.36 respectively.,"Development of absorption furosemide prodrugs: synthesis, in vitro and in vivo evaluation. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1510797/),,14.36,198822,DB00695,Furosemide
,17119933,analysis time,"The analysis time for each sample was 4 min, and more than 300 samples could be analyzed in one day by running the system overnight.","Simultaneous determination of losartan, EXP-3174 and hydrochlorothiazide in plasma via fully automated 96-well-format-based solid-phase extraction and liquid chromatography-negative electrospray tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17119933/),min,4,203124,DB00695,Furosemide
,7205627,renal,"Functional hepatectomy caused no significant changes in either the renal or the nonrenal clearances of furosemide; renal = 124.2 +/- 27.1 (mean +/- SE) and 106.6 +/- 17.5 ml/min and nonrenal = 148.2 +/- 11.4 and 112.6 +/- 21.0 ml/min in sham-operated and hepatectomized dogs, respectively.",Disposition of furosemide in functionally hepatectomized dogs. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205627/),[ml] / [min],124.2,205036,DB00695,Furosemide
,7205627,renal,"Functional hepatectomy caused no significant changes in either the renal or the nonrenal clearances of furosemide; renal = 124.2 +/- 27.1 (mean +/- SE) and 106.6 +/- 17.5 ml/min and nonrenal = 148.2 +/- 11.4 and 112.6 +/- 21.0 ml/min in sham-operated and hepatectomized dogs, respectively.",Disposition of furosemide in functionally hepatectomized dogs. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205627/),[ml] / [min],106.6,205037,DB00695,Furosemide
,7205627,nonrenal,"Functional hepatectomy caused no significant changes in either the renal or the nonrenal clearances of furosemide; renal = 124.2 +/- 27.1 (mean +/- SE) and 106.6 +/- 17.5 ml/min and nonrenal = 148.2 +/- 11.4 and 112.6 +/- 21.0 ml/min in sham-operated and hepatectomized dogs, respectively.",Disposition of furosemide in functionally hepatectomized dogs. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205627/),[ml] / [min],148.2,205038,DB00695,Furosemide
,7205627,nonrenal,"Functional hepatectomy caused no significant changes in either the renal or the nonrenal clearances of furosemide; renal = 124.2 +/- 27.1 (mean +/- SE) and 106.6 +/- 17.5 ml/min and nonrenal = 148.2 +/- 11.4 and 112.6 +/- 21.0 ml/min in sham-operated and hepatectomized dogs, respectively.",Disposition of furosemide in functionally hepatectomized dogs. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205627/),[ml] / [min],112.6,205039,DB00695,Furosemide
,7205627,plasma binding,Devascularization of the liver had no effect on the plasma binding of furosemide which was 90.0% in the sham-operated and 88.2% in the hepatectomized animals.,Disposition of furosemide in functionally hepatectomized dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205627/),%,90.0,205040,DB00695,Furosemide
,7205627,plasma binding,Devascularization of the liver had no effect on the plasma binding of furosemide which was 90.0% in the sham-operated and 88.2% in the hepatectomized animals.,Disposition of furosemide in functionally hepatectomized dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205627/),%,88.2,205041,DB00695,Furosemide
,7205627,steady-state volume of distribution,"The steady-state volume of distribution of furosemide was relatively small, 0.70 +/- 0.09 liters/kg in control dogs and hepatectomy resulted in a reduction in this volume (0.58 +/- 0.09 liters/kg).",Disposition of furosemide in functionally hepatectomized dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205627/),[l] / [kg],0.70,205042,DB00695,Furosemide
,7205627,steady-state volume of distribution,"The steady-state volume of distribution of furosemide was relatively small, 0.70 +/- 0.09 liters/kg in control dogs and hepatectomy resulted in a reduction in this volume (0.58 +/- 0.09 liters/kg).",Disposition of furosemide in functionally hepatectomized dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205627/),[l] / [kg],0.58,205043,DB00695,Furosemide
,7205627,Urinary recoveries,Urinary recoveries of parent drug (43.2% of the dose in sham-operated dogs ad 49.1% in hepatectomized animals) and of its glucuronide (4.3% in sham-operated and 5.5% in hepatectomized dogs) were not influenced by hepatic devascularization.,Disposition of furosemide in functionally hepatectomized dogs. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205627/),%,43.2,205044,DB00695,Furosemide
,7205627,Urinary recoveries,Urinary recoveries of parent drug (43.2% of the dose in sham-operated dogs ad 49.1% in hepatectomized animals) and of its glucuronide (4.3% in sham-operated and 5.5% in hepatectomized dogs) were not influenced by hepatic devascularization.,Disposition of furosemide in functionally hepatectomized dogs. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205627/),%,49.1,205045,DB00695,Furosemide
,7205627,Urinary recoveries,Urinary recoveries of parent drug (43.2% of the dose in sham-operated dogs ad 49.1% in hepatectomized animals) and of its glucuronide (4.3% in sham-operated and 5.5% in hepatectomized dogs) were not influenced by hepatic devascularization.,Disposition of furosemide in functionally hepatectomized dogs. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205627/),%,4.3,205046,DB00695,Furosemide
,7205627,Urinary recoveries,Urinary recoveries of parent drug (43.2% of the dose in sham-operated dogs ad 49.1% in hepatectomized animals) and of its glucuronide (4.3% in sham-operated and 5.5% in hepatectomized dogs) were not influenced by hepatic devascularization.,Disposition of furosemide in functionally hepatectomized dogs. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7205627/),%,5.5,205047,DB00695,Furosemide
,15222723,terminal half-life,Our results are in accordance with the most recent pharmacokinetic studies on furosemide in which a terminal half-life of approximately 20-30 h was reported.,Effects of high altitude exposure on the pharmacokinetics of furosemide in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15222723/),h,20-30,205717,DB00695,Furosemide
,6883908,Elimination t1/2s,Elimination t1/2s were 60 to 90 min.,Effects of piretanide in normal subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883908/),min,60 to 90,206365,DB00695,Furosemide
,6883908,Renal clearance rate,Renal clearance rate was 90 to 100 ml/min and oral clearance was 200 ml/min.,Effects of piretanide in normal subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883908/),[ml] / [min],90 to 100,206366,DB00695,Furosemide
,6883908,oral clearance,Renal clearance rate was 90 to 100 ml/min and oral clearance was 200 ml/min.,Effects of piretanide in normal subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883908/),[ml] / [min],200,206367,DB00695,Furosemide
,6883908,half-maximal response,The piretanide dose that induced half-maximal response was 12.1 +/- 2.6 micrograms/min; it is 69.8 micrograms/min for furosemide and 1 micrograms/min for bumetanide.,Effects of piretanide in normal subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883908/),[μg] / [min],12.1,206368,DB00695,Furosemide
,6883908,half-maximal response,The piretanide dose that induced half-maximal response was 12.1 +/- 2.6 micrograms/min; it is 69.8 micrograms/min for furosemide and 1 micrograms/min for bumetanide.,Effects of piretanide in normal subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883908/),[μg] / [min],69.8,206369,DB00695,Furosemide
,6883908,half-maximal response,The piretanide dose that induced half-maximal response was 12.1 +/- 2.6 micrograms/min; it is 69.8 micrograms/min for furosemide and 1 micrograms/min for bumetanide.,Effects of piretanide in normal subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6883908/),[μg] / [min],1,206370,DB00695,Furosemide
,3447247,renal extractions,The renal extractions of the two substances were closely correlated and averaged 85.9% for PAH and 88.7% for TEA (p less than 0.01).,Superiority of tetraethylammonium to p-aminohippurate as a marker for renal plasma flow during furosemide diuresis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3447247/),%,85.9,207219,DB00695,Furosemide
,3447247,renal extractions,The renal extractions of the two substances were closely correlated and averaged 85.9% for PAH and 88.7% for TEA (p less than 0.01).,Superiority of tetraethylammonium to p-aminohippurate as a marker for renal plasma flow during furosemide diuresis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3447247/),%,88.7,207220,DB00695,Furosemide
,24900544,IC50,"Compound 5 demonstrated inhibitory activities toward human renin (IC50 = 0.9 nM) and human and monkey PRA (IC50 = 1.9 and 6.3 nM, respectively).","Discovery of DS-8108b, a Novel Orally Bioavailable Renin Inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24900544/),nM,0.9,207497,DB00695,Furosemide
,24900544,IC50,"Compound 5 demonstrated inhibitory activities toward human renin (IC50 = 0.9 nM) and human and monkey PRA (IC50 = 1.9 and 6.3 nM, respectively).","Discovery of DS-8108b, a Novel Orally Bioavailable Renin Inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24900544/),nM,1.9,207498,DB00695,Furosemide
,24900544,IC50,"Compound 5 demonstrated inhibitory activities toward human renin (IC50 = 0.9 nM) and human and monkey PRA (IC50 = 1.9 and 6.3 nM, respectively).","Discovery of DS-8108b, a Novel Orally Bioavailable Renin Inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24900544/),nM,6.3,207499,DB00695,Furosemide
,648078,total body clearance,"Normal subjects had a total body clearance of furosemide of 1.53 +/- 0.11 (SE) ml/min/kg, a volume of the central compartment of 2.61 +/- 0.37 L, a volume of the peripheral compartment of 2.48 +/- 0.24 L, and a half-life of 0.8 +/- 0.06 hr and they absorbed 68.9% +/- 7.1% of a solution of furosemide given by mouth.",Furosemide kinetics in renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/648078/),[ml] / [kg·min],1.53,207512,DB00695,Furosemide
,648078,volume of the central compartment,"Normal subjects had a total body clearance of furosemide of 1.53 +/- 0.11 (SE) ml/min/kg, a volume of the central compartment of 2.61 +/- 0.37 L, a volume of the peripheral compartment of 2.48 +/- 0.24 L, and a half-life of 0.8 +/- 0.06 hr and they absorbed 68.9% +/- 7.1% of a solution of furosemide given by mouth.",Furosemide kinetics in renal failure. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/648078/),l,2.61,207513,DB00695,Furosemide
,648078,volume of the peripheral compartment,"Normal subjects had a total body clearance of furosemide of 1.53 +/- 0.11 (SE) ml/min/kg, a volume of the central compartment of 2.61 +/- 0.37 L, a volume of the peripheral compartment of 2.48 +/- 0.24 L, and a half-life of 0.8 +/- 0.06 hr and they absorbed 68.9% +/- 7.1% of a solution of furosemide given by mouth.",Furosemide kinetics in renal failure. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/648078/),l,2.48,207514,DB00695,Furosemide
,648078,half-life,"Normal subjects had a total body clearance of furosemide of 1.53 +/- 0.11 (SE) ml/min/kg, a volume of the central compartment of 2.61 +/- 0.37 L, a volume of the peripheral compartment of 2.48 +/- 0.24 L, and a half-life of 0.8 +/- 0.06 hr and they absorbed 68.9% +/- 7.1% of a solution of furosemide given by mouth.",Furosemide kinetics in renal failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/648078/),h,0.8,207515,DB00695,Furosemide
,648078,bioavailability,"The bioavailability of 500-mg tablets of furosemide in the renal failure patients was 43.4% +/- 7.4%, equivalent to the absorption of the dose given to the same patients in the form of a solution.",Furosemide kinetics in renal failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/648078/),%,43.4,207516,DB00695,Furosemide
,3987786,urinary recovery of unchanged drug,"The mean urinary recovery of unchanged drug was 11.5 mg and 9.41 mg in 24 h after pre- and postprandial administration to 10 patients, whereas the recovery was 14.4 mg in 10 healthy subjects.",Bioavailability and diuretic effect of furosemide during long-term treatment of chronic respiratory failure. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987786/),mg,11.5,207853,DB00695,Furosemide
,3987786,urinary recovery of unchanged drug,"The mean urinary recovery of unchanged drug was 11.5 mg and 9.41 mg in 24 h after pre- and postprandial administration to 10 patients, whereas the recovery was 14.4 mg in 10 healthy subjects.",Bioavailability and diuretic effect of furosemide during long-term treatment of chronic respiratory failure. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987786/),mg,9.41,207854,DB00695,Furosemide
,3987786,recovery,"The mean urinary recovery of unchanged drug was 11.5 mg and 9.41 mg in 24 h after pre- and postprandial administration to 10 patients, whereas the recovery was 14.4 mg in 10 healthy subjects.",Bioavailability and diuretic effect of furosemide during long-term treatment of chronic respiratory failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987786/),mg,14.4,207855,DB00695,Furosemide
,3987786,absolute bioavailability,"The mean absolute bioavailability of furosemide in 6 patients was 41.3% and 63.4%, respectively, calculated from unchanged drug and total drug (unchanged plus glucuronide conjugate).",Bioavailability and diuretic effect of furosemide during long-term treatment of chronic respiratory failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987786/),%,41.3,207856,DB00695,Furosemide
,3987786,absolute bioavailability,"The mean absolute bioavailability of furosemide in 6 patients was 41.3% and 63.4%, respectively, calculated from unchanged drug and total drug (unchanged plus glucuronide conjugate).",Bioavailability and diuretic effect of furosemide during long-term treatment of chronic respiratory failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987786/),%,63.4,207857,DB00695,Furosemide
,3987786,fraction recovered,"In another study, the mean glucuronide fraction recovered in 24-h urine was 20.7% and 7.3% (p less than 0.01) in 38 patients and 12 healthy subjects, respectively.",Bioavailability and diuretic effect of furosemide during long-term treatment of chronic respiratory failure. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987786/),%,20.7,207858,DB00695,Furosemide
,3987786,fraction recovered,"In another study, the mean glucuronide fraction recovered in 24-h urine was 20.7% and 7.3% (p less than 0.01) in 38 patients and 12 healthy subjects, respectively.",Bioavailability and diuretic effect of furosemide during long-term treatment of chronic respiratory failure. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3987786/),%,7.3,207859,DB00695,Furosemide
,6641097,diuresis at steady state,Continuous intravenous infusion of bumetanide (200 micrograms/hr) gave an average diuresis at steady state of 15 +/- 3 ml/min.,Coupling between renal tubular secretion and effect of bumetanide. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641097/),[ml] / [min],15,210441,DB00695,Furosemide
,6641097,plasma,"Corresponding plasma concentration, urinary excretion rate, and renal clearance of bumetanide averaged 14.3 +/- 2.3 ng/ml, 64 +/- 31 micrograms/30 min, and 145 +/- 59 ml/min.",Coupling between renal tubular secretion and effect of bumetanide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641097/),[ng] / [ml],14.3,210442,DB00695,Furosemide
,6641097,urinary excretion rate,"Corresponding plasma concentration, urinary excretion rate, and renal clearance of bumetanide averaged 14.3 +/- 2.3 ng/ml, 64 +/- 31 micrograms/30 min, and 145 +/- 59 ml/min.",Coupling between renal tubular secretion and effect of bumetanide. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641097/),[μg] / [30·min],64,210443,DB00695,Furosemide
,6641097,renal clearance,"Corresponding plasma concentration, urinary excretion rate, and renal clearance of bumetanide averaged 14.3 +/- 2.3 ng/ml, 64 +/- 31 micrograms/30 min, and 145 +/- 59 ml/min.",Coupling between renal tubular secretion and effect of bumetanide. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641097/),[ml] / [min],145,210444,DB00695,Furosemide
,6641097,plasma concentration,"Average plasma concentration rose to 41.7 +/- 8.1 ng/ml, whereas renal clearance and urinary excretion rate fell to 15.1% and 29.5% of control.",Coupling between renal tubular secretion and effect of bumetanide. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6641097/),[ng] / [ml],41.7,210445,DB00695,Furosemide
,15515593,systemic bioavailability,"Median systemic bioavailability was 5.4% (25th percentile, 75th percentile: 3.5, 9.6).",Pharmacokinetics and pharmacodynamics of furosemide after oral administration to horses. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15515593/),%,5.4,210960,DB00695,Furosemide
,15515593,maximum plasma concentration,"The maximum plasma concentration of 0.03 microg/mL after administration PO was not sufficient to increase urine volume compared with control horses (1.2 L [1.0, 1.4] PO versus 1.2 L [1.0, 1.4] control).",Pharmacokinetics and pharmacodynamics of furosemide after oral administration to horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15515593/),[μg] / [ml],0.03,210961,DB00695,Furosemide
,15515593,maximum plasma concentration,"The maximum plasma concentration of 0.03 microg/mL after administration PO was not sufficient to increase urine volume compared with control horses (1.2 L [1.0, 1.4] PO versus 1.2 L [1.0, 1.4] control).",Pharmacokinetics and pharmacodynamics of furosemide after oral administration to horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15515593/),l,1.2,210962,DB00695,Furosemide
,22264484,IC(50),"Among them, 12a containing thioamido moiety displayed both high in vitro functional antagonism and binding affinity [IC(50)=0.42 and 0.13 nM, respectively] and inhibited strongly in vivo AngII-induced pressor response in pithed rats with an ED(50) of 0.018 mg/kg.",Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22264484/),nM,0.42,212494,DB00695,Furosemide
,22264484,IC(50),"Among them, 12a containing thioamido moiety displayed both high in vitro functional antagonism and binding affinity [IC(50)=0.42 and 0.13 nM, respectively] and inhibited strongly in vivo AngII-induced pressor response in pithed rats with an ED(50) of 0.018 mg/kg.",Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22264484/),nM,0.13,212495,DB00695,Furosemide
,22264484,ED(50),"Among them, 12a containing thioamido moiety displayed both high in vitro functional antagonism and binding affinity [IC(50)=0.42 and 0.13 nM, respectively] and inhibited strongly in vivo AngII-induced pressor response in pithed rats with an ED(50) of 0.018 mg/kg.",Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22264484/),[mg] / [kg],0.018,212496,DB00695,Furosemide
,7132061,bioavailability,"A difference was not found in the bioavailability of forosemide in patients with CHF compared to normal volunteers, 31 +/- 12 vs. 38 +/- 20% (mean +/- sd), respectively.",Absorption and disposition of furosemide in congestive heart failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7132061/),%,31,213654,DB00695,Furosemide
,7132061,bioavailability,"A difference was not found in the bioavailability of forosemide in patients with CHF compared to normal volunteers, 31 +/- 12 vs. 38 +/- 20% (mean +/- sd), respectively.",Absorption and disposition of furosemide in congestive heart failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7132061/),%,38,213655,DB00695,Furosemide
,33403255,bioavailability,Furosemide tablet formulation exhibits variable pharmacokinetics (PK) with bioavailability ranging from 10 to almost 100%.,Contribution of Uptake and Efflux Transporters to Oral Pharmacokinetics of Furosemide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33403255/),%,10 to almost 100,214342,DB00695,Furosemide
,3509139,bioavailability,"Compared to the oral solution, all of the formulations exhibited lower peak furosemide concentrations, longer mean residence times, and, in some cases, diminished bioavailability (range, 66-96%).",Influence of tablet dissolution on furosemide bioavailability: a bioequivalence study. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3509139/),%,66-96,214369,DB00695,Furosemide
,6668097,half-life,The mean half-life of furosemide in nephrotic children (38.5 +/- 7.8 min) was significantly longer than in the control group (28.0 +/- 7.7 min).,Clinical pharmacokinetics of furosemide in children with nephrotic syndrome. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668097/),min,38.5,214866,DB00695,Furosemide
,6668097,half-life,The mean half-life of furosemide in nephrotic children (38.5 +/- 7.8 min) was significantly longer than in the control group (28.0 +/- 7.7 min).,Clinical pharmacokinetics of furosemide in children with nephrotic syndrome. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668097/),min,28.0,214867,DB00695,Furosemide
,6668097,serum clearance,The average serum clearance was 4.95 +/- 1.7 ml/min/kg body wt. in the control group and 5.10 +/- 1.4 ml/min/kg body wt. in the nephrotic children.,Clinical pharmacokinetics of furosemide in children with nephrotic syndrome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668097/),[ml] / [body·kg·min·wt],4.95,214868,DB00695,Furosemide
,6668097,serum clearance,The average serum clearance was 4.95 +/- 1.7 ml/min/kg body wt. in the control group and 5.10 +/- 1.4 ml/min/kg body wt. in the nephrotic children.,Clinical pharmacokinetics of furosemide in children with nephrotic syndrome. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6668097/),[ml] / [body·kg·min·wt],5.10,214869,DB00695,Furosemide
,29908331,Tmax,"Additionally, Tmax was shortened from approximately 25 to 20 min.",All-atomistic molecular dynamics (AA-MD) studies and pharmacokinetic performance of PAMAM-dendrimer-furosemide delivery systems. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29908331/),min,25 to 20,216664,DB00695,Furosemide
,8922736,total,"3. In the control group, total, urinary and metabolic clearances of furosemide were 11.8 +/- 1.0, 5.0 +/- 0.4 and 6.8 +/- 0.6 ml min-1 kg-1, respectively.",The influence of moderate hypoalbuminaemia on the renal metabolism and dynamics of furosemide in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8922736/),[ml] / [kg·min],11.8,218070,DB00695,Furosemide
,8922736,urinary,"3. In the control group, total, urinary and metabolic clearances of furosemide were 11.8 +/- 1.0, 5.0 +/- 0.4 and 6.8 +/- 0.6 ml min-1 kg-1, respectively.",The influence of moderate hypoalbuminaemia on the renal metabolism and dynamics of furosemide in the rabbit. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8922736/),[ml] / [kg·min],5.0,218071,DB00695,Furosemide
,8922736,metabolic clearances,"3. In the control group, total, urinary and metabolic clearances of furosemide were 11.8 +/- 1.0, 5.0 +/- 0.4 and 6.8 +/- 0.6 ml min-1 kg-1, respectively.",The influence of moderate hypoalbuminaemia on the renal metabolism and dynamics of furosemide in the rabbit. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8922736/),[ml] / [kg·min],5.0,218072,DB00695,Furosemide
,8922736,metabolic clearances,"3. In the control group, total, urinary and metabolic clearances of furosemide were 11.8 +/- 1.0, 5.0 +/- 0.4 and 6.8 +/- 0.6 ml min-1 kg-1, respectively.",The influence of moderate hypoalbuminaemia on the renal metabolism and dynamics of furosemide in the rabbit. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8922736/),[ml] / [kg·min],6.8,218073,DB00695,Furosemide
,8922736,metabolic clearance (C1m),"Compared with control rabbits, in hypoalbuminaemic rabbits, total clearance of furosemide increased by 40% (P < 0.001), result of the enhancement of furosemide metabolic clearance (C1m) from 5 to 10 ml min-1 kg-1 (P < 0.01).",The influence of moderate hypoalbuminaemia on the renal metabolism and dynamics of furosemide in the rabbit. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8922736/),[ml] / [kg·min],5,218074,DB00695,Furosemide
,8922736,metabolic clearance (C1m),"Compared with control rabbits, in hypoalbuminaemic rabbits, total clearance of furosemide increased by 40% (P < 0.001), result of the enhancement of furosemide metabolic clearance (C1m) from 5 to 10 ml min-1 kg-1 (P < 0.01).",The influence of moderate hypoalbuminaemia on the renal metabolism and dynamics of furosemide in the rabbit. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8922736/),[ml] / [kg·min],10,218075,DB00695,Furosemide
,8922736,urinary excretion,"In hypoalbuminaemic rabbits, urinary excretion of furosemide was reduced by 26% (2451 +/- 115 vs 1818 +/- 134 micrograms h-1, P < 0.01).",The influence of moderate hypoalbuminaemia on the renal metabolism and dynamics of furosemide in the rabbit. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8922736/),[μg] / [h],2451,218076,DB00695,Furosemide
,8922736,urinary excretion,"In hypoalbuminaemic rabbits, urinary excretion of furosemide was reduced by 26% (2451 +/- 115 vs 1818 +/- 134 micrograms h-1, P < 0.01).",The influence of moderate hypoalbuminaemia on the renal metabolism and dynamics of furosemide in the rabbit. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8922736/),[μg] / [h],1818,218077,DB00695,Furosemide
,8922736,total clearance,"In anephric rabbits, furosemide total clearance was 1.77 +/- 0.12 ml min-1 kg-1, value not affected by hypoalbuminaemia, confirming that the increase in C1m induced by hypoalbuminaemia occurs in the kidneys.",The influence of moderate hypoalbuminaemia on the renal metabolism and dynamics of furosemide in the rabbit. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8922736/),[ml] / [kg·min],1.77,218078,DB00695,Furosemide
,8922736,rate of urinary excretion,"4. Compared with controls, in hypoalbuminaemic rabbits, the rate of urinary excretion (142 +/- 9 vs 74 +/- 8 ml h-1, P < 0.001) and the rate of excretion of sodium (18.6 +/- 0.9 vs 9.9 +/- 0.9 mmol h-1, P < 0.001) were very much reduced.",The influence of moderate hypoalbuminaemia on the renal metabolism and dynamics of furosemide in the rabbit. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8922736/),[ml] / [h],142,218079,DB00695,Furosemide
,8922736,rate of urinary excretion,"4. Compared with controls, in hypoalbuminaemic rabbits, the rate of urinary excretion (142 +/- 9 vs 74 +/- 8 ml h-1, P < 0.001) and the rate of excretion of sodium (18.6 +/- 0.9 vs 9.9 +/- 0.9 mmol h-1, P < 0.001) were very much reduced.",The influence of moderate hypoalbuminaemia on the renal metabolism and dynamics of furosemide in the rabbit. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8922736/),[ml] / [h],74,218080,DB00695,Furosemide
,8922736,rate of excretion of sodium,"4. Compared with controls, in hypoalbuminaemic rabbits, the rate of urinary excretion (142 +/- 9 vs 74 +/- 8 ml h-1, P < 0.001) and the rate of excretion of sodium (18.6 +/- 0.9 vs 9.9 +/- 0.9 mmol h-1, P < 0.001) were very much reduced.",The influence of moderate hypoalbuminaemia on the renal metabolism and dynamics of furosemide in the rabbit. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8922736/),[mM] / [h],18.6,218081,DB00695,Furosemide
,8922736,rate of excretion of sodium,"4. Compared with controls, in hypoalbuminaemic rabbits, the rate of urinary excretion (142 +/- 9 vs 74 +/- 8 ml h-1, P < 0.001) and the rate of excretion of sodium (18.6 +/- 0.9 vs 9.9 +/- 0.9 mmol h-1, P < 0.001) were very much reduced.",The influence of moderate hypoalbuminaemia on the renal metabolism and dynamics of furosemide in the rabbit. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8922736/),[mM] / [h],9.9,218082,DB00695,Furosemide
,9783105,maximal concentration,After oral administration of 40 mg furosemide maximal concentration of the drug in the blood (977 +/- 151 ng/ml) was found on the average in a group in 1.3 +/- 0.2 h.,[The pharmacodynamics and pharmacokinetics of furosemide during ordinary life activities and during head-down tilt hypokinesia in a healthy subject]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9783105/),[ng] / [ml],977,219994,DB00695,Furosemide
,9783105,half-life period,"The drug half-life period in this case was 1.1 +/- 0.4 h; total clearance was 24.7 +/- 2.8 liter/h, and the distribution volume was 33.7 +/- 12.7 liters.",[The pharmacodynamics and pharmacokinetics of furosemide during ordinary life activities and during head-down tilt hypokinesia in a healthy subject]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9783105/),h,1.1,219995,DB00695,Furosemide
,9783105,total clearance,"The drug half-life period in this case was 1.1 +/- 0.4 h; total clearance was 24.7 +/- 2.8 liter/h, and the distribution volume was 33.7 +/- 12.7 liters.",[The pharmacodynamics and pharmacokinetics of furosemide during ordinary life activities and during head-down tilt hypokinesia in a healthy subject]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9783105/),[l] / [h],24.7,219996,DB00695,Furosemide
,9783105,distribution volume,"The drug half-life period in this case was 1.1 +/- 0.4 h; total clearance was 24.7 +/- 2.8 liter/h, and the distribution volume was 33.7 +/- 12.7 liters.",[The pharmacodynamics and pharmacokinetics of furosemide during ordinary life activities and during head-down tilt hypokinesia in a healthy subject]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9783105/),l,33.7,219997,DB00695,Furosemide
,3204049,peak,"The concurrent treatment substantially altered digoxin pharmacokinetic properties, with a resultant increase in peak (mean +/- SEM; from 2.1 +/- 0.35 to 3.3 +/- 0.6 ng/ml), 8-hour (from 1.4 +/- 0.35 to 2.5 +/- 0.64 ng/ml), and 48-hour mean (from 1.1 +/- 0.22 to 2.2 +/- 0.57 ng/ml) serum [digoxin]; an increase in the number of hours during which serum [digoxin] was in the toxic range (from 3 +/- 1.7 to 24.7 +/- 9.8 h); and a decrease in oral clearance (from 0.15 +/- 0.04 to 0.08 +/- 0.02 L/h.kg).","Effect of aspirin, furosemide, and commercial low-salt diet on digoxin pharmacokinetic properties in clinically normal cats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3204049/),[ng] / [ml],2.1,220505,DB00695,Furosemide
,3204049,peak,"The concurrent treatment substantially altered digoxin pharmacokinetic properties, with a resultant increase in peak (mean +/- SEM; from 2.1 +/- 0.35 to 3.3 +/- 0.6 ng/ml), 8-hour (from 1.4 +/- 0.35 to 2.5 +/- 0.64 ng/ml), and 48-hour mean (from 1.1 +/- 0.22 to 2.2 +/- 0.57 ng/ml) serum [digoxin]; an increase in the number of hours during which serum [digoxin] was in the toxic range (from 3 +/- 1.7 to 24.7 +/- 9.8 h); and a decrease in oral clearance (from 0.15 +/- 0.04 to 0.08 +/- 0.02 L/h.kg).","Effect of aspirin, furosemide, and commercial low-salt diet on digoxin pharmacokinetic properties in clinically normal cats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3204049/),[ng] / [ml],3.3,220506,DB00695,Furosemide
,3204049,peak,"The concurrent treatment substantially altered digoxin pharmacokinetic properties, with a resultant increase in peak (mean +/- SEM; from 2.1 +/- 0.35 to 3.3 +/- 0.6 ng/ml), 8-hour (from 1.4 +/- 0.35 to 2.5 +/- 0.64 ng/ml), and 48-hour mean (from 1.1 +/- 0.22 to 2.2 +/- 0.57 ng/ml) serum [digoxin]; an increase in the number of hours during which serum [digoxin] was in the toxic range (from 3 +/- 1.7 to 24.7 +/- 9.8 h); and a decrease in oral clearance (from 0.15 +/- 0.04 to 0.08 +/- 0.02 L/h.kg).","Effect of aspirin, furosemide, and commercial low-salt diet on digoxin pharmacokinetic properties in clinically normal cats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3204049/),[ng] / [ml],1.4,220507,DB00695,Furosemide
,3204049,peak,"The concurrent treatment substantially altered digoxin pharmacokinetic properties, with a resultant increase in peak (mean +/- SEM; from 2.1 +/- 0.35 to 3.3 +/- 0.6 ng/ml), 8-hour (from 1.4 +/- 0.35 to 2.5 +/- 0.64 ng/ml), and 48-hour mean (from 1.1 +/- 0.22 to 2.2 +/- 0.57 ng/ml) serum [digoxin]; an increase in the number of hours during which serum [digoxin] was in the toxic range (from 3 +/- 1.7 to 24.7 +/- 9.8 h); and a decrease in oral clearance (from 0.15 +/- 0.04 to 0.08 +/- 0.02 L/h.kg).","Effect of aspirin, furosemide, and commercial low-salt diet on digoxin pharmacokinetic properties in clinically normal cats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3204049/),[ng] / [ml],2.5,220508,DB00695,Furosemide
,3204049,peak,"The concurrent treatment substantially altered digoxin pharmacokinetic properties, with a resultant increase in peak (mean +/- SEM; from 2.1 +/- 0.35 to 3.3 +/- 0.6 ng/ml), 8-hour (from 1.4 +/- 0.35 to 2.5 +/- 0.64 ng/ml), and 48-hour mean (from 1.1 +/- 0.22 to 2.2 +/- 0.57 ng/ml) serum [digoxin]; an increase in the number of hours during which serum [digoxin] was in the toxic range (from 3 +/- 1.7 to 24.7 +/- 9.8 h); and a decrease in oral clearance (from 0.15 +/- 0.04 to 0.08 +/- 0.02 L/h.kg).","Effect of aspirin, furosemide, and commercial low-salt diet on digoxin pharmacokinetic properties in clinically normal cats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3204049/),[ng] / [ml],1.1,220509,DB00695,Furosemide
,3204049,peak,"The concurrent treatment substantially altered digoxin pharmacokinetic properties, with a resultant increase in peak (mean +/- SEM; from 2.1 +/- 0.35 to 3.3 +/- 0.6 ng/ml), 8-hour (from 1.4 +/- 0.35 to 2.5 +/- 0.64 ng/ml), and 48-hour mean (from 1.1 +/- 0.22 to 2.2 +/- 0.57 ng/ml) serum [digoxin]; an increase in the number of hours during which serum [digoxin] was in the toxic range (from 3 +/- 1.7 to 24.7 +/- 9.8 h); and a decrease in oral clearance (from 0.15 +/- 0.04 to 0.08 +/- 0.02 L/h.kg).","Effect of aspirin, furosemide, and commercial low-salt diet on digoxin pharmacokinetic properties in clinically normal cats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3204049/),[ng] / [ml],2.2,220510,DB00695,Furosemide
,3204049,oral clearance,"The concurrent treatment substantially altered digoxin pharmacokinetic properties, with a resultant increase in peak (mean +/- SEM; from 2.1 +/- 0.35 to 3.3 +/- 0.6 ng/ml), 8-hour (from 1.4 +/- 0.35 to 2.5 +/- 0.64 ng/ml), and 48-hour mean (from 1.1 +/- 0.22 to 2.2 +/- 0.57 ng/ml) serum [digoxin]; an increase in the number of hours during which serum [digoxin] was in the toxic range (from 3 +/- 1.7 to 24.7 +/- 9.8 h); and a decrease in oral clearance (from 0.15 +/- 0.04 to 0.08 +/- 0.02 L/h.kg).","Effect of aspirin, furosemide, and commercial low-salt diet on digoxin pharmacokinetic properties in clinically normal cats. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3204049/),[l] / [h·kg],0.15,220511,DB00695,Furosemide
,3204049,oral clearance,"The concurrent treatment substantially altered digoxin pharmacokinetic properties, with a resultant increase in peak (mean +/- SEM; from 2.1 +/- 0.35 to 3.3 +/- 0.6 ng/ml), 8-hour (from 1.4 +/- 0.35 to 2.5 +/- 0.64 ng/ml), and 48-hour mean (from 1.1 +/- 0.22 to 2.2 +/- 0.57 ng/ml) serum [digoxin]; an increase in the number of hours during which serum [digoxin] was in the toxic range (from 3 +/- 1.7 to 24.7 +/- 9.8 h); and a decrease in oral clearance (from 0.15 +/- 0.04 to 0.08 +/- 0.02 L/h.kg).","Effect of aspirin, furosemide, and commercial low-salt diet on digoxin pharmacokinetic properties in clinically normal cats. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3204049/),[l] / [h·kg],0.08,220512,DB00695,Furosemide
,7438654,apparent volume of distribution,"The apparent volume of distribution ranged between 180 and 1206ml/kg body weight and correlated with the serum albumin concentration (r = 0.710, p < 0.05) and the fraction of unbound drug (r = 0.758, p < 0.05).",Frusemide pharmacokinetics in patients with liver disease. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438654/),[ml] / [kg],180 and 1206,222628,DB00695,Furosemide
,7438654,fraction,This fraction was 1.9 +/- 0.2% in controls and 3.1 +/- 0.9% in patients with cirrhosis (p < 0.01).,Frusemide pharmacokinetics in patients with liver disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438654/),%,1.9,222629,DB00695,Furosemide
,7438654,fraction,This fraction was 1.9 +/- 0.2% in controls and 3.1 +/- 0.9% in patients with cirrhosis (p < 0.01).,Frusemide pharmacokinetics in patients with liver disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438654/),%,3.1,222630,DB00695,Furosemide
,7438654,Plasma half-life,"Plasma half-life of frusemide varied 7-fold, between 0.60 and 4.27h, and was prolonged substantially in some patients compared with values in normal subjects.",Frusemide pharmacokinetics in patients with liver disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7438654/),h,0.60 and 4.27,222631,DB00695,Furosemide
,28340405,CL/F,"The mean values of CL/F and Vd/F of furosemide in the patients were 15.054Lh-1 and 4.419L, respectively.",Population pharmacokinetic modeling of furosemide in patients with hypertension and fluid overload conditions. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28340405/),1/[lh],15.054,223129,DB00695,Furosemide
,28340405,Vd/F,"The mean values of CL/F and Vd/F of furosemide in the patients were 15.054Lh-1 and 4.419L, respectively.",Population pharmacokinetic modeling of furosemide in patients with hypertension and fluid overload conditions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28340405/),l,4.419,223130,DB00695,Furosemide
,3358884,bioavailability,"The bioavailability was reduced by colestipol 80%, by cholestyramine 95% and by activated charcoal 99.5%. 6. The interference with the gastrointestinal absorption of most of the basic drugs by colestipol and cholestyramine seems to be minimal.","Effects of resins and activated charcoal on the absorption of digoxin, carbamazepine and frusemide. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358884/),%,80,223597,DB00695,Furosemide
,3358884,bioavailability,"The bioavailability was reduced by colestipol 80%, by cholestyramine 95% and by activated charcoal 99.5%. 6. The interference with the gastrointestinal absorption of most of the basic drugs by colestipol and cholestyramine seems to be minimal.","Effects of resins and activated charcoal on the absorption of digoxin, carbamazepine and frusemide. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358884/),%,95,223598,DB00695,Furosemide
,3358884,bioavailability,"The bioavailability was reduced by colestipol 80%, by cholestyramine 95% and by activated charcoal 99.5%. 6. The interference with the gastrointestinal absorption of most of the basic drugs by colestipol and cholestyramine seems to be minimal.","Effects of resins and activated charcoal on the absorption of digoxin, carbamazepine and frusemide. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3358884/),%,99.5,223599,DB00695,Furosemide
,10093036,area under the tissue concentration versus time curve (AUC),"Intrathecal administration of 125I-3F8 resulted in area under the tissue concentration versus time curve (AUC) values in SK-MEL-1 melanoma xenografts (53.1 microCi*h/g) that were 14-fold greater than in corresponding blood (3.9 microCi*h/g), whereas i.t. administration of a control nonspecific MAb resulted in AUC values in tumors (7.1 microCi*h/g) that were less than those in blood (9.5 microCi*h/g).",Intrathecal administration of an anti-ganglioside antibody results in specific accumulation within meningeal neoplastic xenografts in nude rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10093036/),[h·μci] / [g],53.1,224264,DB00695,Furosemide
,10093036,area under the tissue concentration versus time curve (AUC),"Intrathecal administration of 125I-3F8 resulted in area under the tissue concentration versus time curve (AUC) values in SK-MEL-1 melanoma xenografts (53.1 microCi*h/g) that were 14-fold greater than in corresponding blood (3.9 microCi*h/g), whereas i.t. administration of a control nonspecific MAb resulted in AUC values in tumors (7.1 microCi*h/g) that were less than those in blood (9.5 microCi*h/g).",Intrathecal administration of an anti-ganglioside antibody results in specific accumulation within meningeal neoplastic xenografts in nude rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10093036/),[h·μci] / [g],3.9,224265,DB00695,Furosemide
,10093036,AUC,"Intrathecal administration of 125I-3F8 resulted in area under the tissue concentration versus time curve (AUC) values in SK-MEL-1 melanoma xenografts (53.1 microCi*h/g) that were 14-fold greater than in corresponding blood (3.9 microCi*h/g), whereas i.t. administration of a control nonspecific MAb resulted in AUC values in tumors (7.1 microCi*h/g) that were less than those in blood (9.5 microCi*h/g).",Intrathecal administration of an anti-ganglioside antibody results in specific accumulation within meningeal neoplastic xenografts in nude rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10093036/),[h·μci] / [g],7.1,224266,DB00695,Furosemide
,10093036,AUC,"Intrathecal administration of 125I-3F8 resulted in area under the tissue concentration versus time curve (AUC) values in SK-MEL-1 melanoma xenografts (53.1 microCi*h/g) that were 14-fold greater than in corresponding blood (3.9 microCi*h/g), whereas i.t. administration of a control nonspecific MAb resulted in AUC values in tumors (7.1 microCi*h/g) that were less than those in blood (9.5 microCi*h/g).",Intrathecal administration of an anti-ganglioside antibody results in specific accumulation within meningeal neoplastic xenografts in nude rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10093036/),[h·μci] / [g],9.5,224267,DB00695,Furosemide
,10093036,AUC,"Administration of acetazolamide and furosemide, which slow the clearance of IgG MAb from rat cerebrospinal fluid resulted in a fivefold increase in AUC of 125I-3F8 in melanoma (262.9 microCi*h/g).",Intrathecal administration of an anti-ganglioside antibody results in specific accumulation within meningeal neoplastic xenografts in nude rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10093036/),[h·μci] / [g],262.9,224268,DB00695,Furosemide
up to,31427292,MICs,"The optimal dosing regimens in children with normal renal function, based on the piperacillin component, were 75 mg/kg/dose every 4 h infused over 0.5 h in infants ages 2 to ≤6 months and 130 mg/kg/dose every 8 h infused over 4 h in children ages >6 months to 6 years against bacteria with MICs up to 16 mg/liter.",Population Pharmacokinetics and Safety of Piperacillin-Tazobactam Extended Infusions in Infants and Children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31427292/),[mg] / [l],16,225082,DB00695,Furosemide
,7662598,natriuresis,"In the presence of angiotensin II, the furosemide-induced natriuresis decreased, that is, it was 174 +/- 14 versus 95 +/- 25 mumol/min (p < 0.05) and 187 +/- 17 versus 89 +/- 21 mumol/min (p < 0.05) for the 5 and the 10 mg/kg doses, respectively.",Furosemide dynamics in conscious rabbits: modulation by angiotensin II. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7662598/),[μM] / [min],174,225107,DB00695,Furosemide
,7662598,natriuresis,"In the presence of angiotensin II, the furosemide-induced natriuresis decreased, that is, it was 174 +/- 14 versus 95 +/- 25 mumol/min (p < 0.05) and 187 +/- 17 versus 89 +/- 21 mumol/min (p < 0.05) for the 5 and the 10 mg/kg doses, respectively.",Furosemide dynamics in conscious rabbits: modulation by angiotensin II. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7662598/),[μM] / [min],95,225108,DB00695,Furosemide
,7662598,natriuresis,"In the presence of angiotensin II, the furosemide-induced natriuresis decreased, that is, it was 174 +/- 14 versus 95 +/- 25 mumol/min (p < 0.05) and 187 +/- 17 versus 89 +/- 21 mumol/min (p < 0.05) for the 5 and the 10 mg/kg doses, respectively.",Furosemide dynamics in conscious rabbits: modulation by angiotensin II. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7662598/),[μM] / [min],187,225109,DB00695,Furosemide
,7662598,natriuresis,"In the presence of angiotensin II, the furosemide-induced natriuresis decreased, that is, it was 174 +/- 14 versus 95 +/- 25 mumol/min (p < 0.05) and 187 +/- 17 versus 89 +/- 21 mumol/min (p < 0.05) for the 5 and the 10 mg/kg doses, respectively.",Furosemide dynamics in conscious rabbits: modulation by angiotensin II. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7662598/),[μM] / [min],89,225110,DB00695,Furosemide
,24779201,oral bioavailibility,Due to its limited solubility it has poor and variable oral bioavailibility of 10-90%.,Nanoprecipitation with sonication for enhancement of oral bioavailability of furosemide. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24779201/),%,10-90,225459,DB00695,Furosemide
,24779201,polydispersity index,The preparations showed negative zeta potential and polydispersity index in the range of 0.3 +/- 0.1.,Nanoprecipitation with sonication for enhancement of oral bioavailability of furosemide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24779201/),,0.3,225460,DB00695,Furosemide
,10497140,First order degradation half-lives,"First order degradation half-lives of 26 and 0. 5 h were observed on incubation in buffer of pH 7.4 for the 1-O-acylglucuronides of telmisartan and diclofenac, respectively.",Disposition and chemical stability of telmisartan 1-O-acylglucuronide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497140/),h,26,228719,DB00695,Furosemide
,10497140,First order degradation half-lives,"First order degradation half-lives of 26 and 0. 5 h were observed on incubation in buffer of pH 7.4 for the 1-O-acylglucuronides of telmisartan and diclofenac, respectively.",Disposition and chemical stability of telmisartan 1-O-acylglucuronide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497140/),h,0. 5,228720,DB00695,Furosemide
,10497140,clearance,"After i.v. dosing to rats, telmisartan 1-O-acylglucuronide was rapidly cleared from plasma with a clearance of 180 ml/min/kg, compared with 15.6 ml/min/kg for the parent compound.",Disposition and chemical stability of telmisartan 1-O-acylglucuronide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497140/),[ml] / [kg·min],180,228721,DB00695,Furosemide
,10497140,clearance,"After i.v. dosing to rats, telmisartan 1-O-acylglucuronide was rapidly cleared from plasma with a clearance of 180 ml/min/kg, compared with 15.6 ml/min/kg for the parent compound.",Disposition and chemical stability of telmisartan 1-O-acylglucuronide. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10497140/),[ml] / [kg·min],15.6,228722,DB00695,Furosemide
,7094973,apparent plasma half-lives,"In the first group, the apparent plasma half-lives ranged from 96 to 6.8 h with a significant inverse relationship (p less than 0.01) between the gestational age and the elimination rate.",Pharmacokinetics of furosemide in neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094973/),h,96 to 6.8,228897,DB00695,Furosemide
,7094973,plasma half-life,"In the neonates receiving the drug i.v. for therapeutic reasons, the elimination kinetics appeared to follow a two-compartment open model, with a significant difference in the therminal plasma half-life between premature (26.8 +/- 12.2 h) and full-term newborns (13.4 +/- 8.6 h).",Pharmacokinetics of furosemide in neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094973/),h,26.8,228898,DB00695,Furosemide
,7094973,plasma half-life,"In the neonates receiving the drug i.v. for therapeutic reasons, the elimination kinetics appeared to follow a two-compartment open model, with a significant difference in the therminal plasma half-life between premature (26.8 +/- 12.2 h) and full-term newborns (13.4 +/- 8.6 h).",Pharmacokinetics of furosemide in neonates. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7094973/),h,13.4,228899,DB00695,Furosemide
,1233246,overall elimination half-life (MTX T1/2),"The overall elimination half-life (MTX T1/2) was well defined from one to about six hours after i.v. administration; in 25 patients it ranged from 102 min to 750 min and was inversely related to endogenous creatinine clearance, which ranged from 6 to 140 ml/min.",Renal function and the rate of disappearance of methotrexate from serum. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233246/),h,one to about six,229327,DB00695,Furosemide
,1233246,overall elimination half-life (MTX T1/2),"The overall elimination half-life (MTX T1/2) was well defined from one to about six hours after i.v. administration; in 25 patients it ranged from 102 min to 750 min and was inversely related to endogenous creatinine clearance, which ranged from 6 to 140 ml/min.",Renal function and the rate of disappearance of methotrexate from serum. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233246/),min,102,229328,DB00695,Furosemide
,1233246,overall elimination half-life (MTX T1/2),"The overall elimination half-life (MTX T1/2) was well defined from one to about six hours after i.v. administration; in 25 patients it ranged from 102 min to 750 min and was inversely related to endogenous creatinine clearance, which ranged from 6 to 140 ml/min.",Renal function and the rate of disappearance of methotrexate from serum. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1233246/),min,750,229329,DB00695,Furosemide
,25034211,IC50,"DA-9801 inhibited the in vitro transport activities of OCT1, OCT2, OAT3, and OATP1B1, with IC50 values of 106, 174, 48.1, and 273 μg/mL, respectively, while the other transporters were not inhibited by 300 μg/mL DA-9801.","Evaluation of the transporter-mediated herb-drug interaction potential of DA-9801, a standardized dioscorea extract for diabetic neuropathy, in human in vitro and rat in vivo. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25034211/),[μg] / [ml],106,229770,DB00695,Furosemide
,25034211,IC50,"DA-9801 inhibited the in vitro transport activities of OCT1, OCT2, OAT3, and OATP1B1, with IC50 values of 106, 174, 48.1, and 273 μg/mL, respectively, while the other transporters were not inhibited by 300 μg/mL DA-9801.","Evaluation of the transporter-mediated herb-drug interaction potential of DA-9801, a standardized dioscorea extract for diabetic neuropathy, in human in vitro and rat in vivo. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25034211/),[μg] / [ml],174,229771,DB00695,Furosemide
,25034211,IC50,"DA-9801 inhibited the in vitro transport activities of OCT1, OCT2, OAT3, and OATP1B1, with IC50 values of 106, 174, 48.1, and 273 μg/mL, respectively, while the other transporters were not inhibited by 300 μg/mL DA-9801.","Evaluation of the transporter-mediated herb-drug interaction potential of DA-9801, a standardized dioscorea extract for diabetic neuropathy, in human in vitro and rat in vivo. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25034211/),[μg] / [ml],48.1,229772,DB00695,Furosemide
,25034211,IC50,"DA-9801 inhibited the in vitro transport activities of OCT1, OCT2, OAT3, and OATP1B1, with IC50 values of 106, 174, 48.1, and 273 μg/mL, respectively, while the other transporters were not inhibited by 300 μg/mL DA-9801.","Evaluation of the transporter-mediated herb-drug interaction potential of DA-9801, a standardized dioscorea extract for diabetic neuropathy, in human in vitro and rat in vivo. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25034211/),[μg] / [ml],273,229773,DB00695,Furosemide
,8799873,pA2,In the rabbit isolated aorta EXP3312 inhibited the contractile response to AII competitively with a pA2 value of 8.24.,"Pharmacological and pharmacokinetic evaluation of EXP3312, an orally-active non-peptide angiotensin II-receptor antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799873/),,8.24,230016,DB00695,Furosemide
,8799873,ED30,"In renal hypertensive rats EXP3312 reduced blood pressure with intravenous and oral ED30 values of 0.19 and 0.14 mg kg-1, respectively.","Pharmacological and pharmacokinetic evaluation of EXP3312, an orally-active non-peptide angiotensin II-receptor antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799873/),[mg] / [kg],0.19,230017,DB00695,Furosemide
,8799873,ED30,"In renal hypertensive rats EXP3312 reduced blood pressure with intravenous and oral ED30 values of 0.19 and 0.14 mg kg-1, respectively.","Pharmacological and pharmacokinetic evaluation of EXP3312, an orally-active non-peptide angiotensin II-receptor antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799873/),[mg] / [kg],0.14,230018,DB00695,Furosemide
,8799873,absolute oral bioavailability,"In rats and dogs, the absolute oral bioavailability of EXP3312 averaged 60 and 28%, respectively.","Pharmacological and pharmacokinetic evaluation of EXP3312, an orally-active non-peptide angiotensin II-receptor antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799873/),%,60,230019,DB00695,Furosemide
,8799873,absolute oral bioavailability,"In rats and dogs, the absolute oral bioavailability of EXP3312 averaged 60 and 28%, respectively.","Pharmacological and pharmacokinetic evaluation of EXP3312, an orally-active non-peptide angiotensin II-receptor antagonist. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799873/),%,28,230020,DB00695,Furosemide
,8799873,plasma elimination half-lives,"When EXP3312 was administered intravenously to rats and dogs the plasma elimination half-lives were 1.20 and 2.52 h, respectively.","Pharmacological and pharmacokinetic evaluation of EXP3312, an orally-active non-peptide angiotensin II-receptor antagonist. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799873/),h,1.20,230021,DB00695,Furosemide
,8799873,plasma elimination half-lives,"When EXP3312 was administered intravenously to rats and dogs the plasma elimination half-lives were 1.20 and 2.52 h, respectively.","Pharmacological and pharmacokinetic evaluation of EXP3312, an orally-active non-peptide angiotensin II-receptor antagonist. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799873/),h,2.52,230022,DB00695,Furosemide
,8799873,ED30,M1 is about ten times more potent than EXP3312 in renal hypertensive rats; the intravenous ED30 value was 0.02 mg kg-1.,"Pharmacological and pharmacokinetic evaluation of EXP3312, an orally-active non-peptide angiotensin II-receptor antagonist. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8799873/),[mg] / [kg],0.02,230023,DB00695,Furosemide
,30443705,"Cav,ss","Clinically relevant nitisinone steady-state concentrations were reached after 12 days: mean Cav,ss of 94.08 μM.","Non randomized study on the potential of nitisinone to inhibit cytochrome P450 2C9, 2D6, 2E1 and the organic anion transporters OAT1 and OAT3 in healthy volunteers. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30443705/),μM,94.08,230404,DB00695,Furosemide
,1267539,half life time,The half life time of furosemide is 83 min in 5-day-old rats and 47 min in 55-day-old rats.,[Age dependent differences in the pharmacokinetics of furosemide in rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1267539/),min,83,231566,DB00695,Furosemide
,1267539,half life time,The half life time of furosemide is 83 min in 5-day-old rats and 47 min in 55-day-old rats.,[Age dependent differences in the pharmacokinetics of furosemide in rats]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1267539/),min,47,231567,DB00695,Furosemide
,11745917,plasma protein binding,"After intravenous administration of bumetanide, 10 mg/kg, to analbuminemic rats, the plasma protein binding of bumetanide was 36.8% in the rats mainly due to considerable binding to alpha- and beta-globulins (this value, 36.8%, was considerably greater than only 12% for furosemide), and hence the percentages of intravenous dose of bumetanide excreted in 6 h urine as unchanged drug was 16.0% in the rat (this value was considerably greater than only 7% for furosemide).",Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745917/),%,36.8,232609,DB00695,Furosemide
,11745917,plasma protein binding,"After intravenous administration of bumetanide, 10 mg/kg, to analbuminemic rats, the plasma protein binding of bumetanide was 36.8% in the rats mainly due to considerable binding to alpha- and beta-globulins (this value, 36.8%, was considerably greater than only 12% for furosemide), and hence the percentages of intravenous dose of bumetanide excreted in 6 h urine as unchanged drug was 16.0% in the rat (this value was considerably greater than only 7% for furosemide).",Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745917/),%,36.,232610,DB00695,Furosemide
,11745917,area under the plasma concentration-time curve from time zero to time infinity,"After intravenous administration of bumetanide to analbuminemic rats, the area under the plasma concentration-time curve from time zero to time infinity (1012 compared with 2472 microg min/mL) was significantly smaller [due to significantly faster both renal clearance (1.49 compared with 0.275 ml/min/kg) and nonrenal clearance (8.30 compared with 3.71 ml/min/kg)], terminal half-life (9.94 compared with 22.4 min) and mean residence time (4.25 compared with 5.90 min) were significantly shorter (due to faster total body clearance, 9.88 compared with 4.05 ml/min/kg), and amount of 6 h urinary excretion of unchanged bumetanide (559 compared with 261 microg, due to increase in intrinsic renal excretion) was significantly greater than that in control rats.",Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745917/),[min·μg] / [ml],1012,232611,DB00695,Furosemide
,11745917,area under the plasma concentration-time curve from time zero to time infinity,"After intravenous administration of bumetanide to analbuminemic rats, the area under the plasma concentration-time curve from time zero to time infinity (1012 compared with 2472 microg min/mL) was significantly smaller [due to significantly faster both renal clearance (1.49 compared with 0.275 ml/min/kg) and nonrenal clearance (8.30 compared with 3.71 ml/min/kg)], terminal half-life (9.94 compared with 22.4 min) and mean residence time (4.25 compared with 5.90 min) were significantly shorter (due to faster total body clearance, 9.88 compared with 4.05 ml/min/kg), and amount of 6 h urinary excretion of unchanged bumetanide (559 compared with 261 microg, due to increase in intrinsic renal excretion) was significantly greater than that in control rats.",Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745917/),[min·μg] / [ml],2472,232612,DB00695,Furosemide
,11745917,both renal clearance,"After intravenous administration of bumetanide to analbuminemic rats, the area under the plasma concentration-time curve from time zero to time infinity (1012 compared with 2472 microg min/mL) was significantly smaller [due to significantly faster both renal clearance (1.49 compared with 0.275 ml/min/kg) and nonrenal clearance (8.30 compared with 3.71 ml/min/kg)], terminal half-life (9.94 compared with 22.4 min) and mean residence time (4.25 compared with 5.90 min) were significantly shorter (due to faster total body clearance, 9.88 compared with 4.05 ml/min/kg), and amount of 6 h urinary excretion of unchanged bumetanide (559 compared with 261 microg, due to increase in intrinsic renal excretion) was significantly greater than that in control rats.",Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745917/),[ml] / [kg·min],1.49,232613,DB00695,Furosemide
,11745917,both renal clearance,"After intravenous administration of bumetanide to analbuminemic rats, the area under the plasma concentration-time curve from time zero to time infinity (1012 compared with 2472 microg min/mL) was significantly smaller [due to significantly faster both renal clearance (1.49 compared with 0.275 ml/min/kg) and nonrenal clearance (8.30 compared with 3.71 ml/min/kg)], terminal half-life (9.94 compared with 22.4 min) and mean residence time (4.25 compared with 5.90 min) were significantly shorter (due to faster total body clearance, 9.88 compared with 4.05 ml/min/kg), and amount of 6 h urinary excretion of unchanged bumetanide (559 compared with 261 microg, due to increase in intrinsic renal excretion) was significantly greater than that in control rats.",Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745917/),[ml] / [kg·min],0.275,232614,DB00695,Furosemide
,11745917,nonrenal clearance,"After intravenous administration of bumetanide to analbuminemic rats, the area under the plasma concentration-time curve from time zero to time infinity (1012 compared with 2472 microg min/mL) was significantly smaller [due to significantly faster both renal clearance (1.49 compared with 0.275 ml/min/kg) and nonrenal clearance (8.30 compared with 3.71 ml/min/kg)], terminal half-life (9.94 compared with 22.4 min) and mean residence time (4.25 compared with 5.90 min) were significantly shorter (due to faster total body clearance, 9.88 compared with 4.05 ml/min/kg), and amount of 6 h urinary excretion of unchanged bumetanide (559 compared with 261 microg, due to increase in intrinsic renal excretion) was significantly greater than that in control rats.",Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745917/),[ml] / [kg·min],8.30,232615,DB00695,Furosemide
,11745917,nonrenal clearance,"After intravenous administration of bumetanide to analbuminemic rats, the area under the plasma concentration-time curve from time zero to time infinity (1012 compared with 2472 microg min/mL) was significantly smaller [due to significantly faster both renal clearance (1.49 compared with 0.275 ml/min/kg) and nonrenal clearance (8.30 compared with 3.71 ml/min/kg)], terminal half-life (9.94 compared with 22.4 min) and mean residence time (4.25 compared with 5.90 min) were significantly shorter (due to faster total body clearance, 9.88 compared with 4.05 ml/min/kg), and amount of 6 h urinary excretion of unchanged bumetanide (559 compared with 261 microg, due to increase in intrinsic renal excretion) was significantly greater than that in control rats.",Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745917/),[ml] / [kg·min],3.71,232616,DB00695,Furosemide
,11745917,terminal half-life,"After intravenous administration of bumetanide to analbuminemic rats, the area under the plasma concentration-time curve from time zero to time infinity (1012 compared with 2472 microg min/mL) was significantly smaller [due to significantly faster both renal clearance (1.49 compared with 0.275 ml/min/kg) and nonrenal clearance (8.30 compared with 3.71 ml/min/kg)], terminal half-life (9.94 compared with 22.4 min) and mean residence time (4.25 compared with 5.90 min) were significantly shorter (due to faster total body clearance, 9.88 compared with 4.05 ml/min/kg), and amount of 6 h urinary excretion of unchanged bumetanide (559 compared with 261 microg, due to increase in intrinsic renal excretion) was significantly greater than that in control rats.",Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745917/),min,9.94,232617,DB00695,Furosemide
,11745917,terminal half-life,"After intravenous administration of bumetanide to analbuminemic rats, the area under the plasma concentration-time curve from time zero to time infinity (1012 compared with 2472 microg min/mL) was significantly smaller [due to significantly faster both renal clearance (1.49 compared with 0.275 ml/min/kg) and nonrenal clearance (8.30 compared with 3.71 ml/min/kg)], terminal half-life (9.94 compared with 22.4 min) and mean residence time (4.25 compared with 5.90 min) were significantly shorter (due to faster total body clearance, 9.88 compared with 4.05 ml/min/kg), and amount of 6 h urinary excretion of unchanged bumetanide (559 compared with 261 microg, due to increase in intrinsic renal excretion) was significantly greater than that in control rats.",Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745917/),min,22.4,232618,DB00695,Furosemide
,11745917,mean residence time,"After intravenous administration of bumetanide to analbuminemic rats, the area under the plasma concentration-time curve from time zero to time infinity (1012 compared with 2472 microg min/mL) was significantly smaller [due to significantly faster both renal clearance (1.49 compared with 0.275 ml/min/kg) and nonrenal clearance (8.30 compared with 3.71 ml/min/kg)], terminal half-life (9.94 compared with 22.4 min) and mean residence time (4.25 compared with 5.90 min) were significantly shorter (due to faster total body clearance, 9.88 compared with 4.05 ml/min/kg), and amount of 6 h urinary excretion of unchanged bumetanide (559 compared with 261 microg, due to increase in intrinsic renal excretion) was significantly greater than that in control rats.",Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745917/),min,4.25,232619,DB00695,Furosemide
,11745917,mean residence time,"After intravenous administration of bumetanide to analbuminemic rats, the area under the plasma concentration-time curve from time zero to time infinity (1012 compared with 2472 microg min/mL) was significantly smaller [due to significantly faster both renal clearance (1.49 compared with 0.275 ml/min/kg) and nonrenal clearance (8.30 compared with 3.71 ml/min/kg)], terminal half-life (9.94 compared with 22.4 min) and mean residence time (4.25 compared with 5.90 min) were significantly shorter (due to faster total body clearance, 9.88 compared with 4.05 ml/min/kg), and amount of 6 h urinary excretion of unchanged bumetanide (559 compared with 261 microg, due to increase in intrinsic renal excretion) was significantly greater than that in control rats.",Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745917/),min,5.90,232620,DB00695,Furosemide
,11745917,total body clearance,"After intravenous administration of bumetanide to analbuminemic rats, the area under the plasma concentration-time curve from time zero to time infinity (1012 compared with 2472 microg min/mL) was significantly smaller [due to significantly faster both renal clearance (1.49 compared with 0.275 ml/min/kg) and nonrenal clearance (8.30 compared with 3.71 ml/min/kg)], terminal half-life (9.94 compared with 22.4 min) and mean residence time (4.25 compared with 5.90 min) were significantly shorter (due to faster total body clearance, 9.88 compared with 4.05 ml/min/kg), and amount of 6 h urinary excretion of unchanged bumetanide (559 compared with 261 microg, due to increase in intrinsic renal excretion) was significantly greater than that in control rats.",Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745917/),[ml] / [kg·min],9.88,232621,DB00695,Furosemide
,11745917,total body clearance,"After intravenous administration of bumetanide to analbuminemic rats, the area under the plasma concentration-time curve from time zero to time infinity (1012 compared with 2472 microg min/mL) was significantly smaller [due to significantly faster both renal clearance (1.49 compared with 0.275 ml/min/kg) and nonrenal clearance (8.30 compared with 3.71 ml/min/kg)], terminal half-life (9.94 compared with 22.4 min) and mean residence time (4.25 compared with 5.90 min) were significantly shorter (due to faster total body clearance, 9.88 compared with 4.05 ml/min/kg), and amount of 6 h urinary excretion of unchanged bumetanide (559 compared with 261 microg, due to increase in intrinsic renal excretion) was significantly greater than that in control rats.",Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745917/),[ml] / [kg·min],4.05,232622,DB00695,Furosemide
,11745917,urinary excretion,"After intravenous administration of bumetanide to analbuminemic rats, the area under the plasma concentration-time curve from time zero to time infinity (1012 compared with 2472 microg min/mL) was significantly smaller [due to significantly faster both renal clearance (1.49 compared with 0.275 ml/min/kg) and nonrenal clearance (8.30 compared with 3.71 ml/min/kg)], terminal half-life (9.94 compared with 22.4 min) and mean residence time (4.25 compared with 5.90 min) were significantly shorter (due to faster total body clearance, 9.88 compared with 4.05 ml/min/kg), and amount of 6 h urinary excretion of unchanged bumetanide (559 compared with 261 microg, due to increase in intrinsic renal excretion) was significantly greater than that in control rats.",Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745917/),μg,559,232623,DB00695,Furosemide
,11745917,urinary excretion,"After intravenous administration of bumetanide to analbuminemic rats, the area under the plasma concentration-time curve from time zero to time infinity (1012 compared with 2472 microg min/mL) was significantly smaller [due to significantly faster both renal clearance (1.49 compared with 0.275 ml/min/kg) and nonrenal clearance (8.30 compared with 3.71 ml/min/kg)], terminal half-life (9.94 compared with 22.4 min) and mean residence time (4.25 compared with 5.90 min) were significantly shorter (due to faster total body clearance, 9.88 compared with 4.05 ml/min/kg), and amount of 6 h urinary excretion of unchanged bumetanide (559 compared with 261 microg, due to increase in intrinsic renal excretion) was significantly greater than that in control rats.",Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745917/),μg,261,232624,DB00695,Furosemide
,9120811,partial clearance,"After iv administration of A, the mean fraction of iv dose excreted in 24-h urine as A-sulfate (75.6 versus 67.8%) and the partial clearance of A to A-sulfate (8.10 versus 6.89 mL/ min/kg) were significantly greater in SHRs than in Wistar rats.",Pharmacokinetics of acetaminophen after intravenous and oral administration to spontaneously hypertensive rats and normotensive Wistar rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120811/),[ml] / [kg·min],8.10,234068,DB00695,Furosemide
,9120811,partial clearance,"After iv administration of A, the mean fraction of iv dose excreted in 24-h urine as A-sulfate (75.6 versus 67.8%) and the partial clearance of A to A-sulfate (8.10 versus 6.89 mL/ min/kg) were significantly greater in SHRs than in Wistar rats.",Pharmacokinetics of acetaminophen after intravenous and oral administration to spontaneously hypertensive rats and normotensive Wistar rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120811/),[ml] / [kg·min],6.89,234069,DB00695,Furosemide
,9120811,fraction,"Conversely, the mean fraction of iv dose excreted in 24-h urine as A-glucuronide (9.39 versus 15.0%) and the partial clearance of A to A-glucuronide (1.01 versus 1.49 mL/min/kg) were significantly smaller in these SHRs.",Pharmacokinetics of acetaminophen after intravenous and oral administration to spontaneously hypertensive rats and normotensive Wistar rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120811/),%,9,234070,DB00695,Furosemide
,9120811,fraction,"Conversely, the mean fraction of iv dose excreted in 24-h urine as A-glucuronide (9.39 versus 15.0%) and the partial clearance of A to A-glucuronide (1.01 versus 1.49 mL/min/kg) were significantly smaller in these SHRs.",Pharmacokinetics of acetaminophen after intravenous and oral administration to spontaneously hypertensive rats and normotensive Wistar rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120811/),%,15,234071,DB00695,Furosemide
,9120811,partial clearance,"Conversely, the mean fraction of iv dose excreted in 24-h urine as A-glucuronide (9.39 versus 15.0%) and the partial clearance of A to A-glucuronide (1.01 versus 1.49 mL/min/kg) were significantly smaller in these SHRs.",Pharmacokinetics of acetaminophen after intravenous and oral administration to spontaneously hypertensive rats and normotensive Wistar rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120811/),[ml] / [kg·min],1.01,234072,DB00695,Furosemide
,9120811,partial clearance,"Conversely, the mean fraction of iv dose excreted in 24-h urine as A-glucuronide (9.39 versus 15.0%) and the partial clearance of A to A-glucuronide (1.01 versus 1.49 mL/min/kg) were significantly smaller in these SHRs.",Pharmacokinetics of acetaminophen after intravenous and oral administration to spontaneously hypertensive rats and normotensive Wistar rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9120811/),[ml] / [kg·min],1.49,234073,DB00695,Furosemide
,21623723,bioavailability,It has higher bioavailability (&gt;80%) and a longer elimination half-life (3 to 4 hours) than furosemide.,[Torasemide is the effective loop diuretic for long-term therapy of arterial hypertension]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21623723/),%,80,234510,DB00695,Furosemide
,21623723,elimination half-life,It has higher bioavailability (&gt;80%) and a longer elimination half-life (3 to 4 hours) than furosemide.,[Torasemide is the effective loop diuretic for long-term therapy of arterial hypertension]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21623723/),h,3 to 4,234511,DB00695,Furosemide
,7420267,half-lives,"The mean half-lives associated with each exponent were 5.9 min, 46 min, and 3.1 hr, respectively.",Pharmacokinetics of intravenously administered bumetanide in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7420267/),min,5.9,234734,DB00695,Furosemide
,7420267,half-lives,"The mean half-lives associated with each exponent were 5.9 min, 46 min, and 3.1 hr, respectively.",Pharmacokinetics of intravenously administered bumetanide in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7420267/),min,46,234735,DB00695,Furosemide
,7420267,half-lives,"The mean half-lives associated with each exponent were 5.9 min, 46 min, and 3.1 hr, respectively.",Pharmacokinetics of intravenously administered bumetanide in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7420267/),h,3.1,234736,DB00695,Furosemide
,7420267,total plasma clearance,"The total plasma clearance averaged 228 ml/min, with renal clearance about one-half of this value.",Pharmacokinetics of intravenously administered bumetanide in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7420267/),[ml] / [min],228,234737,DB00695,Furosemide
,7420267,recovery,"The recovery of unchanged bumetanide in urine over 2 days was 47% of the dose, while the total recovery of radioactivity in urine averaged 82% of dose.",Pharmacokinetics of intravenously administered bumetanide in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7420267/),%,47,234738,DB00695,Furosemide
,7420267,total recovery of radioactivity,"The recovery of unchanged bumetanide in urine over 2 days was 47% of the dose, while the total recovery of radioactivity in urine averaged 82% of dose.",Pharmacokinetics of intravenously administered bumetanide in man. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7420267/),%,82,234739,DB00695,Furosemide
,7106167,Ascitic fluid volume,Ascitic fluid volume in the patients ranged from 4.6 to 7.71.,Pharmacokinetics of furosemide in patients with hepatic cirrhosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7106167/),,4.6 to 7.71,235508,DB00695,Furosemide
,7106167,peak concentrations,"The diuretic interchange between this fluid and plasma was slow, as peak concentrations ranged from 0.3 to 0.5 microgram/ml within 3 to 5 h after bolus administration of furosemide.",Pharmacokinetics of furosemide in patients with hepatic cirrhosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7106167/),[μg] / [ml],0.3 to 0.5,235509,DB00695,Furosemide
,6746817,detection limit,The detection limit of furosemide is 10 ng in 0.5 ml of biological sample.,"Quantitative determination of furosemide in plasma, plasma water, urine and ascites fluid by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6746817/),ng,10,235917,DB00695,Furosemide
,2792172,renal clearance,"A decrease in plasma albumin concentration from 33 g.l-1 after albumin infusion to 23 g.l-1 after infusion of dextran caused a substantial increase in the renal clearance (from 84 to 123 ml.min-1), non-renal clearance (from 72 to 138 ml.min-1), and apparent volume of distribution (from 13 to 23 l) of frusemide, probably as a consequence of an increase in the unbound fraction.",Pharmacokinetics and effects of frusemide in patients with the nephrotic syndrome. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792172/),[ml] / [min],84 to 123,239996,DB00695,Furosemide
,2792172,non-renal clearance,"A decrease in plasma albumin concentration from 33 g.l-1 after albumin infusion to 23 g.l-1 after infusion of dextran caused a substantial increase in the renal clearance (from 84 to 123 ml.min-1), non-renal clearance (from 72 to 138 ml.min-1), and apparent volume of distribution (from 13 to 23 l) of frusemide, probably as a consequence of an increase in the unbound fraction.",Pharmacokinetics and effects of frusemide in patients with the nephrotic syndrome. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792172/),[ml] / [min],72 to 138,239997,DB00695,Furosemide
,2792172,apparent volume of distribution,"A decrease in plasma albumin concentration from 33 g.l-1 after albumin infusion to 23 g.l-1 after infusion of dextran caused a substantial increase in the renal clearance (from 84 to 123 ml.min-1), non-renal clearance (from 72 to 138 ml.min-1), and apparent volume of distribution (from 13 to 23 l) of frusemide, probably as a consequence of an increase in the unbound fraction.",Pharmacokinetics and effects of frusemide in patients with the nephrotic syndrome. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792172/),l,13 to 23,239998,DB00695,Furosemide
,12846760,urinary sodium excretion,"In the inpatient phase, furosemide increased urinary sodium excretion from average (+/-SD) 199 +/- 49 mEq/day to 357 +/- 96 mEq/day and torsemide increased urinary sodium excretion from 213 +/- 79 mEq/day to 398 +/- 142 mEq/day.",A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12846760/),[meq] / [d],199,240219,DB00695,Furosemide
,12846760,urinary sodium excretion,"In the inpatient phase, furosemide increased urinary sodium excretion from average (+/-SD) 199 +/- 49 mEq/day to 357 +/- 96 mEq/day and torsemide increased urinary sodium excretion from 213 +/- 79 mEq/day to 398 +/- 142 mEq/day.",A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12846760/),[meq] / [d],357,240220,DB00695,Furosemide
,12846760,urinary sodium excretion,"In the inpatient phase, furosemide increased urinary sodium excretion from average (+/-SD) 199 +/- 49 mEq/day to 357 +/- 96 mEq/day and torsemide increased urinary sodium excretion from 213 +/- 79 mEq/day to 398 +/- 142 mEq/day.",A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12846760/),[meq] / [d],213,240221,DB00695,Furosemide
,12846760,urinary sodium excretion,"In the inpatient phase, furosemide increased urinary sodium excretion from average (+/-SD) 199 +/- 49 mEq/day to 357 +/- 96 mEq/day and torsemide increased urinary sodium excretion from 213 +/- 79 mEq/day to 398 +/- 142 mEq/day.",A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12846760/),[meq] / [d],398,240222,DB00695,Furosemide
,9927057,integral radioactivity ratios,"With lysine, the sa-glyco-Fab:nonglycolated Fab estimated integral radioactivity ratios were 4.7 and 0.7 in the ATAC4 tumor and in the kidney, respectively.",The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9927057/),,4.7,240540,DB00695,Furosemide
,9927057,integral radioactivity ratios,"With lysine, the sa-glyco-Fab:nonglycolated Fab estimated integral radioactivity ratios were 4.7 and 0.7 in the ATAC4 tumor and in the kidney, respectively.",The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9927057/),,0.7,240541,DB00695,Furosemide
,32562572,Cmax,"The following furosemide pharmacokinetic parameters were obtained as median (interquartile range): Cmax , 403 ng/mL (229 to 715 ng/mL); Tmax , 2.00 hours (1.50 to 4.83 hours); elimination half-life (t1/2 ), 2.50 hours (1.77 to 2.97 hours); AUC0-12 h , 1366 ng⋅h/mL (927 to 2531 ng⋅h/mL); AUC0-∞ , 1580 ng⋅h/mL (1270 to 2881 ng⋅h/mL); CL/F 25.3 L/h (13.8 to 31.4 L/h); CLR, 2.50 L/h (1.77 to 2.97 L/h); CLNR, 22.7 L/h (12.1 to 25.6 L/h); and Vd /F 82.8 L (34.4 to 173 L).","A Pilot Study of the Maternal-Fetal Pharmacokinetics of Furosemide in Plasma, Urine, and Amniotic Fluid of Hypertensive Parturient Women Under Cesarean Section. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32562572/),[ng] / [ml],403,240553,DB00695,Furosemide
,32562572,Tmax,"The following furosemide pharmacokinetic parameters were obtained as median (interquartile range): Cmax , 403 ng/mL (229 to 715 ng/mL); Tmax , 2.00 hours (1.50 to 4.83 hours); elimination half-life (t1/2 ), 2.50 hours (1.77 to 2.97 hours); AUC0-12 h , 1366 ng⋅h/mL (927 to 2531 ng⋅h/mL); AUC0-∞ , 1580 ng⋅h/mL (1270 to 2881 ng⋅h/mL); CL/F 25.3 L/h (13.8 to 31.4 L/h); CLR, 2.50 L/h (1.77 to 2.97 L/h); CLNR, 22.7 L/h (12.1 to 25.6 L/h); and Vd /F 82.8 L (34.4 to 173 L).","A Pilot Study of the Maternal-Fetal Pharmacokinetics of Furosemide in Plasma, Urine, and Amniotic Fluid of Hypertensive Parturient Women Under Cesarean Section. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32562572/),h,2.00,240554,DB00695,Furosemide
,32562572,elimination half-life (t1/2 ),"The following furosemide pharmacokinetic parameters were obtained as median (interquartile range): Cmax , 403 ng/mL (229 to 715 ng/mL); Tmax , 2.00 hours (1.50 to 4.83 hours); elimination half-life (t1/2 ), 2.50 hours (1.77 to 2.97 hours); AUC0-12 h , 1366 ng⋅h/mL (927 to 2531 ng⋅h/mL); AUC0-∞ , 1580 ng⋅h/mL (1270 to 2881 ng⋅h/mL); CL/F 25.3 L/h (13.8 to 31.4 L/h); CLR, 2.50 L/h (1.77 to 2.97 L/h); CLNR, 22.7 L/h (12.1 to 25.6 L/h); and Vd /F 82.8 L (34.4 to 173 L).","A Pilot Study of the Maternal-Fetal Pharmacokinetics of Furosemide in Plasma, Urine, and Amniotic Fluid of Hypertensive Parturient Women Under Cesarean Section. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32562572/),h,2.50,240555,DB00695,Furosemide
,32562572,AUC0-12 h,"The following furosemide pharmacokinetic parameters were obtained as median (interquartile range): Cmax , 403 ng/mL (229 to 715 ng/mL); Tmax , 2.00 hours (1.50 to 4.83 hours); elimination half-life (t1/2 ), 2.50 hours (1.77 to 2.97 hours); AUC0-12 h , 1366 ng⋅h/mL (927 to 2531 ng⋅h/mL); AUC0-∞ , 1580 ng⋅h/mL (1270 to 2881 ng⋅h/mL); CL/F 25.3 L/h (13.8 to 31.4 L/h); CLR, 2.50 L/h (1.77 to 2.97 L/h); CLNR, 22.7 L/h (12.1 to 25.6 L/h); and Vd /F 82.8 L (34.4 to 173 L).","A Pilot Study of the Maternal-Fetal Pharmacokinetics of Furosemide in Plasma, Urine, and Amniotic Fluid of Hypertensive Parturient Women Under Cesarean Section. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32562572/),[h·ng] / [ml],1366,240556,DB00695,Furosemide
,32562572,AUC0-∞,"The following furosemide pharmacokinetic parameters were obtained as median (interquartile range): Cmax , 403 ng/mL (229 to 715 ng/mL); Tmax , 2.00 hours (1.50 to 4.83 hours); elimination half-life (t1/2 ), 2.50 hours (1.77 to 2.97 hours); AUC0-12 h , 1366 ng⋅h/mL (927 to 2531 ng⋅h/mL); AUC0-∞ , 1580 ng⋅h/mL (1270 to 2881 ng⋅h/mL); CL/F 25.3 L/h (13.8 to 31.4 L/h); CLR, 2.50 L/h (1.77 to 2.97 L/h); CLNR, 22.7 L/h (12.1 to 25.6 L/h); and Vd /F 82.8 L (34.4 to 173 L).","A Pilot Study of the Maternal-Fetal Pharmacokinetics of Furosemide in Plasma, Urine, and Amniotic Fluid of Hypertensive Parturient Women Under Cesarean Section. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32562572/),[h·ng] / [ml],1580,240557,DB00695,Furosemide
,32562572,CL/F,"The following furosemide pharmacokinetic parameters were obtained as median (interquartile range): Cmax , 403 ng/mL (229 to 715 ng/mL); Tmax , 2.00 hours (1.50 to 4.83 hours); elimination half-life (t1/2 ), 2.50 hours (1.77 to 2.97 hours); AUC0-12 h , 1366 ng⋅h/mL (927 to 2531 ng⋅h/mL); AUC0-∞ , 1580 ng⋅h/mL (1270 to 2881 ng⋅h/mL); CL/F 25.3 L/h (13.8 to 31.4 L/h); CLR, 2.50 L/h (1.77 to 2.97 L/h); CLNR, 22.7 L/h (12.1 to 25.6 L/h); and Vd /F 82.8 L (34.4 to 173 L).","A Pilot Study of the Maternal-Fetal Pharmacokinetics of Furosemide in Plasma, Urine, and Amniotic Fluid of Hypertensive Parturient Women Under Cesarean Section. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32562572/),[l] / [h],25.3,240558,DB00695,Furosemide
,32562572,CLR,"The following furosemide pharmacokinetic parameters were obtained as median (interquartile range): Cmax , 403 ng/mL (229 to 715 ng/mL); Tmax , 2.00 hours (1.50 to 4.83 hours); elimination half-life (t1/2 ), 2.50 hours (1.77 to 2.97 hours); AUC0-12 h , 1366 ng⋅h/mL (927 to 2531 ng⋅h/mL); AUC0-∞ , 1580 ng⋅h/mL (1270 to 2881 ng⋅h/mL); CL/F 25.3 L/h (13.8 to 31.4 L/h); CLR, 2.50 L/h (1.77 to 2.97 L/h); CLNR, 22.7 L/h (12.1 to 25.6 L/h); and Vd /F 82.8 L (34.4 to 173 L).","A Pilot Study of the Maternal-Fetal Pharmacokinetics of Furosemide in Plasma, Urine, and Amniotic Fluid of Hypertensive Parturient Women Under Cesarean Section. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32562572/),[l] / [h],2.50,240559,DB00695,Furosemide
,32562572,CLNR,"The following furosemide pharmacokinetic parameters were obtained as median (interquartile range): Cmax , 403 ng/mL (229 to 715 ng/mL); Tmax , 2.00 hours (1.50 to 4.83 hours); elimination half-life (t1/2 ), 2.50 hours (1.77 to 2.97 hours); AUC0-12 h , 1366 ng⋅h/mL (927 to 2531 ng⋅h/mL); AUC0-∞ , 1580 ng⋅h/mL (1270 to 2881 ng⋅h/mL); CL/F 25.3 L/h (13.8 to 31.4 L/h); CLR, 2.50 L/h (1.77 to 2.97 L/h); CLNR, 22.7 L/h (12.1 to 25.6 L/h); and Vd /F 82.8 L (34.4 to 173 L).","A Pilot Study of the Maternal-Fetal Pharmacokinetics of Furosemide in Plasma, Urine, and Amniotic Fluid of Hypertensive Parturient Women Under Cesarean Section. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32562572/),[l] / [h],22.7,240560,DB00695,Furosemide
,32562572,Vd /F,"The following furosemide pharmacokinetic parameters were obtained as median (interquartile range): Cmax , 403 ng/mL (229 to 715 ng/mL); Tmax , 2.00 hours (1.50 to 4.83 hours); elimination half-life (t1/2 ), 2.50 hours (1.77 to 2.97 hours); AUC0-12 h , 1366 ng⋅h/mL (927 to 2531 ng⋅h/mL); AUC0-∞ , 1580 ng⋅h/mL (1270 to 2881 ng⋅h/mL); CL/F 25.3 L/h (13.8 to 31.4 L/h); CLR, 2.50 L/h (1.77 to 2.97 L/h); CLNR, 22.7 L/h (12.1 to 25.6 L/h); and Vd /F 82.8 L (34.4 to 173 L).","A Pilot Study of the Maternal-Fetal Pharmacokinetics of Furosemide in Plasma, Urine, and Amniotic Fluid of Hypertensive Parturient Women Under Cesarean Section. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32562572/),l,82.8,240561,DB00695,Furosemide
,32562572,transplacental transfer,"The transplacental transfer of furosemide was 0.43 (0.10 to 0.73), and the amniotic fluid concentration was 11.0 ng/mL (5.51 to 14.6 ng/mL).","A Pilot Study of the Maternal-Fetal Pharmacokinetics of Furosemide in Plasma, Urine, and Amniotic Fluid of Hypertensive Parturient Women Under Cesarean Section. ",Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32562572/),,0.43,240562,DB00695,Furosemide
,32562572,amniotic fluid concentration,"The transplacental transfer of furosemide was 0.43 (0.10 to 0.73), and the amniotic fluid concentration was 11.0 ng/mL (5.51 to 14.6 ng/mL).","A Pilot Study of the Maternal-Fetal Pharmacokinetics of Furosemide in Plasma, Urine, and Amniotic Fluid of Hypertensive Parturient Women Under Cesarean Section. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32562572/),[ng] / [ml],11.0,240563,DB00695,Furosemide
,8739815,total,"The total (bound plus unbound) plasma clearance of frusemide during hypoxaemia (arterial oxygen tension, PaO2 < or = 50 Torr) was not significantly different from the value during normoxaemia (PaO2 > or = 60 Torr) [76.9 and 62.4 ml.min-1].",The effect of hypoxaemia on drug disposition in chronic respiratory failure. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739815/),[ml] / [min],76.9,242537,DB00695,Furosemide
,8739815,total,"The total (bound plus unbound) plasma clearance of frusemide during hypoxaemia (arterial oxygen tension, PaO2 < or = 50 Torr) was not significantly different from the value during normoxaemia (PaO2 > or = 60 Torr) [76.9 and 62.4 ml.min-1].",The effect of hypoxaemia on drug disposition in chronic respiratory failure. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739815/),[ml] / [min],62.4,242538,DB00695,Furosemide
,8739815,unbound) plasma clearance,"The total (bound plus unbound) plasma clearance of frusemide during hypoxaemia (arterial oxygen tension, PaO2 < or = 50 Torr) was not significantly different from the value during normoxaemia (PaO2 > or = 60 Torr) [76.9 and 62.4 ml.min-1].",The effect of hypoxaemia on drug disposition in chronic respiratory failure. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739815/),[ml] / [min],76.9,242539,DB00695,Furosemide
,8739815,unbound) plasma clearance,"The total (bound plus unbound) plasma clearance of frusemide during hypoxaemia (arterial oxygen tension, PaO2 < or = 50 Torr) was not significantly different from the value during normoxaemia (PaO2 > or = 60 Torr) [76.9 and 62.4 ml.min-1].",The effect of hypoxaemia on drug disposition in chronic respiratory failure. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739815/),[ml] / [min],62.4,242540,DB00695,Furosemide
,8739815,volume of distribution,The volume of distribution was not affected by acute hypoxaemia (121 ml.kg-1 without and 109 ml.kg-1 with oxygen; P > 0.05).,The effect of hypoxaemia on drug disposition in chronic respiratory failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739815/),[ml] / [kg],121,242541,DB00695,Furosemide
,8739815,volume of distribution,The volume of distribution was not affected by acute hypoxaemia (121 ml.kg-1 without and 109 ml.kg-1 with oxygen; P > 0.05).,The effect of hypoxaemia on drug disposition in chronic respiratory failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739815/),[ml] / [kg],109,242542,DB00695,Furosemide
,8739815,Renal,"Renal and non-renal clearances of frusemide were similar during the period of hypoxaemia (31 and 38 ml.min-1, respectively) compared to respective values during supplemental oxygen delivery (29 and 32 ml.min-1).",The effect of hypoxaemia on drug disposition in chronic respiratory failure. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739815/),[ml] / [min],31,242543,DB00695,Furosemide
,8739815,Renal,"Renal and non-renal clearances of frusemide were similar during the period of hypoxaemia (31 and 38 ml.min-1, respectively) compared to respective values during supplemental oxygen delivery (29 and 32 ml.min-1).",The effect of hypoxaemia on drug disposition in chronic respiratory failure. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739815/),[ml] / [min],38,242544,DB00695,Furosemide
,8739815,Renal,"Renal and non-renal clearances of frusemide were similar during the period of hypoxaemia (31 and 38 ml.min-1, respectively) compared to respective values during supplemental oxygen delivery (29 and 32 ml.min-1).",The effect of hypoxaemia on drug disposition in chronic respiratory failure. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739815/),[ml] / [min],29,242545,DB00695,Furosemide
,8739815,non-renal clearances,"Renal and non-renal clearances of frusemide were similar during the period of hypoxaemia (31 and 38 ml.min-1, respectively) compared to respective values during supplemental oxygen delivery (29 and 32 ml.min-1).",The effect of hypoxaemia on drug disposition in chronic respiratory failure. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739815/),[ml] / [min],38,242546,DB00695,Furosemide
,8739815,non-renal clearances,"Renal and non-renal clearances of frusemide were similar during the period of hypoxaemia (31 and 38 ml.min-1, respectively) compared to respective values during supplemental oxygen delivery (29 and 32 ml.min-1).",The effect of hypoxaemia on drug disposition in chronic respiratory failure. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739815/),[ml] / [min],29,242547,DB00695,Furosemide
,8739815,non-renal clearances,"Renal and non-renal clearances of frusemide were similar during the period of hypoxaemia (31 and 38 ml.min-1, respectively) compared to respective values during supplemental oxygen delivery (29 and 32 ml.min-1).",The effect of hypoxaemia on drug disposition in chronic respiratory failure. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739815/),[ml] / [min],32,242548,DB00695,Furosemide
,8739815,absolute bioavailability,The absolute bioavailability of frusemide during hypoxaemia (0.62) was not different to that obtained during normoxaemia (0.56).,The effect of hypoxaemia on drug disposition in chronic respiratory failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739815/),,0.62,242549,DB00695,Furosemide
,8739815,absolute bioavailability,The absolute bioavailability of frusemide during hypoxaemia (0.62) was not different to that obtained during normoxaemia (0.56).,The effect of hypoxaemia on drug disposition in chronic respiratory failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8739815/),,0.56,242550,DB00695,Furosemide
,3430953,overall response,"Despite similarities in maximal fractional excretion of sodium (18.2 +/- 2.6% with furosemide vs. 19.4 +/- 4.5% with bumetanide, P = 0.687) demonstrating an equal tubular responsiveness to both drugs, overall response as quantified by cumulative natriuresis in the initial eight hour period was 52% greater with furosemide (108 +/- 17 vs. 71 +/- 7 mEq; P = 0.042).",Comparison of loop diuretics in patients with chronic renal insufficiency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3430953/),meq,108,243801,DB00695,Furosemide
,3430953,overall response,"Despite similarities in maximal fractional excretion of sodium (18.2 +/- 2.6% with furosemide vs. 19.4 +/- 4.5% with bumetanide, P = 0.687) demonstrating an equal tubular responsiveness to both drugs, overall response as quantified by cumulative natriuresis in the initial eight hour period was 52% greater with furosemide (108 +/- 17 vs. 71 +/- 7 mEq; P = 0.042).",Comparison of loop diuretics in patients with chronic renal insufficiency. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3430953/),meq,71,243802,DB00695,Furosemide
,3430953,nonrenal clearance,"The difference in total excreted sodium was accounted for by a preserved nonrenal clearance of bumetanide (113 +/- 12 compared to 53 +/- 5 ml/min for furosemide, P = 0.001) which resulted in relatively less bumetanide in serum available to be delivered into the urine.",Comparison of loop diuretics in patients with chronic renal insufficiency. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3430953/),[ml] / [min],113,243803,DB00695,Furosemide
,3430953,nonrenal clearance,"The difference in total excreted sodium was accounted for by a preserved nonrenal clearance of bumetanide (113 +/- 12 compared to 53 +/- 5 ml/min for furosemide, P = 0.001) which resulted in relatively less bumetanide in serum available to be delivered into the urine.",Comparison of loop diuretics in patients with chronic renal insufficiency. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3430953/),[ml] / [min],53,243804,DB00695,Furosemide
,8534784,fraction of the intratra,The mean fraction of the intratracheal dose absorbed was 0.50-0.60 for all doses.,Furosemide pharmacokinetics following intratracheal instillation in the guinea pig. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8534784/),,0.50-0.60,248251,DB00695,Furosemide
,9435168,rate of CSF bulk flow,"We found that an IgM mAb was cleared from rat CSF at the rate of CSF bulk flow (0.0041 ml/min), but an IgG mAb was cleared at a faster rate (0.011 ml/min).",Pharmacokinetics of IgG and IgM anti-ganglioside antibodies in rats and monkeys after intrathecal administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9435168/),[ml] / [min],0.0041,249742,DB00695,Furosemide
,29057472,volume of distribution at steady-state,There was not a significant difference in the volume of distribution at steady-state (0.594 ± 0.178 [4 hrs] and 0.648 ± 0.147 [24 hrs] L/kg) or systemic clearance (0.541 ± 0.094 [4 hrs] and 0.617 ± 0.114 [24 hrs] L/hrs/kg) between horses that were exercised at 4- and 24 hrs postdrug administration.,Pharmacokinetics of furosemide administered 4 and 24 hours prior to high-speed exercise in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29057472/),h,0.594,250697,DB00695,Furosemide
,29057472,volume of distribution at steady-state,There was not a significant difference in the volume of distribution at steady-state (0.594 ± 0.178 [4 hrs] and 0.648 ± 0.147 [24 hrs] L/kg) or systemic clearance (0.541 ± 0.094 [4 hrs] and 0.617 ± 0.114 [24 hrs] L/hrs/kg) between horses that were exercised at 4- and 24 hrs postdrug administration.,Pharmacokinetics of furosemide administered 4 and 24 hours prior to high-speed exercise in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29057472/),[l] / [kg],0.648,250698,DB00695,Furosemide
,29057472,systemic clearance,There was not a significant difference in the volume of distribution at steady-state (0.594 ± 0.178 [4 hrs] and 0.648 ± 0.147 [24 hrs] L/kg) or systemic clearance (0.541 ± 0.094 [4 hrs] and 0.617 ± 0.114 [24 hrs] L/hrs/kg) between horses that were exercised at 4- and 24 hrs postdrug administration.,Pharmacokinetics of furosemide administered 4 and 24 hours prior to high-speed exercise in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29057472/),[l] / [h·kg],0.541,250699,DB00695,Furosemide
,29057472,systemic clearance,There was not a significant difference in the volume of distribution at steady-state (0.594 ± 0.178 [4 hrs] and 0.648 ± 0.147 [24 hrs] L/kg) or systemic clearance (0.541 ± 0.094 [4 hrs] and 0.617 ± 0.114 [24 hrs] L/hrs/kg) between horses that were exercised at 4- and 24 hrs postdrug administration.,Pharmacokinetics of furosemide administered 4 and 24 hours prior to high-speed exercise in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29057472/),[l] / [h·kg],4,250700,DB00695,Furosemide
,29057472,systemic clearance,There was not a significant difference in the volume of distribution at steady-state (0.594 ± 0.178 [4 hrs] and 0.648 ± 0.147 [24 hrs] L/kg) or systemic clearance (0.541 ± 0.094 [4 hrs] and 0.617 ± 0.114 [24 hrs] L/hrs/kg) between horses that were exercised at 4- and 24 hrs postdrug administration.,Pharmacokinetics of furosemide administered 4 and 24 hours prior to high-speed exercise in horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29057472/),[l] / [h·kg],0.617,250701,DB00695,Furosemide
,29057472,elimination half-life,"The mean ± SD elimination half-life was 3.12 ± 0.387 and 3.23 ± 0.407 hrs following administration at 4 and 24 hrs prior to exercise, respectively.",Pharmacokinetics of furosemide administered 4 and 24 hours prior to high-speed exercise in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29057472/),h,3.12,250702,DB00695,Furosemide
,29057472,elimination half-life,"The mean ± SD elimination half-life was 3.12 ± 0.387 and 3.23 ± 0.407 hrs following administration at 4 and 24 hrs prior to exercise, respectively.",Pharmacokinetics of furosemide administered 4 and 24 hours prior to high-speed exercise in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29057472/),h,3.23,250703,DB00695,Furosemide
,18611061,absolute bioavailability,The absolute bioavailability of aliskiren is 2.6%.,Clinical pharmacokinetics and pharmacodynamics of aliskiren. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611061/),%,2.6,252071,DB00695,Furosemide
,18611061,accumulation factor,"Steady-state plasma concentrations of aliskiren are reached after 7-8 days of once-daily dosing, and the accumulation factor for aliskiren is approximately 2.",Clinical pharmacokinetics and pharmacodynamics of aliskiren. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611061/),,2,252072,DB00695,Furosemide
,1433485,half-life (t1/2 beta),The half-life (t1/2 beta) of the late phase of elimination was 0.931 +/- 0.187 h and the apparent volume of distribution at steady state was 0.25 +/- 0.043 l/Kg.,The pharmacokinetics and pharmacodynamics of furosemide in the anaesthetized dog. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433485/),h,0.931,252837,DB00695,Furosemide
,1433485,apparent volume of distribution at steady state,The half-life (t1/2 beta) of the late phase of elimination was 0.931 +/- 0.187 h and the apparent volume of distribution at steady state was 0.25 +/- 0.043 l/Kg.,The pharmacokinetics and pharmacodynamics of furosemide in the anaesthetized dog. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433485/),[l] / [kg],0.25,252838,DB00695,Furosemide
,1433485,total clearance (Cltot),"The total clearance (Cltot) was 0.435 +/- 0.031 l/h/kg, in which the renal clearance was 0.260 +/- 0.020 (about 60% of Cltot).",The pharmacokinetics and pharmacodynamics of furosemide in the anaesthetized dog. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433485/),[l] / [h·kg],0.435,252839,DB00695,Furosemide
,1433485,renal clearance,"The total clearance (Cltot) was 0.435 +/- 0.031 l/h/kg, in which the renal clearance was 0.260 +/- 0.020 (about 60% of Cltot).",The pharmacokinetics and pharmacodynamics of furosemide in the anaesthetized dog. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433485/),,0.260,252840,DB00695,Furosemide
,1433485,half-maximum effect,The half-maximum effect was obtained at 1.5 micrograms/ml of plasma concentration or at 80 micrograms/min of excretion rate of furosemide.,The pharmacokinetics and pharmacodynamics of furosemide in the anaesthetized dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1433485/),,80,252841,DB00695,Furosemide
,3285830,serum elimination half-life,The serum elimination half-life of torasemide was longer (4.8 h) than that of furosemide (2.2 h) in these patients and also longer than that in healthy volunteers (3 h).,Comparison of diuretic effects and pharmacokinetics of torasemide and furosemide after a single oral dose in patients with hydropically decompensated cirrhosis of the liver. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3285830/),h,4.8,254124,DB00695,Furosemide
,3285830,serum elimination half-life,The serum elimination half-life of torasemide was longer (4.8 h) than that of furosemide (2.2 h) in these patients and also longer than that in healthy volunteers (3 h).,Comparison of diuretic effects and pharmacokinetics of torasemide and furosemide after a single oral dose in patients with hydropically decompensated cirrhosis of the liver. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3285830/),h,2.2,254125,DB00695,Furosemide
,3285830,serum elimination half-life,The serum elimination half-life of torasemide was longer (4.8 h) than that of furosemide (2.2 h) in these patients and also longer than that in healthy volunteers (3 h).,Comparison of diuretic effects and pharmacokinetics of torasemide and furosemide after a single oral dose in patients with hydropically decompensated cirrhosis of the liver. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3285830/),h,3,254126,DB00695,Furosemide
,2359020,Steady-state volume of distribution,Steady-state volume of distribution and unbound fraction of furosemide in plasma were both considerably higher in the younger piglets (618 +/- 320 vs.,Pharmacokinetics and dynamics of furosemide in the newborn piglet. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2359020/),,618,255067,DB00695,Furosemide
,2359020,unbound secretory clearance,"0.06 +/- 0.02 ml/kg, p less than .001, respectively) while unbound secretory clearance was several-fold lower in this age group (49.2 +/- 23 vs. 107 +/- 55 ml/min/kg, P less than .01).",Pharmacokinetics and dynamics of furosemide in the newborn piglet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2359020/),[ml] / [kg·min],49.2,255068,DB00695,Furosemide
,2359020,unbound secretory clearance,"0.06 +/- 0.02 ml/kg, p less than .001, respectively) while unbound secretory clearance was several-fold lower in this age group (49.2 +/- 23 vs. 107 +/- 55 ml/min/kg, P less than .01).",Pharmacokinetics and dynamics of furosemide in the newborn piglet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2359020/),[ml] / [kg·min],107,255069,DB00695,Furosemide
,2359020,maximal response,"While basal response and slope parameters did not differ significantly, maximal response and stimulus required for half-maximal response were both reduced in the younger piglets (0.70 +/- 0.24 vs. 1.18 +/- 0.30 mmol/min and 0.06 +/- 0.04 vs. 0.14 +/- 0.06 mumol/min, respectively, P less than 0.05).",Pharmacokinetics and dynamics of furosemide in the newborn piglet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2359020/),[mM] / [min],0.70,255070,DB00695,Furosemide
,2359020,maximal response,"While basal response and slope parameters did not differ significantly, maximal response and stimulus required for half-maximal response were both reduced in the younger piglets (0.70 +/- 0.24 vs. 1.18 +/- 0.30 mmol/min and 0.06 +/- 0.04 vs. 0.14 +/- 0.06 mumol/min, respectively, P less than 0.05).",Pharmacokinetics and dynamics of furosemide in the newborn piglet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2359020/),[mM] / [min],1.18,255071,DB00695,Furosemide
,2359020,stimulus required for half-maximal response,"While basal response and slope parameters did not differ significantly, maximal response and stimulus required for half-maximal response were both reduced in the younger piglets (0.70 +/- 0.24 vs. 1.18 +/- 0.30 mmol/min and 0.06 +/- 0.04 vs. 0.14 +/- 0.06 mumol/min, respectively, P less than 0.05).",Pharmacokinetics and dynamics of furosemide in the newborn piglet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2359020/),[μM] / [min],0.06,255072,DB00695,Furosemide
,2359020,stimulus required for half-maximal response,"While basal response and slope parameters did not differ significantly, maximal response and stimulus required for half-maximal response were both reduced in the younger piglets (0.70 +/- 0.24 vs. 1.18 +/- 0.30 mmol/min and 0.06 +/- 0.04 vs. 0.14 +/- 0.06 mumol/min, respectively, P less than 0.05).",Pharmacokinetics and dynamics of furosemide in the newborn piglet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2359020/),[μM] / [min],0.14,255073,DB00695,Furosemide
,7381633,volume of distributuion,"The volume of distributuion for furosemide was calculated to be 0.24 +/- 0.03 l/kg (mean +/- SE) in all infants studied, regardless of postnatal age.",Pharmacology of furosemide in the premature newborn infant. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7381633/),[l] / [kg],0.24,256785,DB00695,Furosemide
,7381633,half-life,The half-life in the first three weeks of life was found to be 19.9 +/- 3.0 hours.,Pharmacology of furosemide in the premature newborn infant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7381633/),h,19.9,256786,DB00695,Furosemide
,12516076,AUC,"After intravenous administration of torasemide to NARs, the AUC (301 versus 2680 microg/min/ml) was significantly smaller [due to significantly faster both Cl(r) (4.81 versus 0.386 ml/min/kg) and Cl(nr) (28.3 versus 3.33 ml/min/kg)], terminal half-life (18.3 versus 73.5 min) and mean residence time (6.97 versus 61.8 min) were significantly shorter (due to faster Cl, 33.2 versus 3.74 ml/min/kg), and amount of 8-h urinary excretion of unchanged torasemide (446 versus 323 microg, due to increase in intrinsic renal excretion) was significantly greater than those in control rats.",Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant Nagase analbuminemic rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516076/),[μg] / [min·ml],301,258455,DB00695,Furosemide
,12516076,AUC,"After intravenous administration of torasemide to NARs, the AUC (301 versus 2680 microg/min/ml) was significantly smaller [due to significantly faster both Cl(r) (4.81 versus 0.386 ml/min/kg) and Cl(nr) (28.3 versus 3.33 ml/min/kg)], terminal half-life (18.3 versus 73.5 min) and mean residence time (6.97 versus 61.8 min) were significantly shorter (due to faster Cl, 33.2 versus 3.74 ml/min/kg), and amount of 8-h urinary excretion of unchanged torasemide (446 versus 323 microg, due to increase in intrinsic renal excretion) was significantly greater than those in control rats.",Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant Nagase analbuminemic rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516076/),[μg] / [min·ml],2680,258456,DB00695,Furosemide
,12516076,Cl(r),"After intravenous administration of torasemide to NARs, the AUC (301 versus 2680 microg/min/ml) was significantly smaller [due to significantly faster both Cl(r) (4.81 versus 0.386 ml/min/kg) and Cl(nr) (28.3 versus 3.33 ml/min/kg)], terminal half-life (18.3 versus 73.5 min) and mean residence time (6.97 versus 61.8 min) were significantly shorter (due to faster Cl, 33.2 versus 3.74 ml/min/kg), and amount of 8-h urinary excretion of unchanged torasemide (446 versus 323 microg, due to increase in intrinsic renal excretion) was significantly greater than those in control rats.",Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant Nagase analbuminemic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516076/),[ml] / [kg·min],4.81,258457,DB00695,Furosemide
,12516076,Cl(r),"After intravenous administration of torasemide to NARs, the AUC (301 versus 2680 microg/min/ml) was significantly smaller [due to significantly faster both Cl(r) (4.81 versus 0.386 ml/min/kg) and Cl(nr) (28.3 versus 3.33 ml/min/kg)], terminal half-life (18.3 versus 73.5 min) and mean residence time (6.97 versus 61.8 min) were significantly shorter (due to faster Cl, 33.2 versus 3.74 ml/min/kg), and amount of 8-h urinary excretion of unchanged torasemide (446 versus 323 microg, due to increase in intrinsic renal excretion) was significantly greater than those in control rats.",Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant Nagase analbuminemic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516076/),[ml] / [kg·min],0.386,258458,DB00695,Furosemide
,12516076,Cl(nr),"After intravenous administration of torasemide to NARs, the AUC (301 versus 2680 microg/min/ml) was significantly smaller [due to significantly faster both Cl(r) (4.81 versus 0.386 ml/min/kg) and Cl(nr) (28.3 versus 3.33 ml/min/kg)], terminal half-life (18.3 versus 73.5 min) and mean residence time (6.97 versus 61.8 min) were significantly shorter (due to faster Cl, 33.2 versus 3.74 ml/min/kg), and amount of 8-h urinary excretion of unchanged torasemide (446 versus 323 microg, due to increase in intrinsic renal excretion) was significantly greater than those in control rats.",Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant Nagase analbuminemic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516076/),[ml] / [kg·min],28.3,258459,DB00695,Furosemide
,12516076,Cl(nr),"After intravenous administration of torasemide to NARs, the AUC (301 versus 2680 microg/min/ml) was significantly smaller [due to significantly faster both Cl(r) (4.81 versus 0.386 ml/min/kg) and Cl(nr) (28.3 versus 3.33 ml/min/kg)], terminal half-life (18.3 versus 73.5 min) and mean residence time (6.97 versus 61.8 min) were significantly shorter (due to faster Cl, 33.2 versus 3.74 ml/min/kg), and amount of 8-h urinary excretion of unchanged torasemide (446 versus 323 microg, due to increase in intrinsic renal excretion) was significantly greater than those in control rats.",Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant Nagase analbuminemic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516076/),[ml] / [kg·min],3.33,258460,DB00695,Furosemide
,12516076,terminal half-life,"After intravenous administration of torasemide to NARs, the AUC (301 versus 2680 microg/min/ml) was significantly smaller [due to significantly faster both Cl(r) (4.81 versus 0.386 ml/min/kg) and Cl(nr) (28.3 versus 3.33 ml/min/kg)], terminal half-life (18.3 versus 73.5 min) and mean residence time (6.97 versus 61.8 min) were significantly shorter (due to faster Cl, 33.2 versus 3.74 ml/min/kg), and amount of 8-h urinary excretion of unchanged torasemide (446 versus 323 microg, due to increase in intrinsic renal excretion) was significantly greater than those in control rats.",Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant Nagase analbuminemic rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516076/),min,18.3,258461,DB00695,Furosemide
,12516076,terminal half-life,"After intravenous administration of torasemide to NARs, the AUC (301 versus 2680 microg/min/ml) was significantly smaller [due to significantly faster both Cl(r) (4.81 versus 0.386 ml/min/kg) and Cl(nr) (28.3 versus 3.33 ml/min/kg)], terminal half-life (18.3 versus 73.5 min) and mean residence time (6.97 versus 61.8 min) were significantly shorter (due to faster Cl, 33.2 versus 3.74 ml/min/kg), and amount of 8-h urinary excretion of unchanged torasemide (446 versus 323 microg, due to increase in intrinsic renal excretion) was significantly greater than those in control rats.",Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant Nagase analbuminemic rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516076/),min,73.5,258462,DB00695,Furosemide
,12516076,mean residence time,"After intravenous administration of torasemide to NARs, the AUC (301 versus 2680 microg/min/ml) was significantly smaller [due to significantly faster both Cl(r) (4.81 versus 0.386 ml/min/kg) and Cl(nr) (28.3 versus 3.33 ml/min/kg)], terminal half-life (18.3 versus 73.5 min) and mean residence time (6.97 versus 61.8 min) were significantly shorter (due to faster Cl, 33.2 versus 3.74 ml/min/kg), and amount of 8-h urinary excretion of unchanged torasemide (446 versus 323 microg, due to increase in intrinsic renal excretion) was significantly greater than those in control rats.",Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant Nagase analbuminemic rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516076/),min,6.97,258463,DB00695,Furosemide
,12516076,mean residence time,"After intravenous administration of torasemide to NARs, the AUC (301 versus 2680 microg/min/ml) was significantly smaller [due to significantly faster both Cl(r) (4.81 versus 0.386 ml/min/kg) and Cl(nr) (28.3 versus 3.33 ml/min/kg)], terminal half-life (18.3 versus 73.5 min) and mean residence time (6.97 versus 61.8 min) were significantly shorter (due to faster Cl, 33.2 versus 3.74 ml/min/kg), and amount of 8-h urinary excretion of unchanged torasemide (446 versus 323 microg, due to increase in intrinsic renal excretion) was significantly greater than those in control rats.",Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant Nagase analbuminemic rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516076/),min,61.8,258464,DB00695,Furosemide
,12516076,Cl,"After intravenous administration of torasemide to NARs, the AUC (301 versus 2680 microg/min/ml) was significantly smaller [due to significantly faster both Cl(r) (4.81 versus 0.386 ml/min/kg) and Cl(nr) (28.3 versus 3.33 ml/min/kg)], terminal half-life (18.3 versus 73.5 min) and mean residence time (6.97 versus 61.8 min) were significantly shorter (due to faster Cl, 33.2 versus 3.74 ml/min/kg), and amount of 8-h urinary excretion of unchanged torasemide (446 versus 323 microg, due to increase in intrinsic renal excretion) was significantly greater than those in control rats.",Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant Nagase analbuminemic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516076/),[ml] / [kg·min],33.2,258465,DB00695,Furosemide
,12516076,Cl,"After intravenous administration of torasemide to NARs, the AUC (301 versus 2680 microg/min/ml) was significantly smaller [due to significantly faster both Cl(r) (4.81 versus 0.386 ml/min/kg) and Cl(nr) (28.3 versus 3.33 ml/min/kg)], terminal half-life (18.3 versus 73.5 min) and mean residence time (6.97 versus 61.8 min) were significantly shorter (due to faster Cl, 33.2 versus 3.74 ml/min/kg), and amount of 8-h urinary excretion of unchanged torasemide (446 versus 323 microg, due to increase in intrinsic renal excretion) was significantly greater than those in control rats.",Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant Nagase analbuminemic rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516076/),[ml] / [kg·min],3.74,258466,DB00695,Furosemide
,12516076,urinary excretion,"After intravenous administration of torasemide to NARs, the AUC (301 versus 2680 microg/min/ml) was significantly smaller [due to significantly faster both Cl(r) (4.81 versus 0.386 ml/min/kg) and Cl(nr) (28.3 versus 3.33 ml/min/kg)], terminal half-life (18.3 versus 73.5 min) and mean residence time (6.97 versus 61.8 min) were significantly shorter (due to faster Cl, 33.2 versus 3.74 ml/min/kg), and amount of 8-h urinary excretion of unchanged torasemide (446 versus 323 microg, due to increase in intrinsic renal excretion) was significantly greater than those in control rats.",Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant Nagase analbuminemic rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516076/),μg,446,258467,DB00695,Furosemide
,12516076,urinary excretion,"After intravenous administration of torasemide to NARs, the AUC (301 versus 2680 microg/min/ml) was significantly smaller [due to significantly faster both Cl(r) (4.81 versus 0.386 ml/min/kg) and Cl(nr) (28.3 versus 3.33 ml/min/kg)], terminal half-life (18.3 versus 73.5 min) and mean residence time (6.97 versus 61.8 min) were significantly shorter (due to faster Cl, 33.2 versus 3.74 ml/min/kg), and amount of 8-h urinary excretion of unchanged torasemide (446 versus 323 microg, due to increase in intrinsic renal excretion) was significantly greater than those in control rats.",Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant Nagase analbuminemic rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12516076/),μg,323,258468,DB00695,Furosemide
,4026929,Plasma half-life,Plasma half-life values were 1 h for phase alpha and 17 h for phase beta.,Single-dose pharmacokinetics of fenquizone in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026929/),h,1,258596,DB00695,Furosemide
,4026929,Plasma half-life,Plasma half-life values were 1 h for phase alpha and 17 h for phase beta.,Single-dose pharmacokinetics of fenquizone in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026929/),h,17,258597,DB00695,Furosemide
,4026929,half-life,The half-life calculated from urinary concentrations was 18 h.,Single-dose pharmacokinetics of fenquizone in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026929/),h,18,258598,DB00695,Furosemide
,4026929,apparent distribution volume for phase beta,"The apparent distribution volume for phase beta was 686 l; renal clearance was 220 ml/min, and the absorption constant (Ka) was 1055 h-1.",Single-dose pharmacokinetics of fenquizone in healthy volunteers. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026929/),l,686,258599,DB00695,Furosemide
,4026929,renal clearance,"The apparent distribution volume for phase beta was 686 l; renal clearance was 220 ml/min, and the absorption constant (Ka) was 1055 h-1.",Single-dose pharmacokinetics of fenquizone in healthy volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026929/),[ml] / [min],220,258600,DB00695,Furosemide
,4026929,absorption constant (Ka),"The apparent distribution volume for phase beta was 686 l; renal clearance was 220 ml/min, and the absorption constant (Ka) was 1055 h-1.",Single-dose pharmacokinetics of fenquizone in healthy volunteers. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4026929/),1/[h],1055,258601,DB00695,Furosemide
,2778674,retention times,"The retention times for 1 and 2 were 0.6 and 1.0 min, respectively.",Gas-liquid chromatography-mass spectroscopy determination of clopamide in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778674/),min,0.6,259407,DB00695,Furosemide
,2778674,retention times,"The retention times for 1 and 2 were 0.6 and 1.0 min, respectively.",Gas-liquid chromatography-mass spectroscopy determination of clopamide in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778674/),min,1.0,259408,DB00695,Furosemide
,2778674,limit of detection,The limit of detection is 10 ng/mL of 1 in plasma and the calibration curve was shown to be linear between 10 and 500 ng/mL of 1.,Gas-liquid chromatography-mass spectroscopy determination of clopamide in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778674/),[ng] / [ml],10,259409,DB00695,Furosemide
,2778674,recovery,The recovery from the extraction procedure was 92 +/- 2.2%.,Gas-liquid chromatography-mass spectroscopy determination of clopamide in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778674/),%,92,259410,DB00695,Furosemide
,2778674,Peak plasma concentrations,Peak plasma concentrations of 197 +/- 56 ng/mL were observed after 1.1 +/- 0.34 h.,Gas-liquid chromatography-mass spectroscopy determination of clopamide in plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778674/),[ng] / [ml],197,259411,DB00695,Furosemide
,10604283,AUC(0-8) h,"With bile juice administration, the plasma concentrations of furosemide were considerably higher and AUC(0-8) h was significantly greater (2570 versus 658 microg x min/ml) suggesting that absorption of furosemide increased significantly by bile juice.",Enhanced absorption of oral furosemide by bile juice in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10604283/),[min·μg] / [ml],2570,260366,DB00695,Furosemide
,10604283,AUC(0-8) h,"With bile juice administration, the plasma concentrations of furosemide were considerably higher and AUC(0-8) h was significantly greater (2570 versus 658 microg x min/ml) suggesting that absorption of furosemide increased significantly by bile juice.",Enhanced absorption of oral furosemide by bile juice in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10604283/),[min·μg] / [ml],658,260367,DB00695,Furosemide
,6793714,urine flow,"With saline and mannitol volume expansion CDIG/CIN increased from 0.58 +/- 0.33 (S.D) and 0.54 +/- 0.14, respectively, to 1.28 +/- 0.14 and 1.13 +/- 0.22, respectively (P less than .005), as urine flow increased from 0.5 to 24 ml/min.",Effect of volume expansion and furosemide diuresis on the renal clearance of digoxin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6793714/),,0,260396,DB00695,Furosemide
,6793714,urine flow,With furosemide urine flow increased from 0.5 to 22 ml/min but CDIG/CIN remained constant at 0.63 +/- 0.18.,Effect of volume expansion and furosemide diuresis on the renal clearance of digoxin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6793714/),[ml] / [min],0.5,260397,DB00695,Furosemide
,6793714,urine flow,With furosemide urine flow increased from 0.5 to 22 ml/min but CDIG/CIN remained constant at 0.63 +/- 0.18.,Effect of volume expansion and furosemide diuresis on the renal clearance of digoxin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6793714/),[ml] / [min],22,260398,DB00695,Furosemide
,26681081,Volume of distribution,"Volume of distribution, clearance, and half-life median values (95 % CI) for phenobarbital in the whole study population (n=37) were 0.48 (0.41-0.56) l/kg, 0.0034 (0.0028-0.0040) l/h/kg, and 93.7 (88.1-99.2) h, respectively.",Effect of co-medication on the pharmacokinetic parameters of phenobarbital in asphyxiated newborns. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681081/),[l] / [kg],0.48,261685,DB00695,Furosemide
,26681081,clearance,"Volume of distribution, clearance, and half-life median values (95 % CI) for phenobarbital in the whole study population (n=37) were 0.48 (0.41-0.56) l/kg, 0.0034 (0.0028-0.0040) l/h/kg, and 93.7 (88.1-99.2) h, respectively.",Effect of co-medication on the pharmacokinetic parameters of phenobarbital in asphyxiated newborns. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681081/),[l] / [h·kg],0.0034,261686,DB00695,Furosemide
,26681081,half-life,"Volume of distribution, clearance, and half-life median values (95 % CI) for phenobarbital in the whole study population (n=37) were 0.48 (0.41-0.56) l/kg, 0.0034 (0.0028-0.0040) l/h/kg, and 93.7 (88.1-99.2) h, respectively.",Effect of co-medication on the pharmacokinetic parameters of phenobarbital in asphyxiated newborns. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26681081/),h,93.7,261687,DB00695,Furosemide
,2373133,urinary excretion,Similarly the urinary excretion of the gamma-hydroxybutyl metabolite was reduced from 6% in healthy subjects to 2.3% in patients with renal impairment.,Metabolism of the diuretic bumetanide in healthy subjects and patients with renal impairment. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373133/),%,6,262447,DB00695,Furosemide
,2373133,urinary excretion,Similarly the urinary excretion of the gamma-hydroxybutyl metabolite was reduced from 6% in healthy subjects to 2.3% in patients with renal impairment.,Metabolism of the diuretic bumetanide in healthy subjects and patients with renal impairment. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2373133/),%,2.3,262448,DB00695,Furosemide
,28487189,percentage entrapment efficiency (%EE),"The selected optimized formulation (F3) showed optimum particle size (PS), polydispersity index (PDI), zeta potential (ZP) and acceptable percentage entrapment efficiency (%EE) of 253.8nm±4.6, 0.25±0.03, -35mV±1 and 96%±1, respectively.",Mucopenetrating nanoparticles for enhancement of oral bioavailability of furosemide: In vitro and in vivo evaluation/sub-acute toxicity study. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28487189/),nm,253.8,263683,DB00695,Furosemide
,28487189,percentage entrapment efficiency (%EE),"The selected optimized formulation (F3) showed optimum particle size (PS), polydispersity index (PDI), zeta potential (ZP) and acceptable percentage entrapment efficiency (%EE) of 253.8nm±4.6, 0.25±0.03, -35mV±1 and 96%±1, respectively.",Mucopenetrating nanoparticles for enhancement of oral bioavailability of furosemide: In vitro and in vivo evaluation/sub-acute toxicity study. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28487189/),,0.25,263684,DB00695,Furosemide
,28487189,percentage entrapment efficiency (%EE),"The selected optimized formulation (F3) showed optimum particle size (PS), polydispersity index (PDI), zeta potential (ZP) and acceptable percentage entrapment efficiency (%EE) of 253.8nm±4.6, 0.25±0.03, -35mV±1 and 96%±1, respectively.",Mucopenetrating nanoparticles for enhancement of oral bioavailability of furosemide: In vitro and in vivo evaluation/sub-acute toxicity study. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28487189/),%,96,263685,DB00695,Furosemide
,19035874,AUC(tau),"Coadministration of aliskiren and ISMN was associated with only minor changes in the pharmacokinetic parameters of aliskiren (AUC(tau) 1.03 [0.90, 1.18]; C(max) 0.94 [0.69, 1.29]) and ISMN (AUC(tau) 0.88 [0.71, 1.10]; C(max) 0.94 [0.79, 1.13]).",Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19035874/),,1.03,263744,DB00695,Furosemide
,19035874,C(max),"Coadministration of aliskiren and ISMN was associated with only minor changes in the pharmacokinetic parameters of aliskiren (AUC(tau) 1.03 [0.90, 1.18]; C(max) 0.94 [0.69, 1.29]) and ISMN (AUC(tau) 0.88 [0.71, 1.10]; C(max) 0.94 [0.79, 1.13]).",Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19035874/),,0.94,263745,DB00695,Furosemide
,19035874,AUC(tau),"Coadministration of aliskiren and ISMN was associated with only minor changes in the pharmacokinetic parameters of aliskiren (AUC(tau) 1.03 [0.90, 1.18]; C(max) 0.94 [0.69, 1.29]) and ISMN (AUC(tau) 0.88 [0.71, 1.10]; C(max) 0.94 [0.79, 1.13]).",Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19035874/),,0.88,263746,DB00695,Furosemide
,19035874,C(max),"Coadministration of aliskiren and ISMN was associated with only minor changes in the pharmacokinetic parameters of aliskiren (AUC(tau) 1.03 [0.90, 1.18]; C(max) 0.94 [0.69, 1.29]) and ISMN (AUC(tau) 0.88 [0.71, 1.10]; C(max) 0.94 [0.79, 1.13]).",Pharmacokinetic interaction of the direct renin inhibitor aliskiren with furosemide and extended-release isosorbide-5-mononitrate in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19035874/),,0.94,263747,DB00695,Furosemide
,7104188,solubility,The solubility of frusemide was significantly higher in gastric juice from two fasting subjects (83-104 mg l-1) than in buffer solutions with the same pH (52-58 mg 1-1).,In vitro studies on the hydrolysis of frusemide in gastrointestinal juices. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104188/),[mg] / [l],83-104,264484,DB00695,Furosemide
,7104188,solubility,The solubility of frusemide was significantly higher in gastric juice from two fasting subjects (83-104 mg l-1) than in buffer solutions with the same pH (52-58 mg 1-1).,In vitro studies on the hydrolysis of frusemide in gastrointestinal juices. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104188/),mg,52-58,264485,DB00695,Furosemide
,7104188,binding,The binding of frusemide to macromolecules was 28.0 +/- 9.7% in ventricular secretion after fasting while it was 1.4 +/- 2.6% in the fluid obtained after pentagastrin stimulation.,In vitro studies on the hydrolysis of frusemide in gastrointestinal juices. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104188/),%,28.0,264486,DB00695,Furosemide
,7104188,binding,The binding of frusemide to macromolecules was 28.0 +/- 9.7% in ventricular secretion after fasting while it was 1.4 +/- 2.6% in the fluid obtained after pentagastrin stimulation.,In vitro studies on the hydrolysis of frusemide in gastrointestinal juices. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104188/),%,1.4,264487,DB00695,Furosemide
,9429740,area under the plasma concentration-time curves of furosemide from time zero to 4 h (AUC0-4 h,"Furosemide was absorbed considerably after a direct administration of Lasix into the duodenum; the values of the area under the plasma concentration-time curves of furosemide from time zero to 4 h (AUC0-4 h, 93.6 versus 122 micrograms min mL-1, p < 0.123) and the cumulative amounts of the dose excreted in 8 h (10,600 versus 15,000 micrograms, p < 0.0185) and 24 h (11,300 versus 15,400 micrograms, p < 0.0192) urine as unchanged furosemide were significantly higher after a direct administration into the duodenum than after an oral administration.",Pharmacokinetics and pharmacodynamics of furosemide after direct administration into the stomach or duodenum. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429740/),[min·μg] / [ml],93.6,264511,DB00695,Furosemide
,9429740,area under the plasma concentration-time curves of furosemide from time zero to 4 h (AUC0-4 h,"Furosemide was absorbed considerably after a direct administration of Lasix into the duodenum; the values of the area under the plasma concentration-time curves of furosemide from time zero to 4 h (AUC0-4 h, 93.6 versus 122 micrograms min mL-1, p < 0.123) and the cumulative amounts of the dose excreted in 8 h (10,600 versus 15,000 micrograms, p < 0.0185) and 24 h (11,300 versus 15,400 micrograms, p < 0.0192) urine as unchanged furosemide were significantly higher after a direct administration into the duodenum than after an oral administration.",Pharmacokinetics and pharmacodynamics of furosemide after direct administration into the stomach or duodenum. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429740/),[min·μg] / [ml],122,264512,DB00695,Furosemide
,9429740,cumulative amounts,"Furosemide was absorbed considerably after a direct administration of Lasix into the duodenum; the values of the area under the plasma concentration-time curves of furosemide from time zero to 4 h (AUC0-4 h, 93.6 versus 122 micrograms min mL-1, p < 0.123) and the cumulative amounts of the dose excreted in 8 h (10,600 versus 15,000 micrograms, p < 0.0185) and 24 h (11,300 versus 15,400 micrograms, p < 0.0192) urine as unchanged furosemide were significantly higher after a direct administration into the duodenum than after an oral administration.",Pharmacokinetics and pharmacodynamics of furosemide after direct administration into the stomach or duodenum. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429740/),μg,"10,600",264513,DB00695,Furosemide
,9429740,cumulative amounts,"Furosemide was absorbed considerably after a direct administration of Lasix into the duodenum; the values of the area under the plasma concentration-time curves of furosemide from time zero to 4 h (AUC0-4 h, 93.6 versus 122 micrograms min mL-1, p < 0.123) and the cumulative amounts of the dose excreted in 8 h (10,600 versus 15,000 micrograms, p < 0.0185) and 24 h (11,300 versus 15,400 micrograms, p < 0.0192) urine as unchanged furosemide were significantly higher after a direct administration into the duodenum than after an oral administration.",Pharmacokinetics and pharmacodynamics of furosemide after direct administration into the stomach or duodenum. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429740/),μg,"15,000",264514,DB00695,Furosemide
,9429740,cumulative amounts,"Furosemide was absorbed considerably after a direct administration of Lasix into the duodenum; the values of the area under the plasma concentration-time curves of furosemide from time zero to 4 h (AUC0-4 h, 93.6 versus 122 micrograms min mL-1, p < 0.123) and the cumulative amounts of the dose excreted in 8 h (10,600 versus 15,000 micrograms, p < 0.0185) and 24 h (11,300 versus 15,400 micrograms, p < 0.0192) urine as unchanged furosemide were significantly higher after a direct administration into the duodenum than after an oral administration.",Pharmacokinetics and pharmacodynamics of furosemide after direct administration into the stomach or duodenum. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429740/),μg,"11,300",264515,DB00695,Furosemide
,9429740,cumulative amounts,"Furosemide was absorbed considerably after a direct administration of Lasix into the duodenum; the values of the area under the plasma concentration-time curves of furosemide from time zero to 4 h (AUC0-4 h, 93.6 versus 122 micrograms min mL-1, p < 0.123) and the cumulative amounts of the dose excreted in 8 h (10,600 versus 15,000 micrograms, p < 0.0185) and 24 h (11,300 versus 15,400 micrograms, p < 0.0192) urine as unchanged furosemide were significantly higher after a direct administration into the duodenum than after an oral administration.",Pharmacokinetics and pharmacodynamics of furosemide after direct administration into the stomach or duodenum. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9429740/),μg,"15,400",264516,DB00695,Furosemide
,1623899,clearance,"Metamizole significantly reduced furosemide clearance (175 vs 141 ml.min-1), furosemide-stimulated plasma renin activity (1.42 vs 0.79 ng AI.",Metamizole-furosemide interaction study in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623899/),[ml] / [min],175,265220,DB00695,Furosemide
,1623899,clearance,"Metamizole significantly reduced furosemide clearance (175 vs 141 ml.min-1), furosemide-stimulated plasma renin activity (1.42 vs 0.79 ng AI.",Metamizole-furosemide interaction study in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623899/),[ml] / [min],141,265221,DB00695,Furosemide
,1623899,plasma renin activity,"Metamizole significantly reduced furosemide clearance (175 vs 141 ml.min-1), furosemide-stimulated plasma renin activity (1.42 vs 0.79 ng AI.",Metamizole-furosemide interaction study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623899/),ng,1.42,265222,DB00695,Furosemide
,1623899,plasma renin activity,"Metamizole significantly reduced furosemide clearance (175 vs 141 ml.min-1), furosemide-stimulated plasma renin activity (1.42 vs 0.79 ng AI.",Metamizole-furosemide interaction study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1623899/),ng,0.79,265223,DB00695,Furosemide
,3718591,areas under the plasma concentration curve,No significant differences were also found between the areas under the plasma concentration curve (110 vs.,Metabolic fate of the new cardiotonic denopamine in animals. 4th communication: effects of coadministered drugs on the plasma concentration and metabolism of denopamine in dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718591/),,110,266181,DB00695,Furosemide
,3718591,peak plasma concentrations,"127 ng/ml X h, with and without the coadministered drugs, respectively), peak plasma concentrations (32.4 vs. 39.6 ng/ml), times to peak concentration (1.2 vs. 1.0 h) and plasma half-lives (2.2 vs. 2.0 h), respectively.",Metabolic fate of the new cardiotonic denopamine in animals. 4th communication: effects of coadministered drugs on the plasma concentration and metabolism of denopamine in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718591/),[ng] / [ml],32.4,266182,DB00695,Furosemide
,3718591,peak plasma concentrations,"127 ng/ml X h, with and without the coadministered drugs, respectively), peak plasma concentrations (32.4 vs. 39.6 ng/ml), times to peak concentration (1.2 vs. 1.0 h) and plasma half-lives (2.2 vs. 2.0 h), respectively.",Metabolic fate of the new cardiotonic denopamine in animals. 4th communication: effects of coadministered drugs on the plasma concentration and metabolism of denopamine in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718591/),[ng] / [ml],39.6,266183,DB00695,Furosemide
,3718591,times to peak concentration,"127 ng/ml X h, with and without the coadministered drugs, respectively), peak plasma concentrations (32.4 vs. 39.6 ng/ml), times to peak concentration (1.2 vs. 1.0 h) and plasma half-lives (2.2 vs. 2.0 h), respectively.",Metabolic fate of the new cardiotonic denopamine in animals. 4th communication: effects of coadministered drugs on the plasma concentration and metabolism of denopamine in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718591/),h,1.2,266184,DB00695,Furosemide
,3718591,times to peak concentration,"127 ng/ml X h, with and without the coadministered drugs, respectively), peak plasma concentrations (32.4 vs. 39.6 ng/ml), times to peak concentration (1.2 vs. 1.0 h) and plasma half-lives (2.2 vs. 2.0 h), respectively.",Metabolic fate of the new cardiotonic denopamine in animals. 4th communication: effects of coadministered drugs on the plasma concentration and metabolism of denopamine in dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718591/),h,1.0,266185,DB00695,Furosemide
,3718591,plasma half-lives,"127 ng/ml X h, with and without the coadministered drugs, respectively), peak plasma concentrations (32.4 vs. 39.6 ng/ml), times to peak concentration (1.2 vs. 1.0 h) and plasma half-lives (2.2 vs. 2.0 h), respectively.",Metabolic fate of the new cardiotonic denopamine in animals. 4th communication: effects of coadministered drugs on the plasma concentration and metabolism of denopamine in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718591/),h,2.2,266186,DB00695,Furosemide
,3718591,plasma half-lives,"127 ng/ml X h, with and without the coadministered drugs, respectively), peak plasma concentrations (32.4 vs. 39.6 ng/ml), times to peak concentration (1.2 vs. 1.0 h) and plasma half-lives (2.2 vs. 2.0 h), respectively.",Metabolic fate of the new cardiotonic denopamine in animals. 4th communication: effects of coadministered drugs on the plasma concentration and metabolism of denopamine in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3718591/),h,2.0,266187,DB00695,Furosemide
,8630630,elimination half-life (t1/2),The elimination half-life (t1/2) of meloxicam is approximately 20 h.,A review of the clinical pharmacokinetics of meloxicam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8630630/),h,20,268516,DB00695,Furosemide
,8630630,total plasma clearance (CL),This is reflected in a total plasma clearance (CL) of 0.42-0.48 1/h.,A review of the clinical pharmacokinetics of meloxicam. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8630630/),[1] / [h],0.42-0.48,268517,DB00695,Furosemide
,2243149,bioavailability,"The bioavailability of the oral dose on day 1 and day 29 was 13% and 12.5%, respectively.",Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2243149/),%,13,269502,DB00695,Furosemide
,2243149,bioavailability,"The bioavailability of the oral dose on day 1 and day 29 was 13% and 12.5%, respectively.",Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2243149/),%,12.5,269503,DB00695,Furosemide
,2243149,terminal plasma half-life (t1/2),The terminal plasma half-life (t1/2) on day 29 was 22 hours and systemic clearance was 490 mL/min on day 1 and 434 mL/min on day 29 (NS).,Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2243149/),h,22,269504,DB00695,Furosemide
,2243149,systemic clearance,The terminal plasma half-life (t1/2) on day 29 was 22 hours and systemic clearance was 490 mL/min on day 1 and 434 mL/min on day 29 (NS).,Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2243149/),[ml] / [min],490,269505,DB00695,Furosemide
,2243149,systemic clearance,The terminal plasma half-life (t1/2) on day 29 was 22 hours and systemic clearance was 490 mL/min on day 1 and 434 mL/min on day 29 (NS).,Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2243149/),[ml] / [min],434,269506,DB00695,Furosemide
,2243149,protein binding,The protein binding determined by equilibrium dialysis in the six patients with the lowest GFR was 99.74% on day 1 and 99.73% on day 29 and did not differ significantly from previously reported values in healthy subjects.,Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2243149/),%,99.74,269507,DB00695,Furosemide
,2243149,protein binding,The protein binding determined by equilibrium dialysis in the six patients with the lowest GFR was 99.74% on day 1 and 99.73% on day 29 and did not differ significantly from previously reported values in healthy subjects.,Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2243149/),%,99.73,269508,DB00695,Furosemide
,9557809,terminal elimination half-life,The mean (SD) i.v. terminal elimination half-life was 118 (67) minutes.,Plasma pharmacokinetics of intravenous and intramuscular furosemide in the camel (Camelus dromedarius). ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9557809/),min,118,269875,DB00695,Furosemide
,9557809,systemic clearance,The systemic clearance was 5.4 (1.2) ml min(-1) kg(-1).,Plasma pharmacokinetics of intravenous and intramuscular furosemide in the camel (Camelus dromedarius). ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9557809/),[ml] / [kg·min],5.4,269876,DB00695,Furosemide
,9557809,steady-state volume of distribution,and the steady-state volume of distribution was 0.43 (0.14) litre kg(-1).,Plasma pharmacokinetics of intravenous and intramuscular furosemide in the camel (Camelus dromedarius). ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9557809/),[l] / [kg],0.43,269877,DB00695,Furosemide
,9557809,mean absorption time,"The mean absorption time after i.m. dosing was 33 (62) minutes, while the absolute bioavailability was 71 (20) per cent.",Plasma pharmacokinetics of intravenous and intramuscular furosemide in the camel (Camelus dromedarius). ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9557809/),min,33,269878,DB00695,Furosemide
,9557809,absolute bioavailability,"The mean absorption time after i.m. dosing was 33 (62) minutes, while the absolute bioavailability was 71 (20) per cent.",Plasma pharmacokinetics of intravenous and intramuscular furosemide in the camel (Camelus dromedarius). ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9557809/),%,71,269879,DB00695,Furosemide
,7614778,bioavailability,"Theophylline has higher bioavailability in patients with oedema, with a significantly higher Cmax in patients with hepatic cirrhosis and CHF than in healthy volunteers (29 and 22%, respectively).",Pharmacokinetic changes in patients with oedema. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7614778/),%,29,269967,DB00695,Furosemide
,7614778,bioavailability,"Theophylline has higher bioavailability in patients with oedema, with a significantly higher Cmax in patients with hepatic cirrhosis and CHF than in healthy volunteers (29 and 22%, respectively).",Pharmacokinetic changes in patients with oedema. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7614778/),%,22,269968,DB00695,Furosemide
,6617067,lag time of absorption,In the fasting state a lag time of absorption of approximately 1 hr was followed by absorption t 1/2s and elimination t 1/2s of approximately 0.75 and 2 2.5 hr.,Azosemide kinetics and dynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6617067/),h,1,270323,DB00695,Furosemide
,6617067,absorption t 1/2s,In the fasting state a lag time of absorption of approximately 1 hr was followed by absorption t 1/2s and elimination t 1/2s of approximately 0.75 and 2 2.5 hr.,Azosemide kinetics and dynamics. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6617067/),h,0.75,270324,DB00695,Furosemide
,6617067,elimination t 1/2s,In the fasting state a lag time of absorption of approximately 1 hr was followed by absorption t 1/2s and elimination t 1/2s of approximately 0.75 and 2 2.5 hr.,Azosemide kinetics and dynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6617067/),h,0.75,270325,DB00695,Furosemide
,6617067,elimination t 1/2s,In the fasting state a lag time of absorption of approximately 1 hr was followed by absorption t 1/2s and elimination t 1/2s of approximately 0.75 and 2 2.5 hr.,Azosemide kinetics and dynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6617067/),h,2 2.5,270326,DB00695,Furosemide
,6617067,elimination t 1/2,After intravenous dosing the elimination t 1/2 was approximately 2 hr; 20% of a dose was recovered unchanged.,Azosemide kinetics and dynamics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6617067/),h,2,270327,DB00695,Furosemide
,6617067,bioavailability,Thus azosemide has an estimated bioavailability of 10%.,Azosemide kinetics and dynamics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6617067/),%,10,270328,DB00695,Furosemide
,6617067,dose inducing half-maximal response,"The relationship between urinary azosemide excretion rate (""dose"") and natriuretic response follows a sigmoid-shaped curve with a dose inducing half-maximal response of 9.3 +/- 2.6 micrograms/min, whereas it is 69.8, 12.1 and 1 microgram/min for furosemide, piretanide, and bumetanide respectively.",Azosemide kinetics and dynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6617067/),[μg] / [min],9.3,270329,DB00695,Furosemide
,6617067,dose inducing half-maximal response,"The relationship between urinary azosemide excretion rate (""dose"") and natriuretic response follows a sigmoid-shaped curve with a dose inducing half-maximal response of 9.3 +/- 2.6 micrograms/min, whereas it is 69.8, 12.1 and 1 microgram/min for furosemide, piretanide, and bumetanide respectively.",Azosemide kinetics and dynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6617067/),[μg] / [min],69.8,270330,DB00695,Furosemide
,6617067,dose inducing half-maximal response,"The relationship between urinary azosemide excretion rate (""dose"") and natriuretic response follows a sigmoid-shaped curve with a dose inducing half-maximal response of 9.3 +/- 2.6 micrograms/min, whereas it is 69.8, 12.1 and 1 microgram/min for furosemide, piretanide, and bumetanide respectively.",Azosemide kinetics and dynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6617067/),[μg] / [min],12.1,270331,DB00695,Furosemide
,6617067,dose inducing half-maximal response,"The relationship between urinary azosemide excretion rate (""dose"") and natriuretic response follows a sigmoid-shaped curve with a dose inducing half-maximal response of 9.3 +/- 2.6 micrograms/min, whereas it is 69.8, 12.1 and 1 microgram/min for furosemide, piretanide, and bumetanide respectively.",Azosemide kinetics and dynamics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6617067/),[μg] / [min],1,270332,DB00695,Furosemide
,8033751,peak levels,"Because of the increase in urinary volume the peak levels of urinary platinum were decreased from 47.34 micrograms/ml to 13.49 micrograms/ml, so that the rate of the nephrotoxicity was reduced from 36.8% (7/19) to 5.6% (1/18).",[The protective effects of two hydration protocols against cisplatin nephrotoxicity]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8033751/),[μg] / [ml],47.34,272951,DB00695,Furosemide
,8033751,peak levels,"Because of the increase in urinary volume the peak levels of urinary platinum were decreased from 47.34 micrograms/ml to 13.49 micrograms/ml, so that the rate of the nephrotoxicity was reduced from 36.8% (7/19) to 5.6% (1/18).",[The protective effects of two hydration protocols against cisplatin nephrotoxicity]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8033751/),[μg] / [ml],13.49,272952,DB00695,Furosemide
,3370062,plasma elimination half-life,"The plasma elimination half-life for i.v. and oral torasemide was 2.2 h and 2.8 h, its bioavailability after oral administration was 91%, about 25% of the total body clearance was due to renal excretion both after iv.",Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370062/),h,2.2,273096,DB00695,Furosemide
,3370062,plasma elimination half-life,"The plasma elimination half-life for i.v. and oral torasemide was 2.2 h and 2.8 h, its bioavailability after oral administration was 91%, about 25% of the total body clearance was due to renal excretion both after iv.",Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370062/),h,2.8,273097,DB00695,Furosemide
,3370062,bioavailability,"The plasma elimination half-life for i.v. and oral torasemide was 2.2 h and 2.8 h, its bioavailability after oral administration was 91%, about 25% of the total body clearance was due to renal excretion both after iv.",Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370062/),%,91,273098,DB00695,Furosemide
,3370062,plasma elimination half-life,"For furosemide, a plasma elimination half-life of 0.6 h for i.v. and 0.8 h for oral application was found.",Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370062/),h,0.6,273099,DB00695,Furosemide
,3370062,plasma elimination half-life,"For furosemide, a plasma elimination half-life of 0.6 h for i.v. and 0.8 h for oral application was found.",Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370062/),h,0.8,273100,DB00695,Furosemide
,3370062,bioavailability,"The bioavailability was 40%, and about 62% of the drug was excreted via the kidney.",Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370062/),%,40,273101,DB00695,Furosemide
,3370062,bioavailability,"The bioavailability was 40%, and about 62% of the drug was excreted via the kidney.",Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3370062/),%,62,273102,DB00695,Furosemide
,935124,abosrption,"2 The abosrption of aqueous frusemide was 57 +/- 20 percent (SD) and the bioavailability of 500 mg tablets was 42 +/- 12 percent, this differnece not assuming significance.",Pharmacokinetics of frusemide in chronic renal failure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/935124/),%,57,273414,DB00695,Furosemide
,935124,bioavailability,"2 The abosrption of aqueous frusemide was 57 +/- 20 percent (SD) and the bioavailability of 500 mg tablets was 42 +/- 12 percent, this differnece not assuming significance.",Pharmacokinetics of frusemide in chronic renal failure. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/935124/),%,42,273415,DB00695,Furosemide
,935124,renal clearance,3 The renal clearance of frusemide was negligible (1.45 +/- 1.7 ml/min).,Pharmacokinetics of frusemide in chronic renal failure. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/935124/),[ml] / [min],1.45,273416,DB00695,Furosemide
